Unnamed: 0,datetime,title,source,link
0.0,9/26/2016 1:20:23 PM,"BRIEF-Sanofi and Regeneron accepted for priority review by U.S. FDA (REGN, SAN)",Reuters,/news/stocks/brief-sanofi-and-regeneron-accepted-for-priority-review-by-u-s-fda-regn-san-1001417230
1.0,9/26/2016 1:40:20 PM,"Sanofi may win U.S. approval of $3 bln eczema drug by March (SAN, REGN, AZN)",Reuters,/news/stocks/sanofi-may-win-u-s-approval-of-$3-bln-eczema-drug-by-march-san-regn-azn-1001417519
2.0,9/30/2016 4:00:25 PM,BRIEF-Regeneron announces phase 2 study of aflibercept (REGN),Reuters,/news/stocks/brief-regeneron-announces-phase-2-study-of-aflibercept-regn-1001429758
3.0,9/30/2016 4:30:22 PM,Regeneron's Eylea combination therapy fails mid-stage study (REGN),Reuters,/news/stocks/regenerons-eylea-combination-therapy-fails-mid-stage-study-regn-1001429867
4.0,9/30/2016 5:20:23 PM,UPDATE 1-Regeneron's Eylea combination therapy fails mid-stage study (REGN),Reuters,/news/stocks/update-1-regenerons-eylea-combination-therapy-fails-mid-stage-study-regn-1001430010
5.0,10/3/2016 10:10:21 AM,"Regeneron eczema drug reduces itch and anxiety, two studies show (SAN, REGN)",Reuters,/news/stocks/regeneron-eczema-drug-reduces-itch-and-anxiety-two-studies-show-san-regn-1001431491
6.0,10/13/2016 3:10:22 PM,BRIEF-Ocular and Regeneron enter into strategic collaboration to develop sustained release formulation of aflibercept (REGN),Reuters,/news/stocks/brief-ocular-and-regeneron-enter-into-strategic-collaboration-to-develop-sustained-release-formulation-of-aflibercept-regn-1001454399
7.0,10/17/2016 3:10:25 PM,"BRIEF-Regeneron, Teva provide update on fasinumab clinical development programs (REGN, TEVA)",Reuters,/news/stocks/brief-regeneron-teva-provide-update-on-fasinumab-clinical-development-programs-regn-teva-1001459690
8.0,10/17/2016 3:20:20 PM,"FDA places Regeneron and Teva's pain-drug study on hold (REGN, TEVA)",Reuters,/news/stocks/fda-places-regeneron-and-tevas-pain-drug-study-on-hold-regn-teva-1001459741
9.0,10/17/2016 4:20:24 PM,"UPDATE 1-FDA places Regeneron and Teva's pain-drug study on hold (REGN, TEVA)",Reuters,/news/stocks/update-1-fda-places-regeneron-and-tevas-pain-drug-study-on-hold-regn-teva-1001459859
10.0,11/4/2016 12:42:18 PM,"Eylea sales lift Regeneron revenue 7.3 percent (SAN, BAYN, REGN)",Reuters,http://www.businessinsider.com/r-eylea-sales-lift-regeneron-revenue-73-percent-2016-11
11.0,11/4/2016 1:06:22 PM,BRIEF-Regeneron Pharmaceuticals Q3 gaap EPS $2.27 (REGN),Reuters,http://www.businessinsider.com/r-brief-regeneron-pharmaceuticals-q3-gaap-eps-227-2016-11
12.0,11/4/2016 1:18:18 PM,"UPDATE 1-Regeneron profit beats Street, Eylea sales growth slows (SAN, BAYN, REGN)",Reuters,http://www.businessinsider.com/r-update-1-regeneron-profit-beats-street-eylea-sales-growth-slows-2016-11
13.0,11/5/2016 6:34:20 PM,"US STOCKS-S&P 500 losing streak extends to 9th straight day (REGN, HUM)",Reuters,http://www.businessinsider.com/r-us-stocks-sp-500-losing-streak-extends-to-9th-straight-day-2016-11
14.0,11/11/2016 8:06:18 PM,BRIEF-Regeneron and sanofi to present data from clinical trials (REGN),Reuters,http://www.businessinsider.com/r-brief-regeneron-and-sanofi-to-present-data-from-clinical-trials-2016-11
15.0,11/15/2016 10:10:17 PM,"Amgen cholesterol drug reduces artery-clogging plaque in study (SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-amgen-cholesterol-drug-reduces-artery-clogging-plaque-in-study-2016-11
16.0,11/16/2016 4:18:24 PM,"BRIEF-Sanofi says Sarilumab phase 3 study shows positive results (SAN, REGN)",Reuters,http://www.businessinsider.com/r-brief-sanofi-says-sarilumab-phase-3-study-shows-positive-results-2016-11
17.0,11/16/2016 5:06:20 PM,"BRIEF-Regeneron and Sanofi Present Results from late-stage Monarch study at American College of Rheumatology Annual Meeting (REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-and-sanofi-present-results-from-late-stage-monarch-study-at-american-college-of-rheumatology-annual-meeting-2016-11
18.0,11/17/2016 1:16:18 PM,"No early win for Sanofi, Regeneron cholesterol drug in study",Reuters,http://www.businessinsider.com/r-no-early-win-for-sanofi-regeneron-cholesterol-drug-in-study-2016-11
19.0,11/18/2016 2:06:17 PM,BRIEF-Regeneron entered into termination agreement relating to master terms and conditions for warrants (REGN),Reuters,http://www.businessinsider.com/r-brief-regeneron-entered-into-termination-agreement-relating-to-master-terms-and-conditions-for-warrants-2016-11
20.0,12/8/2016 12:34:03 PM,"UPDATE 1-EU regulator accepts Sanofi/Regeneron's Dupixent product for review (SAN, REGN)",Reuters,http://www.businessinsider.com/r-update-1-eu-regulator-accepts-sanofi/regenerons-dupixent-product-for-review-2016-12
21.0,12/12/2016 1:20:05 PM,UPDATE 1-Novartis eye drug franchise hit by failed Fovista studies (REGN),Reuters,http://www.businessinsider.com/r-update-1-novartis-eye-drug-franchise-hit-by-failed-fovista-studies-2016-12
22.0,12/13/2016 3:04:03 PM,"As drug approvals dive in 2016, returns on R&D deteriorate",Reuters,http://www.businessinsider.com/r-as-drug-approvals-dive-in-2016-returns-on-rd-deteriorate-2016-12
23.0,12/30/2016 10:30:05 PM,"BRIEF-Regeneron Pharmaceuticals to purchase existing corporate headquarters from BMR-Landmark at Eastview LLC, BMR-Landmark at Eastview IV LLC (REGN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-pharmaceuticals-to-purchase-existing-corporate-headquarters-from-bmr-landmark-at-eastview-llc-bmr-landmark-at-eastview-iv-llc-2016-12
24.0,1/2/2017 10:18:03 AM,"New drug approvals fall to six-year low in 2016 (SAN, REGN)",Reuters,http://www.businessinsider.com/r-new-drug-approvals-fall-to-six-year-low-in-2016-2017-1
25.0,1/6/2017 7:00:04 AM,"PRESS DIGEST - Wall Street Journal - Jan 6 (7203, AAPL, SHLD, YHOO, VZ, WMT, 005930, SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-press-digest---wall-street-journal---jan-6-2017-1
26.0,1/6/2017 1:44:03 PM,"US STOCKS-Futures flat as investors await jobs data (SAN, REGN)",Reuters,http://www.businessinsider.com/r-us-stocks-futures-flat-as-investors-await-jobs-data-2017-1
27.0,1/6/2017 5:11:54 PM,"2 drugmakers just got banned from selling their cholesterol drug — and their rival's stock is jumping (AMGN, REGN, SNYNF)",Reuters,http://www.businessinsider.com/r-judge-blocks-sanofi-regeneron-from-selling-cholesterol-drug-2017-1
28.0,1/9/2017 11:52:03 PM,BRIEF-Regeneron Pharmaceuticals reports preliminary Q4 U.S. net sales of eylea injection of $858 mln (REGN),Reuters,http://www.businessinsider.com/r-brief-regeneron-pharmaceuticals-reports-preliminary-q4-us-net-sales-of-eylea-injection-of-858-mln-2017-1
29.0,1/10/2017 1:48:05 AM,"BRIEF-Regeneron says Sanofi plant used to fill drugs now deemed acceptable (REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-says-sanofi-plant-used-to-fill-drugs-now-deemed-acceptable-2017-1
30.0,1/10/2017 2:16:08 AM,"Regeneron CEO says Amgen not putting patients first in patent dispute (SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-regeneron-ceo-says-amgen-not-putting-patients-first-in-patent-dispute-2017-1
31.0,1/10/2017 3:14:03 AM,"BRIEF-Amgen comments on Delaware court's ruling on PCSK9 patent litigation (AMGN, REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-amgen-comments-on-delaware-courts-ruling-on-pcsk9-patent-litigation-2017-1
32.0,1/10/2017 5:38:05 AM,"UPDATE 1-Regeneron CEO says Amgen not putting patients first in patent dispute (SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-update-1-regeneron-ceo-says-amgen-not-putting-patients-first-in-patent-dispute-2017-1
33.0,1/31/2017 3:10:07 PM,BRIEF-Tony Coles elected to Regeneron board (REGN),Reuters,http://www.businessinsider.com/r-brief-tony-coles-elected-to-regeneron-board-2017-1
34.0,2/1/2017 7:07:01 AM,Regeneron And Sanofi Say Canada Approves Kevzara ,RTTNews,/news/stocks/regeneron-and-sanofi-say-canada-approves-kevzara-1001711423
35.0,2/8/2017 10:06:11 AM,"UPDATE 1-Drugmaker Sanofi sees weak 2017 earnings, not in hurry for M&A (SAN, JNJ, REGN, PFE, AMGN)",Reuters,http://www.businessinsider.com/r-update-1-drugmaker-sanofi-sees-weak-2017-earnings-not-in-hurry-for-ma-2017-2
36.0,2/8/2017 11:10:09 AM,"BRIEF-Sanofi CEO: no ""Plan B"" regarding anti cholesterol drug Praluent (SAN, REGN)",Reuters,http://www.businessinsider.com/r-brief-sanofi-ceo-no-plan-b-regarding-anti-cholesterol-drug-praluent-2017-2
37.0,2/8/2017 11:50:11 PM,"BRIEF-Regeneron pharmaceuticals says appeals court grants stay of permanent injunction for praluent (REGN, SAN, AMGN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-pharmaceuticals-says-appeals-court-grants-stay-of-permanent-injunction-for-praluent-2017-2
38.0,2/9/2017 2:31:52 AM,Sanofi Says Appeals Court Grants Stay Of Permanent Injunction For Praluent ,RTTNews,/news/stocks/sanofi-says-appeals-court-grants-stay-of-permanent-injunction-for-praluent-1001735367
39.0,2/9/2017 10:20:27 AM,"AGTC On Watch, It's Advantage REGN, No Need For FDA Panel Review For Betrixaban ",RTTNews,/news/stocks/agtc-on-watch-it-s-advantage-regn-no-need-for-fda-panel-review-for-betrixaban-1001736305
40.0,2/9/2017 12:35:18 PM,Regeneron Pharmaceuticals Reports 37% Rise In Q4 Profit,RTTNews,/news/stocks/regeneron-pharmaceuticals-reports-37-rise-in-q4-profit-1001736847
41.0,2/9/2017 12:42:09 PM,Regeneron revenue rises 11.7 pct on Eylea eye drug (REGN),Reuters,http://www.businessinsider.com/r-regeneron-revenue-rises-117-pct-on-eylea-eye-drug-2017-2
42.0,2/9/2017 12:56:09 PM,"BRIEF-Regeneron posts Q4 adj. profit $3.04/shr (REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-posts-q4-adj-profit-304-shr-2017-2
43.0,2/9/2017 1:10:11 PM,"UPDATE 1-Regeneron profit edges past estimates (SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-update-1-regeneron-profit-edges-past-estimates-2017-2
44.0,2/9/2017 4:00:09 PM,"BRIEF-Regeneron says price increases unrelated from innovation will be pushed back on (AMGN, BAYN, REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-says-price-increases-unrelated-from-innovation-will-be-pushed-back-on-2017-2
45.0,2/10/2017 2:42:25 AM,Regeneron Gets Subpoena On Patient Assistance Non-profit ,RTTNews,/news/stocks/regeneron-gets-subpoena-on-patient-assistance-non-profit-1001739702
46.0,2/25/2017 9:22:15 AM,"UPDATE 1-Pfizer subpoenaed in U.S. over patient assistance plans (PFE, VRX, REGN)",Reuters,http://www.businessinsider.com/r-update-1-pfizer-subpoenaed-in-us-over-patient-assistance-plans-2017-2
47.0,2/27/2017 11:43:16 AM,Biotech Stocks Facing FDA Decision In March ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-march-1001785169
48.0,2/27/2017 2:30:00 PM,Regeneron and Sanofi to Present New Data on DUPIXENT® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses,PR Newswire,/news/stocks/regeneron-and-sanofi-to-present-new-data-on-dupixent-dupilumab-for-moderate-to-severe-atopic-dermatitis-at-upcoming-medical-congresses-1001785946
49.0,2/27/2017 2:30:00 PM,Sanofi and Regeneron to Present New Data on Dupixent® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses,PR Newswire,/news/stocks/sanofi-and-regeneron-to-present-new-data-on-dupixent-dupilumab-for-moderate-to-severe-atopic-dermatitis-at-upcoming-medical-congresses-1001785948
50.0,3/1/2017 11:14:20 PM,BRIEF-Adverum says Regeneron Pharma elects to extend research term of deal (REGN),Reuters,http://www.businessinsider.com/r-brief-adverum-says-regeneron-pharma-elects-to-extend-research-term-of-deal-2017-3
51.0,3/4/2017 7:50:20 PM,"Sanofi, Regeneron say latest Dupixent eczema drug tests positive",Reuters,http://www.businessinsider.com/r-sanofi-regeneron-say-latest-dupixent-eczema-drug-tests-positive-2017-3
52.0,3/5/2017 6:42:12 AM,"Regeneron, Sanofi: DUPIXENT Study In Atopic Dermatitis Shows Positive Data ",RTTNews,/news/stocks/regeneron-sanofi-dupixent-study-in-atopic-dermatitis-shows-positive-data-1001804735
53.0,3/7/2017 2:00:00 PM,Regeneron and Sanofi to Present New Phase 3 Praluent® (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions,PR Newswire,/news/stocks/regeneron-and-sanofi-to-present-new-phase-3-praluent-alirocumab-injection-clinical-trial-analyses-at-acc-17-scientific-sessions-1001810991
54.0,3/7/2017 3:50:22 PM,"BRIEF-Regeneron and Sanofi to present new phase 3 praluent (alirocumab) injection clinical trial analyses at ACC.17 Scientific Sessions (REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-and-sanofi-to-present-new-phase-3-praluent-alirocumab-injection-clinical-trial-analyses-at-acc17-scientific-sessions-2017-3
55.0,3/13/2017 6:48:23 AM,"Data on heart benefits of Amgen drug is key to unlocking sales (AMGN, REGN, SAN, ESRX)",Reuters,http://www.businessinsider.com/r-data-on-heart-benefits-of-amgen-drug-is-key-to-unlocking-sales-2017-3
56.0,3/13/2017 11:16:26 AM,"RPT-Data on heart benefits of Amgen drug is key to unlocking sales (AMGN, REGN, SAN, ESRX)",Reuters,http://www.businessinsider.com/r-rpt-data-on-heart-benefits-of-amgen-drug-is-key-to-unlocking-sales-2017-3
57.0,3/13/2017 2:28:23 PM,"Amgen's Repatha lowers need for cholesterol-lowering procedure (AMGN, REGN, SAN)",Reuters,http://www.businessinsider.com/r-amgens-repatha-lowers-need-for-cholesterol-lowering-procedure-2017-3
58.0,3/14/2017 10:00:24 AM,"BRIEF-UK regulator gives positive opinion on Sanofi/Regeneron's dupilumab product (SAN, REGN)",Reuters,http://www.businessinsider.com/r-brief-uk-regulator-gives-positive-opinion-on-sanofi-regenerons-dupilumab-product-2017-3
59.0,3/14/2017 10:24:24 AM,"UK gives early green light to Sanofi eczema drug (SAN, REGN)",Reuters,http://www.businessinsider.com/r-uk-gives-early-green-light-to-sanofi-eczema-drug-2017-3
60.0,3/15/2017 2:29:00 AM,Teen Scientist Researches New Approach to Neurological Damage; Wins Regeneron Science Talent Search 2017,PR Newswire,/news/stocks/teen-scientist-researches-new-approach-to-neurological-damage-wins-regeneron-science-talent-search-2017-1001835605
61.0,3/15/2017 3:45:00 AM,Teen Scientist Researches New Approach to Neurological Damage; Wins Regeneron Science Talent Search 2017,PR Newswire,/news/stocks/teen-scientist-researches-new-approach-to-neurological-damage-wins-regeneron-science-talent-search-2017-1001835653
62.0,3/17/2017 2:34:43 PM,"RPT-Amgen cholesterol drug cuts heart attack, stroke risk more than 20 pct-study (AMGN, REGN, SAN)",Reuters,http://www.businessinsider.com/r-rpt-amgen-cholesterol-drug-cuts-heart-attack-stroke-risk-more-than-20-pct-study-2017-3
63.0,3/17/2017 3:04:33 PM,"Amgen is getting whacked after disappointing study results for its $14,000 heart drug (AMGN)",Reuters,http://www.businessinsider.com/r-amgen-cholesterol-drug-cuts-heart-attack-stroke-risk-more-than-20-percent-study-2017-3
64.0,3/17/2017 4:46:43 PM,"Express Scripts says Amgen data opens door to patients (ESRX, AMGN, SAN, REGN)",Reuters,http://www.businessinsider.com/r-express-scripts-says-amgen-data-opens-door-to-patients-2017-3
65.0,3/17/2017 6:28:43 PM,"CVS Health says Amgen data may increase eligible patients by millions (CVS, SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-cvs-health-says-amgen-data-may-increase-eligible-patients-by-millions-2017-3
66.0,3/17/2017 10:04:45 PM,"Amgen discounts cholesterol drug, but payers want more (AMGN, CVS, ESRX, REGN, SAN, PFE)",Reuters,http://www.businessinsider.com/r-amgen-discounts-cholesterol-drug-but-payers-want-more-2017-3
67.0,3/18/2017 7:00:46 AM,"UPDATE 1-Amgen discounts cholesterol drug, but payers want more (AMGN, CVS, ESRX, REGN, SAN, PFE, MDCO)",Reuters,http://www.businessinsider.com/r-update-1-amgen-discounts-cholesterol-drug-but-payers-want-more-2017-3
68.0,3/21/2017 6:04:45 PM,"Sanofi, Regeneron sue Amgen to protect eczema drug from patent claims",Reuters,http://www.businessinsider.com/r-sanofi-regeneron-sue-amgen-to-protect-eczema-drug-from-patent-claims-2017-3
69.0,3/21/2017 6:28:44 PM,"UPDATE 1-Sanofi, Regeneron sue Amgen to protect eczema drug from patent claims (SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-update-1-sanofi-regeneron-sue-amgen-to-protect-eczema-drug-from-patent-claims-2017-3
70.0,3/23/2017 1:00:00 AM,"U.K. Biobank, Regeneron and GSK Announce Largest Gene Sequencing Initiative on World's Most Detailed Health Database to Improve Drug Discovery and Disease Diagnosis",PR Newswire,/news/stocks/u-k-biobank-regeneron-and-gsk-announce-largest-gene-sequencing-initiative-on-world-s-most-detailed-health-database-to-improve-drug-discovery-and-disease-diagnosis-1001860001
71.0,3/23/2017 1:42:50 AM,"GSK and Regeneron to mine gene data from 500,000 Britons",Reuters,http://www.businessinsider.com/r-gsk-and-regeneron-to-mine-gene-data-from-500000-britons-2017-3
72.0,3/23/2017 9:06:50 AM,"UPDATE 1-UK Stocks-Factors to watch on March 23 (NXT, IGG, KIE, GSK, REGN, RDSA, TSO, CVX, XOM, BARC, TSCO, HEIA, BLT, UKX, BVS, CBG, DNLM, FEV, GFRD, MGGT, RDW, SGRO, HSBA, BHP, SIA, FUM, PVCS, ARBB)",Reuters,http://www.businessinsider.com/r-update-1-uk-stocks-factors-to-watch-on-march-23-2017-3
73.0,3/23/2017 12:46:45 PM,"Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency (SAN, GSK, REGN, AMGN, MYL, HIK, VEC)",Reuters,http://www.businessinsider.com/r-crunch-week-looms-for-sanofi-roche-and-gsk-at-us-drugs-agency-2017-3
74.0,3/28/2017 5:40:00 PM,"Regeneron and Sanofi Announce FDA Approval of DUPIXENT® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis",PR Newswire,/news/stocks/regeneron-and-sanofi-announce-fda-approval-of-dupixent-dupilumab-the-first-targeted-biologic-therapy-for-adults-with-moderate-to-severe-atopic-dermatitis-1001874808
75.0,3/28/2017 5:40:00 PM,"Sanofi and Regeneron Announce FDA Approval of Dupixent® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis",PR Newswire,/news/stocks/sanofi-and-regeneron-announce-fda-approval-of-dupixent-dupilumab-the-first-targeted-biologic-therapy-for-adults-with-moderate-to-severe-atopic-dermatitis-1001874809
76.0,3/28/2017 5:48:49 PM,"FDA approves Regeneron, Sanofi eczema drug (REGN, SAN)",Reuters,http://www.businessinsider.com/r-fda-approves-regeneron-sanofi-eczema-drug-2017-3
77.0,3/28/2017 5:56:49 PM,"BRIEF-U.S. list price for Sanofi, Regeneron's Dupixent $37,000 (SAN, REGN)",Reuters,http://www.businessinsider.com/r-brief-us-list-price-for-sanofi-regenerons-dupixent-37000-2017-3
78.0,3/28/2017 6:04:49 PM,"BRIEF-U.S. FDA says approves new eczema drug Dupixent (REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-us-fda-says-approves-new-eczema-drug-dupixent-2017-3
79.0,3/28/2017 6:42:36 PM,"The FDA just approved a new drug to treat eczema that costs $37,000 a year (REGN, SAN)",Reuters,http://www.businessinsider.com/r-update-1-fda-approves-regeneron-sanofi-37000-per-year-eczema-drug-2017-3
80.0,3/28/2017 6:44:49 PM,"BRIEF-Regeneron and Sanofi announce FDA approval of Dupixent (SAN, REGN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-and-sanofi-announce-fda-approval-of-dupixent-2017-3
81.0,3/28/2017 7:50:00 PM,Regeneron and Sanofi to Host Investor Conference Call to Discuss DUPIXENT® (dupilumab) Approval,PR Newswire,/news/stocks/regeneron-and-sanofi-to-host-investor-conference-call-to-discuss-dupixent-dupilumab-approval-1001875193
82.0,3/29/2017 3:03:59 AM,Regeneron Says FDA Okays New Eczema Drug Dupixent ,RTTNews,/news/stocks/regeneron-says-fda-okays-new-eczema-drug-dupixent-1001875832
83.0,3/29/2017 8:47:42 AM,"First Drug For 2 Forms Of MS Gets FDA Nod, RTTR Abuzz, VRTX Gains On Trial Data ",RTTNews,/news/stocks/first-drug-for-2-forms-of-ms-gets-fda-nod-rttr-abuzz-vrtx-gains-on-trial-data-1001876362
84.0,4/5/2017 12:55:00 PM,"Biotech Stocks on Investors' Radar -- Puma Biotechnology, Regeneron Pharma, Calithera, and Lexicon Pharma",PR Newswire,/news/stocks/biotech-stocks-on-investors-radar-puma-biotechnology-regeneron-pharma-calithera-and-lexicon-pharma-1001898041
85.0,4/6/2017 1:30:50 PM,BRIEF-Regeneron announces Evinacumab has received FDA breakthrough therapy designation (REGN),Reuters,http://www.businessinsider.com/r-brief-regeneron-announces-evinacumab-has-received-fda-breakthrough-therapy-designation-2017-4
86.0,4/14/2017 3:30:00 PM,"Regeneron to Report First Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2017",PR Newswire,/news/stocks/regeneron-to-report-first-quarter-2017-financial-and-operating-results-and-host-conference-call-and-webcast-on-may-4-2017-1001593672
87.0,4/21/2017 8:35:05 PM,"BRIEF-EU Medicines Agency recommendations for April 2017 (BIIB, BMRN, MYL, PFE, REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-eu-medicines-agency-recommendations-for-april-2017-2017-4
88.0,4/21/2017 9:51:09 PM,"EMA panel recommends nod for Sanofi, Regeneron's arthritis drug (SAN, REGN, JNJ, LLY, INCY)",Reuters,http://www.businessinsider.com/r-ema-panel-recommends-nod-for-sanofi-regenerons-arthritis-drug-2017-4
89.0,4/24/2017 7:31:37 AM,"Sanofi, Regeneron Say Kevzara Gets CHMP Positive Opinion For RA In Adults ",RTTNews,/news/stocks/sanofi-regeneron-say-kevzara-gets-chmp-positive-opinion-for-ra-in-adults-1001940422
90.0,4/25/2017 1:47:06 PM,BRIEF-Regeneron Pharmaceuticals say CEO Leonard Schleifer's 2016 total compensation was $28.3 mln - SEC filing (REGN),Reuters,http://www.businessinsider.com/r-brief-regeneron-pharmaceuticals-say-ceo-leonard-schleifers-2016-total-compensation-was-283-mln---sec-filing-2017-4
91.0,4/25/2017 2:00:00 PM,Regeneron and Sanofi Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection,PR Newswire,/news/stocks/regeneron-and-sanofi-announce-fda-approval-of-a-new-once-monthly-dosing-option-for-praluent-alirocumab-injection-1001946211
92.0,4/25/2017 2:15:08 PM,"BRIEF-Sanofi and Regeneron announce FDA approval of a once-monthly dosing option for Praluent (SAN, REGN)",Reuters,http://www.businessinsider.com/r-brief-sanofi-and-regeneron-announce-fda-approval-of-a-once-monthly-dosing-option-for-praluent-2017-4
93.0,4/25/2017 2:41:12 PM,"BRIEF-Regeneron says FDA approved for praluent injection (REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-says-fda-approved-for-praluent-injection-2017-4
94.0,4/26/2017 8:13:29 AM,"AKBA Jumps On Otsuka Deal, MNOV Abuzz, CAPR Counting On HOPE... ",RTTNews,/news/stocks/akba-jumps-on-otsuka-deal-mnov-abuzz-capr-counting-on-hope-1001949569
95.0,4/28/2017 7:00:00 AM,Regeneron and Sanofi Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by U.S. FDA,PR Newswire,/news/stocks/regeneron-and-sanofi-announce-kevzara-sarilumab-biologics-license-application-resubmission-accepted-for-review-by-u-s-fda-1001959684
96.0,4/28/2017 7:19:37 AM,"Sanofi: FDA Sets New Action Date For Kevzara BLA As May 22, 2017 - Quick Facts ",RTTNews,/news/stocks/sanofi-fda-sets-new-action-date-for-kevzara-bla-as-may-22-2017-quick-facts-1001959752
97.0,4/28/2017 8:39:08 AM,"BRIEF-Regeneron and Sanofi announce Kevzara license application resubmission for review by FDA (SAN, REGN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-and-sanofi-announce-kevzara-license-application-resubmission-for-review-by-fda-2017-4
98.0,4/28/2017 10:45:07 AM,"UPDATE 1-Genzyme, CHC lift Sanofi's first-quarter figures, upbeat on Dupixent (REGN, SAN)",Reuters,http://www.businessinsider.com/r-update-1-genzyme-chc-lift-sanofis-first-quarter-figures-upbeat-on-dupixent-2017-4
99.0,4/30/2017 8:16:25 AM,"Monday Is D-Day For AEZS, Watch Out For MRUS, FDA Nod For RDUS & Takeda ",RTTNews,/news/stocks/monday-is-d-day-for-aezs-watch-out-for-mrus-fda-nod-for-rdus-takeda-1001964351
100.0,5/2/2017 2:30:00 PM,"Survey Results Show Eighty Percent of Rheumatoid Arthritis Patients Report Life-Altering Pain Daily or Multiple Times a Week, Despite Treatment",PR Newswire,/news/stocks/survey-results-show-eighty-percent-of-rheumatoid-arthritis-patients-report-life-altering-pain-daily-or-multiple-times-a-week-despite-treatment-624100
101.0,5/2/2017 2:30:00 PM,"Survey Results Show Eighty Percent of Rheumatoid Arthritis Patients Report Life-Altering Pain Daily or Multiple Times a Week, Despite Treatment",PR Newswire,/news/stocks/survey-results-show-eighty-percent-of-rheumatoid-arthritis-patients-report-life-altering-pain-daily-or-multiple-times-a-week-despite-treatment-1001969402
102.0,5/4/2017 12:30:00 PM,Regeneron Reports First Quarter 2017 Financial and Operating Results,PR Newswire,/news/stocks/regeneron-reports-first-quarter-2017-financial-and-operating-results-637465
103.0,5/4/2017 12:42:47 PM,Regeneron Pharmaceuticals Profit Rises 23% In Q1,RTTNews,/news/stocks/regeneron-pharmaceuticals-profit-rises-23-in-q1-1001978904
104.0,5/4/2017 12:46:03 PM,"Biotech Regeneron's profit jumps 37 pct on higher Eylea sales (REGN, SAN, BAYN)",Reuters,http://www.businessinsider.com/r-biotech-regenerons-profit-jumps-37-pct-on-higher-eylea-sales-2017-5
105.0,5/4/2017 2:32:03 PM,BRIEF-Regeneron Pharmaceuticals says it received subpoena (REGN),Reuters,http://www.businessinsider.com/r-brief-regeneron-pharmaceuticals-says-it-received-subpoena-2017-5
106.0,5/4/2017 4:06:02 PM,"BRIEF-Regeneron says over 3,500 new prescriptions been written for Dupixent (REGN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-says-over-3500-new-prescriptions-been-written-for-dupixent-2017-5
107.0,5/4/2017 5:56:04 PM,"US STOCKS-Tech, energy stocks weigh on Wall Street (XOM, CVX, OXY, CHK, AAPL, CAT, TSLA, CHTR, REGN)",Reuters,http://www.businessinsider.com/r-us-stocks-tech-energy-stocks-weigh-on-wall-street-2017-5
108.0,5/4/2017 6:51:50 PM,Regeneron Extending Recent Strong Move To The Upside ,RTTNews,/news/stocks/regeneron-extending-recent-strong-move-to-the-upside-1001980936
109.0,5/4/2017 9:12:03 PM,"US STOCKS-Wall Street drops with oil prices, health bill vote awaited (XOM, CVX, AAPL, TSLA, CHTR, REGN)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-street-drops-with-oil-prices-health-bill-vote-awaited-2017-5
110.0,5/4/2017 9:30:05 PM,"US STOCKS-Wall Street stays flat after House clears health bill (XOM, CVX, TSLA, REGN)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-street-stays-flat-after-house-clears-health-bill-2017-5
111.0,5/5/2017 3:30:00 PM,Regeneron Announces Upcoming Investor Conference Presentations,PR Newswire,/news/stocks/regeneron-announces-upcoming-investor-conference-presentations-1001984342
112.0,5/8/2017 12:48:05 AM,Regeneron shares poised for rebound - Barron's (REGN),Reuters,http://www.businessinsider.com/r-regeneron-shares-poised-for-rebound---barrons-2017-5
113.0,5/8/2017 1:30:00 PM,Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy,PR Newswire,/news/stocks/regeneron-and-inovio-enter-immuno-oncology-clinical-study-agreement-for-glioblastoma-combination-therapy-1001989016
114.0,5/8/2017 1:50:07 PM,"BRIEF-Regeneron and Inovio enter immuno-oncology clinical study agreement (REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-and-inovio-enter-immuno-oncology-clinical-study-agreement-2017-5
115.0,5/8/2017 2:30:00 PM,Regeneron and SillaJen Announce Immuno-Oncology Clinical Study Agreement for Combination Treatment in Kidney Cancer,PR Newswire,/news/stocks/regeneron-and-sillajen-announce-immuno-oncology-clinical-study-agreement-for-combination-treatment-in-kidney-cancer-1001651794
116.0,5/8/2017 3:10:07 PM,"BRIEF-Regeneron and Sillajen report immuno-oncology clinical study agreement (REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-and-sillajen-report-immuno-oncology-clinical-study-agreement-2017-5
117.0,5/22/2017 9:18:07 PM,"Severe asthma drug shows AstraZeneca promise beyond cancer (AZN, GSK, TEVA, PFE, SAN, REGN)",Reuters,http://www.businessinsider.com/r-severe-asthma-drug-shows-astrazeneca-promise-beyond-cancer-2017-5
118.0,5/23/2017 12:48:05 AM,"BRIEF-Regeneron, Sanofi RA drug wins FDA nod; co's price it at $39,000/patient/yr (SAN, REGN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-sanofi-ra-drug-wins-fda-nod-cos-price-it-at-39000-patient-yr-2017-5
119.0,5/23/2017 1:54:02 AM,"Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval (REGN, SAN)",Reuters,http://www.businessinsider.com/r-regeneron-sanofi-rheumatoid-arthritis-drug-wins-us-approval-2017-5
120.0,5/23/2017 1:54:02 AM,"UPDATE 1-Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval (REGN, SAN)",Reuters,http://www.businessinsider.com/r-update-1-regeneron-sanofi-rheumatoid-arthritis-drug-wins-us-approval-2017-5
121.0,5/25/2017 11:24:03 PM,"BRIEF-Diplomat Pharmacy begins dispensing prescriptions for RA drug Kevzara (REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-diplomat-pharmacy-begins-dispensing-prescriptions-for-ra-drug-kevzara-2017-5
122.0,6/4/2017 4:00:00 PM,Regeneron and Sanofi Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting,PR Newswire,/news/stocks/regeneron-and-sanofi-present-positive-study-results-for-investigational-pd-1-antibody-regn2810-at-american-society-of-clinical-oncology-asco-annual-meeting-1002065834
123.0,6/4/2017 6:07:55 PM,"Regeneron, Sanofi Present Positive Study Results For PD-1 Antibody REGN2810 ",RTTNews,/news/stocks/regeneron-sanofi-present-positive-study-results-for-pd-1-antibody-regn2810-1002065892
124.0,6/6/2017 11:48:05 PM,"Regeneron, Sanofi urge court to reverse ban on cholesterol drug (SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-regeneron-sanofi-urge-court-to-reverse-ban-on-cholesterol-drug-2017-6
125.0,6/11/2017 5:00:00 PM,Regeneron and Sanofi Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia,PR Newswire,/news/stocks/regeneron-and-sanofi-announce-positive-results-from-first-dedicated-studies-evaluating-praluent-alirocumab-in-individuals-with-diabetes-and-hypercholesterolemia-1002083768
126.0,6/11/2017 5:01:00 PM,Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia,PR Newswire,/news/stocks/sanofi-and-regeneron-announce-positive-results-from-first-dedicated-studies-evaluating-praluent-alirocumab-in-individuals-with-diabetes-and-hypercholesterolemia-1002083769
127.0,6/11/2017 6:00:10 PM,"Sanofi-Regeneron's Praluent cuts cholesterol in Odyssey trials (SAN, REGN)",Reuters,http://www.businessinsider.com/r-sanofi-regenerons-praluent-cuts-cholesterol-in-odyssey-trials-2017-6
128.0,6/12/2017 3:17:31 AM,Sanofi Announces Results From Two Phase 3b/4 ODYSSEY-DM Trials In Diabetes ,RTTNews,/news/stocks/sanofi-announces-results-from-two-phase-3b-4-odyssey-dm-trials-in-diabetes-1002083936
129.0,6/12/2017 3:22:27 AM,"LXRX Brings Sweet Tidings, PFE's PROSPER Ahead Of Schedule, XBIT Fails To Excite ",RTTNews,/news/stocks/lxrx-brings-sweet-tidings-pfe-s-prosper-ahead-of-schedule-xbit-fails-to-excite-1002083938
130.0,6/14/2017 1:38:05 PM,"UPDATE 1-Sanofi to invest further in biologics (SAN, REGN)",Reuters,http://www.businessinsider.com/r-update-1-sanofi-to-invest-further-in-biologics-2017-6
131.0,6/20/2017 1:20:11 PM,"UPDATE 1-Novartis eye drug works with fewer injections than rivals (REGN, BAYN, AGN)",Reuters,http://www.businessinsider.com/r-update-1-novartis-eye-drug-works-with-fewer-injections-than-rivals-2017-6
132.0,6/20/2017 6:32:14 PM,"UPDATE 2-Novartis eye drug works with fewer injections than rival (REGN, BAYN, AGN)",Reuters,http://www.businessinsider.com/r-update-2-novartis-eye-drug-works-with-fewer-injections-than-rival-2017-6
133.0,6/21/2017 2:30:00 PM,"Regeneron Recognized on ""The Civic 50"" List of the Most Community-Minded Companies in the United States",PR Newswire,/news/stocks/regeneron-recognized-on-the-civic-50-list-of-the-most-community-minded-companies-in-the-united-states-1002111882
134.0,6/21/2017 5:42:03 PM,"US STOCKS-Nasdaq boosted by biotechs; banks weigh on Dow, S&P (CELG, REGN, AMGN, GS, BAC, CAT, GE, ADBE)",Reuters,http://www.businessinsider.com/r-us-stocks-nasdaq-boosted-by-biotechs-banks-weigh-on-dow-sp-2017-6
135.0,6/21/2017 7:26:05 PM,"US STOCKS-Nasdaq boosted by biotechs; energy, banks weigh on Dow, S&P (XOM, CVX, CELG, REGN, AMGN, GS, BAC, CAT, FDX)",Reuters,http://www.businessinsider.com/r-us-stocks-nasdaq-boosted-by-biotechs-energy-banks-weigh-on-dow-sp-2017-6
136.0,6/21/2017 9:32:03 PM,"US STOCKS-S&P, Dow hurt by Energy, banks; biotech boosts Nasdaq (CTL, T, CELG, REGN, CAT, FDX)",Reuters,http://www.businessinsider.com/r-us-stocks-sp-dow-hurt-by-energy-banks-biotech-boosts-nasdaq-2017-6
137.0,6/21/2017 10:48:03 PM,"US STOCKS-S&P, Dow hurt by energy, banks; biotech boosts Nasdaq (CAT, FDX, T, CELG, REGN, BIIB)",Reuters,http://www.businessinsider.com/r-us-stocks-sp-dow-hurt-by-energy-banks-biotech-boosts-nasdaq-2017-6
138.0,6/22/2017 3:12:05 PM,BRIEF-Regeneron details royalty agreement with Novartis for canakinumab (REGN),Reuters,http://www.businessinsider.com/r-brief-regeneron-details-royalty-agreement-with-novartis-for-canakinumab-2017-6
139.0,6/23/2017 4:08:05 PM,"US STOCKS-Wall St weighed down by health, consumer shares (UNH, REGN, AMGN, BAC, JPM, WFC, GS, CAT, BBBY)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-weighed-down-by-health-consumer-shares-2017-6
140.0,6/27/2017 7:00:00 AM,Regeneron and Sanofi Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union,PR Newswire,/news/stocks/regeneron-and-sanofi-announce-approval-of-kevzara-sarilumab-to-treat-adult-patients-with-moderately-to-severely-active-rheumatoid-arthritis-in-the-european-union-1002125713
141.0,6/27/2017 7:15:09 AM,Regeneron: EC Okays Kevzara To Treat Moderately To Severely Active RA ,RTTNews,/news/stocks/regeneron-ec-okays-kevzara-to-treat-moderately-to-severely-active-ra-1002125750
142.0,6/27/2017 7:28:03 AM,"BRIEF-Sanofi and Regeneron announce EU approval for Kevzara (SAN, REGN)",Reuters,http://www.businessinsider.com/r-brief-sanofi-and-regeneron-announce-eu-approval-for-kevzara-2017-6
143.0,7/21/2017 1:32:03 PM,"EU follows U.S. in backing Sanofi, Regeneron eczema drug (REGN, SAN, GSK)",Reuters,http://www.businessinsider.com/r-eu-follows-us-in-backing-sanofi-regeneron-eczema-drug-2017-7
144.0,7/21/2017 1:41:15 PM,"Regeneron, Sanofi Get Positive CHMP Opinion For Dupixent - Quick Facts ",RTTNews,/news/stocks/regeneron-sanofi-get-positive-chmp-opinion-for-dupixent-quick-facts-1002194968
145.0,7/21/2017 1:42:05 PM,"BRIEF-EU Medicines Agency recommends approval of Novartis' leukaemia drug (REGN, SAN, 4568, NKTR)",Reuters,http://www.businessinsider.com/r-brief-eu-medicines-agency-recommends-approval-of-novartis-leukaemia-drug-2017-7
146.0,7/24/2017 5:21:39 AM,One Step Closer To EU Approval... ,RTTNews,/news/stocks/one-step-closer-to-eu-approval-1002197023
147.0,7/26/2017 2:00:00 PM,Generali Global Assistance Publishes White Paper On The Benefits Of Adding Identity Protection Services To Customer Loyalty Programs,PR Newswire,/news/stocks/generali-global-assistance-publishes-white-paper-on-the-benefits-of-adding-identity-protection-services-to-customer-loyalty-programs-1001549142
148.0,7/28/2017 12:24:03 AM,"Amgen gets fast U.S. FDA review for adding heart benefits to cholesterol drug label (AMGN, PFE, REGN, SAN)",Reuters,http://www.businessinsider.com/r-amgen-gets-fast-us-fda-review-for-adding-heart-benefits-to-cholesterol-drug-label-2017-7
149.0,7/28/2017 1:20:03 PM,BRIEF-U.S. Court of Appeals for Federal Circuit affirms Merus' inequitable conduct claim against Regeneron (REGN),Reuters,http://www.businessinsider.com/r-brief-us-court-of-appeals-for-federal-circuit-affirms-merus-inequitable-conduct-claim-against-regeneron-2017-7
150.0,7/31/2017 10:20:05 AM,"UPDATE 1-Sanofi raises outlook after strong Q2 sales growth (SAN, REGN)",Reuters,http://www.businessinsider.com/r-update-1-sanofi-raises-outlook-after-strong-q2-sales-growth-2017-7
151.0,8/1/2017 5:37:03 PM,"US STOCKS-Dow at record on strong earnings; Apple earnings awaited (AAPL, AMZN, PFE, REGN, S)",Reuters,http://www.businessinsider.com/r-us-stocks-dow-at-record-on-strong-earnings-apple-earnings-awaited-2017-8
152.0,8/1/2017 7:07:14 PM,"US STOCKS-Dow hits record on strong earnings; Apple results eyed (REGN, AAPL, VZ, JPM, F, GM, S, XRX)",Reuters,http://www.businessinsider.com/r-us-stocks-dow-hits-record-on-strong-earnings-apple-results-eyed-2017-8
153.0,8/3/2017 12:30:00 PM,Regeneron Reports Second Quarter 2017 Financial and Operating Results,PR Newswire,/news/stocks/regeneron-reports-second-quarter-2017-financial-and-operating-results-1002229803
154.0,8/3/2017 1:17:04 PM,"UPDATE 1-Regeneron profit blows past estimates (REGN, SAN, BAYN)",Reuters,http://www.businessinsider.com/r-update-1-regeneron-profit-blows-past-estimates-2017-8
155.0,8/3/2017 1:47:52 PM,Regeneron Q2 Results Top Estimates; Lifts FY View For EYLEA U.S. Sales Growth ,RTTNews,/news/stocks/regeneron-q2-results-top-estimates-lifts-fy-view-for-eylea-u-s-sales-growth-1002230200
156.0,8/3/2017 2:22:00 PM,Accessing the Regeneron Second Quarter 2017 Financial and Operating Results Webcast,PR Newswire,/news/stocks/accessing-the-regeneron-second-quarter-2017-financial-and-operating-results-webcast-1002230406
157.0,8/3/2017 2:52:03 PM,"US STOCKS-Wall St set to open flat after Dow breaches 22,000 (AAPL, TSLA, AET, REGN, YUM)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-set-to-open-flat-after-dow-breaches-22000-2017-8
158.0,8/3/2017 3:13:11 PM,Regeneron Pharmaceuticals Profit Rises 48% In Q2,RTTNews,/news/stocks/regeneron-pharmaceuticals-profit-rises-48-in-q2-1002230713
159.0,8/3/2017 3:31:00 PM,"Options Trades for Allergan, 3D Systems, Regeneron Pharmaceuticals, Tesla Motors and Yelp include trade ideas that offer returns of 26% or more!",PR Newswire,/news/stocks/options-trades-for-allergan-3d-systems-regeneron-pharmaceuticals-tesla-motors-and-yelp-include-trade-ideas-that-offer-returns-of-26-or-more-1002230795
160.0,8/3/2017 3:42:05 PM,BRIEF-Regeneron says expects that Dupixent will have broad market access in the United States by the end of the year (REGN),Reuters,http://www.businessinsider.com/r-brief-regeneron-says-expects-that-dupixent-will-have-broad-market-access-in-the-united-states-by-the-end-of-the-year-2017-8
161.0,8/3/2017 4:02:03 PM,"US STOCKS-Wall St opens flat as tech stocks slip (AAPL, AMZN, TSLA, AET, REGN, YUM)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-opens-flat-as-tech-stocks-slip-2017-8
162.0,8/14/2017 3:06:00 PM,Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus,PR Newswire,/news/stocks/regeneron-to-discontinue-development-of-suptavumab-for-respiratory-syncytial-virus-1002255470
163.0,8/14/2017 3:07:03 PM,"BRIEF-Temasek Holdings takes stake in JPMorgan, Biogen, Celgene (JPM, BIIB, CELG, AMGN, RDSA, REGN)",Reuters,http://www.businessinsider.com/r-brief-temasek-holdings-takes-stake-in-jpmorgan-biogen-celgene-2017-8
164.0,8/14/2017 3:19:55 PM,Regeneron To Discontinue Development Of Suptavumab For RSV; Stock Down ,RTTNews,/news/stocks/regeneron-to-discontinue-development-of-suptavumab-for-rsv-stock-down-1002255505
165.0,8/14/2017 3:27:07 PM,BRIEF-Regeneron's drug for respiratory virus fails late-stage study (REGN),Reuters,http://www.businessinsider.com/r-brief-regenerons-drug-for-respiratory-virus-fails-late-stage-study-2017-8
166.0,8/14/2017 3:42:08 PM,Regeneron to abandon drug for common respiratory virus (REGN),Reuters,http://www.businessinsider.com/r-regeneron-to-abandon-drug-for-common-respiratory-virus-2017-8
167.0,8/15/2017 7:37:49 AM,"FDA Lifts Hold On CVM's Study, FATE On Track, REGN, OPHT, ZYNE All Flunk Trials ",RTTNews,/news/stocks/fda-lifts-hold-on-cvm-s-study-fate-on-track-regn-opht-zyne-all-flunk-trials-1002257293
168.0,8/23/2017 3:30:00 PM,ALM Intelligence Names KPMG a Global 'Leader' in Employee Experience Consulting,PR Newswire,/news/stocks/alm-intelligence-names-kpmg-a-global-leader-in-employee-experience-consulting-1001946212
169.0,8/23/2017 4:00:00 PM,Luxe Interiors + Design Names New Group Publisher And Chief Revenue Officer,PR Newswire,/news/stocks/luxe-interiors-+-design-names-new-group-publisher-and-chief-revenue-officer-597897
170.0,8/25/2017 2:00:00 PM,Regeneron and Sanofi to Present New Analyses from Praluent® (alirocumab) Injection Trials at the ESC Congress 2017,PR Newswire,/news/stocks/regeneron-and-sanofi-to-present-new-analyses-from-praluent-alirocumab-injection-trials-at-the-esc-congress-2017-1002285257
171.0,8/27/2017 11:27:08 AM,"Novartis hopeful for novel heart drug, despite 'modest' benefit (SAN, REGN)",Reuters,http://www.businessinsider.com/r-novartis-hopeful-for-novel-heart-drug-despite-modest-benefit-2017-8
172.0,8/27/2017 7:22:03 PM,"UPDATE 1-Novartis hopeful for novel heart drug, despite 'modest' benefit (SAN, REGN)",Reuters,http://www.businessinsider.com/r-update-1-novartis-hopeful-for-novel-heart-drug-despite-modest-benefit-2017-8
173.0,8/28/2017 11:25:00 PM,Ellen L. Behrens is recognized by Continental Who's Who,PR Newswire,/news/stocks/ellen-l-behrens-is-recognized-by-continental-who-s-who-1001625163
174.0,8/31/2017 10:01:00 PM,Regeneron Announces Upcoming Investor Conference Presentations,PR Newswire,/news/stocks/regeneron-announces-upcoming-investor-conference-presentations-1002299970
175.0,9/7/2017 12:02:03 PM,"Quest to offer cholesterol testing without fasting requirement (DGX, AMGN, REGN, SAN)",Reuters,http://www.businessinsider.com/r-quest-to-offer-cholesterol-testing-without-fasting-requirement-2017-9
176.0,9/8/2017 7:27:06 AM,"BRIEF-Sanofi, Regeneron say Cemiplimab receives U.S. FDA breakthrough designation for advanced cutaneous squamous cell carcinoma (REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-sanofi-regeneron-say-cemiplimab-receives-us-fda-breakthrough-designation-for-advanced-cutaneous-squamous-cell-carcinoma-2017-9
177.0,9/8/2017 9:02:03 AM,"Sanofi says Cemiplimab skin cancer treatment gets FDA ""Breakthrough Designation"" (SAN, REGN)",Reuters,http://www.businessinsider.com/r-sanofi-says-cemiplimab-skin-cancer-treatment-gets-fda-breakthrough-designation-2017-9
178.0,9/11/2017 7:00:00 AM,Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma,PR Newswire,/news/stocks/regeneron-and-sanofi-announce-positive-dupilumab-topline-results-from-phase-3-trial-in-uncontrolled-persistent-asthma-1001658411
179.0,9/11/2017 7:02:03 AM,"Swiss stocks - Factors to watch on Sept. 11 (ESUN, REGN)",Reuters,http://www.businessinsider.com/r-swiss-stocks---factors-to-watch-on-sept-11-2017-9
180.0,9/11/2017 7:16:09 AM,"Sanofi, Regeneron: Dupilumab Meets Main Objectives In Late-Stage Asthma Trial ",RTTNews,/news/stocks/sanofi-regeneron-dupilumab-meets-main-objectives-in-late-stage-asthma-trial-1002356442
181.0,9/11/2017 8:02:03 AM,"Sanofi and Regeneron announce positive dupilumab topline results (SAN, REGN)",Reuters,http://www.businessinsider.com/r-sanofi-and-regeneron-announce-positive-dupilumab-topline-results-2017-9
182.0,9/11/2017 8:02:03 AM,"BRIEF-Regeneron, Sanofi announce positive Dupilumab topline results from phase 3 trial in uncontrolled persistent Asthma (REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-sanofi-announce-positive-dupilumab-topline-results-from-phase-3-trial-in-uncontrolled-persistent-asthma-2017-9
183.0,9/11/2017 9:02:03 AM,"UPDATE 1-Sanofi and Regeneron score asthma hit with dupilumab (SAN, REGN, GSK, AZN)",Reuters,http://www.businessinsider.com/r-update-1-sanofi-and-regeneron-score-asthma-hit-with-dupilumab-2017-9
184.0,9/12/2017 3:00:00 PM,Companies to Watch as Biotech Makes a Comeback in 2017,PR Newswire,/news/stocks/companies-to-watch-as-biotech-makes-a-comeback-in-2017-1002362146
185.0,9/13/2017 2:00:00 PM,Smart Medical Device Could Save Millions of Lives,PR Newswire,/news/stocks/smart-medical-device-could-save-millions-of-lives-1002365845
186.0,9/14/2017 12:50:00 PM,"Stocks Under Scanner in the Biotech Space -- Puma Biotech, Regeneron Pharma, Sarepta Therapeutics, and Seattle Genetics",PR Newswire,/news/stocks/stocks-under-scanner-in-the-biotech-space-puma-biotech-regeneron-pharma-sarepta-therapeutics-and-seattle-genetics-1002369693
187.0,9/14/2017 3:02:03 PM,"Lilly/Incyte pill beats placebo in mid-stage eczema trial (LLY, INCY, REGN, SAN)",Reuters,http://www.businessinsider.com/r-lilly-incyte-pill-beats-placebo-in-mid-stage-eczema-trial-2017-9
188.0,9/14/2017 8:52:15 PM,"UPDATE 1-Lilly/Incyte pill beats placebo in mid-stage eczema trial (LLY, INCY, REGN, SAN)",Reuters,http://www.businessinsider.com/r-update-1-lilly-incyte-pill-beats-placebo-in-mid-stage-eczema-trial-2017-9
189.0,9/16/2017 8:15:00 AM,Regeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis,PR Newswire,/news/stocks/regeneron-and-sanofi-announce-positive-study-results-for-dupixent-dupilumab-in-patients-with-moderate-to-severe-atopic-dermatitis-686238
190.0,9/21/2017 4:00:00 PM,"ELOQUII Debuts Exclusive Capsule Collection With Digital Influencer & Style Expert, Katie Sturino",PR Newswire,/news/stocks/eloquii-debuts-exclusive-capsule-collection-with-digital-influencer-&-style-expert-katie-sturino-699465
191.0,9/22/2017 11:02:07 PM,"UPDATE 1-U.S. FDA declines to approve J&J arthritis drug (JNJ, SAN, REGN, LLY, PFE)",Reuters,http://www.businessinsider.com/r-update-1-us-fda-declines-to-approve-jj-arthritis-drug-2017-9
192.0,9/28/2017 7:00:00 AM,Regeneron and Sanofi Announce Approval of DUPIXENT® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union,PR Newswire,/news/stocks/regeneron-and-sanofi-announce-approval-of-dupixent-dupilumab-to-treat-adult-patients-with-moderate-to-severe-atopic-dermatitis-in-the-european-union-1002703993
193.0,9/28/2017 7:07:03 AM,"EU approves Sanofi and Regeneron's dupilumab in eczema (REGN, SAN)",Reuters,http://www.businessinsider.com/r-eu-approves-sanofi-and-regenerons-dupilumab-in-eczema-2017-9
194.0,9/28/2017 7:24:13 AM,"Sanofi, Regeneron: Dupixent Gets EU Approval To Treat Atopic Dermatitis ",RTTNews,/news/stocks/sanofi-regeneron-dupixent-gets-eu-approval-to-treat-atopic-dermatitis-1002705292
195.0,9/29/2017 6:22:03 PM,"US invests $170 million in late-stage Ebola vaccines, drugs (MRK, JNJ, REGN)",Reuters,http://www.businessinsider.com/r-us-invests-170-million-in-late-stage-ebola-vaccines-drugs-2017-9
196.0,10/2/2017 1:00:00 PM,"Regeneron Announces New Collaborations with HHS to Develop Antibodies Against Ebola, Influenza and Multiple Other Emerging Pathogens",PR Newswire,/news/stocks/regeneron-announces-new-collaborations-with-hhs-to-develop-antibodies-against-ebola-influenza-and-multiple-other-emerging-pathogens-1002913600
197.0,10/2/2017 1:37:03 PM,"BRIEF-Regeneron Pharmaceuticals ‍announces new collaborations with HHS to develop antibodies against ebola, influenza, multiple other emerging pathogens​ (REGN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-pharmaceuticals-announces-new-collaborations-with-hhs-to-develop-antibodies-against-ebola-influenza-multiple-other-emerging-pathogens-2017-10
198.0,10/3/2017 3:00:00 PM,VOXX International Corporation Sets Date For Its Fiscal 2018 Second Quarter Results And Conference Call,PR Newswire,/news/stocks/voxx-international-corporation-sets-date-for-its-fiscal-2018-second-quarter-results-and-conference-call-1001728458
199.0,10/5/2017 4:17:03 PM,"U.S. court reverses ban on sales of Sanofi, Regeneron drug Praluent (SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-us-court-reverses-ban-on-sales-of-sanofi-regeneron-drug-praluent-2017-10
200.0,10/5/2017 4:32:03 PM,"UPDATE 1-U.S. court reverses ban on sales of Sanofi, Regeneron drug Praluent (SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-update-1-us-court-reverses-ban-on-sales-of-sanofi-regeneron-drug-praluent-2017-10
201.0,10/5/2017 6:30:00 PM,Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab),PR Newswire,/news/stocks/appellate-court-orders-a-new-trial-and-vacates-permanent-injunction-in-ongoing-patent-case-regarding-praluent-alirocumab-1003090534
202.0,10/5/2017 6:52:03 PM,"BRIEF-U.S. Appellate Court rules Sanofi, Regeneron can continue manufacturing PRALUENT in U.S. (SAN, REGN, AMGN)",Reuters,http://www.businessinsider.com/r-brief-us-appellate-court-rules-sanofi-regeneron-can-continue-manufacturing-praluent-in-us-2017-10
203.0,10/11/2017 2:00:00 PM,Internationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis,PR Newswire,/news/stocks/internationally-acclaimed-writer-and-executive-producer-of-hbo-s-the-night-of-reveals-his-personal-story-detailing-the-harsh-realities-of-atopic-dermatitis-1003817426
204.0,10/11/2017 3:30:00 PM,"Regeneron to Report Third Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on November 8, 2017",PR Newswire,/news/stocks/regeneron-to-report-third-quarter-2017-financial-and-operating-results-and-host-conference-call-and-webcast-on-november-8-2017-1002076275
205.0,10/16/2017 2:00:00 PM,Regeneron and Sanofi Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis,PR Newswire,/news/stocks/regeneron-and-sanofi-announce-positive-phase-2-study-results-for-dupilumab-in-patients-with-active-moderate-to-severe-eosinophilic-esophagitis-1001763336
206.0,10/16/2017 2:07:14 PM,"BRIEF-Regeneron and Sanofi announce positive phase 2 study results for dupilumab (SAN, REGN)",Reuters,http://www.businessinsider.com/r-brief-regeneron-and-sanofi-announce-positive-phase-2-study-results-for-dupilumab-2017-10
207.0,10/16/2017 2:15:48 PM,"Regeneron Pharma, Sanofi Announce Positive Phase 2 Study Results For Dupilumab ",RTTNews,/news/stocks/regeneron-pharma-sanofi-announce-positive-phase-2-study-results-for-dupilumab-1004483604
208.0,10/16/2017 2:22:16 PM,"BRIEF-Aimmune Therapeutics collaborates to study AR101 with Regeneron and Sanofi’s dupilumab for peanut allergy (REGN, SAN)",Reuters,http://www.businessinsider.com/r-brief-aimmune-therapeutics-collaborates-to-study-ar101-with-regeneron-and-sanofis-dupilumab-for-peanut-allergy-2017-10
209.0,10/16/2017 2:27:07 PM,"Regeneron-Sanofi throat infection drug succeeds key study (REGN, SAN)",Reuters,http://www.businessinsider.com/r-regeneron-sanofi-throat-infection-drug-succeeds-key-study-2017-10
210.0,10/16/2017 2:57:08 PM,"UPDATE 1-Regeneron-Sanofi food allergy drug succeeds mid-stage study (REGN, SAN, GSK)",Reuters,http://www.businessinsider.com/r-update-1-regeneron-sanofi-food-allergy-drug-succeeds-mid-stage-study-2017-10
211.0,10/16/2017 3:22:03 PM,"Aimmune teams with Regeneron, Sanofi on peanut allergy drug (REGN, SAN)",Reuters,http://www.businessinsider.com/r-aimmune-teams-with-regeneron-sanofi-on-peanut-allergy-drug-2017-10
212.0,10/19/2017 8:30:00 PM,Science Magazine Ranks Regeneron #1 Biopharma Employer for Fifth Time,PR Newswire,/news/stocks/science-magazine-ranks-regeneron-1-biopharma-employer-for-fifth-time-1001781784
213.0,10/23/2017 7:49:33 AM,"DBVT Disappoints, GSK Gets Greenlight, AIMT Catches Eyes, FDA Snubs ATRS ",RTTNews,/news/stocks/dbvt-disappoints-gsk-gets-greenlight-aimt-catches-eyes-fda-snubs-atrs-1005302979
214.0,10/24/2017 5:15:00 PM,IT and Management Consulting Firm Enlightened Selects 5WPR as AOR to Increase Brand Awareness as it Expands into Commercial,PR Newswire,/news/stocks/it-and-management-consulting-firm-enlightened-selects-5wpr-as-aor-to-increase-brand-awareness-as-it-expands-into-commercial-1002116216
215.0,10/27/2017 1:00:00 PM,Regeneron's First Global Day of Service Supports Over 100 Non-Profit and Community Organizations,PR Newswire,/news/stocks/regenerons-first-global-day-of-service-supports-over-100-non-profit-and-community-organizations-452309
216.0,10/27/2017 10:18:00 PM,"Philip Sweet, M.S.N., R.N., PMHCNS-BC, NP is recognized by Continental Who's Who",PR Newswire,/news/stocks/philip-sweet-m-s-n-r-n-pmhcns-bc-np-is-recognized-by-continental-who-s-who-1001804634
217.0,10/31/2017 12:00:00 PM,"Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in Phase 3 Study of People with Severe Steroid-Dependent Asthma",PR Newswire,/news/stocks/dupilumab-significantly-reduced-steroid-use-asthma-attacks-and-improved-lung-function-in-phase-3-study-of-people-with-severe-steroid-dependent-asthma-1006292862
218.0,10/31/2017 12:28:13 PM,Regeneron And Sanofi Say Phase 3 Study On Dupilumab Meets Primary Endpoint ,RTTNews,/news/stocks/regeneron-and-sanofi-say-phase-3-study-on-dupilumab-meets-primary-endpoint-1006294902
219.0,11/1/2017 2:00:00 PM,Regeneron to Share Clinical Progress of REGN1979 and Cemiplimab (REGN2810) in B-Cell Lymphomas at the 2017 ASH Annual Meeting,PR Newswire,/news/stocks/regeneron-to-share-clinical-progress-of-regn1979-and-cemiplimab-regn2810-in-b-cell-lymphomas-at-the-2017-ash-annual-meeting-1006450496
220.0,11/7/2017 2:00:00 PM,Regeneron and Sanofi to Present New Analyses from the Praluent® (alirocumab) Injection ODYSSEY Clinical Trial Program at the AHA Scientific Sessions 2017,PR Newswire,/news/stocks/regeneron-and-sanofi-to-present-new-analyses-from-the-praluent-alirocumab-injection-odyssey-clinical-trial-program-at-the-aha-scientific-sessions-2017-1007155974
221.0,11/7/2017 2:27:03 PM,BRIEF-Regeneron and Sanofi to present new analyses from Praluent injection Odyssey clinical trial (REGN),Reuters,http://www.businessinsider.com/r-brief-regeneron-and-sanofi-to-present-new-analyses-from-praluent-injection-odyssey-clinical-trial-2017-11
222.0,11/8/2017 12:30:00 PM,Regeneron Reports Third Quarter 2017 Financial and Operating Results,PR Newswire,/news/stocks/regeneron-reports-third-quarter-2017-financial-and-operating-results-1007280932
223.0,11/8/2017 12:33:54 PM,Regeneron Pharmaceuticals Earnings Rise 29% In Q3,RTTNews,/news/stocks/regeneron-pharmaceuticals-earnings-rise-29-in-q3-1007280959
224.0,11/8/2017 12:47:03 PM,Drugmaker Regeneron's quarterly profit surges 47 pct (REGN),Reuters,http://www.businessinsider.com/r-drugmaker-regenerons-quarterly-profit-surges-47-pct-2017-11
225.0,11/8/2017 1:37:03 PM,"US STOCKS-Futures slightly lower as investors track progress on tax bill (TTWO, REGN, HUM)",Reuters,http://www.businessinsider.com/r-us-stocks-futures-slightly-lower-as-investors-track-progress-on-tax-bill-2017-11
226.0,11/8/2017 2:47:03 PM,"US STOCKS-Wall St set to open flat with tax bill debate in focus (TTWO, REGN)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-set-to-open-flat-with-tax-bill-debate-in-focus-2017-11
227.0,11/8/2017 4:12:03 PM,"US STOCKS-Wall Street edges lower as bank stocks weigh (GS, BAC, TTWO, REGN)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-street-edges-lower-as-bank-stocks-weigh-2017-11
228.0,11/8/2017 5:42:05 PM,"US STOCKS-Wall Street loses steam as banks, energy stocks weigh (CVX, BAC, TTWO, REGN)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-street-loses-steam-as-banks-energy-stocks-weigh-2017-11
229.0,11/10/2017 11:32:03 PM,"Novartis posts eye drug data amid play for Eylea's turf (BAYN, REGN, AGN)",Reuters,http://www.businessinsider.com/r-novartis-posts-eye-drug-data-amid-play-for-eyleas-turf-2017-11
230.0,11/13/2017 5:07:03 PM,"Nanotech, gene editing used to edit cholesterol gene-US study (REGN, AMGN)",Reuters,http://www.businessinsider.com/r-nanotech-gene-editing-used-to-edit-cholesterol-gene-us-study-2017-11
231.0,11/15/2017 3:30:00 PM,Regeneron Announces Upcoming Investor Conference Presentation,PR Newswire,/news/stocks/regeneron-announces-upcoming-investor-conference-presentation-1008143081
232.0,11/24/2017 6:39:00 PM,"RD Training Systems Is Coming to Salt Lake City, Utah in December 2017",PR Newswire,/news/stocks/rd-training-systems-is-coming-to-salt-lake-city-utah-in-december-2017-532201
233.0,11/27/2017 8:00:00 AM,Regeneron Provides Update on EYLEA® (aflibercept) Injection and Nesvacumab (Ang2 Antibody) Combination Program,PR Newswire,/news/stocks/regeneron-provides-update-on-eylea-aflibercept-injection-and-nesvacumab-ang2-antibody-combination-program-1001895227
234.0,11/27/2017 8:13:13 AM,Regeneron Updates On EYLEA Injection And Nesvacumab Combination Program ,RTTNews,/news/stocks/regeneron-updates-on-eylea-injection-and-nesvacumab-combination-program-1009645601
235.0,11/27/2017 9:02:04 AM,BRIEF-Regeneron Provides Update On Eylea (Aflibercept) Injection And Nesvacumab (Ang2 Antibody) Combination Program (REGN),Reuters,http://www.businessinsider.com/r-brief-regeneron-provides-update-on-eylea-aflibercept-injection-and-nesvacumab-ang2-antibody-combination-program-2017-11
236.0,11/27/2017 1:22:04 PM,"Regeneron drops eye-drug combination as Novartis chases Eylea (REGN, BAYN)",Reuters,http://www.businessinsider.com/r-regeneron-drops-eye-drug-combination-as-novartis-chases-eylea-2017-11
237.0,11/28/2017 7:18:22 AM,"BIIB & ALKS Team Up For MS Drug, REGN's Eylea Combo Fails Again, AEZS Rises ",RTTNews,/news/stocks/biib-alks-team-up-for-ms-drug-regn-s-eylea-combo-fails-again-aezs-rises-1009751989
238.0,11/29/2017 1:00:00 PM,Regeneron and Decibel Therapeutics Announce Strategic Collaboration to Discover and Develop Therapeutics for Hearing Loss and Tinnitus,PR Newswire,/news/stocks/regeneron-and-decibel-therapeutics-announce-strategic-collaboration-to-discover-and-develop-therapeutics-for-hearing-loss-and-tinnitus-1009916181
239.0,11/29/2017 1:09:37 PM,"Regeneron Pharma, Decibel Announce Collaboration - Quick Facts ",RTTNews,/news/stocks/regeneron-pharma-decibel-announce-collaboration-quick-facts-1009916246
240.0,11/29/2017 1:12:06 PM,BRIEF-Regeneron And Decibel Therapeutics Announce Strategic Collaboration (REGN),Reuters,http://www.businessinsider.com/r-brief-regeneron-and-decibel-therapeutics-announce-strategic-collaboration-2017-11
241.0,11/30/2017 7:33:21 AM,"TXMD Giving A 2nd Try, PLX On Watch, NAOV's Shield Against Suicide Disease ",RTTNews,/news/stocks/txmd-giving-a-2nd-try-plx-on-watch-naov-s-shield-against-suicide-disease-1010019422
242.0,12/6/2017 9:52:03 PM,"FACBOX-Corporate alternative minimum tax threat hits pharma, tech (BA, VRTX, INCY, REGN, CDNS, CELG, ADSK)",Reuters,http://www.businessinsider.com/r-facbox-corporate-alternative-minimum-tax-threat-hits-pharma-tech-2017-12
243.0,12/10/2017 12:15:24 PM,Repatha & Praluent: A Tale Of Two Rivals... ,RTTNews,/news/stocks/repatha-praluent-a-tale-of-two-rivals-1010812436
244.0,12/11/2017 1:00:00 PM,Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of EYLEA® (aflibercept) Injection for Patients with Wet AMD,PR Newswire,/news/stocks/regeneron-announces-fda-acceptance-of-sbla-filing-for-12-week-dosing-of-eylea-aflibercept-injection-for-patients-with-wet-amd-580111
245.0,12/11/2017 1:20:21 PM,Regeneron Says FDA Accepts SBLA Filing For 12-week Dosing Of Eylea Injection ,RTTNews,/news/stocks/regeneron-says-fda-accepts-sbla-filing-for-12-week-dosing-of-eylea-injection-1010934782
246.0,12/11/2017 1:22:04 PM,BRIEF-Regeneron Announces FDA Acceptance Of SBLA Filing For 12-Week Dosing Of Eylea(Aflibercept) Injection For Patients With Wet AMD (REGN),Reuters,http://www.businessinsider.com/r-brief-regeneron-announces-fda-acceptance-of-sbla-filing-for-12-week-dosing-of-eyleaaflibercept-injection-for-patients-with-wet-amd-2017-12
247.0,12/13/2017 7:01:00 AM,Regeneron and Sanofi Announce Positive Topline Pivotal Results for PD-1 Antibody Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma,PR Newswire,/news/stocks/regeneron-and-sanofi-announce-positive-topline-pivotal-results-for-pd-1-antibody-cemiplimab-in-advanced-cutaneous-squamous-cell-carcinoma-591108
248.0,12/13/2017 7:07:41 AM,"Regeneron, Sanofi Report Results For PD-1 Antibody Cemiplimab In Advanced CSCC ",RTTNews,/news/stocks/regeneron-sanofi-report-results-for-pd-1-antibody-cemiplimab-in-advanced-cscc-1011193237
249.0,12/13/2017 7:30:00 AM,Regeneron Collaboration Programs Highlighted During Sanofi Analyst Day,PR Newswire,/news/stocks/regeneron-collaboration-programs-highlighted-during-sanofi-analyst-day-1002269745
250.0,12/18/2017 7:00:00 AM,Regeneron and ISA Pharmaceuticals Announce Strategic Immuno-Oncology Collaboration,PR Newswire,/news/stocks/regeneron-and-isa-pharmaceuticals-announce-strategic-immuno-oncology-collaboration-1011613434
251.0,12/18/2017 7:12:19 AM,"Regeneron, ISA Pharma Announce Strategic Immuno-Oncology Collaboration ",RTTNews,/news/stocks/regeneron-isa-pharma-announce-strategic-immuno-oncology-collaboration-1011613496
252.0,12/18/2017 7:22:03 AM,BRIEF-Regeneron And Isa Pharmaceuticals Announce Strategic Immuno-Oncology Collaboration (REGN),Reuters,http://www.businessinsider.com/r-brief-regeneron-and-isa-pharmaceuticals-announce-strategic-immuno-oncology-collaboration-2017-12
253.0,12/21/2017 1:00:00 PM,Vertek Corporation Partners With VeloCloud to Provide Remote Management & Monitoring (RMM) and Helpdesk Services,PR Newswire,/news/stocks/vertek-corporation-partners-with-velocloud-to-provide-remote-management-&-monitoring-rmm-and-helpdesk-services-622379
254.0,1/8/2018 1:00:00 PM,Regeneron Forms Consortium of Leading Life Sciences Companies to Accelerate Largest Widely-Available 'Big Data' Human Sequencing Resource with UK Biobank,PR Newswire,/news/stocks/regeneron-forms-consortium-of-leading-life-sciences-companies-to-accelerate-largest-widely-available-big-data-human-sequencing-resource-with-uk-biobank-1012660493
255.0,1/8/2018 1:04:00 PM,Regeneron and Sanofi To Accelerate and Expand Investment for Cemiplimab and Dupilumab Development Programs,PR Newswire,/news/stocks/regeneron-and-sanofi-to-accelerate-and-expand-investment-for-cemiplimab-and-dupilumab-development-programs-1001652118
256.0,1/8/2018 1:20:10 PM,"Sanofi, Regeneron To Expand Investment For Cemiplimab & Dupilumab Development ",RTTNews,/news/stocks/sanofi-regeneron-to-expand-investment-for-cemiplimab-dupilumab-development-1012660974
257.0,1/8/2018 3:00:00 PM,Infor Releases New Digital Innovation Enabler for Healthcare Industry,PR Newswire,/news/stocks/infor-releases-new-digital-innovation-enabler-for-healthcare-industry-1001647250
258.0,1/22/2018 1:00:00 PM,Regeneron Announces Approval of DUPIXENT® (dupilumab) in Japan for the Treatment of Atopic Dermatitis,PR Newswire,/news/stocks/regeneron-announces-approval-of-dupixent-dupilumab-in-japan-for-the-treatment-of-atopic-dermatitis-685405
259.0,1/22/2018 1:12:14 PM,Regeneron Announces Approval Of DUPIXENT In Japan - Quick Facts ,RTTNews,/news/stocks/regeneron-announces-approval-of-dupixent-in-japan-quick-facts-1013586639
260.0,1/23/2018 6:01:00 PM,Forty of the Nation's Most Promising Young Scientists Named Finalists in Regeneron Science Talent Search 2018,PR Newswire,/news/stocks/forty-of-the-nation-s-most-promising-young-scientists-named-finalists-in-regeneron-science-talent-search-2018-1001688777
261.0,1/23/2018 6:01:00 PM,Forty of the Nation's Most Promising Young Scientists Named Finalists in Regeneron Science Talent Search 2018,PR Newswire,/news/stocks/forty-of-the-nation-s-most-promising-young-scientists-named-finalists-in-regeneron-science-talent-search-2018-1001690637
262.0,1/23/2018 10:05:00 PM,"Regeneron to Report Fourth Quarter and Full Year 2017 Financial and Operating Results and Host Conference Call and Webcast on February 8, 2018",PR Newswire,/news/stocks/regeneron-to-report-fourth-quarter-and-full-year-2017-financial-and-operating-results-and-host-conference-call-and-webcast-on-february-8-2018-1013759756
263.0,1/26/2018 3:00:00 PM,James Flicker Joins Sagent Advisors as a Managing Director and Head of Paper & Forest Products,PR Newswire,/news/stocks/james-flicker-joins-sagent-advisors-as-a-managing-director-and-head-of-paper-&-forest-products-708621
264.0,1/30/2018 4:07:00 PM,"Camp Bow Wow Showcases Impressive Start to 2018, Ranking #1 in Pet Care on Entrepreneur's Franchise 500 List and More",PR Newswire,/news/stocks/camp-bow-wow-showcases-impressive-start-to-2018-ranking-1-in-pet-care-on-entrepreneur-s-franchise-500-list-and-more-1001708290
265.0,2/6/2018 3:00:00 PM,New Molecular Test to Impact Influenza Pandemic Preparedness,PR Newswire,/news/stocks/new-molecular-test-to-impact-influenza-pandemic-preparedness-1002065833
266.0,2/8/2018 12:30:00 PM,Regeneron Reports Fourth Quarter and Full Year 2017 Financial and Operating Results,PR Newswire,/news/stocks/regeneron-reports-fourth-quarter-and-full-year-2017-financial-and-operating-results-1015114058
267.0,2/8/2018 12:34:55 PM,Regeneron Pharmaceuticals Q4 Income Rises,RTTNews,/news/stocks/regeneron-pharmaceuticals-q4-income-rises-1015114084
268.0,2/12/2018 1:00:00 PM,Regeneron Announces Appointment of Marion McCourt as Senior Vice President and Head of Commercial,PR Newswire,/news/stocks/regeneron-announces-appointment-of-marion-mccourt-as-senior-vice-president-and-head-of-commercial-1015506141
269.0,3/2/2018 7:00:00 AM,FDA to Review DUPIXENT® (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma,PR Newswire,/news/stocks/fda-to-review-dupixent-dupilumab-as-potential-treatment-for-moderate-to-severe-asthma-456214
270.0,3/2/2018 7:11:18 AM,Sanofi:FDA Reviews DUPIXENT As Potential Treatment For Moderate-to-Severe Asthma ,RTTNews,/news/stocks/sanofi-fda-reviews-dupixent-as-potential-treatment-for-moderate-to-severe-asthma-1017661658
271.0,3/4/2018 3:19:34 AM,An Ear To The Pharma: 7 Stocks To Watch This Week ,RTTNews,/news/stocks/an-ear-to-the-pharma-7-stocks-to-watch-this-week-1017867022
272.0,3/10/2018 3:00:00 PM,"Praluent® (alirocumab) Injection significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate",PR Newswire,/news/stocks/praluent-alirocumab-injection-significantly-reduced-risk-of-cardiovascular-events-in-high-risk-patients-and-was-associated-with-lower-death-rate-1018611949
273.0,3/10/2018 3:00:00 PM,"Praluent® (alirocumab) Injection Significantly Reduced Risk of Cardiovascular Events in High-Risk Patients, and was Associated with Lower Death Rate",PR Newswire,/news/stocks/praluent-alirocumab-injection-significantly-reduced-risk-of-cardiovascular-events-in-high-risk-patients-and-was-associated-with-lower-death-rate-1018611950
274.0,3/10/2018 3:02:00 PM,Regeneron and Sanofi Announce Plans to Make Praluent® (alirocumab) More Accessible and Affordable for Patients with the Greatest Health Risk and Unmet Need,PR Newswire,/news/stocks/regeneron-and-sanofi-announce-plans-to-make-praluent-alirocumab-more-accessible-and-affordable-for-patients-with-the-greatest-health-risk-and-unmet-need-1018611961
275.0,3/10/2018 3:02:00 PM,Sanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need,PR Newswire,/news/stocks/sanofi-and-regeneron-announce-plans-to-make-praluent-more-accessible-and-affordable-for-patients-with-the-greatest-health-risk-and-unmet-need-1018611960
276.0,3/10/2018 6:37:48 PM,"Regeneron, Sanofi To Cut Heart Drug's Price; Say Praluent Lowers Risk Of Death ",RTTNews,/news/stocks/regeneron-sanofi-to-cut-heart-drug-s-price-say-praluent-lowers-risk-of-death-1018612085
277.0,3/11/2018 6:22:03 AM,An Ear To The Pharma: 4 Stocks To Watch This Week ,RTTNews,/news/stocks/an-ear-to-the-pharma-4-stocks-to-watch-this-week-1018612558
278.0,3/12/2018 5:30:17 AM,"SVRA Disappoints, SNY/REGN's Praluent Price To Be Cut, OBSV On Watch ",RTTNews,/news/stocks/svra-disappoints-sny-regn-s-praluent-price-to-be-cut-obsv-on-watch-1018614563
279.0,3/14/2018 2:29:00 AM,"Teen Scientists Win $1.8 Million at Regeneron Science Talent Search 2018 with Top Awards for Novel Research on Crop Blight, Vaping and Rare Disease",PR Newswire,/news/stocks/teen-scientists-win-$1-8-million-at-regeneron-science-talent-search-2018-with-top-awards-for-novel-research-on-crop-blight-vaping-and-rare-disease-477879
280.0,3/19/2018 12:00:00 PM,EYLEA® (aflibercept) Injection Demonstrates Positive Topline Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial,PR Newswire,/news/stocks/eylea-aflibercept-injection-demonstrates-positive-topline-results-in-phase-3-non-proliferative-diabetic-retinopathy-trial-1018915518
281.0,3/19/2018 12:18:07 PM,Regeneron Reports Positive Results From Phase 3 PANORAMA Trial With EYLEA ,RTTNews,/news/stocks/regeneron-reports-positive-results-from-phase-3-panorama-trial-with-eylea-1018915715
282.0,3/21/2018 10:05:00 PM,Regeneron Genetics Center® Publication in New England Journal of Medicine Identifies New Genetic Variant Providing Protection from Chronic Liver Disease,PR Newswire,/news/stocks/regeneron-genetics-center-publication-in-new-england-journal-of-medicine-identifies-new-genetic-variant-providing-protection-from-chronic-liver-disease-1002184113
283.0,3/21/2018 10:06:00 PM,Regeneron and Alnylam Pharmaceuticals Announce Collaboration to Discover New Treatments for Nonalcoholic Steatohepatitis (NASH),PR Newswire,/news/stocks/regeneron-and-alnylam-pharmaceuticals-announce-collaboration-to-discover-new-treatments-for-nonalcoholic-steatohepatitis-nash-503462
284.0,3/22/2018 7:35:17 AM,"FENC On Fast Track, SPHS To Report Data In Q2, REGN, ALNY Team Up For NASH ",RTTNews,/news/stocks/fenc-on-fast-track-sphs-to-report-data-in-q2-regn-alny-team-up-for-nash-1019042163
285.0,4/3/2018 1:56:00 AM,Caroline S. Koblenzer is recognized by Continental Who's Who,PR Newswire,/news/stocks/caroline-s-koblenzer-is-recognized-by-continental-who-s-who-1001902146
286.0,4/3/2018 7:00:00 AM,EMA to Review Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma,PR Newswire,/news/stocks/ema-to-review-cemiplimab-as-a-potential-treatment-for-advanced-cutaneous-squamous-cell-carcinoma-1020310476
287.0,4/3/2018 7:01:00 AM,EMA to Review DUPIXENT® (dupilumab) as Potential Treatment for Inadequately Controlled Moderate-to-Severe Asthma,PR Newswire,/news/stocks/ema-to-review-dupixent-dupilumab-as-potential-treatment-for-inadequately-controlled-moderate-to-severe-asthma-1001896116
288.0,4/3/2018 7:12:54 AM,Regeneron And Sanofi Say EMA Accepts For Review Application For DUPIXEN ,RTTNews,/news/stocks/regeneron-and-sanofi-say-ema-accepts-for-review-application-for-dupixen-1020311193
289.0,4/6/2018 9:00:00 PM,American Financial Benefits Center on Debt-Free College and Existing Repayment Options,PR Newswire,/news/stocks/american-financial-benefits-center-on-debt-free-college-and-existing-repayment-options-551705
290.0,4/9/2018 3:30:00 PM,"Regeneron to Report First Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2018",PR Newswire,/news/stocks/regeneron-to-report-first-quarter-2018-financial-and-operating-results-and-host-conference-call-and-webcast-on-may-3-2018-1002237220
291.0,4/18/2018 2:30:00 PM,ARTiFACTS and Blockchain in Healthcare Today Partner to Expand Use of Blockchain in Scholarly Publishing,PR Newswire,/news/stocks/artifacts-and-blockchain-in-healthcare-today-partner-to-expand-use-of-blockchain-in-scholarly-publishing-1001940323
292.0,4/23/2018 3:30:00 PM,Regeneron Announces Upcoming Investor Conference Presentations,PR Newswire,/news/stocks/regeneron-announces-upcoming-investor-conference-presentations-1022000366
293.0,4/30/2018 7:00:00 AM,FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma,PR Newswire,/news/stocks/fda-to-conduct-priority-review-of-cemiplimab-as-a-potential-treatment-for-advanced-cutaneous-squamous-cell-carcinoma-1022853370
294.0,4/30/2018 7:00:00 AM,FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma,PR Newswire,/news/stocks/fda-to-conduct-priority-review-of-cemiplimab-as-a-potential-treatment-for-advanced-cutaneous-squamous-cell-carcinoma-1001643607
295.0,4/30/2018 7:11:20 AM,Regeneron And Sanofi Say FDA Accepts Priority Review BLA For Cemiplimab ,RTTNews,/news/stocks/regeneron-and-sanofi-say-fda-accepts-priority-review-bla-for-cemiplimab-1022854358
296.0,5/1/2018 7:42:04 AM,"INGN Soars On Revised Outlook, MRK Faces FDA In Sep., KPTI Taken By STORM ",RTTNews,/news/stocks/ingn-soars-on-revised-outlook-mrk-faces-fda-in-sep-kpti-taken-by-storm-1022974414
297.0,5/1/2018 12:59:00 PM,"Regeneron and Sanofi to Lower Net Price of Praluent® (alirocumab) Injection in Exchange for Straightforward, More Affordable Patient Access for Express Scripts Patients",PR Newswire,/news/stocks/regeneron-and-sanofi-to-lower-net-price-of-praluent-alirocumab-injection-in-exchange-for-straightforward-more-affordable-patient-access-for-express-scripts-patients-1001984218
298.0,5/1/2018 1:00:00 PM,"Sanofi and Regeneron to lower net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable patient access for Express Scripts patients",PR Newswire,/news/stocks/sanofi-and-regeneron-to-lower-net-price-of-praluent-alirocumab-injection-in-exchange-for-straightforward-more-affordable-patient-access-for-express-scripts-patients-1023001115
299.0,5/1/2018 1:58:11 PM,"Sanofi, Renegeron To Lower Net Price Of Praluent Injection - Quick Facts ",RTTNews,/news/stocks/sanofi-renegeron-to-lower-net-price-of-praluent-injection-quick-facts-1023005511
300.0,5/1/2018 2:00:00 PM,2018 Global Channel Report Reveals Clients Attacked Mostly Through Privileged Accounts,PR Newswire,/news/stocks/2018-global-channel-report-reveals-clients-attacked-mostly-through-privileged-accounts-1001625879
301.0,5/2/2018 2:30:00 PM,DocPanel Announces Partnership with the University of Southern California Keck School of Medicine,PR Newswire,/news/stocks/docpanel-announces-partnership-with-the-university-of-southern-california-keck-school-of-medicine-646736
302.0,5/3/2018 12:30:00 PM,Regeneron Reports First Quarter 2018 Financial and Operating Results,PR Newswire,/news/stocks/regeneron-reports-first-quarter-2018-financial-and-operating-results-1023252250
303.0,5/3/2018 12:39:53 PM,Regeneron Pharmaceuticals Q1 adjusted earnings Beat Estimates,RTTNews,/news/stocks/regeneron-pharmaceuticals-q1-adjusted-earnings-beat-estimates-1023252295
304.0,5/16/2018 7:01:00 AM,Positive Phase 3 Trial of DUPIXENT® (dupilumab) in Adolescents with Inadequately Controlled Moderate-to-severe Atopic Dermatitis,PR Newswire,/news/stocks/positive-phase-3-trial-of-dupixent-dupilumab-in-adolescents-with-inadequately-controlled-moderate-to-severe-atopic-dermatitis-1024657017
305.0,5/16/2018 7:26:30 AM,"Regeneron, Sanofi: Phase 3 Dupixent Trial Meets Primary, Key Secondary Endpoints ",RTTNews,/news/stocks/regeneron-sanofi-phase-3-dupixent-trial-meets-primary-key-secondary-endpoints-1024658863
306.0,5/16/2018 2:00:00 PM,Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis,PR Newswire,/news/stocks/dupixent-dupilumab-showed-positive-phase-3-results-in-adolescents-with-inadequately-controlled-moderate-to-severe-atopic-dermatitis-1024695853
307.0,5/16/2018 11:00:00 PM,Regeneron and Sanofi Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ASCO,PR Newswire,/news/stocks/regeneron-and-sanofi-share-first-positive-clinical-data-for-cemiplimab-in-advanced-non-small-cell-lung-cancer-at-asco-1024752454
308.0,5/18/2018 3:30:00 PM,Regeneron Announces Upcoming Investor Conference Presentation,PR Newswire,/news/stocks/regeneron-announces-upcoming-investor-conference-presentation-1024989217
309.0,5/21/2018 8:14:00 PM,New England Journal of Medicine Publishes Two Positive Phase 3 Trials Showing DUPIXENT® (dupilumab) Improved Moderate-to-Severe Asthma,PR Newswire,/news/stocks/new-england-journal-of-medicine-publishes-two-positive-phase-3-trials-showing-dupixent-dupilumab-improved-moderate-to-severe-asthma-1001713899
310.0,5/21/2018 8:15:00 PM,New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma,PR Newswire,/news/stocks/new-england-journal-of-medicine-publishes-two-positive-phase-3-trials-showing-dupixent-dupilumab-improved-moderate-to-severe-asthma-1025069745
311.0,5/31/2018 10:05:00 PM,Regeneron's Investigational Ebola Treatment Shipping to Democratic Republic of the Congo for Use in Current Outbreak,PR Newswire,/news/stocks/regeneron-s-investigational-ebola-treatment-shipping-to-democratic-republic-of-the-congo-for-use-in-current-outbreak-1026022169
312.0,6/4/2018 8:15:00 PM,New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma,PR Newswire,/news/stocks/new-england-journal-of-medicine-publishes-pivotal-cemiplimab-trials-showing-positive-results-in-advanced-cutaneous-squamous-cell-carcinoma-1026470521
313.0,6/4/2018 8:15:00 PM,New England Journal of Medicine Publishes Pivotal Cemiplimab Trials Showing Positive Results in Advanced Cutaneous Squamous Cell Carcinoma,PR Newswire,/news/stocks/new-england-journal-of-medicine-publishes-pivotal-cemiplimab-trials-showing-positive-results-in-advanced-cutaneous-squamous-cell-carcinoma-1026470520
314.0,6/6/2018 1:00:00 PM,Regeneron and Zoetis Announce Collaboration to Research Antibody Therapies for Use in Animal Health,PR Newswire,/news/stocks/regeneron-and-zoetis-announce-collaboration-to-research-antibody-therapies-for-use-in-animal-health-1026693979
315.0,6/6/2018 1:09:02 PM,"Regeneron, Zoetis Announce Research Collaboration - Quick Facts ",RTTNews,/news/stocks/regeneron-zoetis-announce-research-collaboration-quick-facts-1026694055
316.0,7/26/2018 9:39:05 AM,Biotech Stocks Facing FDA Decision In August ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-august-1027401882
317.0,7/31/2018 3:02:52 PM,What Wall Street expects from Regeneron Pharmaceuticals's earnings,Markets Insider Automation,/news/stocks/regeneron-q2-earnings-preview-1027416458
318.0,8/2/2018 12:47:42 PM,Regeneron Pharmaceuticals Q2 adjusted earnings Beat Estimates,RTTNews,/news/stocks/regeneron-pharmaceuticals-q2-adjusted-earnings-beat-estimates-1027425433
319.0,8/2/2018 9:45:08 PM,Regeneron Showing Strong Move To The Upside ,RTTNews,/news/stocks/regeneron-showing-strong-move-to-the-upside-1027427549
320.0,8/4/2018 7:40:57 AM,"Week Ahead In Pharmaceuticals - 10 Stocks To Watch (ALNY, INSM, PRTK...) ",RTTNews,/news/stocks/week-ahead-in-pharmaceuticals-10-stocks-to-watch-alny-insm-prtk-1027430855
321.0,8/6/2018 1:01:48 PM,"Regeneron, Bluebird Bio Announce Collaboration - Quick Facts ",RTTNews,/news/stocks/regeneron-bluebird-bio-announce-collaboration-quick-facts-1027433517
322.0,8/11/2018 5:17:06 AM,"Week Ahead In Pharmaceuticals: 5 Stocks To Watch (REGN, PFE, ALT...) ",RTTNews,/news/stocks/week-ahead-in-pharmaceuticals-5-stocks-to-watch-regn-pfe-alt-1027451315
323.0,8/13/2018 1:15:09 PM,Regeneron Pharma: FDA Issues Response Letter On SBLA For EYLEA - Quick Facts ,RTTNews,/news/stocks/regeneron-pharma-fda-issues-response-letter-on-sbla-for-eylea-quick-facts-1027453132
324.0,8/14/2018 9:44:04 AM,"MBIO & Bubble Boy Disease Gene Therapy, Busy Months Ahead For EIGR, UMRX ",RTTNews,/news/stocks/mbio-bubble-boy-disease-gene-therapy-busy-months-ahead-for-eigr-umrx-1027456018
325.0,8/16/2018 1:11:07 PM,Teva And Regeneron Announce Positive Phase 3 Fasinumab Results ,RTTNews,/news/stocks/teva-and-regeneron-announce-positive-phase-3-fasinumab-results-1027463949
326.0,8/17/2018 1:11:36 PM,Regeneron Pharma: FDA Okays EYLEA Injection SBLA In Wet AMD ,RTTNews,/news/stocks/regeneron-pharma-fda-okays-eylea-injection-sbla-in-wet-amd-1027467004
327.0,8/19/2018 3:08:54 AM,"Week Ahead In Pharmaceuticals: 7 Stocks To Watch (TNXP, REGN, KALA...) ",RTTNews,/news/stocks/week-ahead-in-pharmaceuticals-7-stocks-to-watch-tnxp-regn-kala-1027468476
328.0,9/12/2018 8:28:34 AM,"FOMX Soars On Acne Trial Data, GLPG Abuzz, ACRX To Face FDA Panel In Oct. ",RTTNews,/news/stocks/fomx-soars-on-acne-trial-data-glpg-abuzz-acrx-to-face-fda-panel-in-oct-1027526604
329.0,9/12/2018 2:18:04 PM,Sanofi And Regeneron : FDA To Review SBLA For Praluent Injection ,RTTNews,/news/stocks/sanofi-and-regeneron-fda-to-review-sbla-for-praluent-injection-1027527994
330.0,9/13/2018 9:19:01 AM,"ADIL On Track, PGNX Slumps On Phase III Study Failure, VNDA On Watch ",RTTNews,/news/stocks/adil-on-track-pgnx-slumps-on-phase-iii-study-failure-vnda-on-watch-1027530783
331.0,9/28/2018 11:42:28 AM,Biotech Stocks Facing FDA Decision In October ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-october-1027574035
332.0,9/28/2018 11:45:03 PM,"The FDA just approved a new treatment for a common form of skin cancer (REGN, SNY)",Business Insider,https://www.businessinsider.com/fda-approves-regeneron-and-sanofis-cancer-immunotherapy-libtayo-2018-9
333.0,10/16/2018 7:20:13 AM,Regeneron : Dupixent Shows Positive Results In Two Phase 3 Trials On CRSwNP ,RTTNews,/news/stocks/regeneron-dupixent-shows-positive-results-in-two-phase-3-trials-on-crswnp-1027619003
334.0,10/22/2018 5:43:33 AM,"FDA Extends Date On BMY's SBLA, Genmab Meets Phase 3 Goals, NCNA, LPTX On Watch ",RTTNews,/news/stocks/fda-extends-date-on-bmy-s-sbla-genmab-meets-phase-3-goals-ncna-lptx-on-watch-1027636442
335.0,10/22/2018 1:21:44 PM,Regeneron Pharma: FDA Approves Asthma Indication For Dupixent - Quick Facts ,RTTNews,/news/stocks/regeneron-pharma-fda-approves-asthma-indication-for-dupixent-quick-facts-1027638313
336.0,10/25/2018 3:23:10 PM,"Regeneron: Eylea Phase 3 Panorama Trial Meets Primary, Secondary Endpoints ",RTTNews,/news/stocks/regeneron-eylea-phase-3-panorama-trial-meets-primary-secondary-endpoints-1027655401
337.0,11/4/2018 3:01:58 PM,Regeneron Pharmaceuticals is about to announce its earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/regeneron-q3-earnings-preview-stock-1027687795
338.0,11/6/2018 7:12:17 AM,Regeneron : FDA Grants Priority Review For Dupixent ,RTTNews,/news/stocks/regeneron-fda-grants-priority-review-for-dupixent-1027694409
339.0,11/6/2018 12:47:37 PM,Regeneron Pharmaceuticals Q3 adjusted earnings Beat Estimates,RTTNews,/news/stocks/regeneron-pharmaceuticals-q3-adjusted-earnings-beat-estimates-1027695820
340.0,1/4/2019 7:57:12 PM,Regeneron Posting Strong Gain On Upgrade By Guggenheim ,RTTNews,/news/stocks/regeneron-posting-strong-gain-on-upgrade-by-guggenheim-1027845090
341.0,1/7/2019 8:49:38 AM,"Regeneron, Sanofi Select Two Clinical-stage Antibodies For Ongoing Collaboration ",RTTNews,/news/stocks/regeneron-sanofi-select-two-clinical-stage-antibodies-for-ongoing-collaboration-1027846398
342.0,2/4/2019 3:02:00 PM,Here's what to expect from Regeneron Pharmaceuticals's earnings,Markets Insider Automation,/news/stocks/regeneron-q4-earnings-preview-stock-1027920990
343.0,2/6/2019 12:36:34 PM,Regeneron Pharmaceuticals Q4 adjusted earnings Beat Estimates,RTTNews,/news/stocks/regeneron-pharmaceuticals-q4-adjusted-earnings-beat-estimates-1027929008
344.0,2/11/2019 1:37:06 PM,"Sanofi, Regeneron Offer Praluent At 60% Reduced U.S. List Price - Quick Facts ",RTTNews,/news/stocks/sanofi-regeneron-offer-praluent-at-60-reduced-u-s-list-price-quick-facts-1027940708
345.0,2/25/2019 11:13:40 PM,Amgen: Delaware Jury Upholds Validity Of Two Patents Related To PCSK9 Antibodies ,RTTNews,/news/stocks/amgen-delaware-jury-upholds-validity-of-two-patents-related-to-pcsk9-antibodies-1027981762
346.0,2/27/2019 4:51:26 AM,Biotech Stocks Facing FDA Decision In March ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-march-1027987182
347.0,3/1/2019 2:43:22 PM,Regeneron Says CHMP Recommends Approval Of Dupixent For Asthma Indication ,RTTNews,/news/stocks/regeneron-says-chmp-recommends-approval-of-dupixent-for-asthma-indication-1027997025
348.0,3/8/2019 7:06:22 AM,Regeneron And Sanofi Say FDA Accept For Priority Review SBLA For Dupixent ,RTTNews,/news/stocks/regeneron-and-sanofi-say-fda-accept-for-priority-review-sbla-for-dupixent-1028014468
349.0,3/26/2019 12:16:18 PM,Biotech Stocks Facing FDA Decision In April ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-april-1028058579
350.0,4/8/2019 1:21:56 PM,Regeneron To Invest $800 Mln In Alnylam; To Jointly Develop RNAi Therapeutics ,RTTNews,/news/stocks/regeneron-to-invest-800-mln-in-alnylam-to-jointly-develop-rnai-therapeutics-1028092345
351.0,4/26/2019 9:15:22 AM,Biotech Stocks Facing FDA Decision In May 2019 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-may-2019-1028141774
352.0,4/29/2019 6:52:49 AM,"Sanofi: FDA Approves Praluent To Prevent Heart Attack, Stroke, Unstable Angina ",RTTNews,/news/stocks/sanofi-fda-approves-praluent-to-prevent-heart-attack-stroke-unstable-angina-1028146213
353.0,5/5/2019 3:01:51 PM,Here's what Wall Street expects from Regeneron Pharmaceuticals's earnings,Markets Insider Automation,/news/stocks/regeneron-stock-price-quarter-earnings-preview-q1-1028168249
354.0,5/7/2019 12:37:34 PM,Regeneron Pharmaceuticals Q1 adjusted earnings Miss Estimates,RTTNews,/news/stocks/regeneron-pharmaceuticals-q1-adjusted-earnings-miss-estimates-1028175571
355.0,5/7/2019 3:21:59 PM,Regeneron & Sanofi: Dupixent Approved For Severe Asthma Indication In EU ,RTTNews,/news/stocks/regeneron-sanofi-dupixent-approved-for-severe-asthma-indication-in-eu-1028177243
356.0,5/25/2019 5:16:57 AM,Biotech Stocks Facing FDA Decision In June 2019 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-june-2019-1028230263
357.0,6/14/2019 1:35:09 PM,Regeneron Announces Positive Early-stage Data For REGN1979 - Quick Facts ,RTTNews,/news/stocks/regeneron-announces-positive-early-stage-data-for-regn1979-quick-facts-1028280099
358.0,6/21/2019 7:20:10 AM,Regeneron Pharma: REGN3500 Meets Primary Endpoint In Phase 2 Study ,RTTNews,/news/stocks/regeneron-pharma-regn3500-meets-primary-endpoint-in-phase-2-study-1028297034
359.0,6/26/2019 8:46:45 PM,"Nasdaq Today: Semis Rally, Micron Earnings, Suing FB and GOOGL?",InvestorPlace,/news/stocks/nasdaq-today-semis-rally-micron-earnings-suing-fb-and-googl-1028311984
360.0,6/28/2019 1:11:07 PM,Regeneron Pharma: CHMP Adopts Positive Opinion For Dupixent - Quick Facts ,RTTNews,/news/stocks/regeneron-pharma-chmp-adopts-positive-opinion-for-dupixent-quick-facts-1028316892
361.0,7/1/2019 4:25:39 PM,Sanofi : EU Okays Libtayo For Advanced Cutaneous Squamous Cell Carcinoma ,RTTNews,/news/stocks/sanofi-eu-okays-libtayo-for-advanced-cutaneous-squamous-cell-carcinoma-1028321728
362.0,7/11/2019 8:54:32 PM,Nasdaq Today: Biotech Wrecked; Buy Microsoft? ,InvestorPlace,/news/stocks/nasdaq-today-biotech-wrecked-buy-microsoft-1028347970
363.0,7/26/2019 4:04:19 PM,4 Biotech Stocks Sliding Lower,InvestorPlace,/news/stocks/4-biotech-stocks-sliding-lower-1028389963
364.0,8/4/2019 3:01:57 PM,Regeneron Pharmaceuticals earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/regeneron-stock-price-q2-earnings-preview-1028414530
365.0,8/6/2019 7:24:29 AM,Sanofi:EU Oks Dupixent For Adolescents With Moderate-to-Severe Atopic Dermatitis ,RTTNews,/news/stocks/sanofi-eu-oks-dupixent-for-adolescents-with-moderate-to-severe-atopic-dermatitis-1028420195
366.0,8/6/2019 8:36:23 AM,"ALNY To Face FDA In Feb., PODD Ups Outlook Again, Catalysts Galore For XLRN ",RTTNews,/news/stocks/alny-to-face-fda-in-feb-podd-ups-outlook-again-catalysts-galore-for-xlrn-1028420401
367.0,8/6/2019 12:33:34 PM,Regeneron Pharmaceuticals Q2 adjusted earnings Beat Estimates,RTTNews,/news/stocks/regeneron-pharmaceuticals-q2-adjusted-earnings-beat-estimates-1028421037
368.0,8/13/2019 1:14:43 PM,FDA Approves Regeneron's EYLEA Injection Prefilled Syringe - Quick Facts ,RTTNews,/news/stocks/fda-approves-regeneron-s-eylea-injection-prefilled-syringe-quick-facts-1028441359
369.0,8/14/2019 1:25:24 PM,Regeneron Pharma Reports Positive Phase 3 Results For Evinacumab - Quick Facts ,RTTNews,/news/stocks/regeneron-pharma-reports-positive-phase-3-results-for-evinacumab-quick-facts-1028445322
370.0,8/20/2019 5:06:30 PM,8 Biotech Stocks to Watch After the Q2 Earnings Season,InvestorPlace,/news/stocks/8-biotech-stocks-to-watch-after-the-q2-earnings-season-1028461460
371.0,9/14/2019 10:31:25 AM,"3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector",InvestorPlace,/news/stocks/3-biotech-stocks-that-show-the-good-the-bad-and-the-ugly-side-of-this-sector-1028524601
372.0,9/20/2019 1:17:57 PM,Regeneron And Sanofi Say CHMP Adopts Positive Opinion For Dupixent ,RTTNews,/news/stocks/regeneron-and-sanofi-say-chmp-adopts-positive-opinion-for-dupixent-1028540621
373.0,9/27/2019 7:34:40 PM,7 Big Biotech Stocks to Watch,InvestorPlace,/news/stocks/7-big-biotech-stocks-to-watch-1028560645
374.0,10/3/2019 7:02:17 PM,3 Cancer-Fighting Drug Stocks to Buy Right Now,InvestorPlace,/news/stocks/3-cancer-fighting-drug-stocks-to-buy-right-now-1028575928
375.0,10/14/2019 3:46:28 PM,3 Undervalued Stocks to Buy According to Goldman Sachs,InvestorPlace,/news/stocks/undervalued-stocks-to-buy-goldman-sachs-1028597934
376.0,10/29/2019 2:13:11 PM,"Regeneron, Sanofi: European Commission Approves New Indication For Dupixent ",RTTNews,/news/stocks/regeneron-sanofi-european-commission-approves-new-indication-for-dupixent-1028639652
377.0,11/5/2019 12:36:14 PM,Regeneron Pharmaceuticals Q3 adjusted earnings Beat Estimates,RTTNews,/news/stocks/regeneron-pharmaceuticals-q3-adjusted-earnings-beat-estimates-1028659131
378.0,11/5/2019 12:40:08 PM,Regeneron Pharmaceuticals Board Approves $1 Bln Share Buyback - Quick Facts ,RTTNews,/news/stocks/regeneron-pharmaceuticals-board-approves-1-bln-share-buyback-quick-facts-1028659129
379.0,11/5/2019 12:40:55 PM,Why This Just Might Be the Biggest Week for CARA Stock,InvestorPlace,/news/stocks/biggest-week-cara-stock-1028659655
380.0,11/5/2019 8:27:04 PM,Regeneron Pharmaceuticals Earnings: REGN Stock Rockets 7% on Q3 Beat,InvestorPlace,/news/stocks/regeneron-pharmaceuticals-earnings-send-regn-stock-soaring-1028661895
381.0,11/6/2019 1:46:19 PM,"Regeneron, Vyriad To Collaborate On New Oncolytic Virus Treatments For Cancer ",RTTNews,/news/stocks/regeneron-vyriad-to-collaborate-on-new-oncolytic-virus-treatments-for-cancer-1028664311
382.0,11/7/2019 12:19:09 PM,"3 Big Stock Charts for Thursday: Kraft Heinz, Wabtec, and Regeneron Pharmaceuticals",InvestorPlace,/news/stocks/3-big-stock-charts-for-thursday-kraft-heinz-wabtec-and-regeneron-pharmaceuticals-1028669126
383.0,11/7/2019 9:25:33 PM,"Stock Market Today: Record Highs for Dow, Nasdaq and S&P 500",InvestorPlace,/news/stocks/stock-market-today-record-highs-for-dow-nasdaq-and-sp-500-1028671683
384.0,11/8/2019 9:31:09 PM,This $2.7 Billion Deal Is a Shot Across the Bow for Big Pharma,InvestorPlace,/news/stocks/biotech-stocks-big-pharma-deal-1028674828
385.0,11/12/2019 6:50:33 PM,7 Biotech Stocks to Buy With Plenty of Power in the Pipeline,InvestorPlace,/news/stocks/7-biotech-stocks-to-buy-with-plenty-of-power-in-the-pipeline-1028682538
386.0,12/5/2019 1:19:00 PM,Regeneron Pharma Announces Positive Phase 2 Results In Rare Blood Disorder ,RTTNews,/news/stocks/regeneron-pharma-announces-positive-phase-2-results-in-rare-blood-disorder-1028740345
387.0,12/31/2019 5:01:53 PM,"Vascepa’s Future Looks Rosy, But It Could Still Be Fishy for Amarin Stock",InvestorPlace,/news/stocks/vascepa-future-amarin-stock-amrn-fishy-1028789803
388.0,1/6/2020 5:18:24 PM,7 Investing Resolutions to Follow in 2020,InvestorPlace,/news/stocks/7-investing-resolutions-to-follow-in-2020-1028797249
389.0,1/28/2020 7:41:10 AM,"Regeneron, Sanofi: FDA To Review SBLA For Dupixent - Quick Facts ",RTTNews,/news/stocks/regeneron-sanofi-fda-to-review-sbla-for-dupixent-quick-facts-1028849018
390.0,1/28/2020 2:46:23 PM,7 Big Biotech Stocks to Avoid,InvestorPlace,/news/stocks/7-big-biotech-stocks-to-avoid-1028851372
391.0,2/5/2020 3:02:20 PM,Regeneron Pharmaceuticals earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/regeneron-stock-q4-earnings-preview-1028876801
392.0,2/5/2020 4:43:16 PM,Coronavirus cases remain modest in U.S.,Seeking Alpha,https://seekingalpha.com/news/3538634-coronavirus-cases-remain-modest-in-u-s?utm_source=markets.businessinsider.com&utm_medium=referral
393.0,2/6/2020 10:14:47 AM,"This $3B biotech has been a three-bagger since November, and it still has upside",Seeking Alpha,https://seekingalpha.com/news/3538998-this-3b-biotech-three-bagger-since-november-and-still-upside?utm_source=markets.businessinsider.com&utm_medium=referral
394.0,2/6/2020 12:33:58 PM,Regeneron Pharmaceuticals Q4 adjusted earnings Beat Estimates,RTTNews,/news/stocks/regeneron-pharmaceuticals-q4-adjusted-earnings-beat-estimates-1028880420
395.0,2/6/2020 12:44:29 PM,"Regeneron, Sanofi To Restructure Antibody Collaboration For Kevzara, Praluent ",RTTNews,/news/stocks/regeneron-sanofi-to-restructure-antibody-collaboration-for-kevzara-praluent-1028880453
396.0,2/6/2020 4:49:53 PM,Merck’s Spinoff Plans Place a Big Bet on Cancer-Fighting Keytruda,InvestorPlace,/news/stocks/mercks-spinoff-plans-place-a-big-bet-on-cancer-fighting-keytruda-1028882432
397.0,2/7/2020 4:30:20 PM,Coronavirus cases inch up in U.S. but still very light,Seeking Alpha,https://seekingalpha.com/news/3539753-coronavirus-cases-inch-up-in-u-s-still-light?utm_source=markets.businessinsider.com&utm_medium=referral
398.0,2/10/2020 3:15:53 PM,Kodiak Sciences up 9% on positive early-stage KSI-301 data,Seeking Alpha,https://seekingalpha.com/news/3540063-kodiak-sciences-up-9-on-positive-early-stage-ksiminus-301-data?utm_source=markets.businessinsider.com&utm_medium=referral
399.0,2/10/2020 8:35:52 PM,"Coronavirus outbreak continues to spread, still largely restricted to Hubei province",Seeking Alpha,https://seekingalpha.com/news/3540190-coronavirus-outbreak-continues-to-spread-still-largely-restricted-to-hubei-province?utm_source=markets.businessinsider.com&utm_medium=referral
400.0,2/11/2020 12:54:00 PM,Argus upgrades Regeneron in premarket analyst action,Seeking Alpha,https://seekingalpha.com/news/3540444-argus-upgrades-regeneron-in-premarket-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral
401.0,2/11/2020 5:30:01 PM,China’s Coronavirus Highlights the Risks of a Changing Oil Industry,InvestorPlace,/news/stocks/chinas-coronavirus-highlights-the-risks-of-a-changing-oil-industry-1028895128
402.0,2/18/2020 2:16:49 PM,"Moderna Will Rebound, But Wait for a Dip Lower to Buy Shares",InvestorPlace,/news/stocks/moderna-stock-rebound-wait-for-dip-1028914534
403.0,2/24/2020 5:46:23 PM,Novartis slammed by warning on macular degeneration drug,Seeking Alpha,https://seekingalpha.com/news/3544852-novartis-slammed-warning-on-macular-degeneration-drug?utm_source=markets.businessinsider.com&utm_medium=referral
404.0,2/24/2020 9:25:33 PM,"4 Top Stock Trades for Tuesday: SPY, QQQ, MSFT, REGN",InvestorPlace,/news/stocks/4-top-stock-trades-for-tuesday-spy-qqq-msft-regn-1028933312
405.0,2/24/2020 9:35:34 PM,"Stock Market Today: Coronavirus Sparks 1,000-Point Dow Fall",InvestorPlace,/news/stocks/stock-market-today-coronavirus-sparks-1000-point-dow-fall-1028933310
406.0,2/25/2020 10:00:17 AM,A Stock That Defies Conventions & Corona - Regeneron Pharma ,RTTNews,/news/stocks/a-stock-that-defies-conventions-corona-regeneron-pharma-1028934596
407.0,2/25/2020 1:07:28 PM,"Now That Teva Has Stabilized, Teva Stock Looks Undervalued",InvestorPlace,/news/stocks/stabilized-teva-stock-looks-undervalued-1028935585
408.0,2/25/2020 5:58:24 PM,Regeneron Pharma hits two-year high amid Novartis woes,Seeking Alpha,https://seekingalpha.com/news/3545331-regeneron-pharma-hits-two-year-high-amid-novartis-woes?utm_source=markets.businessinsider.com&utm_medium=referral
409.0,2/27/2020 2:36:23 PM,Fighting The Deadly Coronavirus ,RTTNews,/news/stocks/fighting-the-deadly-coronavirus-1028945765
410.0,2/27/2020 2:51:41 PM,Momentum Stocks Benefitting From Coronavirus ,RTTNews,/news/stocks/momentum-stocks-benefitting-from-coronavirus-1028945853
411.0,2/27/2020 3:13:26 PM,Stock Alert: REGN Shares Gain As Coronavirus Outbreak Intensifies ,RTTNews,/news/stocks/stock-alert-regn-shares-gain-as-coronavirus-outbreak-intensifies-1028946179
412.0,2/28/2020 3:49:19 PM,Traders Are Treating Inovio Like 2018’s Pot Stock Stars,InvestorPlace,/news/stocks/inovio-ino-stock-coronavirus-speculation-1028950545
413.0,3/3/2020 6:42:24 PM,"Coronavirus plays - vaccines, drugs & infection control products",Seeking Alpha,https://seekingalpha.com/news/3548189-coronavirus-plays-vaccines-drugs-infection-control-products?utm_source=markets.businessinsider.com&utm_medium=referral
414.0,3/4/2020 11:40:01 AM,Buy Regeneron Stock for Coronavirus 2.0 and Beyond,InvestorPlace,/news/stocks/buy-regeneron-stock-coronavirus-1028963665
415.0,3/4/2020 4:00:11 PM,Regeneron expects coronavirus med to be ready by August; shares up 4%,Seeking Alpha,https://seekingalpha.com/news/3548591-regeneron-expects-coronavirus-med-to-be-ready-august-shares-up-4?utm_source=markets.businessinsider.com&utm_medium=referral
416.0,3/5/2020 6:56:36 PM,Inovio Pharmaceuticals Rapidly Becoming The Premier Coronavirus Play,InvestorPlace,/news/stocks/ino-stock-rapidly-becoming-the-premier-coronavirus-play-1028969894
417.0,3/6/2020 1:02:03 PM,Regeneron Stock May Need More Than the Coronavirus,InvestorPlace,/news/stocks/regeneron-stock-needs-more-than-vaccine-1028971858
418.0,3/9/2020 2:53:41 PM,Moderna Stock’s Winning Streak Seems Likely to End,InvestorPlace,/news/stocks/moderna-mrna-stock-winning-streak-likely-to-end-1028977188
419.0,3/10/2020 2:29:46 PM,Its Powerful Pipeline Shows Pfizer Stock Is Undervalued by 15%,InvestorPlace,/news/stocks/pfe-stock-is-undervalued-by-at-least-15-1028981675
420.0,3/10/2020 10:23:58 PM,Generic anti-malarial may treat COVID-19 - Raymond James,Seeking Alpha,https://seekingalpha.com/news/3550389-generic-anti-malarial-may-treat-covidminus-19-raymond-james?utm_source=markets.businessinsider.com&utm_medium=referral
421.0,3/11/2020 7:39:18 AM,Which S&P 500 stocks have gained over the past month?,Seeking Alpha,https://seekingalpha.com/news/3550399-which-s-and-p-500-stocks-gained-over-past-month?utm_source=markets.businessinsider.com&utm_medium=referral
422.0,3/11/2020 6:28:42 PM,3 Diverse and Critical Stocks to Watch For a Market Bottom,InvestorPlace,/news/stocks/3-diverse-and-critical-stocks-to-watch-for-a-market-bottom-1028986967
423.0,3/16/2020 12:29:25 PM,Regeneron and Sanofi launch Kevzara clinical program for COVID-19,Seeking Alpha,https://seekingalpha.com/news/3551978-regeneron-and-sanofi-launch-kevzara-clinical-program-for-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral
424.0,3/16/2020 1:30:09 PM,"Sanofi, Regeneron Begin Kevzara Clinical Trial For Severe COVID-19 - Quick Facts ",RTTNews,/news/stocks/sanofi-regeneron-begin-kevzara-clinical-trial-for-severe-covid-19-quick-facts-1028999261
425.0,3/16/2020 2:31:48 PM,7 Biotech Stocks to Buy and Hold in 2020,InvestorPlace,/news/stocks/7-biotech-stocks-to-buy-and-hold-in-2020-1028769847
426.0,3/16/2020 3:05:13 PM,"Focus on iBio’s Tech, Not Its Coronavirus Story",InvestorPlace,/news/stocks/focus-on-ibios-tech-not-its-coronavirus-story-1029000187
427.0,3/17/2020 12:55:59 PM,Stock Alerts: Regeneron Says Identified Antibodies For Treating COVID-19 ,RTTNews,/news/stocks/stock-alerts-regeneron-says-identified-antibodies-for-treating-covid-19-1029003477
428.0,3/17/2020 1:01:29 PM,Regeneron Discovers Antibodies For COVID-19 Treatment ,RTTNews,/news/stocks/regeneron-discovers-antibodies-for-covid-19-treatment-1029003510
429.0,3/17/2020 3:03:32 PM,Stock Alert: Regeneron Pharma Rises 10% ,RTTNews,/news/stocks/stock-alert-regeneron-pharma-rises-10-1029004346
430.0,3/17/2020 5:12:05 PM,8 Best Performing Stocks During the 2020’s Market Meltdown,InvestorPlace,/news/stocks/best-stocks-for-2020-market-meltdown-1029005251
431.0,3/18/2020 6:55:12 AM,"BNTX On Fire, QDEL's Coronavirus Test Gets FDA's EUA, CureVac Back In The News ",RTTNews,/news/stocks/bntx-on-fire-qdel-s-coronavirus-test-gets-fda-s-eua-curevac-back-in-the-news-1029006665
432.0,3/19/2020 4:44:51 PM,"FDA ""close"" to nod for Gilead drug for Covid-19 - President Trump",Seeking Alpha,https://seekingalpha.com/news/3553431-fda-close-to-nod-for-gilead-drug-for-covidminus-19-president-trump?utm_source=markets.businessinsider.com&utm_medium=referral
433.0,3/19/2020 5:00:38 PM,Profit-taking pressures Moderna after Hahn comments on vaccine timeline,Seeking Alpha,https://seekingalpha.com/news/3553448-profit-taking-pressures-moderna-after-hahn-comments-on-vaccine-timeline?utm_source=markets.businessinsider.com&utm_medium=referral
434.0,3/19/2020 5:29:02 PM,Coronavirus-Fighting Tech Makes iBio Stock an Interesting Play,InvestorPlace,/news/stocks/coronavirus-fighting-tech-makes-ibio-stock-an-interesting-play-1029014502
435.0,3/21/2020 7:30:19 PM,Coronavirus offers a rare opportunity in these stocks,Seeking Alpha,https://seekingalpha.com/news/3554021-coronavirus-offers-rare-opportunity-in-stocks?utm_source=markets.businessinsider.com&utm_medium=referral
436.0,3/23/2020 5:31:58 PM,Don’t Forget About Stocks to Buy During the Coronavirus Crisis,InvestorPlace,/news/stocks/dont-forget-about-stocks-to-buy-during-the-coronavirus-crisis-1029024218
437.0,3/24/2020 10:50:33 AM,Why Consider These 2 Stocks When Markets Are Crashing? ,RTTNews,/news/stocks/why-consider-these-2-stocks-when-markets-are-crashing-1029025752
438.0,3/24/2020 5:55:21 PM,Top-Notch Vaccine Technology Makes iBio Stock a Smart Bet,InvestorPlace,/news/stocks/ibio-stock-could-be-worth-speculation-on-a-covid-19-vaccine-1029028361
439.0,3/25/2020 2:26:35 PM,It’s Time for Investors to Run Far Away From iBio Stock,InvestorPlace,/news/stocks/its-time-for-investors-to-run-far-away-from-ibio-stock-1029031724
440.0,3/27/2020 4:59:14 PM,The Easy Gains May Be Over for American Airlines Stock,InvestorPlace,/news/stocks/easy-gains-over-american-airlines-aal-stock-1029040380
441.0,3/30/2020 8:05:42 AM,"Regeneron, Sanofi Begin COVID-19 Clinical Program Outside Of U.S. ",RTTNews,/news/stocks/regeneron-sanofi-begin-covid-19-clinical-program-outside-of-u-s-1029043121
442.0,3/30/2020 8:53:11 AM,"Sanofi, Regeneron expand testing of Kevzara",Seeking Alpha,https://seekingalpha.com/news/3556140-sanofi-regeneron-expand-testing-of-kevzara?utm_source=markets.businessinsider.com&utm_medium=referral
443.0,3/30/2020 8:16:47 PM,Stock Market Today: Healthcare Stocks Leads the Way; Buy Zoom?,InvestorPlace,/news/stocks/stock-market-today-healthcare-stocks-leads-the-way-buy-zoom-1029046564
444.0,3/31/2020 11:32:18 AM,"3 Big Stock Charts for Tuesday: Abbott Laboratories, Johnson & Johnson, and Regeneron Pharmaceuticals",InvestorPlace,/news/stocks/3-big-stock-charts-for-tuesday-abbott-laboratories-johnson-johnson-and-regeneron-pharmaceuticals-1029048681
445.0,3/31/2020 12:45:45 PM,A Market Roadmap Shows the Stimulus Will Save the Economy,InvestorPlace,/news/stocks/market-roadmap-stimulus-package-coronavirus-1029049482
446.0,3/31/2020 3:55:00 PM,5 Hot Stocks for 2020 That Are Soaring While the Market Plunges,InvestorPlace,/news/stocks/5-hot-stocks-2020-soaring-market-plunges-1029050325
447.0,3/31/2020 4:19:54 PM,Is iBio Stock Worth the Risk as Coronavirus Continues to Spread?,InvestorPlace,/news/stocks/is-ibio-stock-worth-the-risk-as-coronavirus-continues-to-spread-1029050739
448.0,4/2/2020 11:13:44 AM,"3 Big Stock Charts for Thursday: Kellogg, Regeneron Pharmaceuticals, Newmont",InvestorPlace,/news/stocks/3-big-stock-charts-for-thursday-kellogg-regeneron-pharmaceuticals-newmont-1029058454
449.0,4/2/2020 7:06:50 PM,Don’t Pull the Trigger on AIM ImmunoTech Stock,InvestorPlace,/news/stocks/dont-pull-the-trigger-on-aim-immunotech-stock-1029060632
450.0,4/3/2020 7:23:24 AM,"Regeneron, Sanofi Announce Detailed Positive Results From Dupixent Trial ",RTTNews,/news/stocks/regeneron-sanofi-announce-detailed-positive-results-from-dupixent-trial-1029061424
451.0,4/3/2020 6:40:36 PM,Regeneron launches studies of Kevzara for COVID-19,Seeking Alpha,https://seekingalpha.com/news/3558341-regeneron-launches-studies-of-kevzara-for-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral
452.0,4/3/2020 8:14:49 PM,Stock Market Today: Huge Jobs Miss; Amazon Prime Day Delay,InvestorPlace,/news/stocks/stock-market-today-huge-jobs-miss-amazon-prime-day-delay-1029064645
453.0,4/5/2020 6:55:44 PM,Incyte details late-stage data on ruxolitinib cream for atopic dermatitis,Seeking Alpha,https://seekingalpha.com/news/3558456-incyte-details-late-stage-data-on-ruxolitinib-cream-for-atopic-dermatitis?utm_source=markets.businessinsider.com&utm_medium=referral
454.0,4/6/2020 9:16:13 PM,Regeneron reworks Praluent agreements with Sanofi,Seeking Alpha,https://seekingalpha.com/news/3558806-regeneron-reworks-praluent-agreements-sanofi?utm_source=markets.businessinsider.com&utm_medium=referral
455.0,4/8/2020 11:25:58 AM,BofA likes Molina Healthcare in premarket analyst action,Seeking Alpha,https://seekingalpha.com/news/3559236-bofa-likes-molina-healthcare-in-premarket-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral
456.0,4/8/2020 12:13:50 PM,"Zai Lab To Commercialize REGN1979 In Oncology In Mainland China, Hong Kong ",RTTNews,/news/stocks/zai-lab-to-commercialize-regn1979-in-oncology-in-mainland-china-hong-kong-1029075012
457.0,4/9/2020 8:39:10 PM,Goldman Sachs: These Are the 5 Best Stocks for an Economic Recovery,InvestorPlace,/news/stocks/goldman-sachs-these-are-the-5-best-stocks-for-an-economic-recovery-1029081925
458.0,4/14/2020 2:46:55 PM,Moderna Stock Is the Greatest Coronavirus Speculation Play,InvestorPlace,/news/stocks/moderna-mrna-stock-greatest-coronavirus-speculation-1029090629
459.0,4/14/2020 6:53:58 PM,Three Reasons to Consider Buying Regeneron Stock,InvestorPlace,/news/stocks/three-reasons-to-consider-buying-regeneron-stock-1029091256
460.0,4/16/2020 11:16:45 AM,FDA accepts Regeneron application for Ebola treatment,Seeking Alpha,https://seekingalpha.com/news/3561202-fda-accepts-regeneron-application-for-ebola-treatment?utm_source=markets.businessinsider.com&utm_medium=referral
461.0,4/16/2020 12:03:07 PM,Stock Alert: Regeneron Touches New High ,RTTNews,/news/stocks/stock-alert-regeneron-touches-new-high-1029097470
462.0,4/16/2020 1:12:55 PM,Regeneron Pharma: FDA To Review BLA For REGN-EB3 - Quick Facts ,RTTNews,/news/stocks/regeneron-pharma-fda-to-review-bla-for-regn-eb3-quick-facts-1029097803
463.0,4/17/2020 7:55:00 AM,"BTAI On Track To Report SERENITY Data, REGN Hits All-time High, THMO On Watch ",RTTNews,/news/stocks/btai-on-track-to-report-serenity-data-regn-hits-all-time-high-thmo-on-watch-1029101040
464.0,4/17/2020 11:18:06 AM,Benchmark likes Regeneron in premarket analyst action,Seeking Alpha,https://seekingalpha.com/news/3561611-benchmark-likes-regeneron-in-premarket-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral
465.0,4/21/2020 12:21:00 PM,7 of the Best Large-Cap Stocks to Buy Now,InvestorPlace,/news/stocks/7-of-the-best-large-cap-stocks-to-buy-now-1029112995
466.0,4/21/2020 4:33:49 PM,10 S&P 500 Stocks That Are Still Overvalued By Discounted Cash Flow,InvestorPlace,/news/stocks/10-sp-500-stocks-that-are-still-overvalued-by-discounted-cash-flow-1029113970
467.0,4/24/2020 3:41:09 PM,7 Beautiful Biotech Stocks to Buy Here,InvestorPlace,/news/stocks/7-beautiful-biotech-stocks-to-buy-here-1029127761
468.0,4/27/2020 11:23:34 AM,Regeneron and Sanofi's Kevzara shows no clinical benefit in COVID-19 study,Seeking Alpha,https://seekingalpha.com/news/3564541-regeneron-and-sanofis-kevzara-shows-no-clinical-benefit-in-covidminus-19-study?utm_source=markets.businessinsider.com&utm_medium=referral
469.0,4/27/2020 11:33:55 AM,Sanofi and Regeneron's Libtayo successful in lung cancer study,Seeking Alpha,https://seekingalpha.com/news/3564552-sanofi-and-regenerons-libtayo-successful-in-lung-cancer-study?utm_source=markets.businessinsider.com&utm_medium=referral
470.0,4/27/2020 1:38:15 PM,"Regeneron, Sanofi: Libtayo Meets Primary Endpoint In Phase 3 Trial ",RTTNews,/news/stocks/regeneron-sanofi-libtayo-meets-primary-endpoint-in-phase-3-trial-1029132372
471.0,4/27/2020 1:57:33 PM,"Regeneron, Sanofi To Amend Trial To Enroll Only Critical COVID-19 Patients ",RTTNews,/news/stocks/regeneron-sanofi-to-amend-trial-to-enroll-only-critical-covid-19-patients-1029132423
472.0,4/27/2020 8:18:18 PM,Stock Market Today: Small-Cap Stocks Roar to Life; GM Cuts Dividend,InvestorPlace,/news/stocks/stock-market-today-small-cap-stocks-roar-to-life-gm-cuts-dividend-1029134906
473.0,4/28/2020 4:29:38 AM,Biotech Stocks Facing FDA Decision In May 2020 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-may-2020-1029135147
474.0,4/28/2020 3:00:56 PM,10 Stocks to Buy for an Aging Population,InvestorPlace,/news/stocks/10-stocks-to-buy-for-an-aging-population-1029139728
475.0,4/30/2020 7:27:25 PM,It’s Still Best to Avoid IBIO Stock Despite Any Hype,InvestorPlace,/news/stocks/its-still-best-to-avoid-ibio-stock-despite-any-hype-1029152394
476.0,5/4/2020 3:01:31 PM,Regeneron Pharmaceuticals earnings: here's what to expect,Markets Insider Automation,/news/stocks/regeneron-q1-earnings-preview-stock-1029160210
477.0,5/4/2020 9:35:56 PM,Regeneron Pharmaceuticals Q1 2020 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3568418-regeneron-pharmaceuticals-q1-2020-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral
478.0,5/5/2020 7:32:27 AM,Sanofi: Libtayo Shows Clinically-Meaningful And Durable Responses In Skin Cancer ,RTTNews,/news/stocks/sanofi-libtayo-shows-clinically-meaningful-and-durable-responses-in-skin-cancer-1029163766
479.0,5/5/2020 11:46:06 AM,Regeneron Pharma Q1 Dupixent sales up 129%; shares up 5% premarket,Seeking Alpha,https://seekingalpha.com/news/3569017-regeneron-pharma-q1-dupixent-sales-up-129-shares-up-5-premarket?utm_source=markets.businessinsider.com&utm_medium=referral
480.0,5/5/2020 12:35:20 PM,Regeneron Pharmaceuticals Q1 adjusted earnings Beat Estimates,RTTNews,/news/stocks/regeneron-pharmaceuticals-q1-adjusted-earnings-beat-estimates-1029164727
481.0,5/5/2020 7:10:15 PM,The Trends are Mostly Friendly for Moderna Stock Investors,InvestorPlace,/news/stocks/the-trends-are-mostly-friendly-for-mrna-stock-investors-1029167815
482.0,5/5/2020 8:48:05 PM,Regeneron widens its lead as the S&P 500's top performer after saying key COVID-19 drug may be available in the fall (REGN),Business Insider,https://markets.businessinsider.com/news/stocks/regeneron-stock-price-earnings-coronavirus-drug-update-sp500-best-performer-2020-5-1029167569
483.0,5/15/2020 5:23:40 PM,3 Earnings Stocks to Buy While They Climb Above Everything Else,InvestorPlace,/news/stocks/3-earnings-stocks-to-buy-while-they-climb-1029207569
484.0,5/22/2020 1:52:27 PM,Gilead Stock Is Worth Owning With or Without a Coronavirus Cure,InvestorPlace,/news/stocks/gilead-stock-is-worth-owning-with-or-without-a-coronavirus-cure-1029227089
485.0,5/25/2020 3:46:08 PM,Regeneron's Dupixent successful in esophagus inflammation study,Seeking Alpha,https://seekingalpha.com/news/3577368-regenerons-dupixent-successful-in-esophagus-inflammation-study?utm_source=markets.businessinsider.com&utm_medium=referral
486.0,5/25/2020 6:08:02 PM,Sanofi to shed 20.6% stake in Regeneron,Seeking Alpha,https://seekingalpha.com/news/3577375-sanofi-to-shed-20_6-stake-in-regeneron?utm_source=markets.businessinsider.com&utm_medium=referral
487.0,5/26/2020 4:13:15 PM,Stock Alert: Regeneron Pharma Down 4% ,RTTNews,/news/stocks/stock-alert-regeneron-pharma-down-4-1029233935
488.0,5/27/2020 2:57:35 AM,Regeneron Announces Pricing Of Secondary Offering Of Its Stock Held By Sanofi At $515.00/shr ,RTTNews,/news/stocks/regeneron-announces-pricing-of-secondary-offering-of-its-stock-held-by-sanofi-at-515-00-shr-1029235441
489.0,5/27/2020 4:07:36 AM,Sanofi : FDA Approves Dupixentas To Treat Moderate-to-severe Atopic Dermatitis ,RTTNews,/news/stocks/sanofi-fda-approves-dupixentas-to-treat-moderate-to-severe-atopic-dermatitis-1029235458
490.0,5/27/2020 7:58:51 AM,Regeneron prices secondary equity offering at $515,Seeking Alpha,https://seekingalpha.com/news/3577758-regeneron-prices-secondary-equity-offering-515?utm_source=markets.businessinsider.com&utm_medium=referral
491.0,5/27/2020 2:55:53 PM,Regeneron Stock Is a Solid Long-Term Buy,InvestorPlace,/news/stocks/regeneron-stock-buy-now-hold-long-run-coronavirus-1029238777
492.0,5/29/2020 6:00:00 AM,All eyes on ASCO,Seeking Alpha,https://seekingalpha.com/news/3578520-all-eyes-on-asco?utm_source=markets.businessinsider.com&utm_medium=referral
493.0,5/29/2020 2:28:08 PM,"Regeneron : Data On Libtayo Shows Longer Durability, Higher Complete Response Rates In Skin Cancer ",RTTNews,/news/stocks/regeneron-data-on-libtayo-shows-longer-durability-higher-complete-response-rates-in-skin-cancer-1029263185
494.0,5/29/2020 3:12:19 PM,Regeneron and Sanofi's cemiplimab shows benefit in type of skin cancer,Seeking Alpha,https://seekingalpha.com/news/3578703-regeneron-and-sanofis-cemiplimab-shows-benefit-in-type-of-skin-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
495.0,5/29/2020 8:09:08 PM,Regeneron completes offering of Sanofi-held stock,Seeking Alpha,https://seekingalpha.com/news/3578773-regeneron-completes-offering-of-sanofi-held-stock?utm_source=markets.businessinsider.com&utm_medium=referral
496.0,6/1/2020 11:56:09 AM,Regeneron and Intellia expand partnership into hemophilia,Seeking Alpha,https://seekingalpha.com/news/3578922-regeneron-and-intellia-expand-partnership-hemophilia?utm_source=markets.businessinsider.com&utm_medium=referral
497.0,6/1/2020 5:31:52 PM,Is Inovio Pharmaceuticals Really Just the Next Theranos?,InvestorPlace,/news/stocks/is-ino-stock-really-just-the-next-theranos-1029269780
498.0,6/2/2020 6:27:39 AM,"NTLA Gains On Amended REGN Deal, GILD Reports SIMPLE Results, MYOV On Watch, NVUS Slumps ",RTTNews,/news/stocks/ntla-gains-on-amended-regn-deal-gild-reports-simple-results-myov-on-watch-nvus-slumps-1029270685
499.0,6/2/2020 9:06:00 AM,Genzyme Corporation -- Moody's affirms Sanofi's A1 ratings following the sale of its stake in Regeneron,Moodys,/news/bonds/genzyme-corporation-moody-s-affirms-sanofi-s-a1-ratings-following-the-sale-of-its-stake-in-regeneron-1029271093
500.0,6/3/2020 11:49:25 AM,Replimune lead drug shows benefit in non-melanoma skin cancer,Seeking Alpha,https://seekingalpha.com/news/3579961-replimune-lead-drug-shows-benefit-in-non-melanoma-skin-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
501.0,6/11/2020 7:14:42 AM,Sanofi To Present Strategy For Dupixent In Type 2 Inflammatory Diseases ,RTTNews,/news/stocks/sanofi-to-present-strategy-for-dupixent-in-type-2-inflammatory-diseases-1029299266
502.0,6/11/2020 11:23:56 AM,Regeneron initiates study of antibody cocktail for COVID-19,Seeking Alpha,https://seekingalpha.com/news/3582201-regeneron-initiates-study-of-antibody-cocktail-for-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral
503.0,6/11/2020 1:02:44 PM,Regeneron's (REGN) Resplendent Journey From $60 To $600 In 9 Years ,RTTNews,/news/stocks/regeneron-s-regn-resplendent-journey-from-60-to-600-in-9-years-1029300043
504.0,6/11/2020 1:29:14 PM,Regeneron Begins Clinical Trial Of Anti-Viral Antibody Cocktail Against COVID-19 ,RTTNews,/news/stocks/regeneron-begins-clinical-trial-of-anti-viral-antibody-cocktail-against-covid-19-1029300159
505.0,6/11/2020 3:22:25 PM,Momentum mover candidates on a down market day,Seeking Alpha,https://seekingalpha.com/news/3582348-momentum-mover-candidates-on-down-market-day?utm_source=markets.businessinsider.com&utm_medium=referral
506.0,6/15/2020 6:09:17 PM,Warren Buffett stock screen yields seven picks,Seeking Alpha,https://seekingalpha.com/news/3583116-warren-buffett-stock-screen-yields-seven-picks?utm_source=markets.businessinsider.com&utm_medium=referral
507.0,6/17/2020 6:50:26 PM,"As Biogen Stock Struggles, Look Elsewhere for Biotech Exposure",InvestorPlace,/news/stocks/as-biogen-stock-struggles-look-elsewhere-for-biotech-exposure-1029319275
508.0,6/19/2020 11:54:37 AM,Regeneron and Sanofi's Dupixent OK'd in China for atopic dermatitis,Seeking Alpha,https://seekingalpha.com/news/3584472-regeneron-and-sanofis-dupixent-okd-in-china-for-atopic-dermatitis?utm_source=markets.businessinsider.com&utm_medium=referral
509.0,6/19/2020 1:46:24 PM,Regeneron : China Okays Dupixent To Treat Moderate-to-Severe Atopic Dermatitis In Adults ,RTTNews,/news/stocks/regeneron-china-okays-dupixent-to-treat-moderate-to-severe-atopic-dermatitis-in-adults-1029325303
510.0,6/22/2020 6:27:39 PM,3 Great Growth Stocks That Kept Climbing in This Tough Market,InvestorPlace,/news/stocks/3-great-growth-stocks-that-kept-climbing-in-this-tough-market-1029331174
511.0,6/24/2020 9:39:51 PM,Regeneron To Defend Allegations On Contributions To Patient Assistance Charity ,RTTNews,/news/stocks/regeneron-to-defend-allegations-on-contributions-to-patient-assistance-charity-1029339595
512.0,6/25/2020 6:19:00 PM,Enough Already! Ditch Moderna Stock,InvestorPlace,/news/stocks/sell-mrna-stock-covid-19-catalyst-inflates-valuation-1029060294
513.0,7/3/2020 7:04:30 AM,"IMMU Continues Ascent, IDXG On Fire, REGN's Kevzara Disappoints In COVID-19 Trial, BLFS On Watch ",RTTNews,/news/stocks/immu-continues-ascent-idxg-on-fire-regn-s-kevzara-disappoints-in-covid-19-trial-blfs-on-watch-1029364611
514.0,7/3/2020 7:45:46 AM,"Sanofi, Regeneron Stop Kevzara COVID-19 Trial In U.S. After Failing To Meet Key Goals ",RTTNews,/news/stocks/sanofi-regeneron-stop-kevzara-covid-19-trial-in-u-s-after-failing-to-meet-key-goals-1029364666
515.0,7/6/2020 1:22:11 PM,Regeneron Begins Late-stage Clinical Trials Evaluating REGN-COV2 - Quick Facts ,RTTNews,/news/stocks/regeneron-begins-late-stage-clinical-trials-evaluating-regn-cov2-quick-facts-1029368476
516.0,7/6/2020 6:43:12 PM,Moderna Stock Has a Bright Future After the Coronavirus,InvestorPlace,/news/stocks/moderna-mrna-stock-coronavirus-vaccine-drug-discovery-1029370223
517.0,7/7/2020 9:45:41 AM,"BLU Plunges On RELIEF Data, FDA Places CLLS' Trial On Hold, IMMU Hits New High, OTIC Music To Ears ",RTTNews,/news/stocks/blu-plunges-on-relief-data-fda-places-clls-trial-on-hold-immu-hits-new-high-otic-music-to-ears-1029371231
518.0,7/7/2020 1:21:01 PM,Regeneron Enters Manufacturing And Supply Deal With BARDA For REGN-COV2 ,RTTNews,/news/stocks/regeneron-enters-manufacturing-and-supply-deal-with-barda-for-regn-cov2-1029371939
519.0,7/8/2020 9:27:24 AM,"CRVS, HEPA Jump On COVID-19 Drug Bandwagon, LVGO In Good Health, NVAX Joins $100 Stock Price Club ",RTTNews,/news/stocks/crvs-hepa-jump-on-covid-19-drug-bandwagon-lvgo-in-good-health-nvax-joins-100-stock-price-club-1029375209
520.0,7/10/2020 12:23:01 PM,Potential Alzheimer’s Drug Not Enough to Excite Biogen Stock Investors,InvestorPlace,/news/stocks/potential-alzheimers-drug-not-enough-to-excite-biogen-stock-investors-1029384005
521.0,7/10/2020 2:43:24 PM,Delta Still a Strong Pick Despite Uptick in Covid-19 Cases,InvestorPlace,/news/stocks/delta-still-a-strong-pick-despite-uptick-in-covid-19-cases-1029384333
522.0,7/15/2020 11:36:51 AM,Novavax Stock Has Probably Topped Out Until Successful Clinical Trials,InvestorPlace,/news/stocks/nvax-stock-topped-out-clinical-trials-1029397795
523.0,8/4/2020 3:03:46 PM,Here's what to expect from Regeneron Pharmaceuticals's earnings,Markets Insider Automation,/news/stocks/regeneron-stock-price-quarter-earnings-preview-q2-1029466846
524.0,8/5/2020 12:59:38 PM,Regeneron Pharmaceuticals Q2 adjusted earnings Beat Estimates,RTTNews,/news/stocks/regeneron-pharmaceuticals-q2-adjusted-earnings-beat-estimates-1029471861
525.0,8/5/2020 1:59:32 PM,Novavax Stock Needs Solid Results Beyond Headlines,InvestorPlace,/news/stocks/nvax-stock-needs-solid-results-beyond-headlines-1029473742
526.0,8/5/2020 4:01:08 PM,Merck Stock Remains a Dull Biotech Play Despite Earnings Success,InvestorPlace,/news/stocks/merck-mrk-stock-remains-a-dull-biotech-play-despite-earnings-success-1029474241
527.0,8/5/2020 5:42:00 PM,"Regeneron Pharmaceuticals, Inc. -- Moody's assigns Baa3 issuer rating to Regeneron",Moodys,/news/bonds/regeneron-pharmaceuticals-inc-moody-s-assigns-baa3-issuer-rating-to-regeneron-1029474142
528.0,8/7/2020 3:56:00 AM,"Regeneron Pharmaceuticals, Inc. -- Moody's assigns Baa3 issuer rating to Regeneron",Moodys,/news/bonds/regeneron-pharmaceuticals-inc-moody-s-assigns-baa3-issuer-rating-to-regeneron-1029480692
529.0,8/7/2020 4:57:00 PM,"Regeneron Pharmaceuticals, Inc. -- Moody's rates Regeneron's sr. notes Baa3; stable outlook",Moodys,/news/bonds/regeneron-pharmaceuticals-inc-moody-s-rates-regeneron-s-sr-notes-baa3-stable-outlook-1029482649
530.0,8/7/2020 8:13:00 PM,"Regeneron Pharmaceuticals, Inc. -- Moody's assigns Baa3 issuer rating to Regeneron",Moodys,/news/bonds/regeneron-pharmaceuticals-inc-moody-s-assigns-baa3-issuer-rating-to-regeneron-1029483162
531.0,8/11/2020 4:38:00 PM,Sanofi -- Moody's announces completion of a periodic review of ratings of Sanofi,Moodys,/news/bonds/sanofi-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-sanofi-1029492648
532.0,8/18/2020 10:30:29 AM,"Regeneron Stock Is a Play For Covid-19, And More",InvestorPlace,/news/stocks/regeneron-stock-a-covid-19-play-and-more-1029512464
533.0,8/19/2020 7:31:19 AM,"Regeneron, Roche Collaborate To Manufacture And Distribute Investigational Drug For COVID-19 ",RTTNews,/news/stocks/regeneron-roche-collaborate-to-manufacture-and-distribute-investigational-drug-for-covid-19-1029515275
534.0,8/19/2020 9:16:39 AM,"Once Slow, Stable Sanofi Stock is Now Pharma’s Most-Talked About Name",InvestorPlace,/news/stocks/once-slow-stable-sny-stock-is-now-pharmas-most-talked-about-name-1029515915
535.0,8/21/2020 5:42:52 PM,7 Index Funds To Buy For A Firm Portfolio Foundation,InvestorPlace,/news/stocks/7-index-funds-to-buy-for-a-firm-portfolio-foundation-1029524805
536.0,8/24/2020 7:21:10 PM,6 Hot Coronavirus Stocks Moving At “Warp Speed”,InvestorPlace,/news/stocks/6-hot-coronavirus-stocks-moving-at-warp-speed-1029529073
537.0,8/25/2020 11:30:20 AM,7 Hot Stocks to Buy Before It’s Too Late,InvestorPlace,/news/stocks/7-hot-stocks-to-buy-before-its-too-late-1029531264
538.0,8/25/2020 1:46:20 PM,The 5 Best Tech ETFs to Buy for Safer Growth,InvestorPlace,/news/stocks/the-5-best-tech-etfs-to-buy-for-safer-growth-1029532192
539.0,9/2/2020 2:21:45 PM,4 Pharmaceutical Stocks With Deep Pipelines,InvestorPlace,/news/stocks/4-pharmaceutical-stocks-deep-pipelines-coronavirus-1029557234
540.0,9/5/2020 7:33:19 PM,Graybug Vision readies IPO,Seeking Alpha,https://seekingalpha.com/news/3611911-graybug-vision-readies-ipo?utm_source=markets.businessinsider.com&utm_medium=referral
541.0,9/8/2020 7:54:31 AM,Sanofi/Regeneron Dupixent shows sustained benefit in asthma extension study,Seeking Alpha,https://seekingalpha.com/news/3611966-sanofi-regeneron-dupixent-shows-sustained-benefit-in-asthma-extension-study?utm_source=markets.businessinsider.com&utm_medium=referral
542.0,9/8/2020 8:25:27 AM,Regeneron/Sanofi Reveal Promising Long-term Data Of Dupixent In Moderate-to-severe Asthma ,RTTNews,/news/stocks/regeneron-sanofi-reveal-promising-long-term-data-of-dupixent-in-moderate-to-severe-asthma-1029567740
543.0,9/10/2020 2:50:34 PM,5 of the Best Pharmaceutical Stocks to Buy Right Now,InvestorPlace,/news/stocks/5-best-pharmaceutical-stocks-buy-right-now-1029342722
544.0,9/14/2020 7:18:51 AM,Regeneron And Sanofi: Dupixent Granted FDA Breakthrough Therapy Designation For EoE ,RTTNews,/news/stocks/regeneron-and-sanofi-dupixent-granted-fda-breakthrough-therapy-designation-for-eoe-1029584396
545.0,9/14/2020 3:12:54 PM,Regeneron's Antibody Cocktail To Be Tested In RECOVERY COVID-19 Phase 3 Trial In UK ,RTTNews,/news/stocks/regeneron-s-antibody-cocktail-to-be-tested-in-recovery-covid-19-phase-3-trial-in-uk-1029586176
546.0,9/16/2020 5:35:56 PM,Eli Lilly Stock Looks Hot on New Antibody Drug Evidence,InvestorPlace,/news/stocks/eli-lilly-stock-looks-hot-on-new-antibody-drug-evidence-1029596051
547.0,9/17/2020 1:35:51 PM,SRNE Stock: Sorrento Therapeutics Pops on Plans to Launch Drug Trials,InvestorPlace,/news/stocks/srne-stock-sorrento-therapeutics-pops-on-plans-to-launch-drug-trials-1029599296
548.0,9/18/2020 5:47:20 PM,Roche Stock Rallies on Promising Coronavirus Drug Results,InvestorPlace,/news/stocks/roche-stock-rallies-on-promising-coronavirus-drug-results-1029604090
549.0,9/21/2020 5:10:56 PM,"Tread Carefully, But Sorrento Stock Could Continue to Bounce Back",InvestorPlace,/news/stocks/tread-carefully-buy-srne-stock-continue-bounce-back-1029608339
550.0,9/26/2020 7:59:23 PM,Biotech Stocks Facing FDA Decision In October 2020 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-october-2020-1029624668
551.0,9/30/2020 3:12:38 PM,Regeneron Says Antibody Cocktail REGN-COV2 Reduced Symptoms In COVID-19 Patients ,RTTNews,/news/stocks/regeneron-says-antibody-cocktail-regn-cov2-reduced-symptoms-in-covid-19-patients-1029635495
552.0,10/4/2020 5:58:53 AM,Trump Says 'real Test' Ahead In His COVID-19 Fight ,RTTNews,/news/stocks/trump-says-real-test-ahead-in-his-covid-19-fight-1029646001
553.0,10/5/2020 2:25:32 PM,This Is Why I’d Still Avoid IBio for Now,InvestorPlace,/news/stocks/this-is-why-id-still-avoid-vaccine-stock-ibio-for-now-cseo-1029649209
554.0,10/5/2020 4:14:48 PM,Stock Alert: Regeneron Pharmaceuticals Gains 6% ,RTTNews,/news/stocks/stock-alert-regeneron-pharmaceuticals-gains-6-1029648746
555.0,10/5/2020 5:51:28 PM,Regeneron jumps 10% as Trump gets the drugmaker's antibody treatment,Business Insider,https://www.businessinsider.com/regeneron-stock-price-trump-receives-antibody-treatment-drugmaker-covid19-2020-10
556.0,10/5/2020 7:38:56 PM,Regeneron Pharmaceuticals Stock Shoots Up 8% on Trump Treatment,InvestorPlace,/news/stocks/regeneron-pharmaceuticals-stock-shoots-up-on-trump-coronavirus-treatment-1029649665
557.0,10/5/2020 8:45:55 PM,"4 Top Stock Trades for Tuesday: SQ, REGN, APHA, TLRY",InvestorPlace,/news/stocks/4-top-stock-trades-for-tuesday-sq-regn-apha-tlry-1029650309
558.0,10/6/2020 3:37:29 AM,Allele Bio files two lawsuits for patent infringement of mNeonGreen used in COVID-19 vaccines,Seeking Alpha,https://seekingalpha.com/news/3619990-allele-bio-files-two-lawsuits-for-patent-infringement-of-mneongreen-used-in-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral
559.0,10/6/2020 11:14:27 AM,Biogen files application in Europe for Lucentis biosimilar,Seeking Alpha,https://seekingalpha.com/news/3620040-biogen-files-application-in-europe-for-lucentis-biosimilar?utm_source=markets.businessinsider.com&utm_medium=referral
560.0,10/6/2020 1:04:20 PM,OGEN Stock: Why Oragenics Is Soaring 25%,InvestorPlace,/news/stocks/ogen-stock-why-oragenics-is-soaring-25-today-1029653068
561.0,10/7/2020 9:01:32 AM,"At This Stage of the Vaccine Race, Is Now a Good Time to Buy iBio Stock?",InvestorPlace,/news/stocks/at-this-stage-of-the-vaccine-race-is-now-a-good-time-to-buy-ibio-stock-1029656066
562.0,10/7/2020 12:28:15 PM,Inovio Pharmaceuticals Does Not Need Any More Misfortune,InvestorPlace,/news/stocks/ino-stock-needs-change-fortunes-1029657681
563.0,10/7/2020 1:01:10 PM,Lilly files for emergency use authorization in U.S. for COVID-19 antibody,Seeking Alpha,https://seekingalpha.com/news/3620445-lilly-files-for-emergency-use-authorization-in-u-s-for-covidminus-19-antibody?utm_source=markets.businessinsider.com&utm_medium=referral
564.0,10/7/2020 10:06:46 PM,Regeneron +2.3% after Trump praises drug in new video,Seeking Alpha,https://seekingalpha.com/news/3620637-regeneronplus-2_3-after-trump-praises-drug-in-new-video?utm_source=markets.businessinsider.com&utm_medium=referral
565.0,10/8/2020 2:55:05 AM,Regeneron seeks FDA emergency clearance for COVID-19 therapy,Seeking Alpha,https://seekingalpha.com/news/3620656-regeneron-seeks-fda-emergency-clearance-for-covidminus-19-therapy?utm_source=markets.businessinsider.com&utm_medium=referral
566.0,10/8/2020 2:55:05 AM,Regeneron seeks FDA emergency use nod for COVID-19 therapy,Seeking Alpha,https://seekingalpha.com/news/3620656-regeneron-seeks-fda-emergency-use-nod-for-covidminus-19-therapy?utm_source=markets.businessinsider.com&utm_medium=referral
567.0,10/8/2020 12:22:49 PM,Regeneron and Lilly to get emergency approval for antibody treatments - Trump,Seeking Alpha,https://seekingalpha.com/news/3620753-regeneron-and-lilly-to-get-emergency-approval-for-antibody-treatments-trump?utm_source=markets.businessinsider.com&utm_medium=referral
568.0,10/8/2020 12:47:23 PM,"Pre-market Movers In Healthcare Sector: CDNA, IMTX, REGN, CRSP, TLC... ",RTTNews,/news/stocks/pre-market-movers-in-healthcare-sector-cdna-imtx-regn-crsp-tlc-1029660747
569.0,10/8/2020 1:56:34 PM,REGN Stock: Regeneron Pops on Trump’s Antibody Support,InvestorPlace,/news/stocks/regn-stock-regeneron-pops-on-trumps-antibody-support-1029662216
570.0,10/8/2020 3:37:58 PM,Regeneron Seeks Emergency Use Authorization For Its Antibody Treatment For Covid-19 ,RTTNews,/news/stocks/regeneron-seeks-emergency-use-authorization-for-its-antibody-treatment-for-covid-19-1029661974
571.0,10/8/2020 11:22:13 PM,Oppenheimer sees divided sector in 'critical' months for biotech,Seeking Alpha,https://seekingalpha.com/news/3620981-oppenheimer-sees-divided-sector-in-critical-months-for-biotech?utm_source=markets.businessinsider.com&utm_medium=referral
572.0,10/9/2020 4:37:25 PM,Covid-19 Therapeutics May Push Novavax Out of the Spotlight,InvestorPlace,/news/stocks/covid-19-therapeutics-may-push-nvax-stock-out-of-the-spotlight-cseo-1029666747
573.0,10/9/2020 6:09:50 PM,Sorrento Stock Investors Should Play Powerball Instead,InvestorPlace,/news/stocks/srne-stock-how-to-get-rich-off-shareholders-1029666739
574.0,10/9/2020 8:25:25 PM,COVID-19 drug developer Atea Pharmaceuticals files for IPO,Seeking Alpha,https://seekingalpha.com/news/3621228-covidminus-19-drug-developer-atea-pharmaceuticals-files-for-ipo?utm_source=markets.businessinsider.com&utm_medium=referral
575.0,10/12/2020 8:58:31 PM,7 Highly Rated Pharmaceutical Stocks for Q4,InvestorPlace,/news/stocks/7-highly-rated-pharmaceutical-stocks-for-q4-1029679826
576.0,10/13/2020 5:48:44 AM,Sanofi/Regeneron Dupixent reduces asthma attacks and improves lung function in children,Seeking Alpha,https://seekingalpha.com/news/3621561-sanofi-regeneron-dupixent-reduces-asthma-attacks-and-improves-lung-function-in-children?utm_source=markets.businessinsider.com&utm_medium=referral
577.0,10/13/2020 7:29:26 AM,Regeneron: Phase 3 Trial Shows Dupixent Significantly Reduces Severe Asthma Attacks In Children ,RTTNews,/news/stocks/regeneron-phase-3-trial-shows-dupixent-significantly-reduces-severe-asthma-attacks-in-children-1029672228
578.0,10/13/2020 6:46:50 PM,Eli Lilly's Covid-19 antibody trial paused over safety concerns,Seeking Alpha,https://seekingalpha.com/news/3621824-eli-lillys-covidminus-19-antibody-trial-paused-over-safety-concerns?utm_source=markets.businessinsider.com&utm_medium=referral
579.0,10/14/2020 8:31:39 AM,"LLY Pauses COVID-19 Antibody Trial, JNJ Boosts Annual Outlook, Double Whammy For GOSS ",RTTNews,/news/stocks/lly-pauses-covid-19-antibody-trial-jnj-boosts-annual-outlook-double-whammy-for-goss-1029677498
580.0,10/14/2020 8:53:13 PM,Regeneron's Inmazeb becomes first FDA-approved Ebola treatment,Seeking Alpha,https://seekingalpha.com/news/3622274-regenerons-inmazeb-becomes-first-fda-approved-ebola-treatment?utm_source=markets.businessinsider.com&utm_medium=referral
581.0,10/15/2020 5:13:33 AM,FDA Approves Regeneron's Inmazeb To Treat Ebola ,RTTNews,/news/stocks/fda-approves-regeneron-s-inmazeb-to-treat-ebola-1029681731
582.0,10/15/2020 8:06:24 AM,"FDA Approves 1st Ebola Drug, CYCN Drops Sickle Cell Disease Drug, VRTX Plunges In After-hours Trade ",RTTNews,/news/stocks/fda-approves-1st-ebola-drug-cycn-drops-sickle-cell-disease-drug-vrtx-plunges-in-after-hours-trade-1029682251
583.0,10/16/2020 10:26:34 AM,Get Ready To Bull Trade Novavax Stock For A Second Wave,InvestorPlace,/news/stocks/get-ready-to-bull-trade-novavax-stock-for-a-second-wave-1029688136
584.0,10/16/2020 12:58:15 PM,European advisory group backs expanded use of Regeneron/Sanofi's Dupixent,Seeking Alpha,https://seekingalpha.com/news/3622868-european-advisory-group-backs-expanded-use-of-regeneron-sanofis-dupixent?utm_source=markets.businessinsider.com&utm_medium=referral
585.0,10/16/2020 1:03:00 PM,7 Short-Term Stocks to Make a Quick Buck,InvestorPlace,/news/stocks/7-short-term-stocks-to-buy-for-quick-buck-1029688757
586.0,10/16/2020 5:53:26 PM,Can Cytonics Pivot Successfully to Covid-19 Therapeutics?,InvestorPlace,/news/stocks/cytonics-stock-pivot-coronavirus-therapeutics-1029689508
587.0,10/16/2020 5:53:36 PM,Novavax Stock Looks Volatile As Vaccine Enthusiasm Wanes,InvestorPlace,/news/stocks/nvax-stock-looks-volatile-as-vaccine-enthusiasm-wanes-1029689507
588.0,10/20/2020 7:37:18 PM,7 Ways to Minimize Your Risk in Growth Stocks,InvestorPlace,/news/stocks/7-ways-to-minimize-your-risk-in-growth-stocks-1029700736
589.0,10/21/2020 4:35:08 PM,"While Risky, Sorrento Therapeutics Has Many Options to Win",InvestorPlace,/news/stocks/while-risky-sorrento-therapeutics-has-many-options-to-win-1029706542
590.0,10/22/2020 5:31:38 PM,Is It Too Late for Novavax to Profit From a Covid-19 Vaccine?,InvestorPlace,/news/stocks/is-it-too-late-for-novavax-to-profit-from-a-covid-19-vaccine-1029712056
591.0,10/22/2020 9:37:48 PM,GILD News: Gilead Stock Pops as FDA Approves Remdesivir Treatment,InvestorPlace,/news/stocks/gild-news-gilead-stock-pops-as-fda-approves-remdesivir-treatment-1029712808
592.0,10/26/2020 6:45:58 AM,Biotech Stocks Facing FDA Decision In November 2020 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-november-2020-1029718001
593.0,10/26/2020 5:19:07 PM,Don’t Get Swept Up In the Unproven Promise of Aptorum Group,InvestorPlace,/news/stocks/apm-stock-late-entry-covid-trade-1029722700
594.0,10/27/2020 6:48:04 AM,Lilly ends COVID-19 antibody trial after lack of improvement,Seeking Alpha,https://seekingalpha.com/news/3626170-lilly-ends-covidminus-19-antibody-trial-after-lack-of-improvement?utm_source=markets.businessinsider.com&utm_medium=referral
595.0,10/27/2020 8:54:51 PM,Repligen scoops up bioprocessing systems provider for $200M,Seeking Alpha,https://seekingalpha.com/news/3626867-repligen-scoops-up-bioprocessing-systems-provider-for-200m?utm_source=markets.businessinsider.com&utm_medium=referral
596.0,10/28/2020 12:59:39 PM,7 Cutting-Edge Biotech Stocks for Tomorrow ,InvestorPlace,/news/stocks/7-cutting-edge-biotech-stocks-for-tomorrow-1029734117
597.0,10/28/2020 9:43:52 PM,Regeneron +2.5% as prospective COVID-19 trial results show reduced medical visits,Seeking Alpha,https://seekingalpha.com/news/3627869-regeneronplus-2_5-prospective-covidminus-19-trial-results-show-reduced-medical-visits?utm_source=markets.businessinsider.com&utm_medium=referral
598.0,10/29/2020 11:42:20 AM,Regeneron Says Its Covid-19 Outpatient Therapy Could Reduce Virus Levels ,RTTNews,/news/stocks/regeneron-says-its-covid-19-outpatient-therapy-could-reduce-virus-levels-1029739764
599.0,10/29/2020 2:18:17 PM,Sanofi/Regeneron prevail in European patent dispute with Amgen over cholesterol drugs,Seeking Alpha,https://seekingalpha.com/news/3628348-sanofi-regeneron-prevail-in-european-patent-dispute-amgen-over-cholesterol-drugs?utm_source=markets.businessinsider.com&utm_medium=referral
600.0,10/29/2020 3:21:32 PM,"European Patent Office Rules In Favor Of Sanofi, Regeneron On Praluent ",RTTNews,/news/stocks/european-patent-office-rules-in-favor-of-sanofi-regeneron-on-praluent-1029742079
601.0,10/30/2020 1:50:44 PM,Regeneron to exclude severely/critically ill COVID-19 patients from antibody cocktail study,Seeking Alpha,https://seekingalpha.com/news/3629118-regeneron-to-exclude-severely-critically-ill-covidminus-19-patients-from-antibody-cocktail?utm_source=markets.businessinsider.com&utm_medium=referral
602.0,10/30/2020 3:21:03 PM,Regeneron : IDMC Recommends To Hold Enrollment In Hospitalized High Risk COVID-19 Patients ,RTTNews,/news/stocks/regeneron-idmc-recommends-to-hold-enrollment-in-hospitalized-high-risk-covid-19-patients-1029746946
603.0,11/2/2020 6:35:52 PM,"Despite Pandemic Catalysts, Tread Carefully With Sorrento Stock",InvestorPlace,/news/stocks/despite-pandemic-catalysts-tread-carefully-srne-stock-1029755014
604.0,11/2/2020 7:57:28 PM,Avoid Taking a Bet on the Deep Correction In Inovio Stock,InvestorPlace,/news/stocks/avoid-taking-a-bet-on-the-deep-correction-in-inovio-ino-stock-1029755366
605.0,11/3/2020 6:52:27 AM,"AUPH's Dry Eye Syndrome Study Fails, KPTI's SEAL Study Hits Goal, REGN Halts Rare Bone Disease Trial ",RTTNews,/news/stocks/auph-s-dry-eye-syndrome-study-fails-kpti-s-seal-study-hits-goal-regn-halts-rare-bone-disease-trial-1029756437
606.0,11/3/2020 1:42:00 PM,Your First Instinct About Sorrento Therapeutics Is Probably Right,InvestorPlace,/news/stocks/srne-stock-day-late-dollar-short-1029759222
607.0,11/3/2020 3:01:20 PM,4 Top Biotech Stocks to Buy for Operation Warp Speed,InvestorPlace,/news/stocks/4-top-biotech-stocks-to-buy-for-operation-warp-speed-1029759219
608.0,11/4/2020 5:09:18 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3631230-notable-earnings-thursdays-open?utm_source=markets.businessinsider.com&utm_medium=referral
609.0,11/4/2020 6:22:59 PM,Regeneron Pharmaceuticals Q3 2020 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3631354-regeneron-pharmaceuticals-q3-2020-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral
610.0,11/5/2020 12:37:31 PM,Regeneron Pharmaceuticals Q3 adjusted earnings Beat Estimates,RTTNews,/news/stocks/regeneron-pharmaceuticals-q3-adjusted-earnings-beat-estimates-1029769618
611.0,11/9/2020 4:55:35 PM,COVID-19 treatment developers under pressure on positive COVID-19 vaccine data,Seeking Alpha,https://seekingalpha.com/news/3633767-covidminus-19-treatment-developers-under-pressure-on-positive-covidminus-19-vaccine-data?utm_source=markets.businessinsider.com&utm_medium=referral
612.0,11/10/2020 10:32:33 PM,Market Insight: What’s Behind Monday’s Huge Rally,InvestorPlace,/news/stocks/market-insight-whats-behind-mondays-huge-rally-1029789442
613.0,11/11/2020 2:24:45 PM,9 Outbreak-Fueled Stocks to Buy This Week,InvestorPlace,/news/stocks/stocks-to-buy-this-week-second-coronavirus-wave-1029421408
614.0,11/16/2020 8:18:13 AM,New Drugs Approved In October ,RTTNews,/news/stocks/new-drugs-approved-in-october-1029804585
615.0,11/17/2020 12:28:35 PM,Health Canada OKs Sanofi/Regeneron's Dupixent for severe asthma,Seeking Alpha,https://seekingalpha.com/news/3637000-health-canada-oks-sanofi-regenerons-dupixent-for-severe-asthma?utm_source=markets.businessinsider.com&utm_medium=referral
616.0,11/17/2020 3:10:41 PM,7 Pharmaceutical Stocks to Buy for 2021 and Beyond ,InvestorPlace,/news/stocks/7-pharmaceutical-stocks-to-buy-for-2021-and-beyond-1029811903
617.0,11/17/2020 10:27:20 PM,Roche on track to produce Regeneron antibody treatment - Reuters,Seeking Alpha,https://seekingalpha.com/news/3637313-roche-on-track-to-produce-regeneron-antibody-treatment-reuters?utm_source=markets.businessinsider.com&utm_medium=referral
618.0,11/18/2020 3:38:01 PM,These 3 Companies Currently Provide Much Better Value Than Nio,InvestorPlace,/news/stocks/these-3-companies-currently-provide-much-better-value-than-nio-stock-cseo-1029817356
619.0,11/20/2020 11:48:18 AM,Roche anticipates COVID-19 antibody deliveries in Q1 2021: CEO Severin Schwan,Seeking Alpha,https://seekingalpha.com/news/3638254-roche-anticipates-covidminus-19-antibody-deliveries-in-q1-2021-ceo-severin-schwan?utm_source=markets.businessinsider.com&utm_medium=referral
620.0,11/20/2020 1:34:02 PM,"Inovio's INO-5401 + INO-9012 with Libtayo combo shows potential treatment for glioblastoma, shares +5%",Seeking Alpha,https://seekingalpha.com/news/3638311-inovios-inominus-5401-inominus-9012-libtayo-combo-shows-potential-treatment-for-glioblastoma?utm_source=markets.businessinsider.com&utm_medium=referral
621.0,11/22/2020 2:53:22 AM,FDA grants emergency clearance for Regeneron's COVID-19 threapy,Seeking Alpha,https://seekingalpha.com/news/3638520-fda-grants-emergency-clearance-for-regenerons-covidminus-19-threapy?utm_source=markets.businessinsider.com&utm_medium=referral
622.0,11/22/2020 4:38:50 PM,"Coronavirus update: Senator in quarantine, U.K. sets lockdown end, Japan spikes",Seeking Alpha,https://seekingalpha.com/news/3638526-coronavirus-update-senator-in-quarantine-u-k-sets-lockdown-end-japan-spikes?utm_source=markets.businessinsider.com&utm_medium=referral
623.0,11/23/2020 7:51:59 AM,FDA Grants Emergency Use Approval To Regeneron's COVID-19 Antibody Therapy ,RTTNews,/news/stocks/fda-grants-emergency-use-approval-to-regeneron-s-covid-19-antibody-therapy-1029828026
624.0,11/23/2020 11:16:48 AM,"Pre-market Movers In Healthcare Sector: EIGR, SNOA, REGN, TTNP, OCGN… ",RTTNews,/news/stocks/pre-market-movers-in-healthcare-sector-eigr-snoa-regn-ttnp-ocgn-1029828667
625.0,11/23/2020 11:31:46 AM,Take Your Victory Lap and Take Your Profits in Moderna,InvestorPlace,/news/stocks/moderna-mrna-stock-take-your-victory-lap-1029829432
626.0,11/23/2020 3:52:03 PM,REGN Stock: 11 Things for Investors to Know About Regeneron Approval,InvestorPlace,/news/stocks/regn-stock-11-things-for-investors-to-know-about-regeneron-approval-1029830793
627.0,11/24/2020 7:21:41 PM,"Pfizer, Moderna Lead the Vaccine Race: Here’s Where 7 Other Top Vaccine Stocks Stand",InvestorPlace,/news/stocks/7-biotech-stocks-locked-in-the-race-for-a-vaccine-1029836075
628.0,11/25/2020 10:56:26 AM,U.S. aims to release 6.4M COVID-19 vaccine doses in first tranche - Reuters,Seeking Alpha,https://seekingalpha.com/news/3639320-u-s-aims-to-release-6_4m-covidminus-19-vaccine-doses-in-first-tranche-reuters?utm_source=markets.businessinsider.com&utm_medium=referral
629.0,11/25/2020 6:25:04 PM,Merck and Biotech’s Swashbuckling Era,InvestorPlace,/news/stocks/swashbuckling-era-merck-mrk-stock-1029839832
630.0,11/30/2020 7:08:25 AM,Regeneron Reports Approval Of Dupixent In Europe For Children With Severe Atopic Dermatitis ,RTTNews,/news/stocks/regeneron-reports-approval-of-dupixent-in-europe-for-children-with-severe-atopic-dermatitis-1029847506
631.0,11/30/2020 9:31:33 AM,EC OKs expanded use of Sanofi/Regeneron's Dupixent for children with atopic dermatitis,Seeking Alpha,https://seekingalpha.com/news/3639833-ec-oks-expanded-use-of-sanofi-regenerons-dupixent-for-children-atopic-dermatitis?utm_source=markets.businessinsider.com&utm_medium=referral
632.0,11/30/2020 4:06:20 PM,Windows of Opportunity Are Tightening for Sorrento Therapeutics,InvestorPlace,/news/stocks/opportunity-tightening-for-sorrento-therapeutics-srne-stock-1029849981
633.0,12/1/2020 6:01:43 PM,4 Pharmaceutical Stocks That Aren’t Worth Their Outsized 2020 Gains,InvestorPlace,/news/stocks/4-pharmaceutical-stocks-ino-regn-abbv-nvax-that-arent-worth-their-2020-gains-1029854808
634.0,12/2/2020 8:11:23 AM,"OVID Plunges, VNDA's Hetlioz Scores Another FDA Nod, Auris Investors Smile Ear To Ear ",RTTNews,/news/stocks/ovid-plunges-vnda-s-hetlioz-scores-another-fda-nod-auris-investors-smile-ear-to-ear-1029856042
635.0,12/4/2020 6:30:49 AM,Reality Hits Home for Shares of Inovio Pharmaceuticals,InvestorPlace,/news/stocks/ino-stock-reality-hits-home-inovio-pharmaceuticals-1029866169
636.0,12/4/2020 9:21:23 PM,Don’t Chase the Rebound in Sorrento — It’s Not Worth the Risk,InvestorPlace,/news/stocks/dont-chase-rebound-in-srne-stock-not-worth-the-risk-1029866504
637.0,12/7/2020 3:26:47 PM,Regeneron Pharmaceuticals stands out at ASH after positive data on lead programs,Seeking Alpha,https://seekingalpha.com/news/3642120-regeneron-pharmaceuticals-stands-out-ash-after-positive-data-on-lead-programs?utm_source=markets.businessinsider.com&utm_medium=referral
638.0,12/8/2020 9:52:33 PM,The 7 Best Coronavirus Vaccine Stocks Still In The Race For A Cure,InvestorPlace,/news/stocks/the-7-best-coronavirus-vaccine-stocks-still-in-the-race-for-a-cure-1029875288
639.0,12/10/2020 11:01:11 AM,Government and Institutional Support Are Positives for Sorrento Stock,InvestorPlace,/news/stocks/government-institutional-support-sorrento-snre-stock-1029880666
640.0,12/15/2020 3:35:00 PM,"Regeneron Pharmaceuticals, Inc. -- Moody's announces completion of a periodic review of ratings of Regeneron Pharmaceuticals, Inc.",Moodys,/news/bonds/regeneron-pharmaceuticals-inc-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-regeneron-pharmaceuticals-inc-1029894379
641.0,12/15/2020 8:04:08 PM,Regeneron's odronextamab hit with FDA partial hold on lymphoma trials,Seeking Alpha,https://seekingalpha.com/news/3644594-regenerons-odronextamab-hit-fda-partial-hold-on-lymphoma-trials?utm_source=markets.businessinsider.com&utm_medium=referral
642.0,12/18/2020 7:41:39 PM,Vir Biotech’s COVID-19 agents could be ‘NPV negative’: Baird,Seeking Alpha,https://seekingalpha.com/news/3645867-vir-biotech-s-covidminus-19-agents-be-npv-negative-baird?utm_source=markets.businessinsider.com&utm_medium=referral
643.0,12/23/2020 10:21:52 AM,7 Short-Term Stocks To Buy for a Happy New Year  ,InvestorPlace,/news/stocks/7-short-term-stocks-to-buy-for-a-happy-new-year-1029916535
644.0,12/24/2020 12:36:39 PM,Judge blocks ‘Most-Favored Nation’ rule for drug pricing,Seeking Alpha,https://seekingalpha.com/news/3647316-judge-blocks-favored-nation-rule-for-drug-pricing?utm_source=markets.businessinsider.com&utm_medium=referral
645.0,12/29/2020 8:08:08 PM,COVID-19 antibody therapies left unused; developers carry on regardless,Seeking Alpha,https://seekingalpha.com/news/3647775-covidminus-19-antibody-therapies-left-unused-developers-carry-on-regardless?utm_source=markets.businessinsider.com&utm_medium=referral
646.0,12/29/2020 10:17:06 PM,Regeneron's COVID-19 antibody therapy yields 'encouraging' trial data,Seeking Alpha,https://seekingalpha.com/news/3647800-regenerons-covidminus-19-antibody-therapy-yields-encouraging-trial-data?utm_source=markets.businessinsider.com&utm_medium=referral
647.0,12/30/2020 6:13:38 AM,Regeneron Says Initial Data From COVID-19 Antibody Cocktail Trial Encouraging ,RTTNews,/news/stocks/regeneron-says-initial-data-from-covid-19-antibody-cocktail-trial-encouraging-1029924395
648.0,12/30/2020 2:08:28 PM,"The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data",Benzinga,/news/stocks/the-daily-biotech-pulse-osmotica-faces-second-fda-rejection-uk-conditionally-approves-astrazeneca-s-vaccine-candidate-hepion-nash-data-1029925168
649.0,12/30/2020 9:14:30 PM,Big Winners In 2020! Could These Stocks Outperform Again In 2021? ,RTTNews,/news/stocks/big-winners-in-2020-could-these-stocks-outperform-again-in-2021-1029926076
650.0,12/31/2020 6:30:40 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3648089-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral
651.0,1/4/2021 10:11:21 AM,Latest Pivot Does Little To Bolster Case for IDEX Stock Charging Higher,InvestorPlace,/news/stocks/latest-pivot-does-little-to-bolster-case-for-idex-stock-charging-higher-1029929897
652.0,1/7/2021 9:30:51 PM,"Moderna Is An Example of Why You Should Buy Systems, Not Drugs",InvestorPlace,/news/stocks/mrna-stock-is-an-example-of-why-you-should-buy-systems-not-drugs-1029942264
653.0,1/8/2021 1:08:50 PM,Regeneron upgraded to Buy at Citi on overlooked Dupixent opportunity,Seeking Alpha,https://seekingalpha.com/news/3649901-regeneron-upgraded-to-buy-citi-on-overlooked-dupixent-opportunity?utm_source=markets.businessinsider.com&utm_medium=referral
654.0,1/11/2021 6:04:42 PM,Regeneron Pharmaceuticals reports Q4 and FY20 net product sales,Seeking Alpha,https://seekingalpha.com/news/3650415-regeneron-pharmaceuticals-reports-q4-and-fy20-net-product-sales?utm_source=markets.businessinsider.com&utm_medium=referral
655.0,1/12/2021 7:36:22 PM,7 Potential IPOs in 2021 That Could Build Out Your Portfolio,InvestorPlace,/news/stocks/7-potential-ipos-in-2021-that-could-build-out-portfolio-1029961808
656.0,1/12/2021 10:59:40 PM,"U.S. Gov to purchase additional COVID-19 antibody cocktail doses from Regeneron, stock +4.2%",Seeking Alpha,https://seekingalpha.com/news/3650922-u-s-gov-to-purchase-additional-covidminus-19-antibody-cocktail-doses-from-regeneron-stockplus?utm_source=markets.businessinsider.com&utm_medium=referral
657.0,1/13/2021 3:27:43 AM,Roche : US To Purchase Addl Doses Of Antibody Cocktail For Use In Non-hospitalised COVID-19 Patients ,RTTNews,/news/stocks/roche-us-to-purchase-addl-doses-of-antibody-cocktail-for-use-in-non-hospitalised-covid-19-patients-1029962233
658.0,1/13/2021 4:05:52 PM,"Benzinga's Top Upgrades, Downgrades For January 13, 2021",Benzinga,/news/stocks/benzinga-s-top-upgrades-downgrades-for-january-13-2021-1029965040
659.0,1/13/2021 7:01:52 PM,"Why Regeneron, Jaguar Health And Seneca Are Moving Today",Benzinga,/news/stocks/why-regeneron-jaguar-health-and-seneca-are-moving-today-1029965717
660.0,1/13/2021 10:27:20 PM,Regeneron secures $2.63B U.S. Army contract,Seeking Alpha,https://seekingalpha.com/news/3651306-regeneron-secures-2_63b-u-s-army-contract?utm_source=markets.businessinsider.com&utm_medium=referral
661.0,1/13/2021 10:36:36 PM,"4 Top Stock Trades for Thursday: AMZN, PLUG, GME, REGN",InvestorPlace,/news/stocks/4-top-stock-trades-for-thursday-amzn-plug-gme-regn-1029966329
662.0,1/18/2021 9:38:34 AM,New drugs and injections to overcome challenges in COVID-19 antibody therapies - WSJ,Seeking Alpha,https://seekingalpha.com/news/3652061-new-drugs-and-injections-to-overcome-challenges-in-covidminus-19-antibody-therapies-wsj?utm_source=markets.businessinsider.com&utm_medium=referral
663.0,1/21/2021 4:25:23 PM,Biden Stocks: 16 Stocks to Watch for a Defense Production Act Boost,InvestorPlace,/news/stocks/biden-stocks-16-stocks-to-watch-for-a-defense-production-act-boost-1029991455
664.0,1/22/2021 10:13:36 PM,The Best 4 Pharmaceutical Stocks to Buy in Any Climate,InvestorPlace,/news/stocks/the-best-4-pharmaceutical-stocks-to-buy-in-any-climate-1030014921
665.0,1/25/2021 4:03:24 PM,"Benzinga's Top Ratings Upgrades, Downgrades For January 25, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-january-25-2021-1029999797
666.0,1/25/2021 5:23:09 PM,Regeneron upgraded at BMO; says ‘well-positioned’ for 2021,Seeking Alpha,https://seekingalpha.com/news/3653976-regeneron-upgraded-at-bmo-says-well-positioned-for-2021?utm_source=markets.businessinsider.com&utm_medium=referral
667.0,1/25/2021 5:29:30 PM,"Why Aurinia Pharma, AstraZeneca And More Are Trading Higher Today",Benzinga,/news/stocks/why-aurinia-pharma-astrazeneca-and-more-are-trading-higher-today-1030000230
668.0,1/25/2021 6:32:59 PM,"Pharma Stock Ideas: Why BMO Is Recommending Regeneron, Constellation",Benzinga,/news/stocks/pharma-stock-ideas-why-bmo-is-recommending-regeneron-constellation-1030000467
669.0,1/25/2021 10:29:05 PM,Germany to become first in EU to use COVID-19 antibody therapy,Seeking Alpha,https://seekingalpha.com/news/3654167-germany-to-become-first-in-eu-to-use-covid-19-antibody-therapy?utm_source=markets.businessinsider.com&utm_medium=referral
670.0,1/26/2021 3:16:17 PM,Regeneron's Interim Late-stage Study Shows Antibody Cocktail Effective To Prevent COVID-19 ,RTTNews,/news/stocks/regeneron-s-interim-late-stage-study-shows-antibody-cocktail-effective-to-prevent-covid-19-1030004885
671.0,1/26/2021 4:08:12 PM,Regeneron COVID-19 antibody drug effective in preventing COVID-19,Seeking Alpha,https://seekingalpha.com/news/3654348-regeneron-covid-19-antibody-drug-effective-in-preventing-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral
672.0,1/27/2021 8:56:46 AM,"AGIO's ACTIVATE-T Hits Goals, EDSA Catches Eye, JNJ Provides Rosy Outlook, VXRT On Watch ",RTTNews,/news/stocks/agio-s-activate-t-hits-goals-edsa-catches-eye-jnj-provides-rosy-outlook-vxrt-on-watch-1030008289
673.0,1/27/2021 12:40:52 PM,Regeneron’s antibody cocktail neutralizes new COVID-19 variants,Seeking Alpha,https://seekingalpha.com/news/3654838-regenerons-antibody-cocktail-neutralizes-new-covid-19-variants?utm_source=markets.businessinsider.com&utm_medium=referral
674.0,1/27/2021 1:33:40 PM,Regeneron: Researchers Confirm Ability Of REGEN-COV To Neutralize SARS-CoV-2 Variants ,RTTNews,/news/stocks/regeneron-researchers-confirm-ability-of-regen-cov-to-neutralize-sars-cov-2-variants-1030009203
675.0,1/27/2021 1:35:59 PM,"The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement",Benzinga,/news/stocks/the-daily-biotech-pulse-sorrento-immutep-surge-on-covid-19-study-data-t2-biosystems-sinks-on-preannouncement-1030009241
676.0,1/29/2021 10:01:50 AM,More Convincing Reasons to Just Buy Palantir Technologies Stock,InvestorPlace,/news/stocks/more-convincing-reasons-to-just-buy-palantir-technologies-stock-1030019233
677.0,1/30/2021 7:19:15 PM,"The Week Ahead In Biotech: Merck, Pfizer In Earnings Mix, Plus Adamas, Mallinckrodt FDA Decisions, IPOs And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-merck-pfizer-in-earnings-mix-plus-adamas-mallinckrodt-fda-decisions-ipos-and-more-1030022250
678.0,1/31/2021 11:22:18 AM,Attention Biotech Investors: Mark Your Calendar For February PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-february-pdufa-dates-1030022689
679.0,2/3/2021 3:02:05 PM,Regeneron Pharmaceuticals earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/regeneron-stock-price-quarter-earnings-preview-q4-1030038599
680.0,2/4/2021 10:46:47 AM,7 Safe Growth Stocks to Put In Your Buy-and-Hold Portfolio,InvestorPlace,/news/stocks/7-safe-growth-stocks-to-put-your-trust-in-this-year-1030042740
681.0,2/4/2021 5:58:30 PM,Regeneron Pharmaceuticals Q4 2020 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3658545-regeneron-pharmaceuticals-q4-2020-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral
682.0,2/4/2021 6:05:16 PM,Notable earnings before Friday's open,Seeking Alpha,https://seekingalpha.com/news/3658555-notable-earnings-before-fridays-open?utm_source=markets.businessinsider.com&utm_medium=referral
683.0,2/5/2021 11:32:49 AM,"Regeneron Pharmaceuticals EPS beats by $1.24, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3658972-regeneron-pharmaceuticals-eps-beats-1_24-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral
684.0,2/5/2021 12:01:49 PM,"Regeneron Pharma posts double-digit top and bottom-line growth, shares up 3%",Seeking Alpha,https://seekingalpha.com/news/3658987-regeneron-pharma-posts-double-digit-top-and-bottom-line-growth-shares-up-3?utm_source=markets.businessinsider.com&utm_medium=referral
685.0,2/5/2021 12:33:41 PM,Regeneron Pharmaceuticals Q4 adjusted earnings Beat Estimates,RTTNews,/news/stocks/regeneron-pharmaceuticals-q4-adjusted-earnings-beat-estimates-1030048002
686.0,2/5/2021 1:44:38 PM,"The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street",Benzinga,/news/stocks/the-daily-biotech-pulse-j-j-files-for-covid-19-vaccine-approval-zimmer-biomet-s-spin-off-ipo-deluge-hits-street-1030048263
687.0,2/5/2021 8:30:24 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3659213-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral
688.0,2/5/2021 10:30:34 PM,"4 Top Stock Trades for Monday: F, CLX, REGN, LKNCY",InvestorPlace,/news/stocks/4-top-stock-trades-for-monday-f-clx-regn-lkncy-1030049953
689.0,2/6/2021 6:42:05 PM,"The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight",Benzinga,/news/stocks/the-week-ahead-in-biotech-feb-7-13-regeneron-fda-decision-earnings-ipos-and-conference-presentations-in-the-spotlight-1030050676
690.0,2/8/2021 2:41:10 PM,3 Under-the-Radar Biotech Stocks to Buy After Dull Earnings Reactions,InvestorPlace,/news/stocks/3-under-the-radar-biotech-stocks-to-buy-after-earnings-1030055864
691.0,2/9/2021 12:35:27 PM,"Jaguar Health Isn’t a Healthy Investment, but It Could Be a Profitable One",InvestorPlace,/news/stocks/jagx-stock-not-healthy-but-could-be-profitable-1030060217
692.0,2/10/2021 1:34:43 PM,"The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-covid-19-antibody-cocktail-approved-for-emergency-use-gamida-genfit-jump-on-data-2-ipos-1030066164
693.0,2/11/2021 9:53:37 AM,"BPTH On Steady Path, CGIX On Watch, GLPG/GILD Scrap IPF Drug, REGN's Libtayo Gets FDA Nod ",RTTNews,/news/stocks/bpth-on-steady-path-cgix-on-watch-glpg-gild-scrap-ipf-drug-regn-s-libtayo-gets-fda-nod-1030071399
694.0,2/11/2021 11:45:23 AM,Regeneron/ Sanofi score an early win for Libtayo in basal cell carcinoma,Seeking Alpha,https://seekingalpha.com/news/3661076-regeneron-sanofi-score-an-early-win-for-libtayo-in-basal-cell-carcinoma?utm_source=markets.businessinsider.com&utm_medium=referral
695.0,2/11/2021 1:26:22 PM,"The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts",Benzinga,/news/stocks/the-daily-biotech-pulse-dermtech-soars-on-contract-fluidigm-plunges-on-earnings-decision-day-for-regeneron-bioventus-debuts-1030072237
696.0,2/11/2021 7:13:20 PM,FDA approves Regeneron's Evkeeza to treat ultra-rare inherited form of high cholesterol,Seeking Alpha,https://seekingalpha.com/news/3661347-fda-approves-regenerons-evkeeza-to-treat-ultra-rare-inherited-form-of-high-cholesterol?utm_source=markets.businessinsider.com&utm_medium=referral
697.0,2/11/2021 11:28:21 PM,"US Federal Court Upholds Appeal In Favor Of Regeneron, Sanofi On Praluent ",RTTNews,/news/stocks/us-federal-court-upholds-appeal-in-favor-of-regeneron-sanofi-on-praluent-1030074901
698.0,2/12/2021 12:06:06 PM,"Regeneron, Sanofi's Libtayo shows extended overall survival in lung cancer study",Seeking Alpha,https://seekingalpha.com/news/3661630-regeneron-sanofis-libtayo-shows-extended-overall-survival-in-lung-cancer-study?utm_source=markets.businessinsider.com&utm_medium=referral
699.0,2/14/2021 2:10:15 PM,"The Week Ahead In Biotech: FDA Decision On G1 Therapeutics, Earnings In The Mix For Light Calendar Week",Benzinga,/news/stocks/the-week-ahead-in-biotech-fda-decision-on-g1-therapeutics-earnings-in-the-mix-for-light-calendar-week-1030080314
700.0,2/22/2021 6:24:16 PM,Regeneron and Sanofi get FDA approval for Libtayo in non-small cell lung cancer,Seeking Alpha,https://seekingalpha.com/news/3664445-regeneron-and-sanofi-get-fda-approval-for-libtayo-in-non-small-cell-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
701.0,2/23/2021 7:02:29 PM,Why You Should Keep Your Distance from Ocugen Stock,InvestorPlace,/news/stocks/ocgn-stock-stay-your-distance-from-ocugen-1030114797
702.0,2/24/2021 1:03:12 PM,Decibel Therapeutics posts hearing loss gene therapy preclinical data,Seeking Alpha,https://seekingalpha.com/news/3665457-decibel-therapeutics-posts-hearing-loss-gene-therapy-preclinical-data?utm_source=markets.businessinsider.com&utm_medium=referral
703.0,2/24/2021 1:17:19 PM,RLFTF: Why Little-Known Relief Therapeutics Is Climbing Today,InvestorPlace,/news/stocks/rlftf-why-little-known-relief-therapeutics-is-climbing-today-brpa-stock-1030119085
704.0,2/25/2021 2:31:07 PM,Regeneron Pharma Stops Placebo Group Enrollment For REGEN-COV On Advice From IDMC ,RTTNews,/news/stocks/regeneron-pharma-stops-placebo-group-enrollment-for-regen-cov-on-advice-from-idmc-1030123866
705.0,2/26/2021 1:41:14 PM,Roche : CHMP Opinion Supports Use Of Casirivimab-imdevimab Antibody Cocktail For COVID Treatment ,RTTNews,/news/stocks/roche-chmp-opinion-supports-use-of-casirivimab-imdevimab-antibody-cocktail-for-covid-treatment-1030129212
706.0,2/26/2021 2:21:08 PM,Regeneron's antibody cocktail is set for marketing approval in EU,Seeking Alpha,https://seekingalpha.com/news/3667153-regenerons-antibody-cocktail-is-set-for-marketing-approval-in-eu?utm_source=markets.businessinsider.com&utm_medium=referral
707.0,2/28/2021 2:04:13 AM,Regeneron’s antibody cocktail shows promise in cat-allergic patients with mild asthma,Seeking Alpha,https://seekingalpha.com/news/3667404-regenerons-antibody-cocktail-shows-promise-in-cat-allergic-patients-with-mild-asthma?utm_source=markets.businessinsider.com&utm_medium=referral
708.0,2/28/2021 4:54:54 PM,Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-march-pdufa-dates-1030132296
709.0,3/3/2021 10:07:23 PM,Regeneron and Kiniksa sign commercial supply agreement for Rilonacept,Seeking Alpha,https://seekingalpha.com/news/3669127-regeneron-and-kiniksa-sign-commercial-supply-agreement-for-rilonacept?utm_source=markets.businessinsider.com&utm_medium=referral
710.0,3/4/2021 6:32:26 AM,"FDA accepts Regeneron, Sanofi's Dupixent application for children with asthma",Seeking Alpha,https://seekingalpha.com/news/3669188-fda-accepts-regenerons-dupixent-application-for-children-with-asthma?utm_source=markets.businessinsider.com&utm_medium=referral
711.0,3/4/2021 7:29:27 AM,Sanofi : FDA Accepts Dupixent For Review In Children With Moderate-to-severe Asthma ,RTTNews,/news/stocks/sanofi-fda-accepts-dupixent-for-review-in-children-with-moderate-to-severe-asthma-1030148564
712.0,3/4/2021 2:12:10 PM,"The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-nod-for-pfizer-kiniksa-rises-on-commercialization-pact-with-regeneron-bio-techne-to-buy-diagnostic-company-1030150188
713.0,3/9/2021 5:46:49 PM,Why Is Graybug Vision Stock Plunging Today?,Benzinga,/news/stocks/why-is-graybug-vision-stock-plunging-today-1030165040
714.0,3/9/2021 8:59:47 PM,Bet on Black With These 7 Risky Stocks  ,InvestorPlace,/news/stocks/bet-on-black-with-these-7-risky-stocks-1030165824
715.0,3/11/2021 4:58:29 PM,7 Stocks That Cathie Wood Likes and You Should Too,InvestorPlace,/news/stocks/7-stocks-that-cathie-wood-likes-and-you-should-too-1030174707
716.0,3/11/2021 9:44:40 PM,What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.,InvestorPlace,/news/stocks/what-did-the-stock-market-do-today-3-big-stories-cpng-stock-ocgn-stock-stimulus-1030175736
717.0,3/12/2021 6:04:49 PM,Merck and Pfizer among top picks to lead 2021 biopharma M&A activity: Goldman Sachs,Seeking Alpha,https://seekingalpha.com/news/3672343-merck-and-pfizer-among-top-picks-to-lead-2021-biopharma-ma-activity-goldman-sachs?utm_source=markets.businessinsider.com&utm_medium=referral
718.0,3/15/2021 7:47:53 AM,Sanofi : Phase 3 Trial Of Libtayo In Advanced Cervical Cancer Stopped Early For Positive Result ,RTTNews,/news/stocks/sanofi-phase-3-trial-of-libtayo-in-advanced-cervical-cancer-stopped-early-for-positive-result-1030200977
719.0,3/15/2021 11:00:56 AM,"Regeneron, Sanofi winds up late-stage Libtayo study after positive data in cervical cancer",Seeking Alpha,https://seekingalpha.com/news/3672496-regeneron-sanofi-winds-up-llibtayo-study-after-positive-data-in-cervical-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
720.0,3/16/2021 7:44:00 AM,"EMA Safety Committee To Further Review AZD1222, RUBY Sparkles, DMD Trial Data Fails To Ignite SLDB ",RTTNews,/news/stocks/ema-safety-committee-to-further-review-azd1222-ruby-sparkles-dmd-trial-data-fails-to-ignite-sldb-1030212169
721.0,3/17/2021 2:15:17 PM,3 Biotech Stocks That Could Double In 12 Months,Benzinga,/news/stocks/3-biotech-stocks-that-could-double-in-12-months-1030219865
722.0,3/23/2021 6:47:24 AM,"Regeneron's COVID-19 antibody reduces hospitalization, death by 70%",Seeking Alpha,https://seekingalpha.com/news/3675066-regenerons-covid-19-antibody-reduces-hospitalization-death-by-70?utm_source=markets.businessinsider.com&utm_medium=referral
723.0,3/23/2021 7:29:24 AM,REGN : Antibody Cocktail Reduces Hospitalization/Death By 70% In Non-hospitalized COVID-19 Patients ,RTTNews,/news/stocks/regn-antibody-cocktail-reduces-hospitalization-death-by-70-in-non-hospitalized-covid-19-patients-1030234691
724.0,3/23/2021 1:18:20 PM,"The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-approvals-for-merck-pacira-and-zealand-roche-regeneron-ace-late-stage-covid-19-study-allovir-appoints-gilead-virology-chief-as-ceo-1030236141
725.0,3/25/2021 4:30:01 PM,Pfizer’s tanezumab in osteoarthritis turned down by FDA expert panel (updated),Seeking Alpha,https://seekingalpha.com/news/3676348-pfizers-marketing-application-on-tanezumab-fails-in-adcom-vote?utm_source=markets.businessinsider.com&utm_medium=referral
726.0,3/26/2021 6:00:46 AM,"Alibaba, Amazon, Palantir, Google, Takeda, Unity — What Cathie Wood's Ark Bought And Sold On Thursday",Benzinga,/news/stocks/alibaba-amazon-palantir-google-takeda-unity-—-what-cathie-wood-s-ark-bought-and-sold-on-thursday-1030248437
727.0,3/26/2021 12:37:55 PM,10 Biggest Price Target Changes For Friday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-friday-1030249587
728.0,3/31/2021 7:58:21 AM,Regeneron's Eylea reduces vision loss by 68% after two years in diabetic retinopathy,Seeking Alpha,https://seekingalpha.com/news/3677905-regenerons-eylea-reduces-vision-loss-by-68-after-two-years-in-diabetic-retinopathy?utm_source=markets.businessinsider.com&utm_medium=referral
729.0,3/31/2021 1:41:12 PM,"The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-vaccine-100-effective-in-adolescents-equillium-readout-amgen-goes-shopping-achilles-ipo-1030263061
730.0,4/2/2021 2:01:55 PM,Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-april-pdufa-dates-1030271706
731.0,4/3/2021 3:11:24 PM,"The Week Ahead In Biotech: Regeneron, Supernus FDA Decisions, Cancer Conference Presentations In The Spotlight",Benzinga,/news/stocks/the-week-ahead-in-biotech-regeneron-supernus-fda-decisions-cancer-conference-presentations-in-the-spotlight-1030272481
732.0,4/6/2021 3:19:02 PM,7 Best Stocks on the Nasdaq,InvestorPlace,/news/stocks/7-best-stocks-on-the-nasdaq-1030278186
733.0,4/9/2021 2:30:37 PM,Regeneron: NIH Panel Recommends Use Of REGEN-COV In COVID-19 Outpatients At High Risk Of Progression ,RTTNews,/news/stocks/regeneron-nih-panel-recommends-use-of-regen-cov-in-covid-19-outpatients-at-high-risk-of-progression-1030289116
734.0,4/11/2021 5:43:59 PM,4 Undervalued Stocks To Watch For In April,Benzinga,/news/stocks/4-undervalued-stocks-to-watch-for-in-april-1030291469
735.0,4/12/2021 6:50:56 AM,Regeneron/Roche's antibody cocktail reduces risk of COVID-19 infections,Seeking Alpha,https://seekingalpha.com/news/3680865-regeneronroches-antibody-cocktail-reduces-risk-of-covid-19-infections?utm_source=markets.businessinsider.com&utm_medium=referral
736.0,4/12/2021 7:29:15 AM,REGN :Phase 3 Trial Shows 81% Reduced Risk Of SARS-CoV-2 Infections With Administration Of REGEN-COV ,RTTNews,/news/stocks/regn-phase-3-trial-shows-81-reduced-risk-of-sars-cov-2-infections-with-administration-of-regen-cov-1030292319
737.0,4/12/2021 5:02:08 PM,Vaccine Passport Potential Could Boost These 7 Pharmaceutical Stocks,InvestorPlace,/news/stocks/vaccine-passport-potential-could-boost-these-7-pharmaceutical-stocks-1030295137
738.0,4/13/2021 9:36:54 AM,"U.K. COVID-19 variant doesn't cause more deaths, study finds",Seeking Alpha,https://seekingalpha.com/news/3681226-uk-covid-19-variant-doesnt-cause-more-deaths-study-finds?utm_source=markets.businessinsider.com&utm_medium=referral
739.0,4/15/2021 2:55:06 PM,"Cramer Weighs In On Paysafe, Xilinx And More",Benzinga,/news/stocks/cramer-weighs-in-on-paysafe-xilinx-and-more-1030308355
740.0,4/15/2021 5:39:05 PM,Merck hurt by another setback in its battle against COVID-19,Seeking Alpha,https://seekingalpha.com/news/3682287-merck-hurt-by-another-setback-in-its-battle-against-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral
741.0,4/19/2021 4:58:40 PM,Large NIH-funded study to explore repurposed drugs for mild-to-moderate COVID-19,Seeking Alpha,https://seekingalpha.com/news/3683056-large-nih-funded-study-to-explore-repurposed-drugs-for-mild-to-moderate-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral
742.0,4/20/2021 7:48:23 AM,"Cathie Wood Buys Peloton, Coinbase Dips, Cuts Nvidia Stake",Benzinga,/news/stocks/cathie-wood-buys-peloton-coinbase-dips-cuts-nvidia-stake-1030321133
743.0,4/22/2021 6:45:08 AM,"Cathie Wood Loads Up Heavily On Debutant Uipath, Trims Tesla",Benzinga,/news/stocks/cathie-wood-loads-up-heavily-on-debutant-uipath-trims-tesla-1030331328
744.0,4/26/2021 3:06:57 PM,7 Healthcare Stocks for a Reopening World,InvestorPlace,/news/stocks/7-healthcare-stocks-for-a-reopening-world-1030346737
745.0,4/29/2021 6:10:51 PM,7 Health-Focused ETFs To Buy Now For the Post-Covid Future,InvestorPlace,/news/stocks/7-health-focused-etfs-to-buy-now-for-the-post-covid-future-1030366420
746.0,4/30/2021 5:39:43 AM,"Cathie Wood Piles Up Teladoc As Shares Slump On Q1 Miss, Also Adds More Tesla",Benzinga,/news/etf/cathie-wood-piles-up-teladoc-as-shares-slump-on-q1-miss-also-adds-more-tesla-1030367623
747.0,5/1/2021 7:19:25 PM,"Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge",Benzinga,/news/stocks/week-ahead-in-biotech-may-2-8-chemocentryx-adcom-ophthalmology-conference-presentations-earnings-deluge-1030373608
748.0,5/4/2021 6:17:24 AM,"Cathie Wood Loads Up More On Alibaba Rivals Pinduoduo, JD — Also Adds Skillz",Benzinga,/news/stocks/cathie-wood-loads-up-more-on-alibaba-rivals-pinduoduo-jd-—-also-adds-skillz-1030381350
749.0,5/4/2021 3:02:12 PM,Regeneron Pharmaceuticals is about to announce earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/regeneron-stock-quarter-earnings-preview-q1-1030384412
750.0,5/4/2021 3:40:26 PM,Shares of major drug makers in focus as House committees hold hearings on drug pricing bill,Seeking Alpha,https://seekingalpha.com/news/3690229-shares-of-major-drug-makers-in-focus-as-house-committees-hold-hearings-on-drug-pricing-bill?utm_source=markets.businessinsider.com&utm_medium=referral
751.0,5/5/2021 8:52:20 AM,Cathie Wood Loaded Up Further On Skillz On Earnings Day,Benzinga,/news/stocks/cathie-wood-loaded-up-further-on-skillz-on-earnings-day-1030388979
752.0,5/5/2021 4:48:53 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3691210-notable-earnings-thursdays-open?utm_source=markets.businessinsider.com&utm_medium=referral
753.0,5/5/2021 4:54:48 PM,Regeneron Pharmaceuticals Q1 2021 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3691215-regeneron-pharmaceuticals-q1-2021-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral
754.0,5/6/2021 7:18:58 AM,"Cathie Wood Loads Up More On Peloton, Skillz, Teladoc On The Dip",Benzinga,/news/stocks/cathie-wood-loads-up-more-on-peloton-skillz-teladoc-on-the-dip-1030394379
755.0,5/6/2021 12:33:18 PM,Regeneron Pharmaceuticals Q1 adjusted earnings Miss Estimates,RTTNews,/news/stocks/regeneron-pharmaceuticals-q1-adjusted-earnings-miss-estimates-1030395441
756.0,5/6/2021 1:49:39 PM,"The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-s-keytruda-snags-another-fda-approval-moderna-slips-on-revenue-miss-chemocentryx-adcom-1030395950
757.0,5/6/2021 6:28:44 PM,"Ocugen Shares Sink Despite OCU200 Being Comparable To Aflibercept In Reducing Neovascularization, Damage To Retina In Animal Study",Benzinga,/news/stocks/ocugen-shares-sink-despite-ocu200-being-comparable-to-aflibercept-in-reducing-neovascularization-damage-to-retina-in-animal-study-1030397918
758.0,5/7/2021 8:22:04 AM,"Cathie Wood Slashes Apple Stake To Half — Also Trims Google, Fastly: What You Need To Know",Benzinga,/news/stocks/cathie-wood-slashes-apple-stake-to-half-—-also-trims-google-fastly-what-you-need-to-know-1030401084
759.0,5/10/2021 10:52:10 AM,Checkmate Pharma teams up with Regeneron to evaluate vidutolimod + Libtayo in skin cancer,Seeking Alpha,https://seekingalpha.com/news/3693677-checkmate-pharma-teams-up-with-regeneron-to-evaluate-vidutolimod-libtayo-in-skin-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
760.0,5/10/2021 11:00:59 PM,"Tesla, Qualcomm Plummet, Lead QQQ Sharply Lower Monday",Benzinga,/news/stocks/tesla-qualcomm-plummet-lead-qqq-sharply-lower-monday-1030411174
761.0,5/11/2021 5:07:42 AM,"Cathie Wood Cuts Apple Stake By 30% And Buys Coinbase, DraftKings",Benzinga,/news/stocks/cathie-wood-cuts-apple-stake-by-30-and-buys-coinbase-draftkings-1030411583
762.0,5/12/2021 7:05:05 AM,Cathie Wood Loads Up $57M In Palantir As Stock Stages Reversal On Q1 Earnings Beat,Benzinga,/news/stocks/cathie-wood-loads-up-57m-in-palantir-as-stock-stages-reversal-on-q1-earnings-beat-1030418631
763.0,5/12/2021 6:32:02 PM,Regeneron and Sanofi updates data from late-stage trial for Libtayo in cervical cancer,Seeking Alpha,https://seekingalpha.com/news/3695433-regeneron-and-sanofi-updates-data-from-late-stage-trial-for-libtayo-in-cervical-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
764.0,5/13/2021 4:21:27 AM,"Cathie Wood Piles Up Palantir For Third Day In A Row, Adding $39M Worth Of Shares",Benzinga,/news/stocks/cathie-wood-piles-up-palantir-for-third-day-in-a-row-adding-39m-worth-of-shares-1030423564
765.0,5/13/2021 6:59:49 AM,Cramer is calling them 'WoodStocks'; latest changes to ARK ETFs,Seeking Alpha,https://seekingalpha.com/news/3695694-cramer-is-calling-them-woodstocks-latest-changes-to-ark-etfs?utm_source=markets.businessinsider.com&utm_medium=referral
766.0,5/14/2021 7:04:33 AM,Cathie Wood Sheds $33.6M Alibaba Shares On Earnings Day,Benzinga,/news/stocks/cathie-wood-sheds-33-6m-alibaba-shares-on-earnings-day-1030429592
767.0,5/17/2021 5:33:43 AM,Cathie Wood Buys $26M Disney Shares And Sells $13M In Netflix: What You Need To Know,Benzinga,/news/stocks/cathie-wood-buys-26m-disney-shares-and-sells-13m-in-netflix-what-you-need-to-know-1030433399
768.0,5/17/2021 2:09:53 PM,"Regeneron, Sanofi post promising data from late-stage Dupixent asthma trial",Seeking Alpha,https://seekingalpha.com/news/3697179-regeneron-sanofi-post-promising-data-from-late-stage-dupixent-asthma-trial?utm_source=markets.businessinsider.com&utm_medium=referral
769.0,5/17/2021 4:23:36 PM,Regeneron Presents Detailed Results From Phase 3 Pivotal Trial For REGEN-COV - Quick Facts ,RTTNews,/news/stocks/regeneron-presents-detailed-results-from-phase-3-pivotal-trial-for-regen-cov-quick-facts-1030437226
770.0,5/17/2021 4:25:51 PM,Regeneron : Phase 3 Data Show Dupixent Reduces Asthma Attacks And Improves Lung Function In Children ,RTTNews,/news/stocks/regeneron-phase-3-data-show-dupixent-reduces-asthma-attacks-and-improves-lung-function-in-children-1030437243
771.0,5/20/2021 6:16:48 PM,Moderna Holds the Key to the Future of mRNA Vaccines,InvestorPlace,/news/stocks/mrna-stock-holds-the-key-to-the-future-of-vaccines-1030452921
772.0,5/24/2021 5:38:17 AM,"EMA advisory group backs Regeneron, Sanofi's Libtayo in lung and skin cancer",Seeking Alpha,https://seekingalpha.com/news/3699313-ema-advisory-group-backs-regeneron-sanofis-libtayo-in-lung-and-skin-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
773.0,5/24/2021 7:20:19 AM,Regeneron : Libtayo Gets Positive CHMP Opinion For Treatment Of Two Advanced Cancers ,RTTNews,/news/stocks/regeneron-libtayo-gets-positive-chmp-opinion-for-treatment-of-two-advanced-cancers-1030457690
774.0,5/26/2021 1:04:33 PM,"Agilent price target lifted after guidance raise,  Travere downgraded on regulatory update; more in today’s analyst action",Seeking Alpha,https://seekingalpha.com/news/3700286-agilent-price-target-lifted-after-guidance-raise-travere-downgraded-on-regulatory-update?utm_source=markets.businessinsider.com&utm_medium=referral
775.0,5/27/2021 3:12:17 AM,GSK/Vir COVID-19 biologic wins FDA Emergency Use Authorization; Vir up 9%,Seeking Alpha,https://seekingalpha.com/news/3700603-gsk-vir-covid-19-biologic-wins-fda-emergency-use-authorization-vir-up-9?utm_source=markets.businessinsider.com&utm_medium=referral
776.0,6/3/2021 2:02:55 PM,Diversifying to Conquer: Fortress Biotech (FBIO) Partnering Expansion Driving Progress in Cancer Immunotherapy and Rare Disease Therapeutics,Benzinga,/news/stocks/diversifying-to-conquer-fortress-biotech-fbio-partnering-expansion-driving-progress-in-cancer-immunotherapy-and-rare-disease-therapeutics-1030490924
777.0,6/4/2021 11:51:31 AM,FDA updates REGEN-COV EUA to treat patients with COVID-19 at lower dose,Seeking Alpha,https://seekingalpha.com/news/3703251-fda-updates-regen-cov-eua-to-treat-patients-with-covid-19-at-lower-dose?utm_source=markets.businessinsider.com&utm_medium=referral
778.0,6/4/2021 1:27:22 PM,"FDA Updates EUA For REGEN-COV With Lower Dosage Of 1,200 Mg - Quick Facts ",RTTNews,/news/stocks/fda-updates-eua-for-regen-cov-with-lower-dosage-of-1-200-mg-quick-facts-1030494782
779.0,6/4/2021 3:39:13 PM,"The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-astrazeneca-novartis-among-early-presenters-at-asco-sanofi-strikes-breast-cancer-study-pact-1030495387
780.0,6/4/2021 7:30:04 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3703423-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral
781.0,6/9/2021 6:40:28 PM,INO Stock: 2 Big Reasons Inovio Pharmaceuticals Is Shooting Higher Today,InvestorPlace,/news/stocks/ino-stock-2-big-reasons-inovio-pharmaceuticals-is-shooting-higher-today-1030509269
782.0,6/15/2021 9:59:16 AM,AstraZeneca’s STORM CHASER trial in COVID-19 misses primary endpoint of preventing COVID-19,Seeking Alpha,https://seekingalpha.com/news/3706281-astrazenecas-storm-chaser-trial-in-covid-19-misses-primary-endpoint-of-preventing-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral
783.0,6/16/2021 5:33:32 AM,Regeneron's REGEN-COV reduces death by 20% in hospitalized COVID-19 patients,Seeking Alpha,https://seekingalpha.com/news/3706734-regenerons-regen-cov-reduces-death-by-20-in-hospitalized-covid-19-patients?utm_source=markets.businessinsider.com&utm_medium=referral
784.0,6/16/2021 7:00:00 AM,"REGEN-COV™ (casirivimab and imdevimab) Phase 3 RECOVERY Trial Meets Primary Outcome, Improving Survival in Hospitalized COVID-19 Patients Lacking an Immune Response to SARS-CoV-2",PR Newswire,/news/stocks/regen-cov-casirivimab-and-imdevimab-phase-3-recovery-trial-meets-primary-outcome-improving-survival-in-hospitalized-covid-19-patients-lacking-an-immune-response-to-sars-cov-2-1030526463
785.0,6/16/2021 7:29:05 AM,Regeneron's REGEN-COV Improves Survival In Hospitalized COVID-19 Patients ,RTTNews,/news/stocks/regeneron-s-regen-cov-improves-survival-in-hospitalized-covid-19-patients-1030526490
786.0,6/16/2021 2:20:39 PM,"The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-regeneron-covid-19-antibody-cocktail-data-fda-nod-for-mallinckrodt-molecular-partners-ipo-1030527915
787.0,6/17/2021 1:44:32 PM,"CureVac downgraded following COVID vaccine data, Regeneron COVID cocktail a boon, and more in analyst action",Seeking Alpha,https://seekingalpha.com/news/3707230-curevac-downgraded-following-lackluster-covid-vaccine-data-and-more-in-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral
788.0,6/18/2021 9:25:21 AM,Dosing underway in BioNTech's BNT111 Phase 2 cancer vaccine trial in advanced melanoma,Seeking Alpha,https://seekingalpha.com/news/3707553-dosing-underway-in-biontechs-phase-2-trial-of-mrna-based-bnt111-in-advanced-melanoma?utm_source=markets.businessinsider.com&utm_medium=referral
789.0,6/18/2021 12:43:34 PM,BioNTech Doses First Patient In BNT111 Phase 2 Cancer Vaccine Trial ,RTTNews,/news/stocks/biontech-doses-first-patient-in-bnt111-phase-2-cancer-vaccine-trial-1030534955
790.0,6/22/2021 10:15:00 PM,Regeneron to Participate in Guggenheim Biopharma Strategy Series,PR Newswire,/news/stocks/regeneron-to-participate-in-guggenheim-biopharma-strategy-series-1030544733
791.0,6/25/2021 5:38:07 AM,Regeneron/Sanofi's Libtayo OK'd in Europe for skin cancer,Seeking Alpha,https://seekingalpha.com/news/3710015-regeneronsanofis-libtayo-okd-in-europe-for-skin-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
792.0,6/25/2021 7:00:00 AM,Libtayo® (cemiplimab) Approved by the European Commission for First-Line Treatment of Patients with Advanced Non-small Cell Lung Cancer with ≥50% PD-L1 Expression,PR Newswire,/news/stocks/libtayo-cemiplimab-approved-by-the-european-commission-for-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-with-50-pd-l1-expression-1030553680
793.0,6/25/2021 7:15:00 AM,Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma,PR Newswire,/news/stocks/libtayo-cemiplimab-approved-by-the-european-commission-as-the-first-immunotherapy-indicated-for-patients-with-advanced-basal-cell-carcinoma-1030553689
794.0,6/25/2021 7:19:53 AM,Regeneron : EC Approves Libtayo For First-line Treatment Of Advanced Non-small Cell Lung Cancer ,RTTNews,/news/stocks/regeneron-ec-approves-libtayo-for-first-line-treatment-of-advanced-non-small-cell-lung-cancer-1030553701
795.0,6/25/2021 1:32:32 PM,"The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-roche-gets-authorization-for-covid-19-treatment-nods-for-sanofi-regeneron-in-europe-osmotica-divestment-2-ipos-1030554577
796.0,6/25/2021 6:39:42 PM,Eli Lilly COVID-19 antibody shipments halted in the U.S. citing prevalence of variants,Seeking Alpha,https://seekingalpha.com/news/3710240-eli-lilly-covid-19-antibody-shipments-halted-in-the-us-citing-prevalence-of-variants?utm_source=markets.businessinsider.com&utm_medium=referral
797.0,6/26/2021 4:05:37 PM,"In a first, Intellia, Regeneron demonstrate CRISPR therapy benefit in the body",Seeking Alpha,https://seekingalpha.com/news/3710317-in-a-first-intellia-regeneron-demonstrate-crispr-therapy-benefit-in-the-body?utm_source=markets.businessinsider.com&utm_medium=referral
798.0,6/26/2021 5:16:00 PM,"Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (AT...",PR Newswire,/news/stocks/intellia-and-regeneron-announce-landmark-clinical-data-showing-deep-reduction-in-disease-causing-protein-after-single-infusion-of-ntla-2001-an-investigational-crispr-therapy-for-transthyretin-at-1030556573
799.0,6/26/2021 5:41:03 PM,Intellia Announces Positive Interim Data On Transthyretin Amyloidosis Study ,RTTNews,/news/stocks/intellia-announces-positive-interim-data-on-transthyretin-amyloidosis-study-1030556579
800.0,6/28/2021 6:59:00 AM,Dupixent® (dupilumab) SmPC Updated with Long-term Data Reinforcing Well-established Safety Profile in Adults with Moderate-to-severe Atopic Dermatitis,PR Newswire,/news/stocks/dupixent-dupilumab-smpc-updated-with-long-term-data-reinforcing-well-established-safety-profile-in-adults-with-moderate-to-severe-atopic-dermatitis-1030557369
801.0,6/28/2021 7:17:20 AM,EMA to update Regeneron/Sanofi's Dupixent SmPC for adults with atopic dermatitis,Seeking Alpha,https://seekingalpha.com/news/3710337-ema-to-update-regeneronsanofis-dupixent-smpc-for-adults-with-atopic-dermatitis?utm_source=markets.businessinsider.com&utm_medium=referral
802.0,6/28/2021 7:45:25 AM,"Regeneron, Sanofi: EMA To Update Dupixent SmPC With Long-term Safety Data ",RTTNews,/news/stocks/regeneron-sanofi-ema-to-update-dupixent-smpc-with-long-term-safety-data-1030557432
803.0,6/28/2021 9:38:42 AM,Gene editing stocks take off as Intellia development slices through sector,Seeking Alpha,https://seekingalpha.com/news/3710343-gene-editing-stocks-take-off-after-intellia-development-slices-through-sector?utm_source=markets.businessinsider.com&utm_medium=referral
804.0,6/28/2021 12:25:07 PM,"Gene Editing Stocks: The Big News Lifting EDIT, BNGO, CRSP and NTLA Stocks",InvestorPlace,/news/stocks/gene-editing-stocks-the-big-news-lifting-edit-bngo-crsp-and-ntla-stocks-1030558761
805.0,6/28/2021 12:25:17 PM,"Intellia in focus after landmark trial data, Unity Biotech wins double upgrade: in today's analyst action",Seeking Alpha,https://seekingalpha.com/news/3710437-intellia-in-focus-after-landmark-trial-data-unity-biotech-wins-double-upgrade-in-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral
806.0,6/28/2021 2:49:22 PM,Why Intellia Therapeutics Stock Is Soaring Today,Benzinga,/news/stocks/why-intellia-therapeutics-stock-is-soaring-today-1030558924
807.0,6/28/2021 6:25:01 PM,Gene editing stocks buoyed in afternoon trading by Intellia CRISPR success,Seeking Alpha,https://seekingalpha.com/news/3710667-gene-editing-stocks-buoyed-in-afternoon-trading-by-intellia-crispr-success?utm_source=markets.businessinsider.com&utm_medium=referral
808.0,6/29/2021 3:54:15 PM,Lilly and Regeneron monoclonal antibodies among preferred therapies in EU against COVID-19,Seeking Alpha,https://seekingalpha.com/news/3711042-lilly-and-regeneron-monoclonal-antibodies-among-preferred-therapies-in-eu-against-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral
809.0,6/29/2021 4:03:41 PM,"Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-june-29-2021-1030563442
810.0,6/29/2021 6:29:56 PM,"Why Regeneron Pharmaceuticals Analyst Says Competitive Concerns Are Overblown, Pipeline Opportunity Underappreciated",Benzinga,/news/stocks/why-regeneron-pharmaceuticals-analyst-says-competitive-concerns-are-overblown-pipeline-opportunity-underappreciated-1030564059
811.0,6/30/2021 12:55:23 PM,"Altimmune price targets lowered, Tilray’s next move predicted at BofA - in today's analyst action",Seeking Alpha,https://seekingalpha.com/news/3711337-altimmune-price-targets-lowered-tilrays-next-move-predicted-at-bofa-in-todays-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral
812.0,6/30/2021 5:37:41 PM,The 3 Biotech Firms Riding High on CRISPR News,InvestorPlace,/news/stocks/the-3-biotech-firms-riding-high-on-crispr-news-1030568633
813.0,6/30/2021 7:53:24 PM,Intellia co-founder and gene editing pioneer Jennifer Doudna outlines future of CRISPR,Seeking Alpha,https://seekingalpha.com/news/3711569-intellia-co-founder-and-gene-editing-pioneer-jennifer-doudna-outlines-future-of-crispr?utm_source=markets.businessinsider.com&utm_medium=referral
814.0,7/1/2021 7:48:05 PM,Regeneron scientists discover genetic mutations associated with obesity protection,Seeking Alpha,https://seekingalpha.com/news/3712154-regeneron-scientists-discover-genetic-mutations-associated-with-obesity-protection?utm_source=markets.businessinsider.com&utm_medium=referral
815.0,7/1/2021 8:05:00 PM,Regeneron Genetics Center Discovers GPR75 Gene Mutations that Protect Against Obesity,PR Newswire,/news/stocks/regeneron-genetics-center-discovers-gpr75-gene-mutations-that-protect-against-obesity-1030572996
816.0,7/1/2021 9:28:26 PM,"4 Top Stock Trades for Friday: SQ, REGN, WBA, CRWD",InvestorPlace,/news/stocks/4-top-stock-trades-for-friday-sq-regn-wba-crwd-1030573802
817.0,7/3/2021 3:26:32 AM,Intellia and gene editors lead weekly healthcare gainers; CEL-SCI and Citius trail,Seeking Alpha,https://seekingalpha.com/news/3712730-intellia-and-gene-editors-lead-weekly-healthcare-gainers-cel-sci-and-citius-trail?utm_source=markets.businessinsider.com&utm_medium=referral
818.0,7/5/2021 6:40:00 PM,Sanofi -- Moody's announces completion of a periodic review of ratings of Sanofi,Moodys,/news/bonds/sanofi-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-sanofi-1030579233
819.0,7/7/2021 11:58:17 AM,Silverback surges 12% after supply agreement with Regeneron (updated),Seeking Alpha,https://seekingalpha.com/news/3713216-regeneron-to-provide-libtayo-to-silverback-for-evaluation-of-nsclc-candidate?utm_source=markets.businessinsider.com&utm_medium=referral
820.0,7/7/2021 10:15:00 PM,"Regeneron to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2021",PR Newswire,/news/stocks/regeneron-to-report-second-quarter-2021-financial-and-operating-results-and-host-conference-call-and-webcast-on-august-5-2021-1030587450
821.0,7/15/2021 10:12:42 PM,AMD And Biogen Lead The QQQ Lower Thursday,Benzinga,/news/stocks/amd-and-biogen-lead-the-qqq-lower-thursday-1030613067
822.0,7/16/2021 5:13:32 PM,Regeneron spending $1.8B to expand footprint in New York,Seeking Alpha,https://seekingalpha.com/news/3716057-regeneron-spending-18b-to-expand-footprint-in-new-york?utm_source=markets.businessinsider.com&utm_medium=referral
823.0,7/20/2021 7:00:00 AM,Japan Becomes First Country to Approve Regeneron Antibody Cocktail (casirivimab and imdevimab) for the Treatment of Mild to Moderate COVID-19,PR Newswire,/news/stocks/japan-becomes-first-country-to-approve-regeneron-antibody-cocktail-casirivimab-and-imdevimab-for-the-treatment-of-mild-to-moderate-covid-19-1030623299
824.0,7/20/2021 7:13:55 AM,Japan Approves Regeneron's Antibody Cocktail To Treat Mild To Moderate COVID-19 ,RTTNews,/news/stocks/japan-approves-regeneron-s-antibody-cocktail-to-treat-mild-to-moderate-covid-19-1030623314
825.0,7/20/2021 10:20:02 AM,Japan approves Regeneron/Roche's antibody cocktail REGEN-COV in COVID-19,Seeking Alpha,https://seekingalpha.com/news/3716701-japan-approves-regeneronroches-antibody-cocktail-regen-cov-in-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral
826.0,7/27/2021 1:00:00 PM,"Regeneron and AstraZeneca to Research, Develop and Commercialize New Small Molecule Medicines for Obesity",PR Newswire,/news/stocks/regeneron-and-astrazeneca-to-research-develop-and-commercialize-new-small-molecule-medicines-for-obesity-1030649466
827.0,7/27/2021 1:48:33 PM,"The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts",Benzinga,/news/stocks/the-daily-biotech-pulse-obseva-surges-on-out-licensing-deal-eyegate-appoints-new-ceo-2-positive-catalysts-for-merck-candel-therapeutics-debuts-1030649705
828.0,7/27/2021 1:55:24 PM,Regeneron In R&D Deal With AstraZeneca For Treatment Of Obesity ,RTTNews,/news/stocks/regeneron-in-r-d-deal-with-astrazeneca-for-treatment-of-obesity-1030649717
829.0,7/29/2021 6:59:00 AM,"Dupixent® (dupilumab) Significantly Improved Itch and Hives in Patients with Chronic Spontaneous Urticaria, a Step Forward in Demonstrating the Role of Type 2 Inflammation in These Patients",PR Newswire,/news/stocks/dupixent-dupilumab-significantly-improved-itch-and-hives-in-patients-with-chronic-spontaneous-urticaria-a-step-forward-in-demonstrating-the-role-of-type-2-inflammation-in-these-patients-1030660351
830.0,7/29/2021 7:27:52 AM,"Regeneron, Sanofi: Phase 3 Trial On Dupixent Met Key Endpoints At 24 Weeks ",RTTNews,/news/stocks/regeneron-sanofi-phase-3-trial-on-dupixent-met-key-endpoints-at-24-weeks-1030660417
831.0,7/29/2021 2:18:48 PM,"The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-s-disappointing-q2-atreca-falls-on-data-fda-nod-for-viatris-nuvalent-icosavax-ipos-1030662210
832.0,7/30/2021 7:35:50 PM,Regeneron wins expanded authorization from FDA for COVID-19 antibody cocktail,Seeking Alpha,https://seekingalpha.com/news/3722627-regeneron-wins-expanded-authorization-from-fda-for-covid-19-antibody-cocktail?utm_source=markets.businessinsider.com&utm_medium=referral
833.0,7/30/2021 7:45:00 PM,FDA Expands Authorized Use of REGEN-COV™ (casirivimab and imdevimab),PR Newswire,/news/stocks/fda-expands-authorized-use-of-regen-cov-casirivimab-and-imdevimab-1030669155
834.0,8/2/2021 1:51:01 PM,10 Biggest Price Target Changes For Monday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-monday-1030675837
835.0,8/3/2021 1:00:00 PM,Regeneron Announces the 2021 Winners of the Regeneron Prize for Creative Innovation,PR Newswire,/news/stocks/regeneron-announces-the-2021-winners-of-the-regeneron-prize-for-creative-innovation-1030682388
836.0,8/3/2021 3:02:13 PM,What Wall Street expects from Regeneron Pharmaceuticals's earnings,Markets Insider Automation,/news/stocks/regeneron-quarter-earnings-preview-q2-1030683241
837.0,8/4/2021 2:00:37 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3724959-notable-earnings-before-thursdays-open?utm_source=markets.businessinsider.com&utm_medium=referral
838.0,8/4/2021 11:05:00 PM,New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Prevent SARS-CoV-2 Infection,PR Newswire,/news/stocks/new-england-journal-of-medicine-publishes-positive-phase-3-trial-results-for-regen-cov-casirivimab-and-imdevimab-to-prevent-sars-cov-2-infection-1030691545
839.0,8/5/2021 10:23:59 AM,Regeneron/Sanofi stops late-stage Libtayo study early after improvement in survival in NSCLC patients,Seeking Alpha,https://seekingalpha.com/news/3725803-regeneronsanofi-stops-late-stage-libtayo-study-early-after-improvement-in-survival-in-nsclc-patients?utm_source=markets.businessinsider.com&utm_medium=referral
840.0,8/5/2021 10:33:51 AM,"Regeneron Pharmaceuticals EPS beats by $8.09, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3725815-regeneron-pharmaceuticals-eps-beats-8_09-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral
841.0,8/5/2021 10:54:06 AM,"Regeneron shares rise on Q2 earnings beat, FY forecast",Seeking Alpha,https://seekingalpha.com/news/3725849-regeneron-shares-rise-on-q2-earnings-beat-fy-forecast?utm_source=markets.businessinsider.com&utm_medium=referral
842.0,8/5/2021 12:00:00 PM,Phase 3 Trial of Libtayo® (cemiplimab-rwlc) Combined with Chemotherapy Stopped Early Due to Significant Improvement in Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer,PR Newswire,/news/stocks/phase-3-trial-of-libtayo-cemiplimab-rwlc-combined-with-chemotherapy-stopped-early-due-to-significant-improvement-in-overall-survival-in-patients-with-first-line-advanced-non-small-cell-lung-cancer-1030694742
843.0,8/5/2021 12:30:00 PM,Regeneron Reports Second Quarter 2021 Financial and Operating Results,PR Newswire,/news/stocks/regeneron-reports-second-quarter-2021-financial-and-operating-results-1030694934
844.0,8/5/2021 12:37:01 PM,Regeneron Pharmaceuticals Q2 adjusted earnings Beat Estimates,RTTNews,/news/stocks/regeneron-pharmaceuticals-q2-adjusted-earnings-beat-estimates-1030694948
845.0,8/5/2021 1:45:20 PM,Regeneron/Sanofi's Libtayo Combined With Chemo Reduced Death By 29% In Non-small Cell Lung Cancer ,RTTNews,/news/stocks/regeneron-sanofi-s-libtayo-combined-with-chemo-reduced-death-by-29-in-non-small-cell-lung-cancer-1030695454
846.0,8/5/2021 2:48:43 PM,"Daimler Truck, Cummins Partner For Medium-duty Engines ",RTTNews,/news/stocks/daimler-truck-cummins-partner-for-medium-duty-engines-1030696042
847.0,8/5/2021 2:52:21 PM,What Will the Stock Market Do Today? 3 Big Stories to Watch.,InvestorPlace,/news/stocks/what-will-the-stock-market-do-today-3-big-stories-eth-hard-fork-mrna-stock-1030696904
848.0,8/6/2021 4:09:35 PM,"Ocular Therapeutix, Regeneron Cull Aflibercept Agreement For Retinal Diseases",Benzinga,/news/stocks/ocular-therapeutix-regeneron-cull-aflibercept-agreement-for-retinal-diseases-1030701793
849.0,8/18/2021 6:20:06 AM,Texas Governor Greg Abbott tests positive for coronavirus,Seeking Alpha,https://seekingalpha.com/news/3731691-texas-governor-greg-abbott-tests-positive-for-coronavirus?utm_source=markets.businessinsider.com&utm_medium=referral
850.0,8/18/2021 1:37:56 PM,"The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline",Benzinga,/news/stocks/the-daily-biotech-pulse-azurrx-jumps-on-data-agios-regulatory-application-for-mitapivat-accepted-for-priority-review-fda-nod-for-glaxosmithkline-1030741574
851.0,8/19/2021 11:04:02 AM,Roche COVID-19 drug is in short supply with pandemic’s resurgence,Seeking Alpha,https://seekingalpha.com/news/3732167-roche-covid-19-drug-is-in-short-supply-with-pandemics-resurgence?utm_source=markets.businessinsider.com&utm_medium=referral
852.0,8/19/2021 1:37:27 PM,"The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck",Benzinga,/news/stocks/the-daily-biotech-pulse-coherus-soars-on-lung-cancer-data-illumina-closes-on-grail-buy-without-regulatory-clearance-adagene-strikes-collaboration-with-merck-1030745371
853.0,8/20/2021 1:00:00 PM,UK Authorizes Regeneron Antibody Cocktail to Prevent and Treat Acute COVID-19 Infection,PR Newswire,/news/stocks/uk-authorizes-regeneron-antibody-cocktail-to-prevent-and-treat-acute-covid-19-infection-1030748590
854.0,8/20/2021 1:21:38 PM,U.K. Authorizes Regeneron's Antibody Cocktail To Prevent & Treat Acute COVID-19 Infection ,RTTNews,/news/stocks/u-k-authorizes-regeneron-s-antibody-cocktail-to-prevent-treat-acute-covid-19-infection-1030748625
855.0,8/20/2021 1:45:43 PM,"The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data",Benzinga,/news/stocks/the-daily-biotech-pulse-j-j-announces-ceo-transition-fibrogen-s-roxadustat-approved-in-europe-geovax-sorrento-announce-covid-19-vaccine-data-1030748705
856.0,8/23/2021 1:27:52 PM,COVID-19 vaccinations pick up as some states face with a ‘tsunami of patients’,Seeking Alpha,https://seekingalpha.com/news/3733039-covid-19-vaccinations-pick-up-as-some-states-face-with-a-tsunami-of-patients?utm_source=markets.businessinsider.com&utm_medium=referral
857.0,8/24/2021 1:00:00 PM,Regeneron Announces Encouraging Topline Phase 2 Data of High-dose aflibercept in Wet Age-related Macular Degeneration,PR Newswire,/news/stocks/regeneron-announces-encouraging-topline-phase-2-data-of-high-dose-aflibercept-in-wet-age-related-macular-degeneration-1030754529
858.0,8/24/2021 2:09:21 PM,"The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal",Benzinga,/news/stocks/the-daily-biotech-pulse-cara-s-korsuva-greenlighted-by-fda-clinical-trial-disappointments-for-novartis-theravance-vertex-inks-crispr-licensing-deal-1030754775
859.0,8/27/2021 1:19:54 PM,7 Best ETFs to Buy to Cover a Broad Spectrum of Opportunities,InvestorPlace,/news/stocks/7-best-etfs-to-buy-to-cover-a-broad-spectrum-of-opportunities-1030763716
860.0,8/27/2021 1:35:25 PM,"The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration",Benzinga,/news/stocks/the-daily-biotech-pulse-morphosys-incyte-snag-european-nod-immutep-granted-chinese-patent-bolt-biotherapeutics-strike-oncology-collaboration-1030763431
861.0,8/30/2021 6:59:00 AM,Dupixent® (dupilumab) Pivotal Trial Meets All Primary and Secondary Endpoints Becoming First Biologic Medicine to Significantly Reduce Signs and Symptoms of Moderate-to-severe Atopic Dermatitis in...,PR Newswire,/news/stocks/dupixent-dupilumab-pivotal-trial-meets-all-primary-and-secondary-endpoints-becoming-first-biologic-medicine-to-significantly-reduce-signs-and-symptoms-of-moderate-to-severe-atopic-dermatitis-in-1030765913
862.0,8/30/2021 7:18:20 AM,Regeneron : Phase 3 Trial Of Dupixent On Atopic Dermatitis Meets Primary And Secondary Endpoints ,RTTNews,/news/stocks/regeneron-phase-3-trial-of-dupixent-on-atopic-dermatitis-meets-primary-and-secondary-endpoints-1030765935
863.0,8/31/2021 2:06:37 PM,"The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical",Benzinga,/news/stocks/the-daily-biotech-pulse-vectivbio-in-m-a-mix-sonnet-biotherapeutics-advances-candidate-to-clinics-ceo-transitions-at-galapagos-talis-biomedical-1030769575
864.0,9/1/2021 1:32:13 PM,"The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-releases-twin-dose-of-positive-tidings-astellas-voluntarily-pauses-gene-therapy-study-ascendis-offering-1030772643
865.0,9/2/2021 2:19:58 PM,"The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab",Benzinga,/news/stocks/the-daily-biotech-pulse-assembly-bio-halts-hbv-study-moderna-initiates-submission-for-covid-19-booster-dose-fda-nod-for-beigene-tiziana-out-licenses-foralumab-1030776427
866.0,9/7/2021 6:43:34 PM,Analyst Ratings For Regeneron Pharmaceuticals,Benzinga,/news/stocks/analyst-ratings-for-regeneron-pharmaceuticals-1030784971
867.0,9/8/2021 1:11:10 PM,GlaxoSmithKline/ Vir COVID-19 antibody drug may get Japanese approval this month - NHK,Seeking Alpha,https://seekingalpha.com/news/3737914-gsk-stock-vir-covid-19-antibody-drug-may-get-japanese-approval-this-month-nhk?utm_source=markets.businessinsider.com&utm_medium=referral
868.0,9/8/2021 10:05:00 PM,Regeneron Announces Investor Conference Presentations,PR Newswire,/news/stocks/regeneron-announces-investor-conference-presentations-1030788331
869.0,9/14/2021 9:18:39 PM,Regeneron Pharmaceuticals nabs $2.94B U.S. Army modification contract for antibody therapeutic doses,Seeking Alpha,https://seekingalpha.com/news/3739719-regeneron-pharmaceuticals-nabs-294b-us-army-modification-contract-for-antibody-therapeutic-doses?utm_source=markets.businessinsider.com&utm_medium=referral
870.0,9/14/2021 11:33:00 PM,Regeneron Announces New U.S. Government Agreement to Purchase Additional Doses of REGEN-COV™ (casirivimab and imdevimab) Antibody Cocktail,PR Newswire,/news/stocks/regeneron-announces-new-u-s-government-agreement-to-purchase-additional-doses-of-regen-cov-casirivimab-and-imdevimab-antibody-cocktail-1030799885
871.0,9/15/2021 5:31:41 AM,Regeneron To Supply Additional 1.4 Mln Doses Of COVID-19 Therapy To U.S. ,RTTNews,/news/stocks/regeneron-to-supply-additional-1-4-mln-doses-of-covid-19-therapy-to-u-s-1030800084
872.0,9/15/2021 1:38:39 PM,"The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-regeneron-ink-covid-19-drug-deal-with-us-regulatory-setback-for-calliditas-theravance-to-cut-75-jobs-4-ipos-1030801226
873.0,9/15/2021 2:27:07 PM,10 Biggest Price Target Changes For Wednesday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-wednesday-1030801508
874.0,9/15/2021 4:35:49 PM,Breaking Down The Inflation Numbers Draws Attention To Oil Prices,Benzinga,/news/stocks/breaking-down-the-inflation-numbers-draws-attention-to-oil-prices-1030802140
875.0,9/15/2021 4:45:22 PM,7 Gene Editing Stocks Promising to Change our DNA,InvestorPlace,/news/stocks/7-gene-editing-stocks-promising-to-change-our-dna-1030802558
876.0,9/15/2021 6:13:07 PM,Analyst Ratings For Regeneron Pharmaceuticals,Benzinga,/news/stocks/analyst-ratings-for-regeneron-pharmaceuticals-1030802416
877.0,9/19/2021 5:30:00 PM,ESMO Late-breaking Data Show Libtayo® (cemiplimab) and Chemotherapy First-line Treatment Combination Significantly Improved Overall Survival in Patients with Advanced NSCLC,PR Newswire,/news/stocks/esmo-late-breaking-data-show-libtayo-cemiplimab-and-chemotherapy-first-line-treatment-combination-significantly-improved-overall-survival-in-patients-with-advanced-nsclc-1030808522
878.0,9/21/2021 6:59:00 AM,New Dupixent® (dupilumab) Data in Patients as Young as Six Years Old With Moderate-to-Severe Atopic Dermatitis to Be Presented at WCPD and EADV,PR Newswire,/news/stocks/new-dupixent-dupilumab-data-in-patients-as-young-as-six-years-old-with-moderate-to-severe-atopic-dermatitis-to-be-presented-at-wcpd-and-eadv-1030811635
879.0,9/21/2021 7:23:57 PM,NNVC Stock: What Is Going on With Red-Hot NanoViricides Today?,InvestorPlace,/news/stocks/nnvc-stock-what-is-going-on-with-red-hot-nanoviricides-today-1030814063
880.0,9/28/2021 1:00:00 PM,FDA Accepts Libtayo® (cemiplimab-rwlc) for Priority Review for Advanced Cervical Cancer,PR Newswire,/news/stocks/fda-accepts-libtayo-cemiplimab-rwlc-for-priority-review-for-advanced-cervical-cancer-1030827586
881.0,9/28/2021 1:50:22 PM,Regeneron's Supplemental BLA For Libtayo To Treat Cervical Cancer Gets Priority Review ,RTTNews,/news/stocks/regeneron-s-supplemental-bla-for-libtayo-to-treat-cervical-cancer-gets-priority-review-1030827704
882.0,9/28/2021 2:18:52 PM,"The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive",Benzinga,/news/stocks/the-daily-biotech-pulse-eisai-biogen-pursue-approval-of-second-alzheimer-s-treatment-sanofi-changes-mrna-strategy-gsk-subsidiary-to-develop-long-acting-hiv-preventive-1030827880
883.0,9/28/2021 7:30:23 PM,7 Biotech Stocks Entering the Golden Boom Phase,InvestorPlace,/news/stocks/7-biotech-stocks-entering-the-golden-boom-phase-1030829968
884.0,9/28/2021 7:36:06 PM,Editas Medicine slips ahead of key data readout for gene editing candidate,Seeking Alpha,https://seekingalpha.com/news/3745477-edit-stock-slips-ahead-of-key-data-readout-for-gene-editing-candidate?utm_source=markets.businessinsider.com&utm_medium=referral
885.0,9/29/2021 11:00:00 PM,New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Treat COVID-19,PR Newswire,/news/stocks/new-england-journal-of-medicine-publishes-positive-phase-3-trial-results-for-regen-cov-casirivimab-and-imdevimab-to-treat-covid-19-1030832320
886.0,9/30/2021 7:00:00 AM,New REGEN-COV™ (casirivimab and imdevimab) Data Show Supportive Results in Patients Hospitalized with COVID-19,PR Newswire,/news/stocks/new-regen-cov-casirivimab-and-imdevimab-data-show-supportive-results-in-patients-hospitalized-with-covid-19-1030832783
887.0,9/30/2021 7:41:21 AM,Regeneron's REGEN-COV Data Show Supportive Results In Patients Hospitalized With COVID-19 ,RTTNews,/news/stocks/regeneron-s-regen-cov-data-show-supportive-results-in-patients-hospitalized-with-covid-19-1030832860
888.0,9/30/2021 8:58:51 AM,Biotech Stocks Facing FDA Decision In October 2021 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-october-2021-1030833014
889.0,10/1/2021 8:17:08 PM,Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-october-pdufa-dates-1030838143
890.0,10/1/2021 8:18:24 PM,Adverum posts promising two-year data for one-time injection in Wet AMD,Seeking Alpha,https://seekingalpha.com/news/3747317-adverum-posts-promising-two-year-data-for-one-time-injection-in-wet-amd?utm_source=markets.businessinsider.com&utm_medium=referral
891.0,10/2/2021 2:00:00 PM,"Moderna, BioNTech top performing pharmas in Q3; Alzheimer's drug developers lag",Seeking Alpha,https://seekingalpha.com/news/3747328-moderna-biontech-top-best-performing-pharmas-in-q3-alzheimers-drug-developers-lag?utm_source=markets.businessinsider.com&utm_medium=referral
892.0,10/7/2021 4:21:57 PM,"Cramer Likes DraftKings, Skyworks, And These Automakers",Benzinga,/news/stocks/cramer-likes-draftkings-skyworks-and-these-automakers-1030850756
893.0,10/8/2021 2:56:49 PM,Intellia Therapeutics slides after insider selling,Seeking Alpha,https://seekingalpha.com/news/3750967-intellia-therapeutics-slides-after-insider-selling?utm_source=markets.businessinsider.com&utm_medium=referral
894.0,10/11/2021 10:15:00 PM,"Regeneron to Report Third Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2021",PR Newswire,/news/stocks/regeneron-to-report-third-quarter-2021-financial-and-operating-results-and-host-conference-call-and-webcast-on-november-4-2021-1030856992
895.0,10/12/2021 6:21:59 PM,Expert Ratings For Regeneron Pharmaceuticals,Benzinga,/news/stocks/expert-ratings-for-regeneron-pharmaceuticals-1030859989
896.0,10/14/2021 1:21:00 PM,FDA Accepts REGEN-COV® (casirivimab and imdevimab) for Priority Review for Treatment and Prophylaxis of COVID-19,PR Newswire,/news/stocks/fda-accepts-regen-cov-casirivimab-and-imdevimab-for-priority-review-for-treatment-and-prophylaxis-of-covid-19-1030866132
897.0,10/14/2021 1:45:49 PM,Regeneron Pharma: FDA To Review BLA For REGEN-COV Antibody Cocktail To Treat COVID-19 ,RTTNews,/news/stocks/regeneron-pharma-fda-to-review-bla-for-regen-cov-antibody-cocktail-to-treat-covid-19-1030866211
898.0,10/15/2021 7:00:55 PM,"Catalyst watch for next week: Apple event, Tesla earnings, WeWork SPAC and earnings rush",Seeking Alpha,https://seekingalpha.com/news/3753345-catalyst-watch-for-next-week-apple-event-tesla-earnings-wework-spac-and-earnings-rush?utm_source=markets.businessinsider.com&utm_medium=referral
899.0,10/18/2021 1:34:17 PM,"The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs",Benzinga,/news/stocks/the-week-ahead-in-biotech-oct-18-23-j-j-biogen-kickstart-big-pharma-earnings-regeneron-sanofi-roche-await-fda-decisions-and-ipos-1030873336
900.0,10/20/2021 3:58:12 PM,Intellia granted Orphan Drug designation for transthyretin amyloidosis program,Seeking Alpha,https://seekingalpha.com/news/3755595-intellia-granted-orphan-drug-designation-for-transthyretin-amyloidosis-program?utm_source=markets.businessinsider.com&utm_medium=referral
901.0,10/20/2021 11:29:00 PM,FDA Expands Approval of Dupixent® (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to-severe Asthma,PR Newswire,/news/stocks/fda-expands-approval-of-dupixent-dupilumab-to-include-children-aged-6-to-11-years-with-moderate-to-severe-asthma-1030883439
902.0,10/21/2021 2:05:16 PM,"The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-authorizes-moderna-j-j-booster-shots-regulatory-approvals-for-bristol-myers-squibb-sanofi-regeneron-ventyx-ipo-1030885538
903.0,10/22/2021 6:59:00 AM,"Dupixent® (dupilumab) is the First Biologic to Significantly Reduce Itch and Skin Lesions in Phase 3 Trial for Prurigo Nodularis, Demonstrating the Role of Type 2 Inflammation in this Disease",PR Newswire,/news/stocks/dupixent-dupilumab-is-the-first-biologic-to-significantly-reduce-itch-and-skin-lesions-in-phase-3-trial-for-prurigo-nodularis-demonstrating-the-role-of-type-2-inflammation-in-this-disease-1030888015
904.0,10/22/2021 7:20:25 AM,Regeneron : Dupixent Reduces Itch And Skin Lesions In Phase 3 Trial For Prurigo Nodularis ,RTTNews,/news/stocks/regeneron-dupixent-reduces-itch-and-skin-lesions-in-phase-3-trial-for-prurigo-nodularis-1030888044
905.0,10/24/2021 5:45:47 PM,"The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-oct-24-30-eyenovia-ani-pharma-clearside-medical-fda-decisions-merck-bristol-myers-squibb-earnings-ipos-and-more-1030891741
906.0,10/25/2021 6:59:00 AM,"Second Dupixent® (dupilumab) Phase 3 Eosinophilic Esophagitis Trial to Demonstrate Significant Disease Improvements, Underscoring Role of Type 2 Inflammation in This Complex Disease",PR Newswire,/news/stocks/second-dupixent-dupilumab-phase-3-eosinophilic-esophagitis-trial-to-demonstrate-significant-disease-improvements-underscoring-role-of-type-2-inflammation-in-this-complex-disease-1030892721
907.0,10/25/2021 7:29:31 AM,"Regeneron, Sanofi Report Positive Data From Second Phase 3 Trial Of Dupixent In EoE Patients ",RTTNews,/news/stocks/regeneron-sanofi-report-positive-data-from-second-phase-3-trial-of-dupixent-in-eoe-patients-1030893462
908.0,10/25/2021 4:28:26 PM,Sanofi's Dupixent could generate over EUR 1B in sales from new indication - BofA,Seeking Alpha,https://seekingalpha.com/news/3757550-sanfis-dupixent-could-generate-over-eur-1b-in-sales-from-new-indication-bofa?utm_source=markets.businessinsider.com&utm_medium=referral
909.0,10/25/2021 4:51:46 PM,Sanofi's Dupixent could generate over EUR 1B in sales from new indication - BofA,Seeking Alpha,https://seekingalpha.com/news/3757550-sanofis-dupixent-could-generate-over-eur-1b-in-sales-from-new-indication-bofa?utm_source=markets.businessinsider.com&utm_medium=referral
910.0,10/26/2021 6:31:52 PM,Where Regeneron Pharmaceuticals Stands With Analysts,Benzinga,/news/stocks/where-regeneron-pharmaceuticals-stands-with-analysts-1030901040
911.0,10/29/2021 11:14:26 AM,Health Canada approves Regeneron/Sanofi's Libtayo for advanced basal cell carcinoma,Seeking Alpha,https://seekingalpha.com/news/3760710-health-canada-approves-regeneronsanofis-libtayo-for-advanced-basal-cell-carcinoma?utm_source=markets.businessinsider.com&utm_medium=referral
912.0,10/30/2021 8:00:00 PM,"BioNTech, GSK top pharma performers in October; Bristol, Amgen biggest laggards",Seeking Alpha,https://seekingalpha.com/news/3761145-biontech-gsk-top-pharma-performers-in-october-bristol-amgen-biggest-laggards?utm_source=markets.businessinsider.com&utm_medium=referral
913.0,10/31/2021 7:23:54 PM,"The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline",Benzinga,/news/stocks/the-week-ahead-in-biotech-oct-31-nov-6-earnings-pick-up-pace-eton-awaits-seizure-drug-approval-kidney-conference-more-ipos-in-the-pipeline-1030917750
914.0,11/3/2021 3:01:13 PM,Here's what to expect from Regeneron Pharmaceuticals's earnings report,Markets Insider Automation,/news/stocks/regeneron-stock-quarter-earnings-preview-q3-1030932390
915.0,11/3/2021 3:55:55 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3764124-notable-earnings-before-thursdays-open?utm_source=markets.businessinsider.com&utm_medium=referral
916.0,11/3/2021 4:16:27 PM,Will Regeneron Pharmaceuticals maintain EPS beat run in Q3?,Seeking Alpha,https://seekingalpha.com/news/3764149-will-regeneron-pharmaceuticals-maintain-eps-beat-run-in-q3?utm_source=markets.businessinsider.com&utm_medium=referral
917.0,11/4/2021 10:33:30 AM,"Regeneron Pharmaceuticals EPS beats by $5.43, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3764903-regeneron-pharmaceuticals-eps-beats-5_43-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral
918.0,11/4/2021 11:07:50 AM,Regeneron posts Q3 beat powered by EYLEA and Dupixent,Seeking Alpha,https://seekingalpha.com/news/3764976-regeneron-posts-q3-beat-powered-by-eylea-and-dupixent?utm_source=markets.businessinsider.com&utm_medium=referral
919.0,11/4/2021 11:30:00 AM,Regeneron Reports Third Quarter 2021 Financial and Operating Results,PR Newswire,/news/stocks/regeneron-reports-third-quarter-2021-financial-and-operating-results-1030936350
920.0,11/4/2021 11:36:09 AM,Regeneron Pharmaceuticals Q3 adjusted earnings Beat Estimates,RTTNews,/news/stocks/regeneron-pharmaceuticals-q3-adjusted-earnings-beat-estimates-1030936345
921.0,11/4/2021 1:14:49 PM,"The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-s-oral-covid-19-pill-authorized-in-uk-novartis-cashes-out-of-roche-chimerix-plunges-on-data-evotec-ipo-1030937079
922.0,11/4/2021 3:00:00 PM,Regeneron Presentations at ASH Highlight Expanding Clinical Research in Blood Cancers and Disorders,PR Newswire,/news/stocks/regeneron-presentations-at-ash-highlight-expanding-clinical-research-in-blood-cancers-and-disorders-1030937898
923.0,11/4/2021 6:35:27 PM,7 European Stocks to Buy to Diversify Your Portfolio,InvestorPlace,/news/stocks/7-european-stocks-to-buy-to-diversify-your-portfolio-1030938704
924.0,11/5/2021 3:07:21 PM,"Benzinga's Top Ratings Upgrades, Downgrades For November 5, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-november-5-2021-1030942943
925.0,11/5/2021 3:12:19 PM,Regeneron Pharmaceuticals files for mixed shelf offering,Seeking Alpha,https://seekingalpha.com/news/3766204-regeneron-pharmaceuticals-files-for-mixed-shelf-offering?utm_source=markets.businessinsider.com&utm_medium=referral
926.0,11/5/2021 5:12:26 PM,What 8 Analyst Ratings Have To Say About Regeneron Pharmaceuticals,Benzinga,/news/stocks/what-8-analyst-ratings-have-to-say-about-regeneron-pharmaceuticals-1030943211
927.0,11/5/2021 6:24:23 PM,"Wall Street Crime and Punishment: Martin Shkreli, The Self-Destructive Pharma Bro",Benzinga,/news/stocks/wall-street-crime-and-punishment-martin-shkreli-the-self-destructive-pharma-bro-1030943422
928.0,11/6/2021 10:25:37 PM,"As Nasdaq 100 extends big winning streak, getting selective on tech can pay: Alpha Tactics",Seeking Alpha,https://seekingalpha.com/news/3766504-as-nasdaq-100-extends-big-winning-streak-getting-selective-on-tech-can-pay?utm_source=markets.businessinsider.com&utm_medium=referral
929.0,11/8/2021 12:25:28 PM,Regeneron says single dose of antibody cocktail cut COVID-19 risk by 82% over six months,Seeking Alpha,https://seekingalpha.com/news/3766652-regeneron-says-single-dose-of-antibody-cocktail-cut-covid-19-risk-by-82-over-six-months?utm_source=markets.businessinsider.com&utm_medium=referral
930.0,11/8/2021 1:00:00 PM,New Phase 3 Analyses Show That a Single Dose of REGEN-COV® (casirivimab and imdevimab) Provides Long-term Protection Against COVID-19,PR Newswire,/news/stocks/new-phase-3-analyses-show-that-a-single-dose-of-regen-cov-casirivimab-and-imdevimab-provides-long-term-protection-against-covid-19-1030948564
931.0,11/8/2021 1:46:32 PM,Regeneron: REGEN-COV Show Long-term Protection Against COVID-19 In Follow-up Period ,RTTNews,/news/stocks/regeneron-regen-cov-show-long-term-protection-against-covid-19-in-follow-up-period-1030948727
932.0,11/8/2021 4:05:36 PM,"What are the differences between Merck, Pfizer, and Regeneron COVID treatments?",Seeking Alpha,https://seekingalpha.com/news/3766836-whats-the-difference-between-merck-pfizer-and-regeneron-covid-treatments?utm_source=markets.businessinsider.com&utm_medium=referral
933.0,11/9/2021 3:27:12 PM,"Intellia Therapeutics, Alnylam seen as potential Regeneron targets, analyst says",Seeking Alpha,https://seekingalpha.com/news/3767761-intellia-therapeutics-alnylam-seen-as-potential-regeneron-targets-analyst-says?utm_source=markets.businessinsider.com&utm_medium=referral
934.0,11/11/2021 3:35:15 PM,Regeneron-Roche COVID-19 antibody cocktail gets European backing for authorization,Seeking Alpha,https://seekingalpha.com/news/3769552-regeneron-covid-19-antibody-cocktail-gets-european-backing-for-authorization?utm_source=markets.businessinsider.com&utm_medium=referral
935.0,11/11/2021 5:03:00 PM,CHMP Recommends EU Approval of Regeneron Antibody Cocktail to Treat and Prevent COVID-19,PR Newswire,/news/stocks/chmp-recommends-eu-approval-of-regeneron-antibody-cocktail-to-treat-and-prevent-covid-19-1030966053
936.0,11/12/2021 4:20:00 PM,Regeneron Antibody Cocktail Approved by European Commission to Treat and Prevent COVID-19,PR Newswire,/news/stocks/regeneron-antibody-cocktail-approved-by-european-commission-to-treat-and-prevent-covid-19-1030970460
937.0,11/12/2021 4:42:14 PM,Regeneron-Roche COVID-19 antibody cocktail approved in Europe,Seeking Alpha,https://seekingalpha.com/news/3770147-regeneron-roche-covid-19-antibody-cocktail-approved-in-europe?utm_source=markets.businessinsider.com&utm_medium=referral
938.0,11/12/2021 9:27:00 PM,Regeneron announces $3 billion share buyback program,Seeking Alpha,https://seekingalpha.com/news/3770298-regeneron-announces-3-billion-share-buyback-program?utm_source=markets.businessinsider.com&utm_medium=referral
939.0,11/12/2021 10:11:00 PM,Regeneron Announces $3 Billion Share Repurchase Program,PR Newswire,/news/stocks/regeneron-announces-3-billion-share-repurchase-program-1030971169
940.0,11/13/2021 5:04:05 AM,EU Approves Regeneron Antibody Cocktail To Treat And Prevent COVID-19 ,RTTNews,/news/stocks/eu-approves-regeneron-antibody-cocktail-to-treat-and-prevent-covid-19-1030971351
941.0,11/15/2021 1:00:00 PM,Regeneron Listed on Dow Jones Sustainability World Index for Third Consecutive Year,PR Newswire,/news/stocks/regeneron-listed-on-dow-jones-sustainability-world-index-for-third-consecutive-year-1030975778
942.0,11/16/2021 5:09:44 AM,Cathie Wood Buys $13.7M In Disney And Sells $7.95M In Google On Monday — Here Are Other Key Trades,Benzinga,/news/etf/cathie-wood-buys-13-7m-in-disney-and-sells-7-95m-in-google-on-monday-—-here-are-other-key-trades-1030978530
943.0,11/16/2021 2:04:33 PM,Pfizer moves to allow cheaper COVID-19 pills sending shares of rivals lower,Seeking Alpha,https://seekingalpha.com/news/3771400-pfizer-moves-to-allow-cheaper-covid-19-pills-sending-shares-of-rivals-lower?utm_source=markets.businessinsider.com&utm_medium=referral
944.0,11/16/2021 10:15:00 PM,Regeneron Announces Investor Conference Presentations,PR Newswire,/news/stocks/regeneron-announces-investor-conference-presentations-1030981959
945.0,11/18/2021 12:19:35 PM,Alnylam Pharma is said to be a potential target for Novartis - Bloomberg,Seeking Alpha,https://seekingalpha.com/news/3772337-alnylam-pharma-is-said-to-be-a-potential-target-for-novartis-bloomberg?utm_source=markets.businessinsider.com&utm_medium=referral
946.0,11/19/2021 2:20:15 PM,"The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial",Benzinga,/news/stocks/the-daily-biotech-pulse-connect-biopharma-sinks-on-eczema-drug-readout-enanta-pulls-plug-on-hbv-drug-clinical-setback-for-merck-in-hiv-trial-1030991438
947.0,11/19/2021 5:53:31 PM,Connect Biopharma sinks 54% following phase 2 results on atopic dermatitis candidate,Seeking Alpha,https://seekingalpha.com/news/3772988-connect-biopharma-sinks-54-following-phase-2-results-on-atopic-dermatitis-candidate?utm_source=markets.businessinsider.com&utm_medium=referral
948.0,11/22/2021 12:09:21 PM,Novartis plans new sales approach for cholesterol lowering drug - WSJ,Seeking Alpha,https://seekingalpha.com/news/3773170-novartis-plans-new-sales-approach-for-cholesterol-lowering-drug-wsj?utm_source=markets.businessinsider.com&utm_medium=referral
949.0,11/22/2021 2:27:36 PM,Decibel up 4% on research extension with Regeneron for hearing loss therapies,Seeking Alpha,https://seekingalpha.com/news/3773276-decibel-up-4-on-research-extension-with-regeneron-for-hearing-loss-therapies?utm_source=markets.businessinsider.com&utm_medium=referral
950.0,11/23/2021 7:57:53 AM,"Nykode Inks Multi-mln Dollar Deal With Regeneron To Develop Cancer, Infectious Diseases Vaccines ",RTTNews,/news/stocks/nykode-inks-multi-mln-dollar-deal-with-regeneron-to-develop-cancer-infectious-diseases-vaccines-1030996755
951.0,11/23/2021 1:44:27 PM,"Nykode Therapeutics in up to $925M license, development deal with Regeneron",Seeking Alpha,https://seekingalpha.com/news/3773771-nykode-therapeutics-in-up-to-925m-license-development-deal-with-regeneron?utm_source=markets.businessinsider.com&utm_medium=referral
952.0,11/29/2021 2:21:46 PM,"Moderna, Pfizer, and Adagio likely to benefit from Omicron variant - Morgan Stanley",Seeking Alpha,https://seekingalpha.com/news/3774880-moderna-pfizer-and-adagio-likely-to-benefit-from-omicron-covid-variant-morgan-stanley?utm_source=markets.businessinsider.com&utm_medium=referral
953.0,11/29/2021 6:58:45 PM,3 Pharma Stocks Morgan Stanley Says Will Be Omicron Variant Beneficiaries,Benzinga,/news/stocks/3-pharma-stocks-morgan-stanley-says-will-be-omicron-variant-beneficiaries-1031009763
954.0,11/29/2021 9:57:43 PM,ADGI Stock Soars as Analysts Lock On to Its Omicron-Fighting Potential,InvestorPlace,/news/stocks/adgi-stock-soars-as-analysts-lock-on-to-its-omicron-fighting-potential-1031010138
955.0,11/30/2021 11:54:22 AM,"Regeneron, Eli Lilly COVID-19 antibody drugs said to lose efficacy against Omicron - WSJ",Seeking Alpha,https://seekingalpha.com/news/3775238-regeneron-eli-lilly-covid-19-antibody-drugs-said-to-lose-efficacy-against-omicron-wsj?utm_source=markets.businessinsider.com&utm_medium=referral
956.0,11/30/2021 12:17:53 PM,Moderna CEO warns “material drop” in vaccine efficacy against new COVID-19 variant,Seeking Alpha,https://seekingalpha.com/news/3775258-moderna-ceo-warns-material-drop-in-vaccine-efficacy-against-new-covid-19-variant?utm_source=markets.businessinsider.com&utm_medium=referral
957.0,11/30/2021 2:12:23 PM,"The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout",Benzinga,/news/stocks/the-daily-biotech-pulse-cumberland-jumps-on-fda-nod-regeneron-says-antibody-treatment-may-be-less-effective-against-omicron-immunogen-readout-1031011982
958.0,11/30/2021 7:29:27 PM,7 Drug Stocks to Buy Now While They’re Still on Sale,InvestorPlace,/news/stocks/7-drug-stocks-to-buy-now-while-theyre-still-on-sale-1031013701
959.0,11/30/2021 9:05:31 PM,Why Are Stocks Down Today? 4 Things to Know.,InvestorPlace,/news/stocks/why-are-stocks-down-today-4-things-to-know-1031013891
960.0,11/30/2021 9:11:26 PM,HC Wainwright Sees 'Buying Opportunity' For This COVID-19 Antibody Stock After Sell-Off,Benzinga,/news/stocks/hc-wainwright-sees-buying-opportunity-for-this-covid-19-antibody-stock-after-sell-off-1031013771
961.0,12/2/2021 6:44:27 PM,"Regeneron: Surfing on Covid, With More Under the Surface",InvestorPlace,/news/stocks/regn-stock-regeneron-surfing-on-covid-1031021097
962.0,12/3/2021 4:00:00 PM,Regeneron to Participate in H.C. Wainwright & Co. Virtual Event,PR Newswire,/news/stocks/regeneron-to-participate-in-h-c-wainwright-co-virtual-event-1031023294
963.0,12/6/2021 12:07:24 PM,"The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-dec-6-dec-11-daré-fda-decision-adcom-tryst-for-reata-multiple-conference-presentations-and-more-1031025543
964.0,12/6/2021 4:05:46 PM,"Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-december-6-2021-1031026544
965.0,12/6/2021 5:11:13 PM,Where Regeneron Pharmaceuticals Stands With Analysts,Benzinga,/news/stocks/where-regeneron-pharmaceuticals-stands-with-analysts-1031026729
966.0,12/6/2021 10:00:50 PM,2 Big Stock Bets That Are Insiders Are Buying Now,InvestorPlace,/news/stocks/2-big-stock-bets-that-are-insiders-are-buying-now-1031027396
967.0,12/8/2021 11:29:00 PM,New England Journal of Medicine Publishes Positive Phase 3 Dupixent® (dupilumab) Results in Children with Moderate-to-severe Asthma,PR Newswire,/news/stocks/new-england-journal-of-medicine-publishes-positive-phase-3-dupixent-dupilumab-results-in-children-with-moderate-to-severe-asthma-1031033805
968.0,12/9/2021 4:27:21 PM,"Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-december-9-2021-1031036161
969.0,12/9/2021 7:19:25 PM,Regeneron initiated at overweight at Wells Fargo on high-dose Eylea potential,Seeking Alpha,https://seekingalpha.com/news/3778854-regeneron-initiated-at-overweight-at-wells-fargo-on-high-dose-eylea-potential?utm_source=markets.businessinsider.com&utm_medium=referral
970.0,12/10/2021 8:00:40 PM,"Catalyst watch for next week: FOMC drama, events for Lowe's and Delta Air Lines, Rivian earnings",Seeking Alpha,https://seekingalpha.com/news/3779254-catalyst-watch-for-next-week-fomc-drama-events-for-lowes-and-delta-air-lines-rivian-earnings?utm_source=markets.businessinsider.com&utm_medium=referral
971.0,12/11/2021 6:00:00 PM,New REGN5458 (BCMAxCD3) Phase 1 Data Show 75% Response Rate at Highest Dose Levels Studied in Patients with Heavily Pretreated Multiple Myeloma,PR Newswire,/news/stocks/new-regn5458-bcmaxcd3-phase-1-data-show-75-response-rate-at-highest-dose-levels-studied-in-patients-with-heavily-pretreated-multiple-myeloma-1031040028
972.0,12/11/2021 6:55:31 PM,Regeneron : REGN5458 Phase 1 Data Show 75% Response Rate At Highest Dose Levels In  Multiple Myeloma ,RTTNews,/news/stocks/regeneron-regn5458-phase-1-data-show-75-response-rate-at-highest-dose-levels-in-multiple-myeloma-1031040031
973.0,12/13/2021 6:32:43 AM,"Regeneron, Sanofi report positive Dupixent data in children 6 months to 5 years with atopic dermatitis",Seeking Alpha,https://seekingalpha.com/news/3779368-regeneron-sanofi-report-positive-dupixent-data-in-children-6-months-to-5-years-with-atopic-dermatitis?utm_source=markets.businessinsider.com&utm_medium=referral
974.0,12/13/2021 6:59:00 AM,Positive Phase 3 Dupixent® (dupilumab) Data in Children 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Featured in RAD 2021 Late-breaking Session,PR Newswire,/news/stocks/positive-phase-3-dupixent-dupilumab-data-in-children-6-months-to-5-years-with-moderate-to-severe-atopic-dermatitis-featured-in-rad-2021-late-breaking-session-1031045716
975.0,12/13/2021 7:20:33 AM,Regeneron : Phase 3 Results Show Dupixen Improved Skin Clearance In Children With  Atopic Dermatitis ,RTTNews,/news/stocks/regeneron-phase-3-results-show-dupixen-improved-skin-clearance-in-children-with-atopic-dermatitis-1031040746
976.0,12/15/2021 2:48:17 PM,Regeneron downgraded at Bernstein on risk to Eylea outlook,Seeking Alpha,https://seekingalpha.com/news/3780392-regeneron-downgraded-at-bernstein-on-risk-to-eylea-outlook?utm_source=markets.businessinsider.com&utm_medium=referral
977.0,12/15/2021 4:05:47 PM,"Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-december-15-2021-1031047709
978.0,12/16/2021 1:50:52 PM,Regeneron says it has experimental monoclonal antibodies effective against Omicron,Seeking Alpha,https://seekingalpha.com/news/3780749-regeneron-says-it-has-experimental-monoclonal-antibodies-effective-against-omicron?utm_source=markets.businessinsider.com&utm_medium=referral
979.0,12/16/2021 8:22:33 PM,Cantor raises Pfizer price target ahead of company event highlighting COVID treatments,Seeking Alpha,https://seekingalpha.com/news/3781034-cantor-raises-pfizer-price-target-ahead-of-company-event-highlighting-covid-treatments?utm_source=markets.businessinsider.com&utm_medium=referral
980.0,12/19/2021 2:00:00 PM,"Alnylam, Crispr Therapeutics among Goldman's biopharma M&A targets for 2022",Seeking Alpha,https://seekingalpha.com/news/3781488-alnylam-pharma-crispr-therapeutics-among-goldmans-healthcare-targets-for-2022?utm_source=markets.businessinsider.com&utm_medium=referral
981.0,12/22/2021 1:37:10 PM,Alnylam Pharma Files Clinical Trial Authorization Application For ALN-APP In The UK ,RTTNews,/news/stocks/alnylam-pharma-files-clinical-trial-authorization-application-for-aln-app-in-the-uk-1031061636
982.0,12/22/2021 4:02:28 PM,Alnylam Pharma slips despite plans for Alzheimer’s disease study in 2022,Seeking Alpha,https://seekingalpha.com/news/3782728-alnylam-pharma-slips-despite-plans-for-alzheimers-disease-study-in-2022?utm_source=markets.businessinsider.com&utm_medium=referral
983.0,12/22/2021 10:15:00 PM,Regeneron Announces Presentation at the 40th Annual J.P. Morgan Healthcare Conference,PR Newswire,/news/stocks/regeneron-announces-presentation-at-the-40th-annual-j-p-morgan-healthcare-conference-1031062810
984.0,12/23/2021 12:27:47 PM,Top 10 Blockbuster Drugs In 2021 ,RTTNews,/news/stocks/top-10-blockbuster-drugs-in-2021-1031063755
985.0,12/28/2021 6:30:25 PM,Why did Intellia soar in 2021 while other gene editing stocks faltered? CRISPR in humans,Seeking Alpha,https://seekingalpha.com/news/3783739-why-did-intellia-soar-in-2021-while-other-gene-editing-stocks-faltered-crispr-in-humans?utm_source=markets.businessinsider.com&utm_medium=referral
986.0,12/31/2021 8:40:54 PM,Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-january-pdufa-dates-1031072671
987.0,1/3/2022 5:36:13 PM,"Benzinga's Top Ratings Upgrades, Downgrades For January 3, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-january-3-2022-1031074541
988.0,1/5/2022 3:34:41 PM,Regeneron downgraded to underperform at BofA on minimal COVID contribution in 2022,Seeking Alpha,https://seekingalpha.com/news/3785458-regeneron-downgraded-to-underperform-at-bofa-on-minimal-covid-contribution-in-2022?utm_source=markets.businessinsider.com&utm_medium=referral
989.0,1/5/2022 4:08:49 PM,"Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-january-5-2022-1031079571
990.0,1/5/2022 6:18:29 PM,"Why This Pfizer, Regeneron Analyst Has Contrasting Recommendations For The COVID Stock Plays",Benzinga,/news/stocks/why-this-pfizer-regeneron-analyst-has-contrasting-recommendations-for-the-covid-stock-plays-1031079936
991.0,1/7/2022 12:08:43 PM,"Regeneron, Ultragenyx collaborate to commercialize Evkeeza outside U.S.",Seeking Alpha,https://seekingalpha.com/news/3786134-regeneron-ultragenyx-collaborate-to-commercialize-evkeeza-outside-us?utm_source=markets.businessinsider.com&utm_medium=referral
992.0,1/7/2022 1:00:00 PM,Regeneron and Ultragenyx Collaborate to Commercialize Evkeeza® (evinacumab) Outside the United States,PR Newswire,/news/stocks/regeneron-and-ultragenyx-collaborate-to-commercialize-evkeeza-evinacumab-outside-the-united-states-1031083471
993.0,1/7/2022 2:25:53 PM,Regeneron Signs Up To $93 Mln Deal With Ultragenyx To Commercialize Evkeeza Outside U.S. ,RTTNews,/news/stocks/regeneron-signs-up-to-93-mln-deal-with-ultragenyx-to-commercialize-evkeeza-outside-u-s-1031083698
994.0,1/7/2022 6:17:06 PM,Biden administration to ask Congress for more COVID funding - WaPo,Seeking Alpha,https://seekingalpha.com/news/3786338-biden-administration-to-ask-congress-for-more-covid-funding?utm_source=markets.businessinsider.com&utm_medium=referral
995.0,1/11/2022 3:24:36 PM,"Regeneron sees Q4 EYLEA U.S. sales of $1.54B, REGEN-COV sales of $2.29B",Seeking Alpha,https://seekingalpha.com/news/3787144-regeneron-sees-q4-eylea-us-sales-of-154b-regen-cov-sales-of-229b?utm_source=markets.businessinsider.com&utm_medium=referral
996.0,1/12/2022 8:20:01 PM,Vir extends gains as Needham lifts sales outlook for COVID-19 antibody therapy,Seeking Alpha,https://seekingalpha.com/news/3787638-vir-extends-gains-as-needham-lifts-sales-outlook-for-covid-19-antibody-therapy?utm_source=markets.businessinsider.com&utm_medium=referral
997.0,1/13/2022 10:05:00 PM,Regeneron to Report Fourth Quarter and Full Year 2021 Financial and Operating Results and Host Conference Call and Webcast on,PR Newswire,/news/stocks/regeneron-to-report-fourth-quarter-and-full-year-2021-financial-and-operating-results-and-host-conference-call-and-webcast-on-1031101516
998.0,1/14/2022 11:51:18 AM,Eli Lilly and GlaxoSmithKline/Vir COVID-19 therapies get WHO backing,Seeking Alpha,https://seekingalpha.com/news/3788201-eli-lilly-and-glaxosmithklinevir-covid-19-therapies-get-who-backing?utm_source=markets.businessinsider.com&utm_medium=referral
999.0,1/19/2022 6:59:00 AM,Second Positive Phase 3 Dupixent® (dupilumab) Trial Confirms Significant Improvements for Patients with Prurigo Nodularis,PR Newswire,/news/stocks/second-positive-phase-3-dupixent-dupilumab-trial-confirms-significant-improvements-for-patients-with-prurigo-nodularis-1031111328
1000.0,1/19/2022 7:34:12 AM,Sanofi Says Second Phase 3 Dupixent Trial Confirms Improvements For Patients With Prurigo Nodularis ,RTTNews,/news/stocks/sanofi-says-second-phase-3-dupixent-trial-confirms-improvements-for-patients-with-prurigo-nodularis-1031111707
1001.0,1/19/2022 12:29:51 PM,Sanofi-Regeneron Dupixent meets main goal of reducing itch in phase 3 skin disease trial,Seeking Alpha,https://seekingalpha.com/news/3789077-sanofi-regeneron-dupixent-meets-main-goal-of-reducing-itch-in-phase-3-skin-disease-trial?utm_source=markets.businessinsider.com&utm_medium=referral
1002.0,1/19/2022 1:00:00 PM,FDA Accepts for Review Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy for First-line Treatment of Advanced NSCLC,PR Newswire,/news/stocks/fda-accepts-for-review-libtayo-cemiplimab-rwlc-in-combination-with-chemotherapy-for-first-line-treatment-of-advanced-nsclc-1031112159
1003.0,1/19/2022 1:27:53 PM,REGN : FDA Accepts For Review Libtayo-Chemotherapy Combination For Advanced Lung Cancer Treatment ,RTTNews,/news/stocks/regn-fda-accepts-for-review-libtayo-chemotherapy-combination-for-advanced-lung-cancer-treatment-1031112248
1004.0,1/19/2022 1:40:21 PM,"The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data",Benzinga,/news/stocks/the-daily-biotech-pulse-gamida-gains-on-positive-regulatory-development-orphazyme-adma-preannouncements-immunitybio-leap-present-positive-data-1031112313
1005.0,1/19/2022 4:52:22 PM,Sanofi-Regeneron's Libtayo combo accepted for review by FDA for lung cancer subtype,Seeking Alpha,https://seekingalpha.com/news/3789265-sanofi-regenerons-libtayo-combo-accepted-for-review-by-fda-for-lung-cancer-subtype?utm_source=markets.businessinsider.com&utm_medium=referral
1006.0,1/20/2022 6:00:00 PM,Forty Accomplished Young Scientists Named Finalists in the 2022 Regeneron Science Talent Search,PR Newswire,/news/stocks/forty-accomplished-young-scientists-named-finalists-in-the-2022-regeneron-science-talent-search-1031117052
1007.0,1/20/2022 6:00:00 PM,Forty Accomplished Young Scientists Named Finalists in the 2022 Regeneron Science Talent Search,PR Newswire,/news/stocks/forty-accomplished-young-scientists-named-finalists-in-the-2022-regeneron-science-talent-search-1031117048
1008.0,1/21/2022 7:09:36 PM,GlaxoSmithKline and Vir to boost U.S. output of COVID-19 antibody - Reuters,Seeking Alpha,https://seekingalpha.com/news/3790412-glaxosmithkline-and-vir-to-boost-us-output-of-covid-19-antibody-reuters?utm_source=markets.businessinsider.com&utm_medium=referral
1009.0,1/24/2022 5:14:47 PM,FDA to restrict COVID-19 antibody therapies from Regeneron and Eli Lilly - WaPo,Seeking Alpha,https://seekingalpha.com/news/3790807-fda-to-restrict-covid-19-antibody-therapies-from-regeneron-and-eli-lilly-wapo?utm_source=markets.businessinsider.com&utm_medium=referral
1010.0,1/28/2022 12:32:46 PM,"Regeneron, Sanofi withdraw Libtayo application in cervical cancer",Seeking Alpha,https://seekingalpha.com/news/3792978-regeneron-sanofi-withdraw-libtayo-application-in-cervical-cancer?utm_source=markets.businessinsider.com&utm_medium=referral
1011.0,1/28/2022 1:00:00 PM,Regeneron and Sanofi Provide Regulatory Update on Libtayo® (cemiplimab-rwlc) in Advanced Cervical Cancer,PR Newswire,/news/stocks/regeneron-and-sanofi-provide-regulatory-update-on-libtayo-cemiplimab-rwlc-in-advanced-cervical-cancer-1031138960
1012.0,1/28/2022 1:40:55 PM,"Regeneron, Sanofi Withdraw SBLA For Libtayo To Treat Advanced Cervical Cancer ",RTTNews,/news/stocks/regeneron-sanofi-withdraw-sbla-for-libtayo-to-treat-advanced-cervical-cancer-1031139133
1013.0,1/28/2022 2:21:16 PM,"The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron",Benzinga,/news/stocks/the-daily-biotech-pulse-biogen-liquidates-out-of-biosimilar-jv-provention-bio-plots-diabetes-drug-resubmission-merck-finds-covid-pill-effective-against-omicron-1031139273
1014.0,1/29/2022 9:00:00 PM,"Vaccines to dominate pharma sales this year, but Bristol could have most best-sellers",Seeking Alpha,https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers?utm_source=markets.businessinsider.com&utm_medium=referral
1015.0,1/30/2022 2:06:35 AM,Goldman screens for best and worst stocks for tightening financial conditions,Seeking Alpha,https://seekingalpha.com/news/3793311-goldman-screens-for-stocks-for-tightening-financial-conditions?utm_source=markets.businessinsider.com&utm_medium=referral
1016.0,1/31/2022 6:59:00 AM,CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation,PR Newswire,/news/stocks/chmp-recommends-approval-of-dupixent-dupilumab-for-children-aged-6-to-11-years-with-severe-asthma-with-type-2-inflammation-1031142905
1017.0,1/31/2022 7:28:39 AM,Sanofi: CHMP Recommends Approval Of Dupixent For Children With Severe Asthma With Type2 Inflammation ,RTTNews,/news/stocks/sanofi-chmp-recommends-approval-of-dupixent-for-children-with-severe-asthma-with-type2-inflammation-1031142986
1018.0,1/31/2022 10:50:03 AM,EMA OKs expanded use of Regeneron/Sanofi's asthma med Dupixent in kids aged 6 to 11,Seeking Alpha,https://seekingalpha.com/news/3793371-ema-oks-expanded-use-of-regeneronsanofis-asthma-med-dupixent-in-kids-aged-6-to-11?utm_source=markets.businessinsider.com&utm_medium=referral
1019.0,1/31/2022 2:20:54 PM,"The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News",Benzinga,/news/stocks/the-week-ahead-in-biotech-jan-31-feb-5-merck-bristol-myers-squibb-lilly-novartis-headline-large-cap-biopharma-earnings-news-1031144306
1020.0,1/31/2022 3:16:17 PM,Analyst Ratings For Regeneron Pharmaceuticals,Benzinga,/news/stocks/analyst-ratings-for-regeneron-pharmaceuticals-1031144718
1021.0,1/31/2022 8:21:28 PM,Why did Regeneron Pharmaceuticals stock drop today? Roche gets FDA OK for Eylea rival,Seeking Alpha,https://seekingalpha.com/news/3793704-why-did-regeneron-pharmaceuticals-stock-drop-today-roche-gets-fda-ok-for-eylea-rival?utm_source=markets.businessinsider.com&utm_medium=referral
1022.0,1/31/2022 9:38:38 PM,5 Things To Expect This Week,InvestorPlace,/news/stocks/5-things-to-expect-this-week-1031147156
1023.0,2/1/2022 11:00:28 AM,3 Biotech Stocks That Could Boom or Bust in Q1,InvestorPlace,/news/stocks/3-biotech-stocks-that-could-boom-or-bust-in-q1-1031148371
1024.0,2/1/2022 3:22:51 PM,Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-these-key-february-pdufa-dates-1031149588
1025.0,2/1/2022 6:57:20 PM,Will the poor performance of biotechs in January be a barometer for 2022? Look to 2016,Seeking Alpha,https://seekingalpha.com/news/3794328-will-the-poor-performance-of-biotechs-in-january-be-a-barometer-for-2022-look-to-2016?utm_source=markets.businessinsider.com&utm_medium=referral
1026.0,2/1/2022 10:04:14 PM,Regeneron-Sanofi report positive Dupixent data in 5 diseases; results at AAAAI meeting,Seeking Alpha,https://seekingalpha.com/news/3794560-regeneron-sanofi-report-positive-dupixent-data-in-5-diseases-results-at-aaaai-meeting?utm_source=markets.businessinsider.com&utm_medium=referral
1027.0,2/1/2022 10:29:00 PM,Positive Dupixent® (dupilumab) Data Across Five Diseases with Underlying Type 2 Inflammation to be Presented at 2022 AAAAI Annual Meeting,PR Newswire,/news/stocks/positive-dupixent-dupilumab-data-across-five-diseases-with-underlying-type-2-inflammation-to-be-presented-at-2022-aaaai-annual-meeting-1031150939
1028.0,2/3/2022 2:12:10 PM,Can Regeneron Pharma top Q4 earnings forecast amid COVID challenges?,Seeking Alpha,https://seekingalpha.com/news/3795545-can-regeneron-pharma-top-q4-earnings-forecast-amid-covid-challenges?utm_source=markets.businessinsider.com&utm_medium=referral
1029.0,2/3/2022 3:01:13 PM,Here's what Wall Street expects from Regeneron Pharmaceuticals's earnings,Markets Insider Automation,/news/stocks/regeneron-stock-price-quarter-earnings-preview-q4-1031158984
1030.0,2/3/2022 3:48:38 PM,Notable earnings before Friday's open,Seeking Alpha,https://seekingalpha.com/news/3795618-notable-earnings-before-fridays-open?utm_source=markets.businessinsider.com&utm_medium=referral
1031.0,2/4/2022 11:31:22 AM,"Regeneron Pharmaceuticals Non-GAAP EPS of $23.72 beats by $3.67, revenue of $4.95B beats by $460M",Seeking Alpha,https://seekingalpha.com/news/3795949-regeneron-pharmaceuticals-non-gaap-eps-of-23_72-beats-3_67-revenue-of-4_95b-beats-460m?utm_source=markets.businessinsider.com&utm_medium=referral
1032.0,2/4/2022 12:01:47 PM,Sanofi meets earnings estimates even as vaccine business underperforms,Seeking Alpha,https://seekingalpha.com/news/3795966-sanofi-meets-earnings-estimates-even-as-vaccine-business-underperforms?utm_source=markets.businessinsider.com&utm_medium=referral
1033.0,2/4/2022 12:30:00 PM,Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results,PR Newswire,/news/stocks/regeneron-reports-fourth-quarter-and-full-year-2021-financial-and-operating-results-1031162138
1034.0,2/4/2022 12:33:13 PM,"Regeneron Pharmaceuticals Q4 Profit Increases, beats estimates",RTTNews,/news/stocks/regeneron-pharmaceuticals-q4-profit-increases-beats-estimates-1031162155
1035.0,2/4/2022 1:03:05 PM,Regeneron more than doubles Q4 revenue powered by sales for COVID-19 antibody,Seeking Alpha,https://seekingalpha.com/news/3795998-regeneron-more-than-doubles-q4-revenue-powered-by-sales-for-covid-19-antibody?utm_source=markets.businessinsider.com&utm_medium=referral
1036.0,2/4/2022 1:34:06 PM,"The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures",Benzinga,/news/stocks/the-daily-biotech-pulse-sanofi-bristol-myers-squibb-gain-on-earnings-valneva-pfizer-tout-positive-lyme-disease-vaccine-data-unity-biotech-restructures-1031162384
1037.0,2/8/2022 2:22:28 PM,10 Biggest Price Target Changes For Tuesday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-tuesday-1031171586
1038.0,2/10/2022 6:59:00 AM,FDA Accepts Dupixent® (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis,PR Newswire,/news/stocks/fda-accepts-dupixent-dupilumab-for-priority-review-in-children-aged-6-months-to-5-years-with-moderate-to-severe-atopic-dermatitis-1031180488
1039.0,2/10/2022 7:19:29 AM,"Regeneron, Sanofi: FDA Accepts Dupixent Priority Review In Children With Atopic Dermatitis ",RTTNews,/news/stocks/regeneron-sanofi-fda-accepts-dupixent-priority-review-in-children-with-atopic-dermatitis-1031180548
1040.0,2/10/2022 11:12:22 AM,Sanofi-Regeneron Dupixent gets FDA priority review as add-on therapy for kids with eczema,Seeking Alpha,https://seekingalpha.com/news/3798393-sanofi-regeneron-dupixent-gets-fda-priority-review-as-add-on-therapy-for-kids-with-eczema?utm_source=markets.businessinsider.com&utm_medium=referral
1041.0,2/10/2022 2:29:52 PM,"The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly",Benzinga,/news/stocks/the-daily-biotech-pulse-astrazeneca-q4-gets-covid-boost-seagen-plunges-on-earnings-adcom-test-awaits-lilly-1031182008
1042.0,2/11/2022 1:50:00 PM,Regeneron Presents Encouraging Phase 2 Results for High-dose Aflibercept 8 mg in Wet Age-related Macular Degeneration at Angiogenesis Meeting,PR Newswire,/news/stocks/regeneron-presents-encouraging-phase-2-results-for-high-dose-aflibercept-8-mg-in-wet-age-related-macular-degeneration-at-angiogenesis-meeting-1031186439
1043.0,2/11/2022 3:06:37 PM,Regeneron: Phase 2 Data In Wet AMD Shows Potential Of Aflibercept 8 Mg Compared To EYLEA ,RTTNews,/news/stocks/regeneron-phase-2-data-in-wet-amd-shows-potential-of-aflibercept-8-mg-compared-to-eylea-1031186735
1044.0,2/11/2022 8:38:42 PM,Regeneron gains on new long-term Phase 2 data for Eylea in wet AMD,Seeking Alpha,https://seekingalpha.com/news/3799334-regeneron-gains-on-new-long-term-phase-2-data-for-eylea-in-wet-amd?utm_source=markets.businessinsider.com&utm_medium=referral
1045.0,2/14/2022 5:12:39 PM,UNITY posts 24-week data from Phase 1 trial for UBX1325 in vascular eye diseases,Seeking Alpha,https://seekingalpha.com/news/3799673-unity-posts-24-week-data-from-phase-1-trial-for-ubx1325-in-vascular-eye-diseases?utm_source=markets.businessinsider.com&utm_medium=referral
1046.0,2/17/2022 10:05:00 PM,Regeneron Announces Investor Conference Presentations,PR Newswire,/news/stocks/regeneron-announces-investor-conference-presentations-1031206418
1047.0,2/18/2022 6:59:00 AM,Regeneron and Sanofi Provide Update on Ongoing Dupixent® (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program,PR Newswire,/news/stocks/regeneron-and-sanofi-provide-update-on-ongoing-dupixent-dupilumab-chronic-spontaneous-urticaria-phase-3-program-1031207499
1048.0,2/18/2022 7:26:44 AM,"Regeneron, Sanofi To Stop Dupixent Phase 3 Trial In Chronic Spontaneous Urticaria Due To Futility ",RTTNews,/news/stocks/regeneron-sanofi-to-stop-dupixent-phase-3-trial-in-chronic-spontaneous-urticaria-due-to-futility-1031207538
1049.0,2/18/2022 11:29:26 AM,Regeneron-Sanofi stopping phase 3 trial of Dupixent to treat hives due to futility,Seeking Alpha,https://seekingalpha.com/news/3801849-regeneron-sanofi-stopping-phase-3-trial-of-dupixent-for-hives-due-to-futility?utm_source=markets.businessinsider.com&utm_medium=referral
1050.0,2/18/2022 1:22:40 PM,"The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings",Benzinga,/news/stocks/the-daily-biotech-pulse-regeneron-sanofi-halt-late-stage-dupixent-study-agios-gets-fda-nod-safety-scare-for-gsk-s-rsv-vaccine-shockwave-jumps-on-earnings-1031208337
1051.0,2/20/2022 2:06:46 PM,"The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow",Benzinga,/news/stocks/the-week-ahead-in-biotech-feb-20-26-reata-awaits-fda-decision-bausch-health-moderna-lead-earnings-news-flow-1031210514
1052.0,2/22/2022 11:00:51 AM,Is Moderna the Next Gilead or the Next Regeneron?,InvestorPlace,/news/stocks/mrna-stock-is-moderna-the-next-gilead-or-the-next-regeneron-1031215173
1053.0,2/23/2022 8:16:22 PM,KOD Stock Alert: Why Is Kodiak Sciences Plunging 80% Today?,InvestorPlace,/news/stocks/kod-stock-alert-why-is-kodiak-sciences-plunging-80-percent-today-1031222899
1054.0,2/23/2022 8:43:44 PM,Kodiak sheds over $2B market cap after wet AMD setback for lead asset,Seeking Alpha,https://seekingalpha.com/news/3804379-kod-stock-crashes-after-wet-amd-trial-setback?utm_source=markets.businessinsider.com&utm_medium=referral
1055.0,2/24/2022 8:58:17 PM,7 Low Volatility Stocks to Buy Right Now for Steady Returns,InvestorPlace,/news/stocks/7-low-volatility-stocks-to-buy-right-now-for-steady-returns-1031228612
1056.0,2/25/2022 3:33:26 PM,3 Moonshot Stocks Insiders Are Buying. What Do They Know?,InvestorPlace,/news/stocks/3-moonshot-stocks-insiders-are-buying-what-do-they-know-1031232679
1057.0,2/26/2022 5:59:00 PM,Late-breaking Phase 3 Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Reduced Itch and Hives in Patients with Chronic Spontaneous Urticaria,PR Newswire,/news/stocks/late-breaking-phase-3-data-at-2022-aaaai-annual-meeting-show-dupixent-dupilumab-significantly-reduced-itch-and-hives-in-patients-with-chronic-spontaneous-urticaria-1031234177
1058.0,2/26/2022 6:04:00 PM,Late-breaking Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Eosinophilic Esophagitis,PR Newswire,/news/stocks/late-breaking-data-at-2022-aaaai-annual-meeting-show-dupixent-dupilumab-significantly-improved-signs-and-symptoms-of-eosinophilic-esophagitis-1031234180
1059.0,2/28/2022 8:34:39 PM,Why did Vir Biotechnology stock drop today?,Seeking Alpha,https://seekingalpha.com/news/3807154-why-did-vir-stock-drop-today-falling-covid-19-cases?utm_source=markets.businessinsider.com&utm_medium=referral
1060.0,2/28/2022 10:02:00 PM,"Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sust...",PR Newswire,/news/stocks/intellia-and-regeneron-announce-updated-phase-1-data-demonstrating-a-single-dose-of-ntla-2001-investigational-crispr-therapy-for-transthyretin-attr-amyloidosis-resulted-in-rapid-deep-and-sust-1031239820
1061.0,3/1/2022 1:51:14 PM,"The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution",Benzinga,/news/stocks/the-daily-biotech-pulse-legend-biotech-cti-biopharma-receive-fda-approvals-abbvie-announces-delay-in-skyrizi-review-editas-gains-on-crispr-patent-resolution-1031242590
1062.0,3/2/2022 1:35:33 PM,"Biden pushes for insulin price cap, Medicare drug negotiations in SOTU",Seeking Alpha,https://seekingalpha.com/news/3808400-biden-pushes-for-insulin-price-cap-medicare-drug-negotiations-in-sotu?utm_source=markets.businessinsider.com&utm_medium=referral
1063.0,3/3/2022 10:31:55 AM,WHO backs restriction of Regeneron's REGEN-COV for Omicron patients,Seeking Alpha,https://seekingalpha.com/news/3808848-who-restricts-use-of-regenerons-antibody-cocktail-regen-cov-in-omicron-patients?utm_source=markets.businessinsider.com&utm_medium=referral
1064.0,3/3/2022 3:57:17 PM,U.S. to share government-backed COVID-19 tech with WHO - Washington Post,Seeking Alpha,https://seekingalpha.com/news/3809199-us-to-share-government-backed-covid-19-tech-with-who-washington-post?utm_source=markets.businessinsider.com&utm_medium=referral
1065.0,3/3/2022 4:24:54 PM,Regeneron maintained as overweight at Piper but concern over Eylea outlook,Seeking Alpha,https://seekingalpha.com/news/3809217-regeneron-maintained-as-overweight-at-piper-but-concern-over-eylea-outlook?utm_source=markets.businessinsider.com&utm_medium=referral
1066.0,3/4/2022 2:23:54 PM,Adicet Bio initiated Buy at Jefferies citing upcoming data readouts,Seeking Alpha,https://seekingalpha.com/news/3809606-acet-stock-higher-as-jefferies-upgrade-citing-upcoming-data?utm_source=markets.businessinsider.com&utm_medium=referral
1067.0,3/8/2022 2:43:33 PM,"BioNTech, Regeneron To Advance Clinical Development Of FixVac And Libtayo Combination In NSCLC ",RTTNews,/news/stocks/biontech-regeneron-to-advance-clinical-development-of-fixvac-and-libtayo-combination-in-nsclc-1031262595
1068.0,3/10/2022 3:35:56 PM,After Amazon these 20 companies could follow a stock split wave,Seeking Alpha,https://seekingalpha.com/news/3812200-after-amazon-these-20-companies-could-follow-a-stock-split-wave?utm_source=markets.businessinsider.com&utm_medium=referral
1069.0,3/10/2022 6:02:14 PM,Upcoming Stock Splits 2022: 20 Companies That Could Follow Amazon’s Lead,InvestorPlace,/news/stocks/upcoming-stock-splits-2022-20-companies-that-could-follow-amazons-lead-1031271410
1070.0,3/16/2022 2:16:00 AM,"Students Win $1.8 Million at Regeneron Science Talent Search 2022 for Exceptional Research on Neutron Star--Black Hole Systems, Narrowband Radar, and Ribosome Movement in Protein Translation",PR Newswire,/news/stocks/students-win-1-8-million-at-regeneron-science-talent-search-2022-for-exceptional-research-on-neutron-star-black-hole-systems-narrowband-radar-and-ribosome-movement-in-protein-translation-1031283193
1071.0,3/26/2022 2:59:00 PM,Late-breaking Phase 3 Data at AAD 2022 Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Prurigo Nodularis,PR Newswire,/news/stocks/late-breaking-phase-3-data-at-aad-2022-show-dupixent-dupilumab-significantly-improved-signs-and-symptoms-of-prurigo-nodularis-1031309487
1072.0,3/28/2022 7:31:43 AM,Biotech Stocks Facing FDA Decision In April 2022 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-april-2022-1031310826
1073.0,4/1/2022 10:37:35 AM,World's 1st COVID human challenge trial suggests spread of virus not correlated to symptoms,Seeking Alpha,https://seekingalpha.com/news/3819725-worlds-1st-covid-human-challenge-trial-suggests-spread-of-virus-not-correlated-to-symptoms?utm_source=markets.businessinsider.com&utm_medium=referral
1074.0,4/1/2022 9:16:51 PM,Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-april-pdufa-dates-1031327374
1075.0,4/4/2022 6:59:00 AM,FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis,PR Newswire,/news/stocks/fda-accepts-dupixent-dupilumab-for-priority-review-in-patients-aged-12-years-and-older-with-eosinophilic-esophagitis-1031328700
1076.0,4/4/2022 7:21:34 AM,Regeneron : FDA Accepts Dupixent For Priority Review In Patients Aged 12 Yrs And Older With EoE ,RTTNews,/news/stocks/regeneron-fda-accepts-dupixent-for-priority-review-in-patients-aged-12-yrs-and-older-with-eoe-1031328728
1077.0,4/4/2022 9:00:38 PM,Lawmakers agree on $10 billion additional funding for U.S. COVID response (Updated),Seeking Alpha,https://seekingalpha.com/news/3820489-lawmakers-set-to-announce-10-billion-additional-funding-for-us-covid-response?utm_source=markets.businessinsider.com&utm_medium=referral
1078.0,4/5/2022 3:00:00 PM,Annual Boosters Might Not Give Moderna the Boost It Needs,InvestorPlace,/news/stocks/mrna-stock-annual-booster-may-not-give-it-the-boost-it-needs-1031333944
1079.0,4/5/2022 10:05:00 PM,"Regeneron to Report First Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2022",PR Newswire,/news/stocks/regeneron-to-report-first-quarter-2022-financial-and-operating-results-and-host-conference-call-and-webcast-on-may-4-2022-1031334615
1080.0,4/5/2022 10:17:17 PM,7 Safe Stocks to Buy to Guard Against a Recession,InvestorPlace,/news/stocks/7-safe-stocks-to-buy-to-guard-against-a-recession-1031334812
1081.0,4/6/2022 1:33:41 AM,"GlaxoSmithKline, Vir COVID-19 therapy is no longer authorized in U.S. - FDA",Seeking Alpha,https://seekingalpha.com/news/3820993-glaxosmithkline-vir-covid-19-therapy-is-no-longer-authorized-in-us-fda?utm_source=markets.businessinsider.com&utm_medium=referral
1082.0,4/7/2022 6:59:00 AM,Dupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation,PR Newswire,/news/stocks/dupixent-dupilumab-approved-by-european-commission-for-children-aged-6-to-11-years-with-severe-asthma-with-type-2-inflammation-1031338685
1083.0,4/7/2022 7:28:42 AM,"Regeneron, Sanofi: EU Approves Dupixent For Children Aged 6 To 11 Years With Severe Asthma ",RTTNews,/news/stocks/regeneron-sanofi-eu-approves-dupixent-for-children-aged-6-to-11-years-with-severe-asthma-1031338728
1084.0,4/7/2022 1:27:58 PM,"Regeneron, Sanofi win EU approval for Dupixent in younger children with asthma",Seeking Alpha,https://seekingalpha.com/news/3821670-regeneron-sanofi-win-eu-nod-for-dupixent-in-younger-children-with-asthma?utm_source=markets.businessinsider.com&utm_medium=referral
1085.0,4/7/2022 2:24:52 PM,"The Daily Biotech Pulse: Pfizer Goes Shopping, AstraZeneca Inks Bispecific Antibody Deal, Aptinyx Faces Clinical Study Setback, Erytech Jumps On Data And More",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-goes-shopping-astrazeneca-inks-bispecific-antibody-deal-aptinyx-faces-clinical-study-setback-erytech-jumps-on-data-and-more-1031339904
1086.0,4/7/2022 7:38:30 PM,Life sciences companies drive healthcare stocks to lead S&P 500,Seeking Alpha,https://seekingalpha.com/news/3821820-life-sciences-companies-drive-healthcare-stocks-to-lead-sp-500?utm_source=markets.businessinsider.com&utm_medium=referral
1087.0,4/10/2022 10:42:49 PM,"The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-april-10-april-16-regeneron-fda-decision-cancer-conference-presentations-and-more-1031344759
1088.0,4/11/2022 6:05:53 PM,Michael Grimm Purchases $5.66 Million Worth Of Energy Transfer & Other Notable Insider Buys,Benzinga,/news/stocks/michael-grimm-purchases-5-66-million-worth-of-energy-transfer-other-notable-insider-buys-1031347106
1089.0,4/12/2022 7:25:20 PM,Analyst Ratings for Regeneron Pharmaceuticals,Benzinga,/news/stocks/analyst-ratings-for-regeneron-pharmaceuticals-1031350722
1090.0,4/13/2022 2:15:54 PM,"The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More",Benzinga,/news/stocks/the-daily-biotech-pulse-glaxosmithkline-and-halozyme-go-shopping-mylan-s-insulin-glargine-recall-turning-point-shares-lung-cancer-data-and-more-1031353335
1091.0,4/14/2022 11:59:20 AM,FDA extends review of Regeneron's REGEN-COV to treat/prevent COVID-19,Seeking Alpha,https://seekingalpha.com/news/3823380-fda-extends-review-of-regenerons-regen-cov-to-treatprevent-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral
1092.0,4/14/2022 1:00:00 PM,U.S. FDA Extends Review of Biologics License Application for REGEN-COV® (casirivimab and imdevimab) for Treatment and Prophylaxis of COVID-19,PR Newswire,/news/stocks/u-s-fda-extends-review-of-biologics-license-application-for-regen-cov-casirivimab-and-imdevimab-for-treatment-and-prophylaxis-of-covid-19-1031356293
1093.0,4/14/2022 1:36:36 PM,Regeneron Says FDA Extends Review Of BLA For REGEN-COV By 3 Months ,RTTNews,/news/stocks/regeneron-says-fda-extends-review-of-bla-for-regen-cov-by-3-months-1031356464
1094.0,4/14/2022 3:35:45 PM,"The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-biontech-covid-19-booster-data-in-kids-regeneron-s-covid-19-therapy-decision-pushed-protagonist-s-rusfertide-breakthrough-tag-update-and-more-1031357104
1095.0,4/17/2022 8:31:32 PM,"The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-april-17-april-23-j-j-abbott-earnings-adcom-test-for-tg-therapeutics-and-more-1031359853
1096.0,4/19/2022 11:31:08 AM,Regeneron to acquire Checkmate Pharma in $250 million all-cash deal,Seeking Alpha,https://seekingalpha.com/news/3824208-cmpi-stock-soars-on-plans-by-regeneron-to-acquire-it-in-250-million-deal?utm_source=markets.businessinsider.com&utm_medium=referral
1097.0,4/19/2022 1:00:00 PM,Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types,PR Newswire,/news/stocks/regeneron-to-acquire-checkmate-pharmaceuticals-and-its-investigational-immune-activator-for-potential-use-in-multiple-tumor-types-1031363503
1098.0,4/19/2022 1:07:23 PM,"SpringWorks, Regeneron To Evaluate Nirogacestat In Combination With REGN5458 In Multiple Myeloma ",RTTNews,/news/stocks/springworks-regeneron-to-evaluate-nirogacestat-in-combination-with-regn5458-in-multiple-myeloma-1031363562
1099.0,4/19/2022 1:32:25 PM,Regeneron Pharma To Buy Checkmate Pharmaceuticals In $250 Mln All Cash Deal ,RTTNews,/news/stocks/regeneron-pharma-to-buy-checkmate-pharmaceuticals-in-250-mln-all-cash-deal-1031363645
1100.0,4/19/2022 2:48:29 PM,Regeneron - Checkmate deal propels other developers with similar drugs,Seeking Alpha,https://seekingalpha.com/news/3824326-corp-idra-stocks-gain-on-regeneron---checkmate-deal?utm_source=markets.businessinsider.com&utm_medium=referral
1101.0,4/19/2022 3:05:03 PM,"The Daily Biotech Pulse: Regeneron Acquires Checkmate Pharma, Moderna's Bivalent Booster COVID-19 Vaccine Update, Priority Review For AstraZeneca's Enhertu",Benzinga,/news/stocks/the-daily-biotech-pulse-regeneron-acquires-checkmate-pharma-moderna-s-bivalent-booster-covid-19-vaccine-update-priority-review-for-astrazeneca-s-enhertu-1031364260
1102.0,4/19/2022 4:57:59 PM,Why Is Checkmate Pharmaceuticals (CMPI) Stock Up 300% Today?,InvestorPlace,/news/stocks/why-is-checkmate-pharmaceuticals-cmpi-stock-up-300-today-1031364947
1103.0,4/19/2022 6:16:31 PM,38 Stocks Moving In Tuesday's Mid-Day Session,Benzinga,/news/stocks/38-stocks-moving-in-tuesday-s-mid-day-session-1031364862
1104.0,4/20/2022 11:43:34 AM,54 Biggest Movers From Yesterday,Benzinga,/news/stocks/54-biggest-movers-from-yesterday-1031367316
1105.0,4/20/2022 3:37:14 PM,Adaptimmune in two-day rally thanks to Regeneron/Checkmate deal; shares up 15%,Seeking Alpha,https://seekingalpha.com/news/3824792-adaptimmune-in-two-day-rally-thanks-to-regeneroncheckmate-deal-shares-up-15?utm_source=markets.businessinsider.com&utm_medium=referral
1106.0,4/23/2022 8:00:00 PM,COVID therapies and vaccines propel rise in spending on medicines in 2021,Seeking Alpha,https://seekingalpha.com/news/3825965-covid-therapies-and-vaccines-propel-rise-in-spending-on-medicines-in-2021?utm_source=markets.businessinsider.com&utm_medium=referral
1107.0,4/28/2022 9:19:04 AM,"Sanofi Q1 sales climb on the back of Dupixent, consumer healthcare show; maintains outlook",Seeking Alpha,https://seekingalpha.com/news/3828323-sanofi-q1-sales-climb-on-the-back-of-dupixent-consumer-healthcare-show-maintains-outlook?utm_source=markets.businessinsider.com&utm_medium=referral
1108.0,4/28/2022 5:24:27 PM,Intellia wins Outperform rating at Credit Suisse on ATTR potential,Seeking Alpha,https://seekingalpha.com/news/3828773-ntla-stock-gains-on-outperform-rating-at-credit-suisse?utm_source=markets.businessinsider.com&utm_medium=referral
1109.0,5/2/2022 2:26:53 PM,"The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-may-1-7-phathom-fda-decision-pfizer-vertex-pharma-lead-earnings-news-ophthalmology-conference-presentations-and-more-1031408449
1110.0,5/2/2022 9:46:27 PM,Here's Why This Analyst Cut Price Target On Regeneron,Benzinga,/news/stocks/here-s-why-this-analyst-cut-price-target-on-regeneron-1031410197
1111.0,5/2/2022 10:04:25 PM,Where Regeneron Pharmaceuticals Stands With Analysts,Benzinga,/news/stocks/where-regeneron-pharmaceuticals-stands-with-analysts-1031410285
1112.0,5/2/2022 10:15:00 PM,Regeneron Announces Investor Conference Presentations,PR Newswire,/news/stocks/regeneron-announces-investor-conference-presentations-1031410295
1113.0,5/3/2022 3:01:13 PM,Here's what Wall Street expects from Regeneron Pharmaceuticals's earnings,Markets Insider Automation,/news/stocks/regeneron-stock-q1-earnings-preview-1031413639
1114.0,5/3/2022 3:43:39 PM,Notable earnings before Wednesday's open,Seeking Alpha,https://seekingalpha.com/news/3831146-notable-earnings-before-wednesdays-open?utm_source=markets.businessinsider.com&utm_medium=referral
1115.0,5/3/2022 5:10:46 PM,"All eyes on Regeneron Q1 earnings amid REGEN-COV, Eylea challenges",Seeking Alpha,https://seekingalpha.com/news/3831239-all-eyes-on-regeneron-q1-earnings-amid-regen-cov-eylea-challenges?utm_source=markets.businessinsider.com&utm_medium=referral
1116.0,5/4/2022 10:33:23 AM,"Regeneron Pharmaceuticals Non-GAAP EPS of $11.49 beats by $1.69, revenue of $2.97B beats by $280M",Seeking Alpha,https://seekingalpha.com/news/3831809-regeneron-pharmaceuticals-non-gaap-eps-of-11_49-beats-1_69-revenue-of-2_97b-beats-280m?utm_source=markets.businessinsider.com&utm_medium=referral
1117.0,5/4/2022 11:35:34 AM,"Regeneron Q1 revenue rises on the back of blockbuster drugs Eylea, Dupixent",Seeking Alpha,https://seekingalpha.com/news/3831892-regeneron-q1-revenue-rises-on-the-back-of-blockbuster-drugs-eylea-dupixent?utm_source=markets.businessinsider.com&utm_medium=referral
1118.0,5/4/2022 12:30:00 PM,Regeneron Reports First Quarter 2022 Financial and Operating Results,PR Newswire,/news/stocks/regeneron-reports-first-quarter-2022-financial-and-operating-results-1031418881
1119.0,5/4/2022 12:44:11 PM,"Regeneron Pharmaceuticals Q1 Profit Decreases, but beats estimates",RTTNews,/news/stocks/regeneron-pharmaceuticals-q1-profit-decreases-but-beats-estimates-1031418941
1120.0,5/4/2022 2:44:29 PM,"The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints",Benzinga,/news/stocks/the-daily-biotech-pulse-kezar-life-s-lead-asset-fails-brickell-biotech-offloads-late-stage-asset-connect-biopharma-ulcerative-colitis-trial-disappoints-1031419730
1121.0,5/12/2022 2:14:54 PM,Federal flags to fly at half-staff to mark one million COVID deaths,Seeking Alpha,https://seekingalpha.com/news/3837849-federal-flags-to-fly-at-half-staff-to-mark-one-million-covid-deaths?utm_source=markets.businessinsider.com&utm_medium=referral
1122.0,5/13/2022 5:52:00 PM,"High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at Regeneron International Science and Engineering Fair",PR Newswire,/news/stocks/high-school-scientists-from-around-the-world-win-nearly-8m-in-awards-scholarships-at-regeneron-international-science-and-engineering-fair-1031459367
1123.0,5/13/2022 7:13:00 PM,"High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at Regeneron International Science and Engineering Fair",PR Newswire,/news/stocks/high-school-scientists-from-around-the-world-win-nearly-8m-in-awards-scholarships-at-regeneron-international-science-and-engineering-fair-1031459523
1124.0,5/17/2022 1:00:00 PM,"Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics Entrepreneur",PR Newswire,/news/stocks/vyriad-inc-raises-29-5m-in-series-b-funding-led-by-renowned-genetics-entrepreneur-1031467802
1125.0,5/20/2022 7:24:28 PM,Sanofi wins FDA label expansion for Dupixent for new inflammatory condition,Seeking Alpha,https://seekingalpha.com/news/3841473-sanofi-wins-fda-label-expansion-for-dupixent-for-new-inflammatory-condition?utm_source=markets.businessinsider.com&utm_medium=referral
1126.0,5/20/2022 9:15:00 PM,FDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis,PR Newswire,/news/stocks/fda-approves-dupixent-dupilumab-as-first-treatment-for-adults-and-children-aged-12-and-older-with-eosinophilic-esophagitis-1031479461
1127.0,5/21/2022 1:00:00 PM,Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol,PR Newswire,/news/stocks/evkeeza-evinacumab-phase-3-trial-demonstrates-48-ldl-c-reduction-in-children-with-ultra-rare-form-of-high-cholesterol-1031479707
1128.0,5/22/2022 9:58:01 PM,"The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More",Benzinga,/news/stocks/the-week-ahead-in-biotech-may-22-28-verrica-bristol-myers-squibb-fda-decisions-medtronic-earnings-conference-presentations-more-1031480317
1129.0,5/23/2022 9:55:20 AM,"Regeneron, Ultragenyx's Evkeeza helps reduce bad cholesterol in kids 5 to 11 with rare disorder in study",Seeking Alpha,https://seekingalpha.com/news/3841595-regeneron-ultragenyxs-evkeeza-helps-reduce-bad-cholesterol-in-kids-5-to-11-with-rare-disorder-in-study?utm_source=markets.businessinsider.com&utm_medium=referral
1130.0,5/23/2022 2:11:23 PM,FDA Approves Regeneron's Dupixent To Treat Eosinophilic Esophagitis ,RTTNews,/news/stocks/fda-approves-regeneron-s-dupixent-to-treat-eosinophilic-esophagitis-1031481730
1131.0,5/23/2022 3:38:14 PM,"Regeneron initiated at outperform at Leerink on strength of Dupixent, Eylea, and pipeline",Seeking Alpha,https://seekingalpha.com/news/3841788-regeneron-initiated-at-outperform-at-leerink-on-strength-of-dupixent-eylea-and-pipeline?utm_source=markets.businessinsider.com&utm_medium=referral
1132.0,5/23/2022 4:33:42 PM,"Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-may-23-2022-1031482320
1133.0,5/27/2022 4:04:02 PM,Biotech Stocks Facing FDA Decision In June 2022 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-june-2022-1031493578
1134.0,5/28/2022 4:22:39 PM,BioPharma M&A premiums could moderate amid rate hikes – Wells Fargo,Seeking Alpha,https://seekingalpha.com/news/3843664-biopharma-ma-premiums-could-moderate-amid-rate-hikes?utm_source=markets.businessinsider.com&utm_medium=referral
1135.0,5/30/2022 4:51:59 PM,"As COVID Subsidies, Here Are 8 Infectious Diseases That Could Emerge As Potent Threats",Benzinga,/news/stocks/as-covid-subsidies-here-are-8-infectious-diseases-that-could-emerge-as-potent-threats-1031496301
1136.0,5/31/2022 6:59:00 AM,FDA Accepts Dupixent® (dupilumab) for Priority Review in Adults with Prurigo Nodularis,PR Newswire,/news/stocks/fda-accepts-dupixent-dupilumab-for-priority-review-in-adults-with-prurigo-nodularis-1031496994
1137.0,5/31/2022 7:28:36 AM,Regeneron : FDA Accepts Dupixent For Priority Review In Adults With Prurigo Nodularis ,RTTNews,/news/stocks/regeneron-fda-accepts-dupixent-for-priority-review-in-adults-with-prurigo-nodularis-1031497041
1138.0,5/31/2022 2:31:00 PM,Regeneron Completes Acquisition of Checkmate Pharmaceuticals,PR Newswire,/news/stocks/regeneron-completes-acquisition-of-checkmate-pharmaceuticals-1031498228
1139.0,5/31/2022 7:44:43 PM,Takeda CEO says drugmakers face pricing pressure due to global crises,Seeking Alpha,https://seekingalpha.com/news/3844113-takeda-ceo-says-drugmakers-face-pricing-pressure-due-to-global-crises?utm_source=markets.businessinsider.com&utm_medium=referral
1140.0,5/31/2022 8:24:35 PM,7 Analysts Have This to Say About Regeneron Pharmaceuticals,Benzinga,/news/stocks/7-analysts-have-this-to-say-about-regeneron-pharmaceuticals-1031499558
1141.0,5/31/2022 9:42:54 PM,Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-these-june-pdufa-dates-1031499656
1142.0,6/2/2022 9:25:31 AM,Xoma to get $2.5M from Kuros as Checkmate's acquisition by Regeneron triggers milestone payout,Seeking Alpha,https://seekingalpha.com/news/3844870-xoma-to-get-25m-from-kuros-as-checkmates-acquisition-by-regeneron-triggers-milestone-payout?utm_source=markets.businessinsider.com&utm_medium=referral
1143.0,6/2/2022 1:30:00 PM,"Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo® (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of ...",PR Newswire,/news/stocks/regeneron-strengthens-commitment-to-oncology-through-purchase-of-sanofi-s-stake-in-the-regeneron-and-sanofi-collaboration-on-libtayo-cemiplimab-a-pd-1-inhibitor-approved-for-multiple-forms-of-1031504901
1144.0,6/2/2022 1:57:43 PM,"Regeneron To Acquire Global Rights To Libtayo From Sanofi For $900 Mln, Plus Royalties ",RTTNews,/news/stocks/regeneron-to-acquire-global-rights-to-libtayo-from-sanofi-for-900-mln-plus-royalties-1031504971
1145.0,6/5/2022 10:09:23 PM,"The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-june-5-11-adcom-test-for-novavax-asco-presentations-enzo-biochem-earnings-and-more-1031509946
1146.0,6/6/2022 5:12:03 PM,"Benzinga's Top Ratings Upgrades, Downgrades For June 6, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-june-6-2022-1031511325
1147.0,6/7/2022 9:04:18 PM,"FDA approves Regeneron, Sanofi's Dupixent in babies, young children for eczema",Seeking Alpha,https://seekingalpha.com/news/3846498-fda-approves-regeneron-sanofis-dupixent-in-babies-young-children-for-eczema?utm_source=markets.businessinsider.com&utm_medium=referral
1148.0,6/7/2022 10:44:00 PM,FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis,PR Newswire,/news/stocks/fda-approves-dupixent-dupilumab-as-first-biologic-medicine-for-children-aged-6-months-to-5-years-with-moderate-to-severe-atopic-dermatitis-1031514664
1149.0,6/8/2022 4:27:20 AM,Sanofi : FDA Approves Dupixent For Young Children With Moderate-to-severe Atopic Dermatitis ,RTTNews,/news/stocks/sanofi-fda-approves-dupixent-for-young-children-with-moderate-to-severe-atopic-dermatitis-1031514826
1150.0,6/8/2022 3:07:53 PM,"The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-adcomm-backing-for-novavax-s-covid-19-shot-new-data-on-moderna-s-omicron-vaccine-dbv-tech-s-encouraging-peanut-allergy-trial-data-1031516521
1151.0,6/9/2022 11:22:09 AM,Alnylam says kidney disease therapy led to 37% drop in key indicator,Seeking Alpha,https://seekingalpha.com/news/3847095-alny-stock-in-focus-as-kidney-disease-drug-causes-37-drop-in-key-indicator?utm_source=businessinsider&utm_medium=referral
1152.0,6/9/2022 1:31:18 PM,Alnylam Pharma Reports Positive Topline Results From Phase 2 Study Of Cemdisiran ,RTTNews,/news/stocks/alnylam-pharma-reports-positive-topline-results-from-phase-2-study-of-cemdisiran-1031518926
1153.0,6/9/2022 2:47:31 PM,Adverum wet AMD candidate ADVM-022 shows long-term benefit after single injection,Seeking Alpha,https://seekingalpha.com/news/3847228-adverum-wet-amd-candidate-advm-022-shows-long-term-benefit-after-single-injection?utm_source=businessinsider&utm_medium=referral
1154.0,6/24/2022 12:56:24 PM,"Intellia, Regeneron post 12-month data for gene editing therapy in ATTR amyloidosis",Seeking Alpha,https://seekingalpha.com/news/3851508-ntla-regn-stocks-in-focus-after-long-term-data-for-gene-editing-therapy?utm_source=businessinsider&utm_medium=referral
1155.0,6/24/2022 1:31:00 PM,Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions ...,PR Newswire,/news/stocks/intellia-and-regeneron-present-updated-interim-data-from-phase-1-study-of-crispr-based-ntla-2001-for-the-treatment-of-transthyretin-attr-amyloidosis-demonstrating-that-deep-serum-ttr-reductions-1031548486
1156.0,6/24/2022 2:03:57 PM,NTLA : Study Of NTLA-2001 On Transthyretin Amyloidosis Shows Serum TTR Reductions Remained Durable ,RTTNews,/news/stocks/ntla-study-of-ntla-2001-on-transthyretin-amyloidosis-shows-serum-ttr-reductions-remained-durable-1031548571
1157.0,6/28/2022 9:17:30 AM,Biotech Stocks Facing FDA Decision In July 2022 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-july-2022-1031553516
1158.0,6/29/2022 1:30:00 PM,EYLEA® (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic Retinopathy Accepted for FDA Review,PR Newswire,/news/stocks/eylea-aflibercept-injection-sbla-for-every-16-week-dosing-regimen-in-patients-with-diabetic-retinopathy-accepted-for-fda-review-1031557129
1159.0,6/29/2022 1:55:11 PM,Regeneron's EYLEA SBLA For 16-week Dosing Regimen In Diabetic Retinopathy Accepted For FDA Review ,RTTNews,/news/stocks/regeneron-s-eylea-sbla-for-16-week-dosing-regimen-in-diabetic-retinopathy-accepted-for-fda-review-1031557201
1160.0,6/29/2022 2:17:52 PM,FDA accepts Regeneron's application for Eylea extended regimen to treat diabetic blindness,Seeking Alpha,https://seekingalpha.com/news/3852874-fda-accepts-regenerons-application-for-eylea-extended-regimen-to-treat-diabetic-blindness?utm_source=businessinsider&utm_medium=referral
1161.0,7/1/2022 11:26:23 AM,Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-these-july-pdufa-dates-1031562548
1162.0,7/1/2022 1:00:00 PM,Regeneron Completes Purchase of Sanofi's Stake in Libtayo® (cemiplimab),PR Newswire,/news/stocks/regeneron-completes-purchase-of-sanofi-s-stake-in-libtayo-cemiplimab-1031562785
1163.0,7/1/2022 1:17:14 PM,Regeneron Completes Acquiring Sanofi's Stake In Libtayo ,RTTNews,/news/stocks/regeneron-completes-acquiring-sanofi-s-stake-in-libtayo-1031562845
1164.0,7/6/2022 5:22:36 PM,U.S. Senate Democrats advance deal to lower drug prices,Seeking Alpha,https://seekingalpha.com/news/3854684-us-senate-democrats-in-agreement-to-lower-drug-prices?utm_source=businessinsider&utm_medium=referral
1165.0,7/6/2022 10:01:00 PM,"Regeneron to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2022",PR Newswire,/news/stocks/regeneron-to-report-second-quarter-2022-financial-and-operating-results-and-host-conference-call-and-webcast-on-august-3-2022-1031571486
1166.0,7/7/2022 1:00:29 PM,Alvotech starts confirmatory study for its AVT06 biosimilar to Regeneron's Eylea,Seeking Alpha,https://seekingalpha.com/news/3854978-alvotech-starts-confirmatory-study-for-its-avt06-biosimilar-to-regenerons-eylea?utm_source=businessinsider&utm_medium=referral
1167.0,7/8/2022 6:30:36 PM,"Catalyst watch: Inflation reads, major banks report and Alphabet splits",Seeking Alpha,https://seekingalpha.com/news/3855426-catalyst-watch-inflation-reads-major-banks-report-and-alphabet-splits?utm_source=businessinsider&utm_medium=referral
1168.0,7/8/2022 7:53:05 PM,7 Moonshot Investments Upending a $10 Trillion Industry,InvestorPlace,/news/stocks/7-moonshot-investments-upending-a-10-trillion-industry-1031576272
1169.0,7/8/2022 8:12:42 PM,The 3 Leaders of the Gene Editing Revolution,InvestorPlace,/news/stocks/the-3-leaders-of-the-gene-editing-revolution-1031576321
1170.0,7/12/2022 3:00:00 PM,Ultima Genomics signs development agreement with Regeneron aimed at driving the scale of genomic information for drug discovery and development,PR Newswire,/news/stocks/ultima-genomics-signs-development-agreement-with-regeneron-aimed-at-driving-the-scale-of-genomic-information-for-drug-discovery-and-development-1031581233
1171.0,7/13/2022 3:00:53 PM,"The Daily Biotech Pulse: AstraZeneca's COVID-19 Vaccine As Effective As mRNA Shots, Humanigen's Lenzilumab Disappoints In COVID-19 Study, Positive Preclinical Data From Hoth's Alzheimer's Program",Benzinga,/news/stocks/the-daily-biotech-pulse-astrazeneca-s-covid-19-vaccine-as-effective-as-mrna-shots-humanigen-s-lenzilumab-disappoints-in-covid-19-study-positive-preclinical-data-from-hoth-s-alzheimer-s-program-1031584590
1172.0,7/14/2022 6:59:00 AM,Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis,PR Newswire,/news/stocks/dupixent-dupilumab-phase-3-trial-shows-positive-results-in-children-1-to-11-years-of-age-with-eosinophilic-esophagitis-1031586521
1173.0,7/14/2022 7:30:46 AM,Regeneron: Phase 3 Trial Of Dupixent In Children With Eosinophilic Esophagitis Meets Main Goal ,RTTNews,/news/stocks/regeneron-phase-3-trial-of-dupixent-in-children-with-eosinophilic-esophagitis-meets-main-goal-1031586559
1174.0,7/14/2022 3:01:11 PM,"The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures",Benzinga,/news/stocks/the-daily-biotech-pulse-much-awaited-fda-nod-for-novavax-s-covid-19-shot-dsmb-suggests-contrafect-to-stop-antimicrobial-resistant-infection-study-cytomx-restructures-1031587666
1175.0,7/20/2022 7:06:26 PM,Where Regeneron Pharmaceuticals Stands With Analysts,Benzinga,/news/stocks/where-regeneron-pharmaceuticals-stands-with-analysts-1031602001
1176.0,7/21/2022 3:49:50 PM,AstraZeneca COVID-19 therapy less effective against new Omicron strains: study,Seeking Alpha,https://seekingalpha.com/news/3859171-astrazeneca-covid-19-therapy-less-protection-against-new-omicron-strains?utm_source=businessinsider&utm_medium=referral
1177.0,7/23/2022 8:15:00 PM,"Drug pricing legislation will affect biopharma revenue, but impact is manageable - RBC",Seeking Alpha,https://seekingalpha.com/news/3859761-drug-pricing-legislation-will-affect-biopharma-revenue-but-impact-is-manageable-rbc?utm_source=businessinsider&utm_medium=referral
1178.0,7/25/2022 2:31:28 PM,Meta Platforms To $250? Plus This Analyst Lowers Price Target On Microsoft,Benzinga,/news/stocks/meta-platforms-to-250-plus-this-analyst-lowers-price-target-on-microsoft-1031611412
1179.0,7/25/2022 4:22:53 PM,"Benzinga's Top Ratings Upgrades, Downgrades For July 25, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-july-25-2022-1031611937
1180.0,7/25/2022 6:25:57 PM,Regeneron's Price Target Cut On Dim Prospects For Its Flagship Eye Product,Benzinga,/news/stocks/regeneron-s-price-target-cut-on-dim-prospects-for-its-flagship-eye-product-1031612275
1181.0,7/26/2022 1:00:00 PM,Regeneron Announces the 2022 Winners of the Regeneron Prize for Creative Innovation,PR Newswire,/news/stocks/regeneron-announces-the-2022-winners-of-the-regeneron-prize-for-creative-innovation-1031614794
1182.0,7/26/2022 10:34:29 PM,7 Cathie Wood Stocks Trading at a Discount Right Now,InvestorPlace,/news/stocks/cathie-wood-stocks-trading-a-discount-1031620033
1183.0,7/27/2022 11:14:00 PM,Regeneron Genetics Center Discovers Rare Mutations In The CIDEB Gene That Protect Against Liver Disease,PR Newswire,/news/stocks/regeneron-genetics-center-discovers-rare-mutations-in-the-cideb-gene-that-protect-against-liver-disease-1031622512
1184.0,7/28/2022 9:05:28 AM,Sanofi raises FY22 outlook while Q2 sales boosted by blockbuster Dupixent,Seeking Alpha,https://seekingalpha.com/news/3862033-sanofi-raises-fy22-outlook-while-q2-sales-boosted-by-blockbuster-dupixent?utm_source=businessinsider&utm_medium=referral
1185.0,7/28/2022 8:20:28 PM,Senate Democrats propose $21B funding for next phase of COVID-19 response,Seeking Alpha,https://seekingalpha.com/news/3862718-senate-democrats-propose-21b-funding-for-next-phase-of-covid-19-response?utm_source=businessinsider&utm_medium=referral
1186.0,7/31/2022 3:21:24 PM,Biotech Investors: August's Key PDUFA Catalysts You Must Know,Benzinga,/news/stocks/biotech-investors-august-s-key-pdufa-catalysts-you-must-know-1031631857
1187.0,8/2/2022 2:48:35 PM,Notable earnings before Wednesday's open,Seeking Alpha,https://seekingalpha.com/news/3864711-notable-earnings-before-wednesdays-open?utm_source=businessinsider&utm_medium=referral
1188.0,8/2/2022 3:01:13 PM,Regeneron Pharmaceuticals earnings preview: what to expect,Markets Insider Automation,/news/stocks/regeneron-stock-quarter-earnings-preview-q2-1031640061
1189.0,8/2/2022 4:20:13 PM,"Eyes on sales of blockbuster drugs Eylea, Dupixent for Regeneron's Q2 2022 earnings",Seeking Alpha,https://seekingalpha.com/news/3864805-eyes-on-sales-of-blockbuster-drugs-eylea-dupixent-for-regenerons-q2-2022-earnings?utm_source=businessinsider&utm_medium=referral
1190.0,8/3/2022 10:34:09 AM,"Regeneron Pharmaceuticals Non-GAAP EPS of $9.77 beats by $1.02, revenue of $2.86B beats by $60M",Seeking Alpha,https://seekingalpha.com/news/3865525-regeneron-pharmaceuticals-non-gaap-eps-of-9_77-beats-1_02-revenue-of-2_86b-beats-60m?utm_source=businessinsider&utm_medium=referral
1191.0,8/3/2022 11:44:39 AM,Regeneron posts 2Q revenue drop as sales of COVID-19 therapy plummet,Seeking Alpha,https://seekingalpha.com/news/3865621-regn-stock-gains-despite-2q-revenue-drop?utm_source=businessinsider&utm_medium=referral
1192.0,8/3/2022 12:25:00 PM,Novel Costimulatory Bispecific Antibody Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo® (cemiplimab) in Advanced Metastatic Castration-resistant Prostate Cancer (m...,PR Newswire,/news/stocks/novel-costimulatory-bispecific-antibody-shows-encouraging-anti-tumor-activity-when-combined-with-pd-1-inhibitor-libtayo-cemiplimab-in-advanced-metastatic-castration-resistant-prostate-cancer-m-1031644495
1193.0,8/3/2022 12:30:00 PM,Regeneron Reports Second Quarter 2022 Financial and Operating Results,PR Newswire,/news/stocks/regeneron-reports-second-quarter-2022-financial-and-operating-results-1031644519
1194.0,8/3/2022 12:49:32 PM,"Alnylam drives Intellia, Ionis higher with amyloidosis data; BridgeBio slips",Seeking Alpha,https://seekingalpha.com/news/3865700-ntla-stock-ions-stock-climb-after-alnylam-data-on-amyloidosis?utm_source=businessinsider&utm_medium=referral
1195.0,8/3/2022 1:05:15 PM,Regeneron's REGN5678 Shows Encouraging Anti-tumor Activity When Combined With Libtayo ,RTTNews,/news/stocks/regeneron-s-regn5678-shows-encouraging-anti-tumor-activity-when-combined-with-libtayo-1031644679
1196.0,8/3/2022 1:24:20 PM,"Regeneron Q2 Profit Down On Weak Revenues; Revises FY22 Margin, R&D Outlook ",RTTNews,/news/stocks/regeneron-q2-profit-down-on-weak-revenues-revises-fy22-margin-r-d-outlook-1031644756
1197.0,8/3/2022 7:38:16 PM,"Moderna, CVS Health, Regeneron lead S&P 500 after Q2 earnings",Seeking Alpha,https://seekingalpha.com/news/3866296-mrna-stock-cvs-stock-regn-stock-lead-sp-500-after-2q-earnings?utm_source=businessinsider&utm_medium=referral
1198.0,8/3/2022 8:42:38 PM,7 Cheap Biotech Stocks to Buy Now,InvestorPlace,/news/stocks/cheap-biotech-stocks-1031647456
1199.0,8/7/2022 10:19:22 PM,$35 per month capped insulin for private insurance kept out of Inflation Reduction Act,Seeking Alpha,https://seekingalpha.com/news/3868539-35-per-month-capped-insulin-for-private-insurance-kept-out-of-inflation-reduction-act-passed-by-senate?utm_source=businessinsider&utm_medium=referral
1200.0,8/8/2022 1:45:59 PM,Kodiak gains as late-stage trial for eye disease candidate meets key goal,Seeking Alpha,https://seekingalpha.com/news/3868809-kodiak-gains-as-late-stage-trial-for-eye-disease-candidate-meets-key-goal?utm_source=businessinsider&utm_medium=referral
1201.0,8/8/2022 2:40:28 PM,Kodiak's Eye Disease Candidate At Par With Regeneron's Eylea In Visual Acuity Gains,Benzinga,/news/stocks/kodiak-s-eye-disease-candidate-at-par-with-regeneron-s-eylea-in-visual-acuity-gains-1031661122
1202.0,8/11/2022 1:40:26 PM,Regeneron IPR hearing suggests Eylea patent may be in trouble - analyst,Seeking Alpha,https://seekingalpha.com/news/3871614-regeneron-ipr-hearing-suggests-eylea-patent-may-be-in-trouble-analyst?utm_source=businessinsider&utm_medium=referral
1203.0,8/11/2022 7:26:06 PM,CDC eases COVID guidance for unvaccinated people,Seeking Alpha,https://seekingalpha.com/news/3871779-cdc-eases-covid-guidance-for-unvaccinated-people?utm_source=businessinsider&utm_medium=referral
1204.0,8/11/2022 8:44:15 PM,3 Best Funds for Aggressive Investors,InvestorPlace,/news/stocks/best-funds-for-aggressive-investors-1031677463
1205.0,8/11/2022 9:22:02 PM,"J&J, Merck, Regeneron most exposed to Medicare drug price negotiation - Bloomberg",Seeking Alpha,https://seekingalpha.com/news/3871983-johnson-johnson-merck-regeneron-most-exposed-to-medicare-drug-price-negotiation-bloomberg?utm_source=businessinsider&utm_medium=referral
1206.0,8/12/2022 11:39:31 AM,Unity Biotech jumps 93% after data for lead asset in diabetic macular edema,Seeking Alpha,https://seekingalpha.com/news/3872259-ubx-stock-jumps-after-data-for-lead-asset-in-diabetic-macular-edema?utm_source=businessinsider&utm_medium=referral
1207.0,8/13/2022 8:00:00 PM,"AbbVie, Roche, Regeneron could significantly benefit as AMD market expected to soar",Seeking Alpha,https://seekingalpha.com/news/3872108-abbvie-roche-regeneron-could-significantly-benefit-as-amd-market-expected-to-soar?utm_source=businessinsider&utm_medium=referral
1208.0,8/14/2022 5:48:06 PM,Analysts rule out major industry impact from drug pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/3872629-analysts-rule-out-major-industry-impact-from-drug-pricing-negotiations?utm_source=businessinsider&utm_medium=referral
1209.0,8/15/2022 10:51:43 AM,Unity extends gains on data for lead asset in diabetic macular edema,Seeking Alpha,https://seekingalpha.com/news/3872733-ubx-stock-extends-gains-on-data-for-lead-asset-in-diabetic-macular-edema?utm_source=businessinsider&utm_medium=referral
1210.0,8/17/2022 10:54:23 AM,"U.S. govt. to stop buying COVID-19 vaccines, therapies, tests from this fall – Jha",Seeking Alpha,https://seekingalpha.com/news/3874012-us-govt-to-stop-buying-covid-19-vaccines-therapies-tests-from-this-fall-jha?utm_source=businessinsider&utm_medium=referral
1211.0,8/17/2022 5:10:23 PM,CDC seeks reforms to correct COVID missteps,Seeking Alpha,https://seekingalpha.com/news/3874241-cdc-to-implement-reforms-to-correct-covid-missteps?utm_source=businessinsider&utm_medium=referral
1212.0,8/19/2022 10:45:00 AM,Regeneron monoclonal antibody gets WHO recommendation for Ebola,Seeking Alpha,https://seekingalpha.com/news/3874958-regeneron-monoclonal-antibody-gets-who-recommendation-for-ebola?utm_source=businessinsider&utm_medium=referral
1213.0,8/21/2022 4:00:16 PM,Biotech in recovery; but Piper Sandler cites negative fund flows,Seeking Alpha,https://seekingalpha.com/news/3875226-biotech-in-recovery-but-piper-sandler-cites-negative-fund-flows?utm_source=businessinsider&utm_medium=referral
1214.0,8/22/2022 6:00:58 PM,7 Cathie Wood Stocks to Buy on the Dip,InvestorPlace,/news/stocks/cathie-wood-stocks-to-buy-on-the-dip-1031588252
1215.0,8/25/2022 7:42:04 PM,Verve upgraded to Buy at Stifel on near term catalysts for heart disease therapy,Seeking Alpha,https://seekingalpha.com/news/3876782-verv-stock-upgraded-at-stifel-on-catalysts-for-heart-disease-therapy?utm_source=businessinsider&utm_medium=referral
1216.0,8/25/2022 10:05:00 PM,Regeneron Announces Investor Conference Presentations,PR Newswire,/news/stocks/regeneron-announces-investor-conference-presentations-1031706877
1217.0,8/26/2022 8:53:05 PM,5 Top Stocks Cathie Wood Is Selling This Week,InvestorPlace,/news/stocks/5-top-stocks-cathie-wood-is-selling-this-week-1031708967
1218.0,8/27/2022 9:08:07 AM,Biotech Stocks Facing FDA Decision In September ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-september-1031709034
1219.0,8/29/2022 2:21:04 PM,"Alnylam: Additional Data Shows Favorable Effects Of Cemdisiran On Different Measures Of 
proteinuria ",RTTNews,/news/stocks/alnylam-additional-data-shows-favorable-effects-of-cemdisiran-on-different-measures-of-proteinuria-1031710700
1220.0,8/31/2022 8:52:36 PM,"Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know",Benzinga,/news/stocks/bluebird-bio-seeks-back-to-back-nods-go-or-no-go-for-revance-s-botox-rival-amylyx-twin-hurdles-and-more-september-s-key-pdufa-catalysts-biotech-investors-must-know-1031717312
1221.0,9/4/2022 1:18:40 PM,"M&A may be a tailwind for biotech sector into end of year, analyst says",Seeking Alpha,https://seekingalpha.com/news/3880197-ma-may-be-a-tailwind-for-biotech-sector-into-end-of-year-analyst-says?utm_source=businessinsider&utm_medium=referral
1222.0,9/5/2022 12:05:00 AM,"ESMO Presentations of Libtayo® (cemiplimab), Fianlimab and Novel Bispecific Antibodies Showcase Expanding Potential of Regeneron's Oncology Pipeline in Multiple Cancers",PR Newswire,/news/stocks/esmo-presentations-of-libtayo-cemiplimab-fianlimab-and-novel-bispecific-antibodies-showcase-expanding-potential-of-regeneron-s-oncology-pipeline-in-multiple-cancers-1031723465
1223.0,9/5/2022 9:28:29 AM,Sanofi: Dupixent Data Show Sustained Improvement For Up To 2 Yrs In 6-11 Years With Asthma ,RTTNews,/news/stocks/sanofi-dupixent-data-show-sustained-improvement-for-up-to-2-yrs-in-6-11-years-with-asthma-1031723820
1224.0,9/5/2022 10:18:09 AM,Sanofi/Regeneron Dupixent shows efficacy for up to 2 years in children with asthma,Seeking Alpha,https://seekingalpha.com/news/3880235-sanofiregeneron-dupixent-shows-efficacy-for-up-to-2-years-in-children-with-asthma?utm_source=businessinsider&utm_medium=referral
1225.0,9/5/2022 1:29:00 PM,Late-Breaking Dupixent® (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safety Profile for Up to Two Years in Children Aged 6 to 11 Years with Moderate-to-severe Asthma,PR Newswire,/news/stocks/late-breaking-dupixent-dupilumab-data-at-ers-2022-show-consistent-efficacy-and-safety-profile-for-up-to-two-years-in-children-aged-6-to-11-years-with-moderate-to-severe-asthma-1031724138
1226.0,9/8/2022 1:17:10 PM,Regeneron says pivotal trials for less frequent Eylea injections reached main goals,Seeking Alpha,https://seekingalpha.com/news/3881228-regn-stock-on-watch-as-less-frequent-eylea-reaches-main-goals-in-trials?utm_source=businessinsider&utm_medium=referral
1227.0,9/8/2022 1:53:34 PM,Regeneron jumps 16% as pivotal trials for less frequent Eylea reach main goals,Seeking Alpha,https://seekingalpha.com/news/3881226-regn-stock-on-watch-as-less-frequent-eylea-reaches-main-goals-in-trials?utm_source=businessinsider&utm_medium=referral
1228.0,9/8/2022 3:00:00 PM,"Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD, with a Vast Majority of Patients Maintained on 12- and 16-week Dosing Intervals",PR Newswire,/news/stocks/aflibercept-8-mg-meets-primary-endpoints-in-two-global-pivotal-trials-for-dme-and-wamd-with-a-vast-majority-of-patients-maintained-on-12-and-16-week-dosing-intervals-1031732094
1229.0,9/8/2022 3:23:31 PM,Regeneron: Aflibercept 8 Mg Meets Primary Endpoints In Two Trials For DME And WAMD ,RTTNews,/news/stocks/regeneron-aflibercept-8-mg-meets-primary-endpoints-in-two-trials-for-dme-and-wamd-1031732226
1230.0,9/8/2022 4:42:22 PM,"AeroVironment, Snap And Some Other Big Stocks Moving Higher On Thursday",Benzinga,/news/stocks/aerovironment-snap-and-some-other-big-stocks-moving-higher-on-thursday-1031732569
1231.0,9/8/2022 4:54:38 PM,"PTN, ERAS  and Merc among mid-day movers",Seeking Alpha,https://seekingalpha.com/news/3881320-ptn-eras-and-merc-among-mid-day-movers?utm_source=businessinsider&utm_medium=referral
1232.0,9/8/2022 5:29:00 PM,Dupixent® (dupilumab) Late-breaking Phase 3 Data at the EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis,PR Newswire,/news/stocks/dupixent-dupilumab-late-breaking-phase-3-data-at-the-eadv-2022-congress-showed-significant-improvements-in-signs-and-symptoms-of-prurigo-nodularis-1031732732
1233.0,9/8/2022 6:15:08 PM,"Why Bilibili Is Trading Lower By Over Around 14%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session",Benzinga,/news/stocks/why-bilibili-is-trading-lower-by-over-around-14-here-are-50-stocks-moving-in-thursday-s-mid-day-session-1031732864
1234.0,9/9/2022 12:17:21 AM,"Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary",Benzinga,/news/stocks/important-biotech-catalysts-for-september-8-2022---end-of-the-day-summary-1031733508
1235.0,9/9/2022 8:58:43 AM,Sanofi/Regeneron presents full data of Dupixent efficacy in skin disease prurigo nodularis,Seeking Alpha,https://seekingalpha.com/news/3881547-sanofiregeneron-presents-full-results-of-dupixent-efficacy-in-skin-disease-prurigo-nodularis?utm_source=businessinsider&utm_medium=referral
1236.0,9/9/2022 10:14:31 AM,Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday,Benzinga,/news/stocks/why-shiftpixy-surged-around-177-here-are-71-biggest-movers-from-yesterday-1031734097
1237.0,9/9/2022 11:41:43 AM,US Stock Futures Surge; Fed Speakers In Focus,Benzinga,/news/stocks/us-stock-futures-surge-fed-speakers-in-focus-1031734210
1238.0,9/9/2022 12:07:19 PM,Regeneron draws upgrades after data for high dose Eylea,Seeking Alpha,https://seekingalpha.com/news/3881595-regn-stock-draws-upgrades-after-data-for-high-dose-eylea?utm_source=businessinsider&utm_medium=referral
1239.0,9/9/2022 1:56:06 PM,Regeneron Pharmaceuticals To $851? Here Are 5 Other Price Target Changes For Friday,Benzinga,/news/stocks/regeneron-pharmaceuticals-to-851-here-are-5-other-price-target-changes-for-friday-1031734478
1240.0,9/9/2022 4:00:00 PM,Regeneron Announces Investor Call and Webcast at ESMO 2022,PR Newswire,/news/stocks/regeneron-announces-investor-call-and-webcast-at-esmo-2022-1031734830
1241.0,9/9/2022 4:40:57 PM,"Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-september-9-2022-1031734920
1242.0,9/9/2022 5:15:29 PM,'Highly Compelling' Eye Drug Data Has Wall Street Stampeding To Buy This 'Large Cap Growth Story.' Even After $15B In Market Cap Was Added,Benzinga,/news/stocks/highly-compelling-eye-drug-data-has-wall-street-stampeding-to-buy-this-large-cap-growth-story-even-after-15b-in-market-cap-was-added-1031735020
1243.0,9/9/2022 6:08:43 PM,Jefferies Upgrades Regeneron Pharmaceuticals: Here's What You Need To Know,Benzinga,/news/stocks/jefferies-upgrades-regeneron-pharmaceuticals-here-s-what-you-need-to-know-1031735143
1244.0,9/9/2022 6:23:55 PM,Analyst Ratings for Regeneron Pharmaceuticals,Benzinga,/news/stocks/analyst-ratings-for-regeneron-pharmaceuticals-1031735199
1245.0,9/9/2022 7:16:36 PM,9 Analysts Have This to Say About Regeneron Pharmaceuticals,Benzinga,/news/stocks/9-analysts-have-this-to-say-about-regeneron-pharmaceuticals-1031735273
1246.0,9/9/2022 10:00:48 PM,The 3 Best Healthcare Stocks to Buy Now,InvestorPlace,/news/stocks/best-healthcare-stocks-1031568641
1247.0,9/10/2022 8:30:00 AM,Novel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors,PR Newswire,/news/stocks/novel-regeneron-bispecific-antibodies-show-encouraging-anti-tumor-activity-in-two-advanced-solid-tumors-1031735615
1248.0,9/12/2022 8:30:00 AM,Fianlimab (LAG-3 Inhibitor) Combined with Libtayo® (cemiplimab) Demonstrates Greater than 60% Response Rates in Two Independent Cohorts of Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 In...,PR Newswire,/news/stocks/fianlimab-lag-3-inhibitor-combined-with-libtayo-cemiplimab-demonstrates-greater-than-60-response-rates-in-two-independent-cohorts-of-patients-with-advanced-melanoma-naïve-to-pd-1-or-pd-l1-in-1031736428
1249.0,9/12/2022 8:54:06 AM,Regeneron: Fianlimab With Libtayo Shows Greater Than 60% Response Rates In Phase 1 Trial ,RTTNews,/news/stocks/regeneron-fianlimab-with-libtayo-shows-greater-than-60-response-rates-in-phase-1-trial-1031736459
1250.0,9/12/2022 10:30:00 AM,Positive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable Cutaneous Squamous Cell Carcinoma Presented at ESMO and Published in NEJM,PR Newswire,/news/stocks/positive-neoadjuvant-libtayo-cemiplimab-monotherapy-data-in-resectable-cutaneous-squamous-cell-carcinoma-presented-at-esmo-and-published-in-nejm-1031736583
1251.0,9/13/2022 12:49:52 AM,"Regeneron Stock: Next Stop, $900?",TipRanks,/news/stocks/regeneron-stock-next-stop-900-1031738499
1252.0,9/13/2022 8:02:35 PM,"A Major October Catalyst Could Make This Eye Stock A Ten Bagger, Analyst Says",Benzinga,/news/stocks/a-major-october-catalyst-could-make-this-eye-stock-a-ten-bagger-analyst-says-1031740991
1253.0,9/14/2022 2:18:38 PM,"End in sight for COVID-19 pandemic, WHO chief says",Seeking Alpha,https://seekingalpha.com/news/3882728-end-in-sight-for-covid-19-pandemic-who-chief-says?utm_source=businessinsider&utm_medium=referral
1254.0,9/15/2022 11:29:28 AM,Alnylam/Regeneron say early-stage data support Phase 2 trial for NASH therapy,Seeking Alpha,https://seekingalpha.com/news/3882947-alnylam-regeneron-say-early-stage-data-back-phase-2-trial-for-nash-drug?utm_source=businessinsider&utm_medium=referral
1255.0,9/15/2022 1:00:00 PM,Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers,PR Newswire,/news/stocks/regeneron-and-alnylam-report-promising-data-from-ongoing-phase-1-study-of-aln-hsd-in-nash-patients-and-healthy-volunteers-1031744989
1256.0,9/16/2022 12:38:00 AM,Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet,PR Newswire,/news/stocks/positive-dupixent-dupilumab-phase-3-data-in-children-aged-6-months-to-5-years-with-moderate-to-severe-atopic-dermatitis-published-in-the-lancet-1031746988
1257.0,9/16/2022 12:47:03 AM,"Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary",Benzinga,/news/stocks/important-biotech-catalysts-for-september-15-2022---end-of-the-day-summary-1031746992
1258.0,9/16/2022 10:32:21 AM,"WHO advises against use of GSK/Vir, Regeneron COVID drugs, backs limited use of Gilead's remdesivir",Seeking Alpha,https://seekingalpha.com/news/3883338-who-advises-against-gskvir-regeneron-covid-drugs-backs-limited-use-of-gileads-remdesivir?utm_source=businessinsider&utm_medium=referral
1259.0,9/16/2022 12:08:13 PM,"Intellia, Regeneron post early data to highlight gene editing in ATTR amyloidosis cardiomyopathy",Seeking Alpha,https://seekingalpha.com/news/3883370-intellia-regeneron-tout-gene-editing-in-attr-amyloidosis-cardiomyopathy?utm_source=businessinsider&utm_medium=referral
1260.0,9/16/2022 1:15:00 PM,"Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis",PR Newswire,/news/stocks/intellia-and-regeneron-announce-initial-data-from-the-cardiomyopathy-arm-of-ongoing-phase-1-study-of-ntla-2001-an-investigational-crispr-therapy-for-the-treatment-of-transthyretin-attr-amyloidosis-1031747874
1261.0,9/16/2022 1:36:00 PM,Intellia: Interim Data Show NTLA-2001 Can Profoundly Reduce Serum TTR Levels ,RTTNews,/news/stocks/intellia-interim-data-show-ntla-2001-can-profoundly-reduce-serum-ttr-levels-1031747945
1262.0,9/16/2022 4:16:02 PM,Intellia falls as analysts react to CRISPR readouts,Seeking Alpha,https://seekingalpha.com/news/3883494-intellia-falls-as-analysts-react-to-crispr-readouts?utm_source=businessinsider&utm_medium=referral
1263.0,9/17/2022 8:00:18 PM,"BioNTech, Moderna, Pfizer led biopharma revenue growth from 2020-2021",Seeking Alpha,https://seekingalpha.com/news/3883566-biontech-moderna-pfizer-led-biopharma-revenue-growth-from-2020-2021?utm_source=businessinsider&utm_medium=referral
1264.0,9/19/2022 11:39:37 AM,Roche wins European approval for Vabysmo for wet AMD and diabetic macular edema,Seeking Alpha,https://seekingalpha.com/news/3883682-roche-wins-european-approval-for-vabysmo-for-wet-amd-and-diabetic-macular-edema?utm_source=businessinsider&utm_medium=referral
1265.0,9/20/2022 5:45:25 PM,The 7 Best Biotech Stocks to Buy,InvestorPlace,/news/stocks/best-biotech-stocks-1031575358
1266.0,9/21/2022 12:20:51 PM,Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and Baudax Bio (BXRX),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-and-baudax-bio-bxrx-1031756422
1267.0,9/22/2022 3:55:15 PM,"WHO chief reiterates belief that COVID-19 pandemic end near, says work still needed",Seeking Alpha,https://seekingalpha.com/news/3885339-who-chief-reiterates-belief-that-covid-19-pandemic-end-near-says-work-still-needed?utm_source=businessinsider&utm_medium=referral
1268.0,9/23/2022 8:43:14 PM,The Top 5 Stocks Cathie Wood Is Buying This Week,InvestorPlace,/news/stocks/the-top-5-stocks-cathie-wood-is-buying-this-week-1031762742
1269.0,9/27/2022 11:07:53 AM,Ocular stock rises as eye drug implant OTX-TKI shows promise in vision disorder in trial,Seeking Alpha,https://seekingalpha.com/news/3886254-ocular-stock-rises-as-eye-implant-otx-tki-shows-promise-in-vision-disorder-in-trial?utm_source=businessinsider&utm_medium=referral
1270.0,9/27/2022 11:15:11 AM,The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market,InvestorPlace,/news/stocks/the-7-best-stocks-to-buy-to-tap-into-a-hidden-bull-market-1031766644
1271.0,9/27/2022 4:21:02 PM,"Ocular Therapeutix's Wet AMD Candidate Shows Sustained, Comparable Clinical Activity Vs. Eylea",Benzinga,/news/stocks/ocular-therapeutix-s-wet-amd-candidate-shows-sustained-comparable-clinical-activity-vs-eylea-1031767475
1272.0,9/28/2022 11:44:00 PM,Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis,PR Newswire,/news/stocks/dupixent-dupilumab-approved-by-fda-as-the-first-and-only-treatment-indicated-for-prurigo-nodularis-1031771410
1273.0,9/29/2022 4:30:31 AM,Regeneron : FDA Approves Dupixent For Prurigo Nodularis Treatment ,RTTNews,/news/stocks/regeneron-fda-approves-dupixent-for-prurigo-nodularis-treatment-1031771519
1274.0,9/29/2022 10:51:02 AM,"Sanofi, Regeneron win FDA label expansion for Dupixent in chronic, skin condition",Seeking Alpha,https://seekingalpha.com/news/3887050-sanofi-regeneron-win-fda-label-expansion-for-dupixent-in-chronic-skin-condition?utm_source=businessinsider&utm_medium=referral
1275.0,9/30/2022 11:04:00 PM,Aflibercept 8 mg Positive Pivotal Results in Diabetic Macular Edema and Wet Age-Related Macular Degeneration Presented at AAO,PR Newswire,/news/stocks/aflibercept-8-mg-positive-pivotal-results-in-diabetic-macular-edema-and-wet-age-related-macular-degeneration-presented-at-aao-1031776867
1276.0,10/2/2022 4:00:31 PM,COVID stocks lag U.S. biopharma in Q3; Alzheimer’s theme regains focus,Seeking Alpha,https://seekingalpha.com/news/3887740-covid-stocks-lag-us-biopharma-in-q3-alzheimers-theme-regains-focus?utm_source=businessinsider&utm_medium=referral
1277.0,10/3/2022 10:14:22 AM,"Svante Pääbo gets Nobel Prize for Medicine for discoveries on genome, human evolution",Seeking Alpha,https://seekingalpha.com/news/3887839-svante-pbo-gets-nobel-prize-for-medicine-for-discoveries-on-genome-human-evolution?utm_source=businessinsider&utm_medium=referral
1278.0,10/3/2022 1:00:00 PM,Regeneron Elects Dr. Craig B. Thompson to Board of Directors,PR Newswire,/news/stocks/regeneron-elects-dr-craig-b-thompson-to-board-of-directors-1031778376
1279.0,10/3/2022 4:18:32 PM,Analyst Ratings for Regeneron Pharmaceuticals,Benzinga,/news/stocks/analyst-ratings-for-regeneron-pharmaceuticals-1031779157
1280.0,10/3/2022 4:35:17 PM,Goldman Sachs Sticks to Their Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/goldman-sachs-sticks-to-their-buy-rating-for-regeneron-regn-1031779530
1281.0,10/3/2022 7:23:24 PM,AstraZeneca COVID-19 antibodies unlikely to protect against new Omicron subvariant,Seeking Alpha,https://seekingalpha.com/news/3888160-astrazeneca-covid-19-antibody-unlikely-to-act-against-new-omicron-subvariant?utm_source=businessinsider&utm_medium=referral
1282.0,10/3/2022 9:38:35 PM,What 13 Analyst Ratings Have To Say About Regeneron Pharmaceuticals,Benzinga,/news/stocks/what-13-analyst-ratings-have-to-say-about-regeneron-pharmaceuticals-1031779884
1283.0,10/3/2022 11:04:23 PM,13 Analysts Have This to Say About Regeneron Pharmaceuticals,Benzinga,/news/stocks/13-analysts-have-this-to-say-about-regeneron-pharmaceuticals-1031780097
1284.0,10/4/2022 2:00:44 PM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Aeglea Biotherapeutics (AGLE) and Autolus Therapeutics (AUTL)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-regeneron-regn-aeglea-biotherapeutics-agle-and-autolus-therapeutics-autl-1031782098
1285.0,10/4/2022 10:00:00 PM,"Regeneron to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on November 3, 2022",PR Newswire,/news/stocks/regeneron-to-report-third-quarter-2022-financial-and-operating-results-and-host-conference-call-and-webcast-on-november-3-2022-1031782897
1286.0,10/5/2022 7:04:15 PM,"Apple Short Sellers Made $2B In Profits In September, And Shorts In This Biotech Stock Lost $307M",Benzinga,/news/stocks/apple-short-sellers-made-2b-in-profits-in-september-and-shorts-in-this-biotech-stock-lost-307m-1031785435
1287.0,10/10/2022 10:15:48 AM,These 7 Biotech Stocks Are Set to Boom in 2023,InvestorPlace,/news/stocks/7-biotech-stocks-set-to-boom-2023-1031792647
1288.0,10/10/2022 6:09:22 PM,GOP senators introduce bill to undo Medicare prescription drug negotiation,Seeking Alpha,https://seekingalpha.com/news/3890099-gop-senators-introduce-bill-to-undo-medicare-prescription-drug-negotiation?utm_source=businessinsider&utm_medium=referral
1289.0,10/11/2022 6:59:00 AM,Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old,PR Newswire,/news/stocks/dupixent-dupilumab-late-breaking-phase-3-data-presented-at-ueg-week-2022-showed-significant-histological-remission-of-eosinophilic-esophagitis-eoe-in-children-1-to-11-years-old-1031794713
1290.0,10/11/2022 7:22:50 AM,Regeneron Reports Positive Results From Dupixent Phase 3 Trial In 1 To 11 Yrs With EoE ,RTTNews,/news/stocks/regeneron-reports-positive-results-from-dupixent-phase-3-trial-in-1-to-11-yrs-with-eoe-1031794756
1291.0,10/11/2022 9:34:36 AM,Sanofi/Regeneron Dupixent shows efficacy in kids with esophagus inflammation in phase 3 trial,Seeking Alpha,https://seekingalpha.com/news/3890221-sanofiregeneron-dupixent-shows-efficacy-in-kids-with-esophagus-inflammation-in-phase-3-trial?utm_source=businessinsider&utm_medium=referral
1292.0,10/12/2022 12:53:54 PM,"Regeneron, Bayer Eylea gets FDA priority review for eye disorder in infants",Seeking Alpha,https://seekingalpha.com/news/3890687-regeneron-bayer-eylea-gets-fda-priority-review-for-eye-disorder-in-infants?utm_source=businessinsider&utm_medium=referral
1293.0,10/12/2022 1:00:00 PM,EYLEA® (aflibercept) Injection sBLA for Treatment of Retinopathy of Prematurity (ROP) Accepted for FDA Priority Review,PR Newswire,/news/stocks/eylea-aflibercept-injection-sbla-for-treatment-of-retinopathy-of-prematurity-rop-accepted-for-fda-priority-review-1031799016
1294.0,10/12/2022 1:18:20 PM,Regeneron: EYLEA SBLA Gets FDA Priority Review - Quick Facts ,RTTNews,/news/stocks/regeneron-eylea-sbla-gets-fda-priority-review-quick-facts-1031799100
1295.0,10/14/2022 12:24:33 PM,Biden to sign Executive Order tasking HHS to find additional ways to lower drug costs,Seeking Alpha,https://seekingalpha.com/news/3891387-biden-to-sign-executive-order-tasking-hhs-to-find-additional-ways-to-lower-drug-costs-medicare?utm_source=businessinsider&utm_medium=referral
1296.0,10/14/2022 1:04:00 PM,Libtayo® (cemiplimab) Receives Positive CHMP Opinion Recommending Approval to Treat Advanced Cervical Cancer,PR Newswire,/news/stocks/libtayo-cemiplimab-receives-positive-chmp-opinion-recommending-approval-to-treat-advanced-cervical-cancer-1031805821
1297.0,10/14/2022 1:07:48 PM,EMA committee recommends expanded approval of Regeneron's Libtayo for cervical cancer,Seeking Alpha,https://seekingalpha.com/news/3891410-ema-committee-recommends-expanded-approval-of-regenerons-libtayo-for-cervical-cancer?utm_source=businessinsider&utm_medium=referral
1298.0,10/14/2022 1:27:37 PM,Regeneron Pharma: CHMP Adopts Positive Opinion For Libtayo - Quick Facts ,RTTNews,/news/stocks/regeneron-pharma-chmp-adopts-positive-opinion-for-libtayo-quick-facts-1031805874
1299.0,10/17/2022 12:27:54 PM,Regeneron downgraded at Evercore citing eyecare landscape,Seeking Alpha,https://seekingalpha.com/news/3891781-regeneron-downgraded-at-evercore-citing-eyecare-landscape?utm_source=businessinsider&utm_medium=referral
1300.0,10/17/2022 12:50:35 PM,Decibel stock surges 18% as FDA clears hearing loss gene therapy to enter trial,Seeking Alpha,https://seekingalpha.com/news/3891792-decibel-stock-surges-as-fda-clears-hearing-loss-gene-therapy-to-enter-trial?utm_source=businessinsider&utm_medium=referral
1301.0,10/17/2022 2:34:50 PM,Morgan Stanley says large cap healthcare remains attractive amid macro concerns,Seeking Alpha,https://seekingalpha.com/news/3891861-morgan-stanely-says-large-cap-healthcare-remains-attractive-amid-macro-concerns?utm_source=businessinsider&utm_medium=referral
1302.0,10/17/2022 3:13:09 PM,13 Analysts Have This to Say About Regeneron Pharmaceuticals,Benzinga,/news/stocks/13-analysts-have-this-to-say-about-regeneron-pharmaceuticals-1031810137
1303.0,10/17/2022 4:02:32 PM,"Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-october-17-2022-1031810315
1304.0,10/17/2022 8:32:16 PM,Analyst Ratings for Regeneron Pharmaceuticals,Benzinga,/news/stocks/analyst-ratings-for-regeneron-pharmaceuticals-1031810971
1305.0,10/18/2022 3:30:49 PM,Decibel Therapeutics hears it may be a takeout target after Lilly acquisition of Akouos,Seeking Alpha,https://seekingalpha.com/news/3892281-decibel-therapeutics-hears-it-may-be-a-takeou-ttarget-after-eli-lilly-acquisition-of-akouos?utm_source=businessinsider&utm_medium=referral
1306.0,10/20/2022 5:19:54 PM,Prescription drugs make up a rising share of Medicare spending – study,Seeking Alpha,https://seekingalpha.com/news/3893317-prescription-drugs-account-for-a-rising-chunk-of-medicare-spending-study?utm_source=businessinsider&utm_medium=referral
1307.0,10/21/2022 11:38:17 AM,Regeneron wins six-month pediatric exclusivity for Eylea in U.S. market,Seeking Alpha,https://seekingalpha.com/news/3893624-regeneron-wins-six-month-pediatric-exclusivity-for-eylea-in-us-market?utm_source=businessinsider&utm_medium=referral
1308.0,10/21/2022 1:00:00 PM,Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA® (aflibercept) Injection,PR Newswire,/news/stocks/regeneron-receives-six-months-of-u-s-pediatric-exclusivity-for-eylea-aflibercept-injection-1031824017
1309.0,10/21/2022 1:19:10 PM,Regeneron: FDA Grants Pediatric Exclusivity For EYLEA ,RTTNews,/news/stocks/regeneron-fda-grants-pediatric-exclusivity-for-eylea-1031824078
1310.0,10/21/2022 5:56:11 PM,"Talks begin with pharma, health insurers over negotiating drug prices for Medicare",Seeking Alpha,https://seekingalpha.com/news/3893788-talks-begin-with-pharma-health-insurers-over-negotiating-drug-prices-for-medicare?utm_source=businessinsider&utm_medium=referral
1311.0,10/26/2022 11:41:21 AM,Regeneron slips as Raymond James downgrades on Eylea concerns,Seeking Alpha,https://seekingalpha.com/news/3895394-regn-stock-slips-as-raymond-james-downgrades-on-eylea-concerns?utm_source=businessinsider&utm_medium=referral
1312.0,10/26/2022 4:07:48 PM,"Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-october-26-2022-1031838805
1313.0,10/27/2022 8:48:32 AM,GSK to abandon regulatory filings for arthritis drug as phase 3 trial fails,Seeking Alpha,https://seekingalpha.com/news/3896202-gsk-to-abandon-regulatory-filings-for-arthritis-drug-as-a-phase-3-trial-fails?utm_source=businessinsider&utm_medium=referral
1314.0,10/27/2022 9:19:06 AM,Roche Vabysmo matches Eylea in 2 phase 3 trials for vision disorder,Seeking Alpha,https://seekingalpha.com/news/3896209-roche-vabysmo-matches-eylea-in-2-phase-3-trials-for-vision-disorder?utm_source=businessinsider&utm_medium=referral
1315.0,10/27/2022 3:54:30 PM,Midterm Elections 2022: 3 Stocks to Avoid Like the Plague for a ‘Blue Wave’,InvestorPlace,/news/stocks/midterm-elections-2022-3-stocks-to-avoid-like-the-plague-for-a-blue-wave-1031844449
1316.0,10/28/2022 9:09:39 AM,"Sanofi Q3 sales boosted by Dupixent, Vaccines business; raises FY22 outlook again",Seeking Alpha,https://seekingalpha.com/news/3897079-sanofi-q3-sales-boosted-by-dupixent-vaccines-business-raises-fy22-outlook-again?utm_source=businessinsider&utm_medium=referral
1317.0,10/28/2022 2:00:00 PM,"Inmazeb™ (atoltivimab, maftivimab, and odesivimab-ebgn) Wins Prestigious 2022 Prix Galien USA Best Biotechnology Product Award",PR Newswire,/news/stocks/inmazeb-atoltivimab-maftivimab-and-odesivimab-ebgn-wins-prestigious-2022-prix-galien-usa-best-biotechnology-product-award-1031848126
1318.0,11/1/2022 3:27:53 PM,"Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-november-1-2022-1031859215
1319.0,11/2/2022 3:01:13 PM,What Wall Street expects from Regeneron Pharmaceuticals's earnings,Markets Insider Automation,/news/stocks/regeneron-q3-earnings-preview-stock-1031864404
1320.0,11/2/2022 6:15:48 PM,Can Regeneron maintain EPS beat run in Q3 as eye care space heats up?,Seeking Alpha,https://seekingalpha.com/news/3900058-can-regeneron-maintain-eps-beat-run-in-q3-as-eye-care-space-heats-up?utm_source=businessinsider&utm_medium=referral
1321.0,11/3/2022 10:31:52 AM,"Regeneron Pharmaceuticals Non-GAAP EPS of $11.14 beats by $1.52, revenue of $2.94B beats by $80M",Seeking Alpha,https://seekingalpha.com/news/3900659-regeneron-pharmaceuticals-non-gaap-eps-of-11_14-beats-1_52-revenue-of-2_94b-beats-80m?utm_source=businessinsider&utm_medium=referral
1322.0,11/3/2022 11:12:19 AM,Regeneron Q3 sales sans COVID products grow on back of blockbuster Eylea,Seeking Alpha,https://seekingalpha.com/news/3900728-regeneron-q3-sales-sans-covid-products-grow-on-back-of-bloackbuster-eylea?utm_source=businessinsider&utm_medium=referral
1323.0,11/3/2022 11:30:00 AM,Regeneron Reports Third Quarter 2022 Financial and Operating Results,PR Newswire,/news/stocks/regeneron-reports-third-quarter-2022-financial-and-operating-results-1031869460
1324.0,11/3/2022 11:44:23 AM,"Regeneron Pharmaceuticals Q3 Profit Decreases, but beats estimates",RTTNews,/news/stocks/regeneron-pharmaceuticals-q3-profit-decreases-but-beats-estimates-1031869538
1325.0,11/3/2022 12:12:16 PM,"US Stocks In For Another Tough Day After Fed Rate Hike As Nasdaq, S&P 500 Futures Fall — Roku, Qualcomm Plunge On Earnings Disappointment",Benzinga,/news/stocks/us-stocks-in-for-another-tough-day-after-fed-rate-hike-as-nasdaq-s-p-500-futures-fall-—-roku-qualcomm-plunge-on-earnings-disappointment-1031869714
1326.0,11/3/2022 2:00:00 PM,Regeneron Presents New Data at ASH from Advancing Hematology Pipeline across Multiple Blood Cancers and Disorders,PR Newswire,/news/stocks/regeneron-presents-new-data-at-ash-from-advancing-hematology-pipeline-across-multiple-blood-cancers-and-disorders-1031870529
1327.0,11/3/2022 9:05:00 PM,Regeneron Announces Investor Conference Presentations,PR Newswire,/news/stocks/regeneron-announces-investor-conference-presentations-1031872325
1328.0,11/4/2022 12:16:39 PM,"Analysts Conflicted on These Healthcare Names: Humana (HUM), Myriad Genetics (MYGN) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-humana-hum-myriad-genetics-mygn-and-regeneron-regn-1031875727
1329.0,11/4/2022 12:46:38 PM,"Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL), Illumina (ILMN) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-avadel-pharmaceuticals-avdl-illumina-ilmn-and-regeneron-regn-1031875849
1330.0,11/4/2022 1:56:05 PM,BMO Capital Sticks to Their Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/bmo-capital-sticks-to-their-buy-rating-for-regeneron-regn-1031876202
1331.0,11/4/2022 6:22:18 PM,7 Cash-Rich Stocks to Buy for Peace of Mind ,InvestorPlace,/news/stocks/7-cash-rich-stocks-to-buy-for-peace-of-mind-1031876991
1332.0,11/4/2022 9:04:17 PM,"Supreme Court to hear Amgen appeal on Repatha spat with Sanofi, Regeneron",Seeking Alpha,https://seekingalpha.com/news/3902317-supreme-court-to-hear-amgen-appeal-on-repatha-spat-with-sanofi-regeneron?utm_source=businessinsider&utm_medium=referral
1333.0,11/5/2022 12:30:00 AM,Aflibercept 8 mg Late-breaking Data Presented at Retina Society in Diabetic Macular Edema and Wet Age-related Macular Degeneration,PR Newswire,/news/stocks/aflibercept-8-mg-late-breaking-data-presented-at-retina-society-in-diabetic-macular-edema-and-wet-age-related-macular-degeneration-1031877286
1334.0,11/8/2022 10:41:00 PM,Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC),PR Newswire,/news/stocks/libtayo-cemiplimab-rwlc-in-combination-with-chemotherapy-approved-by-the-fda-as-first-line-treatment-for-advanced-non-small-cell-lung-cancer-nsclc-1031888646
1335.0,11/8/2022 10:52:20 PM,Regeneron's Libtayo approved as first-line advanced NSCLC treatment with chemotherapy,Seeking Alpha,https://seekingalpha.com/news/3904187-regeneron-libtayo-approved-as-first-line-advanced-nsclc-treatment-with-chemotherapy?utm_source=businessinsider&utm_medium=referral
1336.0,11/9/2022 7:18:25 PM,Regeneron pares gains after PTAB rules agains Eylea patent claims (update),Seeking Alpha,https://seekingalpha.com/news/3904717-ptab-rules-against-regeron-eylea-patent?utm_source=businessinsider&utm_medium=referral
1337.0,11/10/2022 6:36:22 PM,"Apellis, IVERIC bio cut to Hold at Jefferies; says Street overestimates GA market",Seeking Alpha,https://seekingalpha.com/news/3905875-apls-stock-isee-stock-cut-to-hold-at-jefferies-on-overestimated-ga-market?utm_source=businessinsider&utm_medium=referral
1338.0,11/11/2022 12:00:12 PM,Sanofi wins EU nod for Dupixent to include new skin condition,Seeking Alpha,https://seekingalpha.com/news/3906338-sanofi-wins-eu-nod-for-dupixent-to-include-new-skin-condition?utm_source=businessinsider&utm_medium=referral
1339.0,11/11/2022 12:30:04 PM,"EMA panel backs approval of Regeneron, Bayer's Eylea for eye disorder in infants",Seeking Alpha,https://seekingalpha.com/news/3906356-ema-panel-back-approval-of-regeneron-bayers-eylea-for-eye-disorder-in-infants?utm_source=businessinsider&utm_medium=referral
1340.0,11/11/2022 12:59:00 PM,Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis,PR Newswire,/news/stocks/dupixent-dupilumab-recommended-for-eu-approval-by-the-chmp-for-the-treatment-of-prurigo-nodularis-1031904218
1341.0,11/11/2022 1:08:05 PM,"Regeneron, Sanofi: CHMP Recommends Approval Of Dupixent In The EU ",RTTNews,/news/stocks/regeneron-sanofi-chmp-recommends-approval-of-dupixent-in-the-eu-1031904259
1342.0,11/13/2022 1:59:54 AM,U.S. COVID health emergency to stay in place,Seeking Alpha,https://seekingalpha.com/news/3906753-us-covid-health-emergency-to-stay-in-place?utm_source=businessinsider&utm_medium=referral
1343.0,11/14/2022 8:15:54 PM,4D Molecular says its wet AMD therapy cuts Eylea burden,Seeking Alpha,https://seekingalpha.com/news/3907376-fdmt-stock-spikes-as-wet-amd-therapy-cuts-eylea-burden?utm_source=businessinsider&utm_medium=referral
1344.0,11/16/2022 5:17:42 PM,"Pfizer, Roche, Lilly COVID treatments get draft recommendation from UK NHS advisors",Seeking Alpha,https://seekingalpha.com/news/3908715-pfizer-roche-lilly-covid-treatments-get-draft-recommendation-from-uk-nhs-advisors?utm_source=businessinsider&utm_medium=referral
1345.0,11/17/2022 1:50:22 AM,"Analysts Are Neutral on These Healthcare Stocks: Amgen (AMGN), Regeneron (REGN)",TipRanks,/news/stocks/analysts-are-neutral-on-these-healthcare-stocks-amgen-amgn-regeneron-regn-1031920436
1346.0,11/17/2022 1:00:00 PM,Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer,PR Newswire,/news/stocks/regeneron-and-cytomx-announce-strategic-research-collaboration-in-the-field-of-conditional-bispecific-therapeutics-for-the-treatment-of-cancer-1031921721
1347.0,11/17/2022 3:47:51 PM,Why Is CytomX Therapeutics (CTMX) Stock Up 29% Today?,InvestorPlace,/news/stocks/why-is-cytomx-therapeutics-ctmx-stock-up-29-today-1031922868
1348.0,11/18/2022 2:36:50 PM,"Cramer On This Stock Down 65% Year-To-Date: 'I Do Believe It's Bottoming, But I Don't Know What Gets It Higher'",Benzinga,/news/stocks/cramer-on-this-stock-down-65-year-to-date-i-do-believe-it-s-bottoming-but-i-don-t-know-what-gets-it-higher-1031925193
1349.0,11/22/2022 1:00:00 PM,Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy in Second Line Recurrent or Metastatic Cervical Cancer Irrespective of PD-L1 Expression Level or Tumor Histology,PR Newswire,/news/stocks/libtayo-cemiplimab-approved-by-the-european-commission-as-the-first-immunotherapy-in-second-line-recurrent-or-metastatic-cervical-cancer-irrespective-of-pd-l1-expression-level-or-tumor-histology-1031930814
1350.0,11/22/2022 1:29:14 PM,Regeneron :EC Oks Libtayo As First Immunotherapy In Second Line Recurrent/Metastatic Cervical Cancer ,RTTNews,/news/stocks/regeneron-ec-oks-libtayo-as-first-immunotherapy-in-second-line-recurrent-metastatic-cervical-cancer-1031930946
1351.0,11/24/2022 1:52:02 AM,Analysts’ Opinions Are Mixed on These Healthcare Stocks: Regeneron (REGN) and Medios AG (OtherMEDOF),TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-regeneron-regn-and-medios-ag-othermedof-1031935209
1352.0,11/30/2022 2:05:00 PM,Evkeeza® (evinacumab-dgnb) sBLA for Children with Ultra-rare Inherited Form of High Cholesterol Accepted for FDA Priority Review,PR Newswire,/news/stocks/evkeeza-evinacumab-dgnb-sbla-for-children-with-ultra-rare-inherited-form-of-high-cholesterol-accepted-for-fda-priority-review-1031944739
1353.0,11/30/2022 2:14:45 PM,Regeneron Pharma: Evkeeza SBLA Granted FDA Priority Review ,RTTNews,/news/stocks/regeneron-pharma-evkeeza-sbla-granted-fda-priority-review-1031944777
1354.0,12/1/2022 1:00:00 PM,Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo® (cemiplimab) in Multiple Solid Tumor Types,PR Newswire,/news/stocks/regeneron-esmo-io-presentations-highlight-potential-of-fianlimab-and-libtayo-cemiplimab-in-multiple-solid-tumor-types-1031947402
1355.0,12/7/2022 4:30:46 AM,"Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Ascendis Pharma (ASND) and Beam Therapeutics (BEAM)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-ascendis-pharma-asnd-and-beam-therapeutics-beam-1031956941
1356.0,12/9/2022 10:42:48 PM,Our 7 Top Biotech Stock Picks for 2023,InvestorPlace,/news/stocks/our-7-top-biotech-stock-picks-for-2023-1031963677
1357.0,12/11/2022 4:30:00 PM,Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH,PR Newswire,/news/stocks/pivotal-odronextamab-cd20xcd3-phase-2-data-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-debut-at-ash-1031964159
1358.0,12/12/2022 1:30:00 PM,Regeneron Named on Dow Jones Sustainability World Index for Fourth Consecutive Year,PR Newswire,/news/stocks/regeneron-named-on-dow-jones-sustainability-world-index-for-fourth-consecutive-year-1031965077
1359.0,12/12/2022 4:00:00 PM,Linvoseltamab (BCMAxCD3) Initial Pivotal Phase 2 Data Show Clinically Meaningful Responses in Patients with Heavily Pre-treated Multiple Myeloma,PR Newswire,/news/stocks/linvoseltamab-bcmaxcd3-initial-pivotal-phase-2-data-show-clinically-meaningful-responses-in-patients-with-heavily-pre-treated-multiple-myeloma-1031965536
1360.0,12/12/2022 6:55:43 PM,Regeneron Pharma Announces Positive Data From Mid-stage Study Of Linvoseltamab ,RTTNews,/news/stocks/regeneron-pharma-announces-positive-data-from-mid-stage-study-of-linvoseltamab-1031967418
1361.0,12/12/2022 11:30:00 PM,Odronextamab (CD20xCD3) Demonstrates High and Durable Complete Response Rate among Patients with Relapsed/Refractory Follicular Lymphoma in Pivotal Phase 2 Trial,PR Newswire,/news/stocks/odronextamab-cd20xcd3-demonstrates-high-and-durable-complete-response-rate-among-patients-with-relapsed-refractory-follicular-lymphoma-in-pivotal-phase-2-trial-1031967802
1362.0,12/15/2022 6:59:00 AM,Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis,PR Newswire,/news/stocks/dupixent-dupilumab-approved-by-european-commission-as-the-first-and-only-targeted-medicine-indicated-for-prurigo-nodularis-1031973593
1363.0,12/15/2022 7:16:19 AM,"Regeneron, Sanofi: Dupixent Approved In EU For Prurigo Nodularis ",RTTNews,/news/stocks/regeneron-sanofi-dupixent-approved-in-eu-for-prurigo-nodularis-1031973619
1364.0,12/15/2022 10:02:08 AM,"Sanofi, Regeneron Dupixent gets approval in EU for expanded use in skin disorder",Seeking Alpha,https://seekingalpha.com/news/3917422-sanofiregeneron-dupixent-gets-approval-in-eu-for-expanded-use-in-skin-disorder?utm_source=businessinsider&utm_medium=referral
1365.0,12/16/2022 5:25:33 AM,SVB Securities Keeps Their Hold Rating on Regeneron (REGN),TipRanks,/news/stocks/svb-securities-keeps-their-hold-rating-on-regeneron-regn-1031976238
1366.0,12/16/2022 1:29:00 PM,Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis,PR Newswire,/news/stocks/dupixent-dupilumab-recommended-for-eu-approval-by-the-chmp-for-the-treatment-of-eosinophilic-esophagitis-1031977148
1367.0,12/16/2022 1:58:30 PM,Regeneron: CHMP Recommends Dupixent For EU Approval To Treat Eosinophilic Esophagitis ,RTTNews,/news/stocks/regeneron-chmp-recommends-dupixent-for-eu-approval-to-treat-eosinophilic-esophagitis-1031977213
1368.0,12/16/2022 2:18:34 PM,"Sanofi, Regeneron Dupixent's expanded use gets EMA panel nod for approval in EU",Seeking Alpha,https://seekingalpha.com/news/3918011-sanofi-regeneron-dupixents-expanded-use-gets-ema-panel-nod-for-approval-in-eu?utm_source=businessinsider&utm_medium=referral
1369.0,12/19/2022 10:01:00 PM,Regeneron Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference,PR Newswire,/news/stocks/regeneron-announces-presentation-at-the-41st-annual-j-p-morgan-healthcare-conference-1031981141
1370.0,12/21/2022 11:29:00 PM,Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine,PR Newswire,/news/stocks/positive-dupixent-dupilumab-phase-3-results-in-adults-and-adolescents-with-eosinophilic-esophagitis-published-in-the-new-england-journal-of-medicine-1031985944
1371.0,12/22/2022 2:01:13 AM,Regeneron : Positive Dupixent Phase 3 Results In Eosinophilic Esophagitis Published ,RTTNews,/news/stocks/regeneron-positive-dupixent-phase-3-results-in-eosinophilic-esophagitis-published-1031986006
1372.0,12/23/2022 2:01:57 PM,Regeneron's Libtayo approved in Japan for cervical cancer,Seeking Alpha,https://seekingalpha.com/news/3920272-regeneron-libtayo-approved-in-japan-for-cervical-cancer?utm_source=businessinsider&utm_medium=referral
1373.0,12/23/2022 2:30:00 PM,Libtayo® (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical Cancer,PR Newswire,/news/stocks/libtayo-cemiplimab-approved-in-japan-for-advanced-or-recurrent-cervical-cancer-1031988846
1374.0,12/23/2022 2:39:20 PM,Regeneron Granted Marketing Authorization For Libtayo In Japan For Recurrent Cervical Cancer ,RTTNews,/news/stocks/regeneron-granted-marketing-authorization-for-libtayo-in-japan-for-recurrent-cervical-cancer-1031988858
1375.0,12/27/2022 3:11:57 PM,"Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors",Benzinga,/news/stocks/biogen-s-2nd-alzheimer-s-antibody-beigene-s-cancer-drug-label-expansion-adcom-test-for-regeneron-and-more-january-pdufa-catalysts-for-biotech-investors-1031991144
1376.0,12/29/2022 4:30:22 PM,7 Undervalued Biotech Stocks to Buy Before They Boom,InvestorPlace,/news/stocks/undervalued-biotech-stocks-1031612013
1377.0,1/5/2023 2:19:19 PM,"Regeneron, Sensei in clinical supply agreement for tumor studies",Seeking Alpha,https://seekingalpha.com/news/3922345-regeneron-sensei-in-clinical-supply-agreement-for-tumor-studies?utm_source=businessinsider&utm_medium=referral
1378.0,1/5/2023 2:23:10 PM,Sensei Biotherapeutics Enters Clinical Supply Agreement With Regeneron For Libtayo ,RTTNews,/news/stocks/sensei-biotherapeutics-enters-clinical-supply-agreement-with-regeneron-for-libtayo-1032002045
1379.0,1/6/2023 3:42:41 AM,Jim Cramer Says He's 'Still Feeling Good' About These 5 Stocks From 'Mutilated' Nasdaq,Benzinga,/news/stocks/jim-cramer-says-he-s-still-feeling-good-about-these-5-stocks-from-mutilated-nasdaq-1032003315
1380.0,1/6/2023 11:26:24 PM,5 Top Pharma Stocks of 2022 to Buy for the Long Haul,InvestorPlace,/news/stocks/5-top-pharma-stocks-of-2022-to-buy-for-the-long-haul-1032005182
1381.0,1/7/2023 1:50:17 AM,"Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Regeneron (REGN) and Illumina (ILMN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-alnylam-pharma-alny-regeneron-regn-and-illumina-ilmn-1032005207
1382.0,1/9/2023 4:16:27 PM,Coherus stock dips amid deal to acquire US rights to Eylea biosimilar FYB203,Seeking Alpha,https://seekingalpha.com/news/3923032-coherus-stock-dips-amid-deal-to-acquire-rights-to-eylea-biosimilar-fyb203?utm_source=businessinsider&utm_medium=referral
1383.0,1/9/2023 5:49:29 PM,Regeneron slips after $0.21 per share impact to Q4 2022 earnings,Seeking Alpha,https://seekingalpha.com/news/3923069-regn-stock-slips-after-impact-to-q4-2022-earnings?utm_source=businessinsider&utm_medium=referral
1384.0,1/11/2023 12:30:30 PM,Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and Halozyme (HALO),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-and-halozyme-halo-1032012114
1385.0,1/11/2023 2:40:32 PM,"Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), AbbVie (ABBV) and Establishment Labs Holdings (ESTA)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-abbvie-abbv-and-establishment-labs-holdings-esta-1032012560
1386.0,1/11/2023 5:00:32 PM,Analyst Ratings for Regeneron Pharmaceuticals,Benzinga,/news/stocks/analyst-ratings-for-regeneron-pharmaceuticals-1032012807
1387.0,1/11/2023 8:35:28 PM,Medicare to publish drugs targeted for pricing negotiations in September,Seeking Alpha,https://seekingalpha.com/news/3923880-medicare-publish-drugs-targeted-pricing-negotiations-in-september?utm_source=businessinsider&utm_medium=referral
1388.0,1/12/2023 5:31:02 AM,"Analysts Conflicted on These Healthcare Names: Regeneron (REGN), Illumina (ILMN) and Dexcom (DXCM)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-regeneron-regn-illumina-ilmn-and-dexcom-dxcm-1032013960
1389.0,1/13/2023 5:23:21 PM,"WHO updates COVID-19 guidelines on masks, treatments",Seeking Alpha,https://seekingalpha.com/news/3924561-who-updates-covid-19-guidelines-on-masks-treatments?utm_source=businessinsider&utm_medium=referral
1390.0,1/17/2023 1:50:31 AM,Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN) and Teleflex (TFX),TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-regeneron-regn-and-teleflex-tfx-1032021083
1391.0,1/20/2023 1:38:18 PM,Regeneron upgraded at JPMorgan on upcoming catalysts,Seeking Alpha,https://seekingalpha.com/news/3926311-regn-stock-upgraded-at-jpmorgan-on-upcoming-catalysts?utm_source=businessinsider&utm_medium=referral
1392.0,1/20/2023 4:00:43 PM,"Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-january-20-2023-1032031061
1393.0,1/22/2023 5:00:19 PM,Global drug spending to reach $1.9T by 2027 – IQVIA,Seeking Alpha,https://seekingalpha.com/news/3926554-global-drug-spending-reach-usd-two-trillion-2027-iqvia?utm_source=businessinsider&utm_medium=referral
1394.0,1/24/2023 12:48:17 PM,"Decibel, Regeneron get UK regulator nod to start trial of hearing loss gene therapy",Seeking Alpha,https://seekingalpha.com/news/3927084-decibel-regeneron-get-uk-regulator-nod-to-start-trial-of-hearing-loss-gene-therapy?utm_source=businessinsider&utm_medium=referral
1395.0,1/24/2023 4:30:18 PM,Analysts Conflicted on These Healthcare Names: Regeneron (REGN) and Revance Therapeutics (RVNC),TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-regeneron-regn-and-revance-therapeutics-rvnc-1032037532
1396.0,1/24/2023 6:02:00 PM,"Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation's Oldest and Most Prestigious Science and Math Competition",PR Newswire,/news/stocks/top-40-high-school-scientists-selected-as-finalists-in-the-regeneron-science-talent-search-the-nation-s-oldest-and-most-prestigious-science-and-math-competition-1032037590
1397.0,1/27/2023 9:30:24 AM,"Sanofi, Regeneron Dupixent gets EMA panel nod to treat eczema in kids under 5",Seeking Alpha,https://seekingalpha.com/news/3928835-sanofi-regeneron-dupixent-gets-ema-panel-nod-to-treat-eczema-in-kids-under-5?utm_source=businessinsider&utm_medium=referral
1398.0,1/27/2023 2:47:08 PM,Regeneron Pharma: CHMP Adopts Positive Opinion For Dupixent ,RTTNews,/news/stocks/regeneron-pharma-chmp-adopts-positive-opinion-for-dupixent-1032046779
1399.0,1/27/2023 5:55:12 PM,"Earnings week ahead: Amazon, Apple, Meta, Alphabet, ExxonMobil, GM, AMD and more",Seeking Alpha,https://seekingalpha.com/news/3929027-earnings-week-ahead-amazon-apple-meta-alphabet-exxonmobil-gm-amd-and-more?utm_source=businessinsider&utm_medium=referral
1400.0,1/29/2023 12:18:56 PM,Biotech Stocks Facing FDA Decision In February 2023 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-february-2023-1032048270
1401.0,1/29/2023 11:25:33 PM,"Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch",Benzinga,/news/stocks/can-market-sustain-upward-momentum-in-tech-heavy-earnings-week-apple-amazon-amd-alphabet-ford-among-key-quarterly-reports-to-watch-1032048678
1402.0,1/30/2023 9:26:14 AM,"Sanofi, Regeneron Dupixent gets approval in EU for expanded use in eosinophilic esophagitis",Seeking Alpha,https://seekingalpha.com/news/3929244-sanofi-regeneron-dupixent-gets-approval-in-eu-for-expanded-use-in-eosinophilic-esophagitis?utm_source=businessinsider&utm_medium=referral
1403.0,1/30/2023 2:50:33 PM,Regeneron upgraded at Cowen on potential of high dose Eylea,Seeking Alpha,https://seekingalpha.com/news/3929389-regn-stock-upgraded-cowen-potential-high-dose-eylea?utm_source=businessinsider&utm_medium=referral
1404.0,1/30/2023 3:00:46 PM,What 8 Analyst Ratings Have To Say About Regeneron Pharmaceuticals,Benzinga,/news/stocks/what-8-analyst-ratings-have-to-say-about-regeneron-pharmaceuticals-1032051072
1405.0,1/30/2023 4:00:50 PM,"Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-january-30-2023-1032051242
1406.0,1/31/2023 12:10:35 AM,7 CRISPR Stocks With the Best Long-Term Potential ,InvestorPlace,/news/stocks/7-crispr-stocks-with-the-best-long-term-potential-1032052123
1407.0,1/31/2023 8:33:01 PM,"February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More",Benzinga,/news/stocks/february-pdufa-catalysts-biotech-investors-must-know-sanofi-s-bleeding-disorder-drug-regeneron-s-twin-eylea-label-expansions-3-delayed-approvals-and-more-1032055559
1408.0,2/1/2023 7:07:28 PM,"Editas, Beam win bullish views as Cantor launches gene editing coverage",Seeking Alpha,https://seekingalpha.com/news/3930688-edit-stock-beam-stock-bullish-views-cantor-gene-editing?utm_source=businessinsider&utm_medium=referral
1409.0,2/1/2023 9:10:43 PM,The 7 Most Undervalued Nasdaq Stocks to Buy in February 2023,InvestorPlace,/news/stocks/the-7-most-undervalued-nasdaq-stocks-to-buy-in-february-2023-1032060416
1410.0,2/2/2023 1:12:31 PM,Clearside gains 12% as eye disease therapy cuts need for additional treatment,Seeking Alpha,https://seekingalpha.com/news/3931204-clsd-stock-gains-eye-disease-therapy-cuts-additional-treatment?utm_source=businessinsider&utm_medium=referral
1411.0,2/2/2023 3:01:13 PM,Regeneron Pharmaceuticals earnings: here's what to expect,Markets Insider Automation,/news/stocks/regeneron-stock-price-q4-earnings-preview-1032062955
1412.0,2/2/2023 3:29:38 PM,Notable earnings before Friday's open,Seeking Alpha,https://seekingalpha.com/news/3931310-notable-earnings-before-fridays-open?utm_source=businessinsider&utm_medium=referral
1413.0,2/2/2023 4:31:00 PM,"All eyes on Regeneron Q4 results with focus on blockbusters Dupixent, Eylea",Seeking Alpha,https://seekingalpha.com/news/3931344-all-eyes-on-regeneron-q4-results-with-focus-on-blockbusters-dupixent-eylea?utm_source=businessinsider&utm_medium=referral
1414.0,2/2/2023 7:19:39 PM,The 7 Most Undervalued Biotech Stocks to Buy in February 2023,InvestorPlace,/news/stocks/the-7-most-undervalued-biotech-stocks-to-buy-in-february-2023-1032063992
1415.0,2/2/2023 8:19:36 PM,The 7 Most Undervalued Stocks to Buy in February 2023,InvestorPlace,/news/stocks/the-7-most-undervalued-stocks-to-buy-in-february-2023-1032064059
1416.0,2/3/2023 10:13:13 AM,Sanofi stock dips as Q4 revenue grows but vaccine sales fall; Dupixent drives moderate profit outlook,Seeking Alpha,https://seekingalpha.com/news/3931721-sanofi-q4-revenue-grows-on-dupixent-but-vaccine-sales-fall-dupixent-demand-drives-modes-profit-outlook?utm_source=businessinsider&utm_medium=referral
1417.0,2/3/2023 11:05:12 AM,Bank of America Securities Keeps Their Sell Rating on Regeneron (REGN),TipRanks,/news/stocks/bank-of-america-securities-keeps-their-sell-rating-on-regeneron-regn-1032065675
1418.0,2/3/2023 11:34:18 AM,Regeneron Pharmaceuticals reports Q4 earnings beat; initiates FY23 guidance,Seeking Alpha,https://seekingalpha.com/news/3931749-regeneron-pharmaceuticals-reports-q4-earnings-beat-initiates-fy23-guidance?utm_source=businessinsider&utm_medium=referral
1419.0,2/3/2023 12:28:01 PM,Regeneron posts Q4 beat as COVID therapy offsets Eylea impact,Seeking Alpha,https://seekingalpha.com/news/3931776-regeneron-posts-q4-beat-as-covid-therapy-offsets-eylea-impact?utm_source=businessinsider&utm_medium=referral
1420.0,2/3/2023 12:40:40 PM,Regeneron Pharmaceuticals Q4 Profit Declines,RTTNews,/news/stocks/regeneron-pharmaceuticals-q4-profit-declines-1032065770
1421.0,2/3/2023 1:03:43 PM,Regeneron Pharma Q4 Profit Declines; Adj. Total Revenues Up 14% ,RTTNews,/news/stocks/regeneron-pharma-q4-profit-declines-adj-total-revenues-up-14-1032065817
1422.0,2/3/2023 5:00:21 PM,4D Molecular cleared to start mid-stage trial for diabetic macular edema candidate,Seeking Alpha,https://seekingalpha.com/news/3931754-fdmt-stock-gains-as-fda-clears-mid-stage-diabetic-macular-edema-trial?utm_source=businessinsider&utm_medium=referral
1423.0,2/3/2023 7:30:12 PM,"Catalyst watch: Google talks AI, Nordstrom drama and Canada Goose event",Seeking Alpha,https://seekingalpha.com/news/3931946-catalyst-watch-google-talks-ai-nordstrom-drama-and-canada-goose-event?utm_source=businessinsider&utm_medium=referral
1424.0,2/5/2023 5:00:57 PM,Drug price inflation continues upward momentum at 3.8% – report,Seeking Alpha,https://seekingalpha.com/news/3932101-drug-price-inflation-continues-upward-momentum-at-38-report?utm_source=businessinsider&utm_medium=referral
1425.0,2/6/2023 12:06:13 PM,BMO Capital Releases a Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/bmo-capital-releases-a-buy-rating-on-regeneron-regn-1032070060
1426.0,2/6/2023 12:10:37 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032070049
1427.0,2/6/2023 12:30:37 PM,"Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Genmab (GMAB) and Immunovant (IMVT)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-genmab-gmab-and-immunovant-imvt-1032070133
1428.0,2/6/2023 4:31:12 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Regeneron (REGN) and Seagen (SGEN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-regeneron-regn-and-seagen-sgen-1032070948
1429.0,2/7/2023 10:03:22 AM,Bayer files for approval of high/extended dosing regimens of Eylea in EU,Seeking Alpha,https://seekingalpha.com/news/3932692-bayer-files-for-approval-of-highextended-dosing-regimens-of-eylea-in-eu?utm_source=businessinsider&utm_medium=referral
1430.0,2/7/2023 6:51:59 PM,The 7 Best Biotech Stocks to Buy for February 2023,InvestorPlace,/news/stocks/the-7-best-biotech-stocks-to-buy-for-february-2023-1032075170
1431.0,2/9/2023 12:47:18 PM,Regeneron wins FDA nod for Eylea to prevent infant blindness,Seeking Alpha,https://seekingalpha.com/news/3934169-regeneron-wins-fda-nod-eylea-prevent-infant-blindness?utm_source=businessinsider&utm_medium=referral
1432.0,2/10/2023 10:29:24 AM,Roche Vabysmo matches Eylea in 2 phase 3 trials for eye disorder,Seeking Alpha,https://seekingalpha.com/news/3934689-roche-vabysmo-matches-eylea-in-2-phase-3-trials-for-eye-disorder?utm_source=businessinsider&utm_medium=referral
1433.0,2/13/2023 10:05:21 AM,Ocular stock rises ~15% as eye drug implant shows promise in ongoing phase 1 trial,Seeking Alpha,https://seekingalpha.com/news/3935085-ocular-stock-rises-15-as-eye-drug-implant-shows-promise-in-ongoing-phase-1-trial?utm_source=businessinsider&utm_medium=referral
1434.0,2/13/2023 7:49:54 PM,ARK Invest: The 7 Words That Explain Why Wall Street Can’t Stand Cathie Wood,InvestorPlace,/news/stocks/ark-invest-the-7-words-that-explain-why-wall-street-cant-stand-cathie-wood-1032092169
1435.0,2/16/2023 1:52:22 PM,"3 Super Profitable S&P 500 Stocks to Buy, Other Than ExxonMobil",TipRanks,/news/stocks/3-super-profitable-s-p-500-stocks-to-buy-other-than-exxonmobil-1032102851
1436.0,2/17/2023 4:31:25 PM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Bio-Rad Laboratories (BIO), Shockwave Medical (SWAV) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-bio-rad-laboratories-bio-shockwave-medical-swav-and-regeneron-regn-1032106651
1437.0,2/19/2023 5:00:10 PM,The next big wave of patent cliffs is ahead; expect biopharma M&A to rise – report,Seeking Alpha,https://seekingalpha.com/news/3937885-next-big-wave-of-patent-cliffs-ahead-biopharma-m-and-a-to-rise?utm_source=businessinsider&utm_medium=referral
1438.0,2/21/2023 2:04:53 PM,Regeneron Pharma: FDA Accepts For Priority Review BLA For Pozelimab ,RTTNews,/news/stocks/regeneron-pharma-fda-accepts-for-priority-review-bla-for-pozelimab-1032111460
1439.0,2/23/2023 1:24:06 PM,Regeneron's high-dose Eylea application accepted for FDA priority review,Seeking Alpha,https://seekingalpha.com/news/3939903-regeneron-high-dose-eylea-application-accepted-for-fda-priority-review?utm_source=businessinsider&utm_medium=referral
1440.0,2/23/2023 1:42:01 PM,"Intellia, Novartis end gene editing partnership for sickle cell disease",Seeking Alpha,https://seekingalpha.com/news/3939919-intellia-novartis-end-gene-editing-partnership-for-sickle-cell-disease?utm_source=businessinsider&utm_medium=referral
1441.0,2/24/2023 12:30:18 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032123469
1442.0,2/24/2023 1:53:45 PM,Regeneron wins EU nod for Libtayo in PD-L1 positive lung cancer,Seeking Alpha,https://seekingalpha.com/news/3940635-regeneron-wins-eu-nod-libtayo-in-pd-l1-positive-lung-cancer?utm_source=businessinsider&utm_medium=referral
1443.0,2/25/2023 9:00:00 PM,"Pharmas, medtechs dominate list of innovation leaders thanks to patents",Seeking Alpha,https://seekingalpha.com/news/3940793-pharmas-medtechs-dominate-list-of-innovation-leaders-thanks-to-patents?utm_source=businessinsider&utm_medium=referral
1444.0,2/27/2023 7:42:19 PM,Replimune ends selloff after FDA response to mid-stage cancer trial,Seeking Alpha,https://seekingalpha.com/news/3941352-repl-stock-ends-selloff-fda-response-mid-stage-cancer-trial?utm_source=businessinsider&utm_medium=referral
1445.0,2/28/2023 9:45:54 AM,Biotech Stocks Facing FDA Decision In March 2023 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-march-2023-1032130420
1446.0,2/28/2023 10:43:10 AM,"Bayer's Q4 sales grow on back of crop products, pharma declines; FY23 EPS to see impact",Seeking Alpha,https://seekingalpha.com/news/3941611-bayers-q4-sales-grow-on-back-of-crop-products-pharma-declines-fy23-eps-to-see-impact?utm_source=businessinsider&utm_medium=referral
1447.0,3/1/2023 2:44:23 AM,FDA Approves Regeneron's Kevzara To Treat Inflammatory Rheumatic Disease ,RTTNews,/news/stocks/fda-approves-regeneron-s-kevzara-to-treat-inflammatory-rheumatic-disease-1032133644
1448.0,3/1/2023 9:36:47 AM,Bayer files for approval of high dose Eylea in Japan,Seeking Alpha,https://seekingalpha.com/news/3942383-bayer-files-for-approval-of-high-dose-eylea-in-japan?utm_source=businessinsider&utm_medium=referral
1449.0,3/6/2023 7:11:36 AM,Roche Announces FDA Approval Of Label Expansion For VENTANA PD-L1 Assay ,RTTNews,/news/stocks/roche-announces-fda-approval-of-label-expansion-for-ventana-pd-l1-assay-1032146267
1450.0,3/6/2023 6:45:59 PM,Merck to start phase 3 of oral PCSK9 inhibitor for cholesterol following mid-stage results,Seeking Alpha,https://seekingalpha.com/news/3944574-merck-to-start-phase-3-of-oral-pcsk9-inhibitor-for-cholesterol-following-mid-stage-results?utm_source=businessinsider&utm_medium=referral
1451.0,3/7/2023 11:39:11 AM,FDA accepts for review Regeneron/Sanofi's Dupixent application for inflammatory skin condition,Seeking Alpha,https://seekingalpha.com/news/3944785-fda-accepts-for-review-regeneronsanofis-dupixent-application-for-inflammatory-skin-condition?utm_source=businessinsider&utm_medium=referral
1452.0,3/9/2023 3:01:33 PM,Where Regeneron Pharmaceuticals Stands With Analysts,Benzinga,/news/stocks/where-regeneron-pharmaceuticals-stands-with-analysts-1032157025
1453.0,3/9/2023 6:55:10 PM,Biden budget to save $160B by allowing Medicare to negotiate prices for more drugs,Seeking Alpha,https://seekingalpha.com/news/3946094-biden-budget-to-save-160b-by-allowing-medicare-to-negotiate-prices-for-more-drugs?utm_source=businessinsider&utm_medium=referral
1454.0,3/13/2023 9:20:07 AM,Analysts’ Opinions Are Mixed on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD) and Regeneron (REGN),TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-acadia-pharmaceuticals-acad-and-regeneron-regn-1032162542
1455.0,3/15/2023 3:56:00 AM,"Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease",PR Newswire,/news/stocks/students-win-more-than-1-8-million-at-2023-regeneron-science-talent-search-for-remarkable-scientific-research-on-rna-molecule-structure-media-bias-and-diagnostics-for-pediatric-heart-disease-1032167769
1456.0,3/15/2023 3:31:39 PM,The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector,InvestorPlace,/news/stocks/the-7-best-biotech-etfs-to-buy-for-exposure-to-the-healthcare-sector-1032170074
1457.0,3/19/2023 7:47:43 PM,Easing COVID pandemic sees many pharmas seeking alternate revenue streams,Seeking Alpha,https://seekingalpha.com/news/3948704-easing-covid-pandemic-pfizer-astrazeneca-seeking-alternate-revenue-streams?utm_source=businessinsider&utm_medium=referral
1458.0,3/21/2023 7:47:44 AM,Sanofi : EU Approves Dupixent To Treat Severe Atopic Dermatitis In Children ,RTTNews,/news/stocks/sanofi-eu-approves-dupixent-to-treat-severe-atopic-dermatitis-in-children-1032180870
1459.0,3/21/2023 8:33:15 AM,Sanofi and Regeneron's Dupixent gets approval in EU to treat eczema in kids over 6 months,Seeking Alpha,https://seekingalpha.com/news/3949321-sanofi-regeneron-dupixent-gets-approval-in-eu-to-treat-eczema-in-kids-over-6-months?utm_source=businessinsider&utm_medium=referral
1460.0,3/22/2023 11:54:23 AM,Regeneron gets FDA approval for expanded use of high cholesterol drug Evkeeza in kids,Seeking Alpha,https://seekingalpha.com/news/3949847-regeneron-gets-fda-approval-for-expanded-use-of-high-cholesterol-drug-evkeeza-in-kids?utm_source=businessinsider&utm_medium=referral
1461.0,3/22/2023 1:00:52 PM,Regeneron : FDA Approves Evkeeza To Treat Ultra-rare Form Of High Cholesterol In Young Children ,RTTNews,/news/stocks/regeneron-fda-approves-evkeeza-to-treat-ultra-rare-form-of-high-cholesterol-in-young-children-1032184634
1462.0,3/22/2023 7:46:16 PM,7 Value Stocks Worth Buying at These 52-Week Highs,InvestorPlace,/news/stocks/7-value-stocks-worth-buying-at-these-52-week-highs-1032185977
1463.0,3/23/2023 9:31:06 AM,"Sanofi stock rises as Dupixent shows benefit in lung disease smokers, meets phase 3 goals",Seeking Alpha,https://seekingalpha.com/news/3950240-sanofi-stock-rises-as-dupixent-shows-benefit-in-lung-disease-smokers-meets-phase-3-goals?utm_source=businessinsider&utm_medium=referral
1464.0,3/23/2023 12:30:32 PM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Regeneron (REGN) and Alcon (ALC)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-regeneron-regn-and-alcon-alc-1032187724
1465.0,3/23/2023 2:43:13 PM,REGN Stock Alert: Regeneron Pharmaceuticals Gains on Dupixent Drug Data,InvestorPlace,/news/stocks/regn-stock-alert-regeneron-pharmaceuticals-gains-on-dupixent-drug-data-1032188385
1466.0,3/23/2023 3:07:27 PM,"Regeneron up 7% following Dupixent data, Raymond James upgrade",Seeking Alpha,https://seekingalpha.com/news/3950434-regeneron-up-7-following-dupixent-data-raymond-james-upgrade?utm_source=businessinsider&utm_medium=referral
1467.0,3/23/2023 3:10:20 PM,Why Are Stocks Up Today?,InvestorPlace,/news/stocks/why-are-stocks-up-today-march-23-1032188383
1468.0,3/24/2023 10:05:33 AM,Bank of America Securities Keeps Their Sell Rating on Regeneron (REGN),TipRanks,/news/stocks/bank-of-america-securities-keeps-their-sell-rating-on-regeneron-regn-1032190347
1469.0,3/24/2023 10:25:47 AM,Morgan Stanley Reaffirms Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/morgan-stanley-reaffirms-their-buy-rating-on-regeneron-regn-1032190388
1470.0,3/24/2023 12:12:26 PM,US Stocks Cautiously Rebound Amid Positive Economic Data Following Banking Stocks Selloff,Benzinga,/news/stocks/us-stocks-on-track-for-weak-start-friday-amid-renewed-banking-concerns-and-contagion-fears-1032190537
1471.0,3/24/2023 12:44:10 PM,Regeneron draws more bullish views from analysts after Dupixent COPD data,Seeking Alpha,https://seekingalpha.com/news/3950893-regeneron-stock-wins-bullish-views-on-dupixent-data?utm_source=businessinsider&utm_medium=referral
1472.0,3/24/2023 3:09:48 PM,Regeneron Pharmaceuticals Analysts React To Drug Trial Results: Why Whales Are Diving In,Benzinga,/news/stocks/regeneron-pharmaceuticals-analysts-react-to-drug-trial-results-why-whales-are-diving-in-1032191074
1473.0,3/24/2023 4:00:26 PM,"Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-march-24-2023-1032191210
1474.0,3/24/2023 6:00:31 PM,Baird Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know,Benzinga,/news/stocks/baird-maintains-neutral-rating-for-regeneron-pharmaceuticals-here-s-what-you-need-to-know-1032191500
1475.0,3/27/2023 12:32:38 PM,Unity Biotech sheds 48% after mid-stage setback for wet AMD candidate,Seeking Alpha,https://seekingalpha.com/news/3951420-unity-biotech-stock-falls-phase-2-data-wet-amd-data?utm_source=businessinsider&utm_medium=referral
1476.0,3/27/2023 1:38:55 PM,Pinterest To Rally Over 27%? Here Are 10 Other Analyst Forecasts For Monday,Benzinga,/news/stocks/pinterest-to-rally-over-27-here-are-10-other-analyst-forecasts-for-monday-1032193749
1477.0,3/27/2023 3:00:55 PM,Analyst Ratings for Regeneron Pharmaceuticals,Benzinga,/news/stocks/analyst-ratings-for-regeneron-pharmaceuticals-1032194136
1478.0,3/27/2023 5:00:30 PM,"Benzinga's Top Ratings Upgrades, Downgrades For March 27, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-march-27-2023-1032194547
1479.0,3/27/2023 5:45:10 PM,Supreme Court hears arguments in Amgen Repatha patent case against Sanofi,Seeking Alpha,https://seekingalpha.com/news/3951571-supreme-court-arguments-repatha-patent-case-sanofi-regeneron?utm_source=businessinsider&utm_medium=referral
1480.0,3/28/2023 10:26:08 AM,RBC Capital Reaffirms Their Hold Rating on Regeneron (REGN),TipRanks,/news/stocks/rbc-capital-reaffirms-their-hold-rating-on-regeneron-regn-1032196477
1481.0,3/28/2023 12:52:07 PM,Regeneron to pay Sonoma $75M upfront in pact to develop autoimmune disease drugs,Seeking Alpha,https://seekingalpha.com/news/3951840-regeneron-pay-sonoma-75m-upfront--pact--develop-autoimmune-disease-drugs?utm_source=businessinsider&utm_medium=referral
1482.0,3/28/2023 2:16:08 PM,Regeneron Partners With Sonoma Biotherapeutics To Develop T Cell Therapies ,RTTNews,/news/stocks/regeneron-partners-with-sonoma-biotherapeutics-to-develop-t-cell-therapies-1032196979
1483.0,3/29/2023 9:26:13 AM,"Amgen, AstraZeneca's asthma therapy Tezspire gets UK's NICE backing",Seeking Alpha,https://seekingalpha.com/news/3952134-amgen-astrazenecas-asthma-therapy-tezspire-gets-uks-nice-backing?utm_source=businessinsider&utm_medium=referral
1484.0,3/29/2023 9:50:30 AM,"Analysts Conflicted on These Healthcare Names: Regeneron (REGN), Intra-Cellular Therapies (ITCI) and uniQure (QURE)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-regeneron-regn-intra-cellular-therapies-itci-and-uniqure-qure-1032199702
1485.0,3/29/2023 11:31:48 AM,Regeneron Libtayo gets expanded approval in EU for lung cancer subtype,Seeking Alpha,https://seekingalpha.com/news/3952178-regeneron-libtayo-gets-expanded-approval-eu-lung-cancer?utm_source=businessinsider&utm_medium=referral
1486.0,3/30/2023 11:17:56 AM,Regeneron in research agreement with Xeris Biopharma,Seeking Alpha,https://seekingalpha.com/news/3952622-xeris-biopharma--stock-in-research-pact-with-regeneron?utm_source=businessinsider&utm_medium=referral
1487.0,3/31/2023 2:44:21 PM,NVIDIA To Rally Around 18%? Here Are 10 Other Analyst Forecasts For Friday,Benzinga,/news/stocks/nvidia-to-rally-around-18-here-are-10-other-analyst-forecasts-for-friday-1032207050
1488.0,3/31/2023 7:00:31 PM,JP Morgan Maintains Overweight Rating for Regeneron Pharmaceuticals: Here's What You Need To Know,Benzinga,/news/stocks/jp-morgan-maintains-overweight-rating-for-regeneron-pharmaceuticals-here-s-what-you-need-to-know-1032207929
1489.0,4/8/2023 1:50:26 AM,"Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Amgen (AMGN) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-alnylam-pharma-alny-amgen-amgn-and-regeneron-regn-1032220940
1490.0,4/10/2023 11:33:47 AM,Regeneron Pharmaceuticals Q1 one-off charges to be ~$56M,Seeking Alpha,https://seekingalpha.com/news/3955244-regeneron-pharmaceuticals-q1-one-off-charges-to-be-56m?utm_source=businessinsider&utm_medium=referral
1491.0,4/11/2023 2:25:44 AM,U.S. launches $5B program to speed up development of next-gen COVID vaccines,Seeking Alpha,https://seekingalpha.com/news/3955481-us-launches-5b-program-develop-next-gen-covid-vaccines?utm_source=businessinsider&utm_medium=referral
1492.0,4/12/2023 9:10:09 PM,S&P 500 will see 11% upside from the current levels - Piper Sandler's Craig Johnson,Seeking Alpha,https://seekingalpha.com/news/3956043-sp-500-will-see-11-upside-from-the-current-levels-piper-sandlers-craig-johnson?utm_source=businessinsider&utm_medium=referral
1493.0,4/13/2023 3:54:32 PM,Intellia up 12% as Canaccord starts with Buy citing gene editing approach,Seeking Alpha,https://seekingalpha.com/news/3956345-intellia-stock-gain-canaccord-starts-with-buy?utm_source=businessinsider&utm_medium=referral
1494.0,4/14/2023 9:32:00 AM,Ghana 1st in world to approve new malaria vaccine by Oxford,Seeking Alpha,https://seekingalpha.com/news/3956507-ghana-1st-in-world-approve-new-malaria-vaccine-oxford?utm_source=businessinsider&utm_medium=referral
1495.0,4/18/2023 12:40:43 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032239603
1496.0,4/19/2023 6:12:13 AM,"Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), UnitedHealth (UNH) and Sarepta Therapeutics (SRPT)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-unitedhealth-unh-and-sarepta-therapeutics-srpt-1032242384
1497.0,4/20/2023 12:18:28 PM,Sensei gains FDA IND clearance for solid tumors candidate,Seeking Alpha,https://seekingalpha.com/news/3958192-sensei-gains-fda-ind-clearance-solid-tumors-candidate?utm_source=businessinsider&utm_medium=referral
1498.0,4/20/2023 12:35:27 PM,Jefferies Reaffirms Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/jefferies-reaffirms-their-buy-rating-on-regeneron-regn-1032246879
1499.0,4/20/2023 5:07:09 PM,The Greatest 7 Blue-Chip Stocks to Buy for Your Portfolio,InvestorPlace,/news/stocks/the-greatest-7-blue-chip-stocks-to-buy-for-your-portfolio-1032247873
1500.0,4/26/2023 10:30:22 AM,"Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Akebia Therapeutics (AKBA) and Panbela Therapeutics (PBLA)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-akebia-therapeutics-akba-and-panbela-therapeutics-pbla-1032262756
1501.0,4/26/2023 5:21:35 PM,Democratic senators introduce bill to enhance CMS drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/3960629-democratic-senators-introduce-bill-enhance-cms-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral
1502.0,4/26/2023 9:15:43 PM,"Partial clinical hold placed on Alnylam, Regeneron RNAi Alzheimer's candidate",Seeking Alpha,https://seekingalpha.com/news/3960979-partial-clinical-hold-placed-alnylam-regeneron-rnai-alzheimers-candidate?utm_source=businessinsider&utm_medium=referral
1503.0,4/27/2023 10:08:25 AM,Sanofi Q1 profit climbs on Dupixent as drug on track for €10B this year,Seeking Alpha,https://seekingalpha.com/news/3961128-sanofi-q1-profit-climbs-on-back-of-dupixent-drug-to-see-10b-this-year?utm_source=businessinsider&utm_medium=referral
1504.0,4/27/2023 11:20:32 AM,"Analysts Are Bullish on Top Healthcare Stocks: Edwards Lifesciences (EW), Humana (HUM)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-edwards-lifesciences-ew-humana-hum-1032268206
1505.0,5/1/2023 12:40:13 PM,"Analysts Offer Insights on Healthcare Companies: TG Therapeutics (TGTX), PTC Therapeutics (PTCT) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-tg-therapeutics-tgtx-ptc-therapeutics-ptct-and-regeneron-regn-1032277966
1506.0,5/1/2023 2:04:48 PM,Where Regeneron Pharmaceuticals Stands With Analysts,Benzinga,/news/stocks/where-regeneron-pharmaceuticals-stands-with-analysts-1032277869
1507.0,5/3/2023 5:37:49 PM,Regeneron Pharmaceuticals Q1 2023 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3964750-regeneron-pharmaceuticals-q1-2023-earnings-preview?utm_source=businessinsider&utm_medium=referral
1508.0,5/3/2023 5:59:06 PM,"Regeneron looks to strong Dupixent, Eylea sales in Q1 report",Seeking Alpha,https://seekingalpha.com/news/3964570-regeneron-looks-strong-eylea-dupixent-sales-q1-report?utm_source=businessinsider&utm_medium=referral
1509.0,5/4/2023 10:32:01 AM,"Regeneron Pharmaceuticals Non-GAAP EPS of $10.09 beats by $0.53, revenue of $3.16B beats by $160M",Seeking Alpha,https://seekingalpha.com/news/3965407-regeneron-pharmaceuticals-non-gaap-eps-of-10_09-beats-0_53-revenue-of-3_16b-beats-160m?utm_source=businessinsider&utm_medium=referral
1510.0,5/4/2023 11:29:02 AM,Regeneron stock dips amid decline in Eylea sales despite Q1 beat,Seeking Alpha,https://seekingalpha.com/news/3965508-regeneron-stock-dips-amid-decline-in-eylea-sales-despite-q1-beat?utm_source=businessinsider&utm_medium=referral
1511.0,5/4/2023 12:43:10 PM,"Regeneron Pharmaceuticals Q1 Profit Decreases, but beats estimates",RTTNews,/news/stocks/regeneron-pharmaceuticals-q1-profit-decreases-but-beats-estimates-1032291867
1512.0,5/5/2023 3:35:06 AM,Goldman Sachs Keeps Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/goldman-sachs-keeps-their-buy-rating-on-regeneron-regn-1032294779
1513.0,5/5/2023 10:30:20 AM,"Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Regeneron (REGN) and Puma Biotechnology (PBYI)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-cytokinetics-cytk-regeneron-regn-and-puma-biotechnology-pbyi-1032296794
1514.0,5/5/2023 11:40:19 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Ultragenyx Pharmaceutical (RARE) and Surface Oncology (SURF)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-regeneron-regn-ultragenyx-pharmaceutical-rare-and-surface-oncology-surf-1032297076
1515.0,5/5/2023 12:20:28 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032297355
1516.0,5/8/2023 4:31:16 PM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Karuna Therapeutics (KRTX) and Pennant Group (PNTG)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-regeneron-regn-karuna-therapeutics-krtx-and-pennant-group-pntg-1032303160
1517.0,5/10/2023 10:21:20 AM,"Alvotech, Polifarma ink pact to sell potential Eylea biosimilar in Turkey",Seeking Alpha,https://seekingalpha.com/news/3968900-alvotech-polifarma-ink-pact-to-sell-potential-eylea-biosimilar-in-turkey?utm_source=businessinsider&utm_medium=referral
1518.0,5/11/2023 9:22:44 AM,"Bayer Q1 sales dips as crop, pharma segments decline; glyphosate prices weigh on outlook",Seeking Alpha,https://seekingalpha.com/news/3969835-bayer-q1-sales-dips-as-crop-pharma-fall-glyphosate-weigh-on-outlook?utm_source=businessinsider&utm_medium=referral
1519.0,5/12/2023 11:58:17 AM,"Regeneron, Decibel's hearing loss gene therapy trial application gets approval in Spain",Seeking Alpha,https://seekingalpha.com/news/3970742-regeneron-decibels-hearing-loss-gene-therapy-trial-application-gets-approval-in-spain?utm_source=businessinsider&utm_medium=referral
1520.0,5/12/2023 5:11:43 PM,AI-Run ETF Dumps Apple In Favor Of This Chip Stock And Hints At New Opportunity Brewing In Market,Benzinga,/news/etf/ai-run-etf-dumps-apple-in-favor-of-this-chip-stock-and-hints-at-new-opportunity-brewing-in-market-1032323317
1521.0,5/16/2023 4:31:17 PM,"Analysts Conflicted on These Healthcare Names: Regeneron (REGN), Viking Therapeutics (VKTX) and UpHealth (UPH)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-regeneron-regn-viking-therapeutics-vktx-and-uphealth-uph-1032332182
1522.0,5/17/2023 2:42:12 PM,Regeneron CEO supports FTC suit against Amgen acquisition of Horizon - FT,Seeking Alpha,https://seekingalpha.com/news/3972603-regeneron-ceo-supports-ftc-suit-against-amgen-acquistion-horizon?utm_source=businessinsider&utm_medium=referral
1523.0,5/17/2023 7:15:57 PM,The 7 Growth Stocks You Need to Own Now for Maximum Returns,InvestorPlace,/news/stocks/the-7-growth-stocks-you-need-to-own-now-for-maximum-returns-1032335944
1524.0,5/18/2023 4:13:46 PM,Supreme Court rules against Amgen in Repatha patent dispute with Sanofi/ Regeneron,Seeking Alpha,https://seekingalpha.com/news/3973082-supreme-court-rules-against-amgen-rapatha-patent-dispute?utm_source=businessinsider&utm_medium=referral
1525.0,5/19/2023 4:37:11 AM,U.S. Supreme Court Rules Against Amgen In Cholesterol Drug Patent Dispute With Sanofi ,RTTNews,/news/stocks/u-s-supreme-court-rules-against-amgen-in-cholesterol-drug-patent-dispute-with-sanofi-1032338671
1526.0,5/19/2023 1:01:12 PM,"Analysts Are Bullish on Top Healthcare Stocks: Moderna (MRNA), Regeneron (REGN)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-moderna-mrna-regeneron-regn-1032339830
1527.0,5/19/2023 7:00:19 PM,"Catalyst watch: Eyes on Ford event, Virgin Galactic launch, Nvidia earnings and Microsoft conference",Seeking Alpha,https://seekingalpha.com/news/3973501-catalyst-watch-eyes-on-ford-event-virgin-galactic-launch-nvidia-earnings-and-microsoft-conference?utm_source=businessinsider&utm_medium=referral
1528.0,5/19/2023 9:32:00 PM,High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023,PR Newswire,/news/stocks/high-school-scientists-and-engineers-win-nearly-9-million-at-the-regeneron-international-science-and-engineering-fair-2023-1032340488
1529.0,5/22/2023 4:10:56 AM,Sanofi:Dupixent Phase 3 COPD Results Presented At ATS & Published In New England Journal Of Medicine ,RTTNews,/news/stocks/sanofi-dupixent-phase-3-copd-results-presented-at-ats-published-in-new-england-journal-of-medicine-1032341401
1530.0,5/22/2023 11:30:11 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032342364
1531.0,5/23/2023 3:25:05 AM,Bank of America Securities Keeps Their Sell Rating on Regeneron (REGN),TipRanks,/news/stocks/bank-of-america-securities-keeps-their-sell-rating-on-regeneron-regn-1032343913
1532.0,6/1/2023 12:26:11 PM,Roche to divest biologics production plant in California – Reuters,Seeking Alpha,https://seekingalpha.com/news/3976552-roche-divest-biologics-production-plant-california?utm_source=businessinsider&utm_medium=referral
1533.0,6/2/2023 12:31:25 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032367235
1534.0,6/6/2023 1:11:23 PM,3 Biotech Stocks to Sell in June Before They Crash and Burn,InvestorPlace,/news/stocks/3-biotech-stocks-to-sell-in-june-before-they-crash-and-burn-1032373119
1535.0,6/9/2023 11:11:57 AM,AstraZeneca in pact with Quell Therapeutics for Treg cell therapies,Seeking Alpha,https://seekingalpha.com/news/3978896-astrazeneca-stock-co-develop-treg-cell-therapies?utm_source=businessinsider&utm_medium=referral
1536.0,6/9/2023 1:26:24 PM,"AbbVie, Amgen among firms targeted for Medicare inflation penalties",Seeking Alpha,https://seekingalpha.com/news/3978943-abbvie-among-firms-targeted-for-medicare-inflation-penalties?utm_source=businessinsider&utm_medium=referral
1537.0,6/9/2023 10:01:24 PM,18 Analysts Have This to Say About Regeneron Pharmaceuticals,Benzinga,/news/stocks/18-analysts-have-this-to-say-about-regeneron-pharmaceuticals-1032381574
1538.0,6/12/2023 12:05:20 PM,Jefferies Reaffirms Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/jefferies-reaffirms-their-buy-rating-on-regeneron-regn-1032383348
1539.0,6/12/2023 7:01:57 PM,Ocular falls after 12-month data for wet AMD candidate,Seeking Alpha,https://seekingalpha.com/news/3979306-ocular-stock-falls-12-month-data-wet-amd-drug-otx-tki?utm_source=businessinsider&utm_medium=referral
1540.0,6/14/2023 4:55:37 AM,SVB Securities Remains a Buy on Regeneron (REGN),TipRanks,/news/stocks/svb-securities-remains-a-buy-on-regeneron-regn-1032387731
1541.0,6/14/2023 9:14:33 PM,"EyePoint's EYP-1901 Tipped to Transform Wet AMD Market, Analyst Predicts Potential $870M Sales by 2035",Benzinga,/news/stocks/eyepoint-s-eyp-1901-tipped-to-transform-wet-amd-market-analyst-predicts-potential-870m-sales-by-2035-1032389967
1542.0,6/15/2023 10:10:38 AM,"Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Healthequity (HQY) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-acadia-pharmaceuticals-acad-healthequity-hqy-and-regeneron-regn-1032391141
1543.0,6/15/2023 11:10:07 AM,Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN) and BioMarin Pharmaceutical (BMRN),TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-regeneron-regn-and-biomarin-pharmaceutical-bmrn-1032391325
1544.0,6/18/2023 8:56:10 PM,How to Retire Rich: Biotech Stocks Edition,InvestorPlace,/news/stocks/how-to-retire-rich-biotech-stocks-edition-1032395848
1545.0,6/23/2023 12:31:41 PM,"Analysts Are Bullish on These Healthcare Stocks: Sarepta Therapeutics (SRPT), Kezar Life Sciences (KZR)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-sarepta-therapeutics-srpt-kezar-life-sciences-kzr-1032406863
1546.0,6/27/2023 12:30:38 PM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Edwards Lifesciences (EW) and Tonix Pharma (TNXP)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-regeneron-regn-edwards-lifesciences-ew-and-tonix-pharma-tnxp-1032412234
1547.0,6/27/2023 4:30:24 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032413110
1548.0,6/27/2023 7:18:00 PM,Regeneron falls as FDA rejects high-dose Eylea (update),Seeking Alpha,https://seekingalpha.com/news/3983374-regeneron-high-dose-eylea-rejected-by-fda?utm_source=businessinsider&utm_medium=referral
1549.0,6/27/2023 8:01:06 PM,Where Regeneron Pharmaceuticals Stands With Analysts,Benzinga,/news/stocks/where-regeneron-pharmaceuticals-stands-with-analysts-1032413256
1550.0,6/28/2023 9:01:14 AM,"Analysts’ Top Healthcare Picks: Paycor HCM (PYCR), Regeneron (REGN)",TipRanks,/news/stocks/analysts-top-healthcare-picks-paycor-hcm-pycr-regeneron-regn-1032414327
1551.0,6/28/2023 9:10:26 AM,"Analysts Conflicted on These Healthcare Names: Paycor HCM (PYCR), Regeneron (REGN) and Pharvaris (PHVS)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-paycor-hcm-pycr-regeneron-regn-and-pharvaris-phvs-1032414318
1552.0,6/28/2023 11:05:18 AM,BMO Capital Sticks to Its Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/bmo-capital-sticks-to-its-buy-rating-for-regeneron-regn-1032414641
1553.0,6/28/2023 12:20:33 PM,"Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Radnet (RDNT)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-regeneron-regn-radnet-rdnt-1032414881
1554.0,6/28/2023 12:44:32 PM,Regeneron cut to Neutral at Cannacord on FDA snub for high-dose Eylea,Seeking Alpha,https://seekingalpha.com/news/3983613-regeneron-cut-cannacord-fda-snubs-high-dose-eylea?utm_source=businessinsider&utm_medium=referral
1555.0,6/28/2023 1:45:36 PM,SVB Securities Sticks to Its Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/svb-securities-sticks-to-its-buy-rating-for-regeneron-regn-1032415333
1556.0,6/28/2023 1:53:01 PM,Amazon.com To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Wednesday,Benzinga,/news/stocks/amazon-com-to-rally-over-16-here-are-10-other-analyst-forecasts-for-wednesday-1032414733
1557.0,6/28/2023 2:42:32 PM,Catalent confirmed as manufacturer of Regeneron’s high-dose Eylea rejected by FDA,Seeking Alpha,https://seekingalpha.com/news/3983718-catalent-linked-fda-snub-regenerons-high-dose-eylea?utm_source=businessinsider&utm_medium=referral
1558.0,6/28/2023 5:03:03 PM,"Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-june-28-2023-1032415597
1559.0,7/4/2023 5:30:13 PM,"Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Regeneron (REGN) and Blueprint Medicines (BPMC)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-madrigal-pharmaceuticals-mdgl-regeneron-regn-and-blueprint-medicines-bpmc-1032425958
1560.0,7/5/2023 5:05:57 PM,The 3 Best Biotech Stocks to Buy In July,InvestorPlace,/news/stocks/biotech-stocks-to-buy-2-1032428210
1561.0,7/6/2023 2:43:36 PM,Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday,Benzinga,/news/stocks/meta-platforms-to-rally-around-14-here-are-10-other-analyst-forecasts-for-thursday-1032430007
1562.0,7/11/2023 1:50:34 AM,"Analysts Conflicted on These Healthcare Names: Pacira Pharmaceuticals (PCRX), Regeneron (REGN) and Thermo Fisher (TMO)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-pacira-pharmaceuticals-pcrx-regeneron-regn-and-thermo-fisher-tmo-1032436031
1563.0,7/12/2023 12:53:33 AM,Why These 7 Stocks Are the Best Ways to Play Biotech Right Now,InvestorPlace,/news/stocks/why-these-7-stocks-are-the-best-ways-to-play-biotech-right-now-1032439054
1564.0,7/13/2023 11:31:49 AM,Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Regeneron (REGN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-and-regeneron-regn-1032444194
1565.0,7/14/2023 1:24:24 AM,3 Pharma Stocks That AI is Loving in July,InvestorPlace,/news/stocks/3-pharma-stocks-that-ai-is-loving-in-july-1032445958
1566.0,7/16/2023 4:00:00 PM,"Eli Lilly, Merck among top pharma picks in Barclays Q2 preview",Seeking Alpha,https://seekingalpha.com/news/3987868-eli-lilly-merck-among-top-pharma-picks-in-barclays-q2-preview?utm_source=businessinsider&utm_medium=referral
1567.0,7/17/2023 9:10:25 AM,"Alnylam Presents ALN-APP's Updated Positive Interim Phase 1 Results In Alzheimer's Disease, CAA ",RTTNews,/news/stocks/alnylam-presents-aln-app-s-updated-positive-interim-phase-1-results-in-alzheimer-s-disease-caa-1032450212
1568.0,7/24/2023 11:32:36 AM,Kodiak drops eye disease candidate after Phase 3 setback,Seeking Alpha,https://seekingalpha.com/news/3989978-kodiak-stock-falls-discontinues-eye-disease-candidate?utm_source=businessinsider&utm_medium=referral
1569.0,7/24/2023 2:25:30 PM,Why Are Kodiak Sciences Shares Trading Lower Today?,Benzinga,/news/stocks/why-are-kodiak-sciences-shares-trading-lower-today-1032469988
1570.0,7/24/2023 9:55:38 PM,The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023,InvestorPlace,/news/stocks/the-3-most-undervalued-biotech-stocks-to-buy-now-july-2023-2-1032471656
1571.0,7/26/2023 5:23:00 PM,"If You Can Only Buy One Biotech Stock, It Better Be One of These 3 Names",InvestorPlace,/news/stocks/if-you-can-only-buy-one-biotech-stock-it-better-be-one-of-these-3-names-1032481009
1572.0,7/26/2023 7:04:29 PM,Weight loss drugs excluded from WHO’s 'essential' medicines list,Seeking Alpha,https://seekingalpha.com/news/3991468-weight-loss-drugs-not-in-latest-who-essential-medicines-list?utm_source=businessinsider&utm_medium=referral
1573.0,7/28/2023 9:20:31 AM,"Analysts Conflicted on These Healthcare Names: Exelixis (EXEL), HCA Healthcare (HCA) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-exelixis-exel-hca-healthcare-hca-and-regeneron-regn-1032489174
1574.0,7/28/2023 11:45:23 AM,BMO Capital Remains a Buy on Regeneron (REGN),TipRanks,/news/stocks/bmo-capital-remains-a-buy-on-regeneron-regn-1032489800
1575.0,7/31/2023 9:46:38 AM,Biotech Stocks Facing FDA Decision In August 2023 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-august-2023-1032494050
1576.0,8/1/2023 6:59:01 PM,Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points,InvestorPlace,/news/stocks/biotech-stocks-to-buy-3-1032502314
1577.0,8/2/2023 3:01:13 PM,Regeneron Pharmaceuticals is about to announce its earnings — here's what to expect,Markets Insider Automation,/news/stocks/regeneron-stock-price-q2-earnings-preview-1032506842
1578.0,8/2/2023 3:58:20 PM,Regeneron Pharmaceuticals Q2 2023 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3995295-regeneron-pharmaceuticals-q2-2023-earnings-preview?utm_source=businessinsider&utm_medium=referral
1579.0,8/3/2023 1:50:49 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Zimmer Biomet Holdings (ZBH), Regeneron (REGN) and Addus Homecare (ADUS)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-zimmer-biomet-holdings-zbh-regeneron-regn-and-addus-homecare-adus-1032509162
1580.0,8/3/2023 10:31:33 AM,"Regeneron Pharmaceuticals Non-GAAP EPS of $10.24 beats by $0.34, revenue of $3.16B beats by $140M",Seeking Alpha,https://seekingalpha.com/news/3996298-regeneron-pharmaceuticals-non-gaap-eps-of-10_24-beats-0_34-revenue-of-3_16b-beats-140m?utm_source=businessinsider&utm_medium=referral
1581.0,8/3/2023 10:50:14 AM,"Analysts Conflicted on These Healthcare Names: United Therapeutics (UTHR), Humana (HUM) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-united-therapeutics-uthr-humana-hum-and-regeneron-regn-1032511965
1582.0,8/3/2023 12:00:28 PM,Regeneron gains after Q2 beat; FDA action on high-dose Eylea expected in Q3,Seeking Alpha,https://seekingalpha.com/news/3996461-regeneron-stock-gains-after-q2-beat?utm_source=businessinsider&utm_medium=referral
1583.0,8/3/2023 1:53:42 PM,"Regeneron Pharmaceuticals Q2 Profit Increases, beats estimates",RTTNews,/news/stocks/regeneron-pharmaceuticals-q2-profit-increases-beats-estimates-1032512287
1584.0,8/3/2023 4:57:55 PM,"Clorox, Boot Barn, Herbalife, Upwork And Other Big Stocks Moving Higher On Thursday",Benzinga,/news/stocks/clorox-boot-barn-herbalife-upwork-and-other-big-stocks-moving-higher-on-thursday-1032513509
1585.0,8/3/2023 5:05:14 PM,Replimmune down 8% on skin cancer cancer candidate data delay,Seeking Alpha,https://seekingalpha.com/news/3996749-replimmune-down-8-skin-cancer-cancer-candidate-data-delay?utm_source=businessinsider&utm_medium=referral
1586.0,8/4/2023 7:31:45 AM,"Analysts Conflicted on These Healthcare Names: Penumbra (PEN), Zimmer Biomet Holdings (ZBH) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-penumbra-pen-zimmer-biomet-holdings-zbh-and-regeneron-regn-1032516644
1587.0,8/4/2023 11:45:17 AM,BMO Capital Gives a Buy Rating to Regeneron (REGN),TipRanks,/news/stocks/bmo-capital-gives-a-buy-rating-to-regeneron-regn-1032517737
1588.0,8/4/2023 1:26:20 PM,Regeneron halts enrollment in prostate cancer trial following two deaths,Seeking Alpha,https://seekingalpha.com/news/3997503-regeneron-halts-enrollment-prostate-cancer-trial-two-deaths?utm_source=businessinsider&utm_medium=referral
1589.0,8/7/2023 9:20:25 AM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Becton Dickinson (BDX) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-becton-dickinson-bdx-and-regeneron-regn-1032523168
1590.0,8/8/2023 4:15:25 PM,"Stifel, Guggenheim, Jefferies, Wedbush start Apogee Therapeutics at buy",Seeking Alpha,https://seekingalpha.com/news/3999177-stifel-guggenheim-jefferies-wedbush-start-apogee-therapeutics-at-buy?utm_source=businessinsider&utm_medium=referral
1591.0,8/8/2023 7:06:02 PM,3 AI Stocks You’ll Regret Not Buying Soon,InvestorPlace,/news/stocks/3-ai-stocks-youll-regret-not-buying-soon-1032530487
1592.0,8/9/2023 2:30:25 AM,"Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (AXSM), Stryker (SYK) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-axsome-therapeutics-axsm-stryker-syk-and-regeneron-regn-1032531344
1593.0,8/9/2023 12:06:59 PM,Regeneron to acquire gene therapy developer Decibel for $4 per share,Seeking Alpha,https://seekingalpha.com/news/3999964-decibel-stock-rises-regeneron-inks-buyout-deal?utm_source=businessinsider&utm_medium=referral
1594.0,8/9/2023 2:00:22 PM,Decibel Therapeutics (DBTX) Stock Skyrockets 71% on Regeneron Deal,InvestorPlace,/news/stocks/decibel-therapeutics-dbtx-stock-skyrockets-71-on-regeneron-deal-1032535672
1595.0,8/10/2023 5:25:23 PM,Baird downgrades Decibel to neutral to reflect Regeneron takeover,Seeking Alpha,https://seekingalpha.com/news/4001204-baird-downgrades-decibel-to-neutral-to-reflect-regeneron-takeover?utm_source=businessinsider&utm_medium=referral
1596.0,8/11/2023 1:15:18 AM,The 7 Best Value Stocks to Buy in August,InvestorPlace,/news/stocks/the-7-best-value-stocks-to-buy-in-august-1032542533
1597.0,8/11/2023 4:20:36 PM,"Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), Alcon (ALC) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-cogent-biosciences-cogt-alcon-alc-and-regeneron-regn-1032547457
1598.0,8/11/2023 4:54:57 PM,Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet,Benzinga,/news/stocks/benzinga-s-stock-whisper-index-5-stocks-investors-are-secretly-monitoring-but-not-talking-about-yet-1032547189
1599.0,8/13/2023 6:00:00 PM,Pharma under threat from bill to expand drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4002034-pharma-under-threat-bill-expand-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral
1600.0,8/15/2023 7:44:44 PM,Regeneron could see share price bounce with potential approvals,Seeking Alpha,https://seekingalpha.com/news/4003175-regeneron-could-see-share-price-bounce-potential-approvals?utm_source=businessinsider&utm_medium=referral
1601.0,8/16/2023 9:00:49 PM,18 Analysts Have This to Say About Regeneron Pharmaceuticals,Benzinga,/news/stocks/18-analysts-have-this-to-say-about-regeneron-pharmaceuticals-1032561036
1602.0,8/17/2023 1:28:09 PM,Regeneron lymphoma therapy accepted for EU review,Seeking Alpha,https://seekingalpha.com/news/4003958-regeneron-granted-eu-review-lymphoma-drug?utm_source=businessinsider&utm_medium=referral
1603.0,8/17/2023 2:30:11 PM,Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma,GlobeNewswire,/news/stocks/odronextamab-receives-ema-filing-acceptance-for-treatment-of-relapsed-refractory-follicular-lymphoma-and-diffuse-large-b-cell-lymphoma-1032563169
1604.0,8/17/2023 2:49:23 PM,Regeneron Pharma: EMA To Review MAA For Odronextamab ,RTTNews,/news/stocks/regeneron-pharma-ema-to-review-maa-for-odronextamab-1032563225
1605.0,8/18/2023 5:10:25 PM,"AARP, Public Citizen file briefs in Medicare drug price negotiations case",Seeking Alpha,https://seekingalpha.com/news/4004411-aarp-public-citizen-file-briefs-medicare-drug-price-negotiations-case?utm_source=businessinsider&utm_medium=referral
1606.0,8/18/2023 6:23:01 PM,Regeneron wins approval for rare immune disease therapy pozelimab,Seeking Alpha,https://seekingalpha.com/news/4004438-regeneron-wins-approval-rare-immune-disease-therapy-pozelimab-veopoz?utm_source=businessinsider&utm_medium=referral
1607.0,8/18/2023 7:00:03 PM,"Catalyst watch: Nvidia earnings, Twilio event, AMC drama and Jackson Hole jitters",Seeking Alpha,https://seekingalpha.com/news/4004407-catalyst-watch-nvidia-earnings-twilio-event-and-jackson-hole-jitters?utm_source=businessinsider&utm_medium=referral
1608.0,8/18/2023 7:43:19 PM,Veopoz™ (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease,GlobeNewswire,/news/stocks/veopoz-pozelimab-bbfg-receives-fda-approval-as-the-first-treatment-for-children-and-adults-with-chaple-disease-1032567343
1609.0,8/18/2023 9:20:55 PM,Regeneron Pharma's Veopoz Receives FDA Approval For Veopoz ,RTTNews,/news/stocks/regeneron-pharma-s-veopoz-receives-fda-approval-for-veopoz-1032567445
1610.0,8/19/2023 12:35:00 AM,"EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)",GlobeNewswire,/news/stocks/eylea-hd-aflibercept-injection-8-mg-approved-by-fda-for-treatment-of-wet-age-related-macular-degeneration-wamd-diabetic-macular-edema-dme-and-diabetic-retinopathy-dr-1032567600
1611.0,8/19/2023 1:10:28 AM,Regeneron high-dose Eylea gains FDA approval,Seeking Alpha,https://seekingalpha.com/news/4004493-regeneron-high-dose-eylea-gains-fda-approval?utm_source=businessinsider&utm_medium=referral
1612.0,8/19/2023 6:00:56 PM,"With two approvals in one day, Regeneron could be headed higher",Seeking Alpha,https://seekingalpha.com/news/4004500-two-approvals-one-day-regeneron-could-headed-higher?utm_source=businessinsider&utm_medium=referral
1613.0,8/21/2023 10:30:20 AM,"Analysts Are Bullish on These Healthcare Stocks: Nuvation Bio (NUVB), Finch Therapeutics Group (FNCH)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-nuvation-bio-nuvb-finch-therapeutics-group-fnch-1032569254
1614.0,8/21/2023 10:50:06 AM,"Analysts Offer Insights on Healthcare Companies: Nemaura Medical (NMRD), Kineta (KA) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-nemaura-medical-nmrd-kineta-ka-and-regeneron-regn-1032569283
1615.0,8/21/2023 11:20:19 AM,Analysts Offer Insights on Healthcare Companies: Calliditas Therapeutics (CALT) and Regeneron (REGN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-calliditas-therapeutics-calt-and-regeneron-regn-1032569390
1616.0,8/21/2023 12:20:11 PM,"Analysts Are Bullish on These Healthcare Stocks: Supernus Pharmaceuticals (SUPN), Viatris (VTRS)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-supernus-pharmaceuticals-supn-viatris-vtrs-1032569601
1617.0,8/21/2023 7:53:10 PM,Value Stocks Outshine Growth Amidst Rising Treasury Yields: Key Sectors and Stocks Analyzed,Benzinga,/news/etf/value-stocks-outshine-growth-amidst-rising-treasury-yields-key-sectors-and-stocks-analyzed-1032570802
1618.0,8/21/2023 7:58:31 PM,"Lilly's market cap soared 36% in Q2, eclipsing J&J, Merck, Novo Nordisk",Seeking Alpha,https://seekingalpha.com/news/4004913-lillys-market-cap-soared-in-q2-eclipsing-jnj-merck-novo-nordisk?utm_source=businessinsider&utm_medium=referral
1619.0,8/21/2023 9:04:31 PM,Regeneron's Crucial Eylea HD Approval: A Shield Against Potential Biosimilar Competition?,Benzinga,/news/stocks/regeneron-s-crucial-eylea-hd-approval-a-shield-against-potential-biosimilar-competition-1032570892
1620.0,8/22/2023 10:11:27 AM,"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Regeneron (REGN) and Syndax Pharmaceuticals (SNDX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-regeneron-regn-and-syndax-pharmaceuticals-sndx-1032572377
1621.0,8/22/2023 6:52:24 PM,"Regeneron, J&J receive millions to develop new COVID therapies",Seeking Alpha,https://seekingalpha.com/news/4005267-regeneron-johnson-johnson-receive-millions-develop-covid-therapies?utm_source=businessinsider&utm_medium=referral
1622.0,8/22/2023 8:15:41 PM,Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention,GlobeNewswire,/news/stocks/regeneron-announces-agreement-with-barda-supporting-development-of-next-generation-antibody-therapy-for-covid-19-prevention-1032574227
1623.0,8/23/2023 1:58:45 PM,Top 5 Health Care Stocks That May Fall Off A Cliff,Benzinga,/news/stocks/top-5-health-care-stocks-that-may-fall-off-a-cliff-1032576078
1624.0,8/23/2023 10:05:00 PM,Regeneron Announces Investor Conference Presentations,GlobeNewswire,/news/stocks/regeneron-announces-investor-conference-presentations-1032577795
1625.0,8/25/2023 2:43:48 PM,Merck starts phase 3 program for oral PCSK9 inhibitor to lower cholesterol,Seeking Alpha,https://seekingalpha.com/news/4006430-merck-starts-phase-3-oral-pcsk9-inhibitor-lower-cholesterol?utm_source=businessinsider&utm_medium=referral
1626.0,8/26/2023 7:21:22 PM,These Are the ONLY 7 Penny Stocks to Consider in August 2023,InvestorPlace,/news/stocks/these-are-the-only-7-penny-stocks-to-consider-in-august-2023-1032583984
1627.0,9/2/2023 6:00:00 PM,"Lilly, Novo Nordisk top pharma performers in August; AstraZeneca, Roche lag",Seeking Alpha,https://seekingalpha.com/news/4008548-lilly-novo-nordisk-top-pharma-performers-august-astrazeneca-roche-lag?utm_source=businessinsider&utm_medium=referral
1628.0,9/8/2023 8:58:16 PM,Regeneron CFO Robert Landry to retire,Seeking Alpha,https://seekingalpha.com/news/4010403-regeneron-cfo-robert-landry-to-retire?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1629.0,9/8/2023 10:45:00 PM,Regeneron Announces Updates to Board of Directors,GlobeNewswire,/news/stocks/regeneron-announces-updates-to-board-of-directors-1032617282
1630.0,9/8/2023 10:46:00 PM,Regeneron Provides Update on Planned Chief Financial Officer Transition,GlobeNewswire,/news/stocks/regeneron-provides-update-on-planned-chief-financial-officer-transition-1032617288
1631.0,9/11/2023 7:30:31 PM,AI Integration In Biotech & Pharma: Companies Positioned To Benefit,Benzinga,/news/stocks/ai-integration-in-biotech-pharma-companies-positioned-to-benefit-1032621068
1632.0,9/15/2023 5:00:48 PM,"Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-september-15-2023-1032634298
1633.0,9/19/2023 7:04:06 PM,3 Stocks to Buy to Ride Europe’s Coming Market Surge,InvestorPlace,/news/stocks/3-stocks-to-buy-to-ride-europes-coming-market-surge-1032641432
1634.0,9/21/2023 6:00:37 PM,Analyst Expectations for Regeneron Pharmaceuticals's Future,Benzinga,/news/stocks/analyst-expectations-for-regeneron-pharmaceuticals-s-future-1032647761
1635.0,9/25/2023 2:34:45 PM,"Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss ",GlobeNewswire,/news/stocks/regeneron-completes-acquisition-of-decibel-therapeutics-adding-promising-gene-therapy-programs-for-hearing-loss-1032652806
1636.0,9/26/2023 7:29:00 AM,Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review,GlobeNewswire,/news/stocks/dupixent-dupilumab-sbla-for-treatment-of-eosinophilic-esophagitis-eoe-in-children-aged-1-to-11-accepted-for-fda-priority-review-1032654537
1637.0,9/28/2023 10:05:00 PM,"Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023",GlobeNewswire,/news/stocks/regeneron-to-report-third-quarter-2023-financial-and-operating-results-and-host-conference-call-and-webcast-on-november-2-2023-1032664475
1638.0,9/29/2023 11:12:27 AM,"Analysts Conflicted on These Healthcare Names: PTC Therapeutics (PTCT), Regeneron (REGN) and Mirati Therapeutics (MRTX)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-ptc-therapeutics-ptct-regeneron-regn-and-mirati-therapeutics-mrtx-1032666057
1639.0,9/29/2023 2:30:12 PM,Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review,GlobeNewswire,/news/stocks/odronextamab-bla-for-treatment-of-relapsed-refractory-follicular-lymphoma-fl-and-diffuse-large-b-cell-lymphoma-dlbcl-accepted-for-fda-priority-review-1032666312
1640.0,9/29/2023 2:50:44 PM,Regeneron Pharma Reports FDA Priority Review For Odronextamab BLA - Quick Facts ,RTTNews,/news/stocks/regeneron-pharma-reports-fda-priority-review-for-odronextamab-bla-quick-facts-1032666378
1641.0,10/3/2023 1:00:00 PM,Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases,GlobeNewswire,/news/stocks/regeneron-and-intellia-announce-expanded-research-collaboration-to-develop-crispr-based-therapies-for-the-treatment-of-neurological-and-muscular-diseases-1032673940
1642.0,10/3/2023 2:33:10 PM,MAIA Biotechnology Obtains FDA Clearance To Extend Go-to-market THIO-101 Trial To The U.S. ,RTTNews,/news/stocks/maia-biotechnology-obtains-fda-clearance-to-extend-go-to-market-thio-101-trial-to-the-u-s-1032674327
1643.0,10/5/2023 3:43:00 PM,EYLEA® HD (aflibercept) Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA,GlobeNewswire,/news/stocks/eylea-hd-aflibercept-injection-8-mg-two-year-results-from-pivotal-pulsar-trial-in-wet-age-related-macular-degeneration-presented-at-euretina-1032681999
1644.0,10/6/2023 1:50:24 AM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Regeneron (REGN) and Alnylam Pharma (ALNY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-regeneron-regn-and-alnylam-pharma-alny-1032683118
1645.0,10/11/2023 11:00:23 PM,The Latest Analyst Ratings for Regeneron Pharmaceuticals,Benzinga,/news/stocks/the-latest-analyst-ratings-for-regeneron-pharmaceuticals-1032698166
1646.0,10/13/2023 10:10:31 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Alnylam Pharma (ALNY), Regeneron (REGN) and HashiCorp (HCP)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-alnylam-pharma-alny-regeneron-regn-and-hashicorp-hcp-1032703277
1647.0,10/14/2023 1:45:33 AM,Regeneron (REGN) Receives a Hold from RBC Capital,TipRanks,/news/stocks/regeneron-regn-receives-a-hold-from-rbc-capital-1032705206
1648.0,10/16/2023 12:05:23 AM,Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO,GlobeNewswire,/news/stocks/regeneron-to-showcase-progress-from-innovative-oncology-portfolio-in-several-difficult-to-treat-cancers-at-esmo-1032706044
1649.0,10/16/2023 7:00:26 PM,Cantor Fitzgerald Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know,Benzinga,/news/stocks/cantor-fitzgerald-maintains-neutral-rating-for-regeneron-pharmaceuticals-here-s-what-you-need-to-know-1032709568
1650.0,10/17/2023 9:21:19 AM,Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and Iovance Biotherapeutics (IOVA),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-and-iovance-biotherapeutics-iova-1032711630
1651.0,10/18/2023 1:43:52 PM,Intellia Therapeutics: FDA Allows To Begin Phase 3 Trial Of NTLA-2001 - Quick Facts ,RTTNews,/news/stocks/intellia-therapeutics-fda-allows-to-begin-phase-3-trial-of-ntla-2001-quick-facts-1032716497
1652.0,10/18/2023 3:00:00 PM,"Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for...",GlobeNewswire,/news/stocks/together-for-change-genomics-and-equity-initiative-launched-by-a-coalition-of-meharry-medical-college-regeneron-genetics-center-astrazeneca-novo-nordisk-and-roche-to-improve-health-outcomes-for-1032717028
1653.0,10/18/2023 3:30:00 PM,"Regeneron builds on Together for CHANGE™ initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN",GlobeNewswire,/news/stocks/regeneron-builds-on-together-for-change-initiative-with-five-year-5-million-commitment-to-fuel-the-stem-talent-pipeline-in-nashville-tn-1032717151
1654.0,10/20/2023 11:20:36 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032724039
1655.0,10/20/2023 11:00:37 PM,Regeneron and Sanofi Provide Update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria,GlobeNewswire,/news/stocks/regeneron-and-sanofi-provide-update-on-dupixent-dupilumab-sbla-for-chronic-spontaneous-urticaria-1032725260
1656.0,10/21/2023 2:48:15 PM,Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC),GlobeNewswire,/news/stocks/libtayo-cemiplimab-neoadjuvant-treatment-demonstrates-encouraging-event-free-survival-in-patients-with-resectable-cutaneous-squamous-cell-carcinoma-cscc-1032725598
1657.0,10/22/2023 8:59:00 PM,Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE),GlobeNewswire,/news/stocks/dupixent-dupilumab-phase-3-results-show-sustained-efficacy-for-up-to-one-year-in-children-1-to-11-years-of-age-with-eosinophilic-esophagitis-eoe-1032726106
1658.0,10/23/2023 4:20:12 AM,Regeneron : Dupixent Phase 3 Results Show Sustained Efficacy For Up To One Year In Children With EoE ,RTTNews,/news/stocks/regeneron-dupixent-phase-3-results-show-sustained-efficacy-for-up-to-one-year-in-children-with-eoe-1032726139
1659.0,10/23/2023 11:20:16 AM,"Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Akero Therapeutics (AKRO) and ESSA Pharma (EPIX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-akero-therapeutics-akro-and-essa-pharma-epix-1032733094
1660.0,10/25/2023 10:05:00 PM,Regeneron Announces Investor Conference Presentations,GlobeNewswire,/news/stocks/regeneron-announces-investor-conference-presentations-1032740326
1661.0,10/26/2023 11:48:40 AM,Regeneron’s Growth Potential and R&D Conversion: Key Drivers for Buy Rating,TipRanks,/news/stocks/regeneron-s-growth-potential-and-r-d-conversion-key-drivers-for-buy-rating-1032745959
1662.0,10/26/2023 10:00:07 PM,Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss,GlobeNewswire,/news/stocks/regeneron-shares-preliminary-results-showing-gene-therapy-improves-auditory-responses-in-child-with-profound-genetic-hearing-loss-1032745488
1663.0,10/27/2023 1:25:10 PM,SNY Stock Sinks 15% as Sanofi Plans Consumer Unit Spinoff,InvestorPlace,/news/stocks/sny-stock-sinks-15-as-sanofi-plans-consumer-unit-spinoff-1032748736
1664.0,11/1/2023 3:01:13 PM,Regeneron Pharmaceuticals is about to announce its earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/regeneron-stock-price-q3-earnings-preview-1032765589
1665.0,11/1/2023 9:00:00 PM,EYLEA® HD (aflibercept) Injection 8 mg Data Presentations at AAO Reinforce Efficacy and Safety Profile in Wet Age-related Macular Degeneration and Diabetic Macular Edema,GlobeNewswire,/news/stocks/eylea-hd-aflibercept-injection-8-mg-data-presentations-at-aao-reinforce-efficacy-and-safety-profile-in-wet-age-related-macular-degeneration-and-diabetic-macular-edema-1032767135
1666.0,11/2/2023 11:30:00 AM,Regeneron Reports Third Quarter 2023 Financial and Operating Results,GlobeNewswire,/news/stocks/regeneron-reports-third-quarter-2023-financial-and-operating-results-1032769545
1667.0,11/2/2023 1:12:49 PM,"Regeneron Pharmaceuticals Q3 Profit Decreases, but beats estimates",RTTNews,/news/stocks/regeneron-pharmaceuticals-q3-profit-decreases-but-beats-estimates-1032770107
1668.0,11/2/2023 6:20:32 PM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Humana (HUM), Glaukos (GKOS) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-humana-hum-glaukos-gkos-and-regeneron-regn-1032774906
1669.0,11/2/2023 6:58:06 PM,"Green Wave Boosts Stocks, Bonds As Traders Embrace Fed's Stance, Await Apple Earnings: What's Driving Markets Thursday?",Benzinga,/news/etf/green-wave-boosts-stocks-bonds-as-traders-embrace-fed-s-stance-await-apple-earnings-what-s-driving-markets-thursday-1032771843
1670.0,11/2/2023 9:40:17 PM,"Analysts Are Bullish on These Healthcare Stocks: Generation Bio (GBIO), Regeneron (REGN)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-generation-bio-gbio-regeneron-regn-1032775572
1671.0,11/2/2023 10:10:17 PM,"Analysts Are Bullish on Top Healthcare Stocks: United Therapeutics (UTHR), Regeneron (REGN)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-united-therapeutics-uthr-regeneron-regn-1032775672
1672.0,11/3/2023 9:01:02 AM,"Analysts Offer Insights on Healthcare Companies: Zoetis (ZTS), Moderna (MRNA) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-zoetis-zts-moderna-mrna-and-regeneron-regn-1032777638
1673.0,11/3/2023 11:40:33 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD), Trupanion (TRUP) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-inmode-inmd-trupanion-trup-and-regeneron-regn-1032777825
1674.0,11/3/2023 12:00:14 PM,Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH,GlobeNewswire,/news/stocks/regeneron-to-highlight-scientific-advancements-across-diversified-pipeline-in-difficult-to-treat-blood-cancers-and-disorders-at-ash-1032775794
1675.0,11/3/2023 8:32:58 PM,"Regeneron Pharmaceuticals Stock Upgraded After Q3, But There Is A Headwind - Analyst Review",Benzinga,/news/stocks/regeneron-pharmaceuticals-stock-upgraded-after-q3-but-there-is-a-headwind---analyst-review-1032777467
1676.0,11/6/2023 5:58:29 AM,"Positive Outlook for Regeneron: Eylea HD Success, Dupixent COPD Phase 3 Advancement & Future Obesity Research Developments Prompts Buy Rating",TipRanks,/news/stocks/positive-outlook-for-regeneron-eylea-hd-success-dupixent-copd-phase-3-advancement-future-obesity-research-developments-prompts-buy-rating-1032783280
1677.0,11/7/2023 2:40:18 AM,"Analysts’ Top Healthcare Picks: Lantheus (LNTH), Cytokinetics (CYTK)",TipRanks,/news/stocks/analysts-top-healthcare-picks-lantheus-lnth-cytokinetics-cytk-1032788295
1678.0,11/8/2023 9:50:07 PM,Wall Street Analysts Are Neutral on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-neutral-on-top-healthcare-picks-1032799748
1679.0,11/9/2023 8:37:06 PM,3 Biotech Stocks That Are Betting on the Future of Gene Editing ,InvestorPlace,/news/stocks/3-gene-editing-stocks-that-may-define-the-future-of-biotech-1032802453
1680.0,11/9/2023 10:00:39 PM,Where Regeneron Pharmaceuticals Stands With Analysts,Benzinga,/news/stocks/where-regeneron-pharmaceuticals-stands-with-analysts-1032802499
1681.0,11/10/2023 3:01:38 AM,7 Underappreciated Biotech Stocks to Pick Up on the Cheap,InvestorPlace,/news/stocks/7-underappreciated-biotech-stocks-to-pick-up-on-the-cheap-1032803108
1682.0,11/13/2023 3:00:00 PM,Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF),GlobeNewswire,/news/stocks/regeneron-commits-34-million-over-five-years-to-continue-to-sponsor-the-regeneron-international-science-and-engineering-fair-isef-1032813300
1683.0,11/15/2023 10:05:00 PM,Regeneron Announces Investor Conference Presentation,GlobeNewswire,/news/stocks/regeneron-announces-investor-conference-presentation-1032824569
1684.0,11/21/2023 1:10:30 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032841067
1685.0,11/27/2023 7:30:00 AM,"Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This...",GlobeNewswire,/news/stocks/dupixent-dupilumab-significantly-reduced-copd-exacerbations-in-second-positive-phase-3-trial-accelerating-fda-submission-and-confirming-potential-to-become-first-approved-biologic-for-this-1032849954
1686.0,11/27/2023 8:57:19 AM,Sanofi Posts Positive NOTUS Trial Result Of Dupixent In COPD ,RTTNews,/news/stocks/sanofi-posts-positive-notus-trial-result-of-dupixent-in-copd-1032850120
1687.0,11/27/2023 10:10:04 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032853971
1688.0,11/28/2023 10:20:30 AM,"Analysts Conflicted on These Healthcare Names: Johnson & Johnson (JNJ), Masimo (MASI) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-johnson-johnson-jnj-masimo-masi-and-regeneron-regn-1032856472
1689.0,11/28/2023 12:51:22 PM,"Analysts’ Top Healthcare Picks: Merus (MRUS), Regeneron (REGN)",TipRanks,/news/stocks/analysts-top-healthcare-picks-merus-mrus-regeneron-regn-1032856657
1690.0,11/28/2023 1:20:14 PM,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Exact Sciences (EXAS) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biogen-biib-exact-sciences-exas-and-regeneron-regn-1032856675
1691.0,11/28/2023 8:00:16 PM,11 Analysts Have This to Say About Regeneron Pharmaceuticals,Benzinga,/news/stocks/11-analysts-have-this-to-say-about-regeneron-pharmaceuticals-1032856120
1692.0,11/29/2023 6:30:24 AM,"Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Regeneron (REGN) and Outlook Therapeutics (OTLK)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-veeva-systems-veev-regeneron-regn-and-outlook-therapeutics-otlk-1032859833
1693.0,11/30/2023 2:30:21 AM,"Analysts Offer Insights on Healthcare Companies: POINT Biopharma Global (PNT), Regeneron (REGN) and Incyte (INCY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-point-biopharma-global-pnt-regeneron-regn-and-incyte-incy-1032862831
1694.0,11/30/2023 10:05:00 PM,"Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio",GlobeNewswire,/news/stocks/regeneron-to-host-investor-call-and-webcast-on-december-14-2023-to-provide-updates-across-its-hematology-portfolio-1032864259
1695.0,12/2/2023 6:14:39 PM,GOOG Stock Alert: Alphabet Is Spending Money in All the Wrong Places,InvestorPlace,/news/stocks/goog-stock-alert-alphabet-is-spending-money-in-all-the-wrong-places-1032868110
1696.0,12/5/2023 9:51:55 AM,"Analysts Conflicted on These Healthcare Names: Regeneron (REGN), AbbVie (ABBV) and Taysha Gene Therapies (TSHA)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-regeneron-regn-abbvie-abbv-and-taysha-gene-therapies-tsha-1032876061
1697.0,12/6/2023 10:50:15 AM,"Analysts’ Top Healthcare Picks: Sanofi (SNYNF), Regeneron (REGN)",TipRanks,/news/stocks/analysts-top-healthcare-picks-sanofi-snynf-regeneron-regn-1032879943
1698.0,12/7/2023 8:02:26 AM,"Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Regeneron (REGN) and Arvinas Holding Company (ARVN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-argenx-se-argx-regeneron-regn-and-arvinas-holding-company-arvn-1032883436
1699.0,12/7/2023 8:30:59 AM,Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IO,GlobeNewswire,/news/stocks/regeneron-to-share-progress-of-novel-combination-therapies-in-oncology-at-esmo-io-1032880636
1700.0,12/7/2023 1:00:45 PM,Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma,GlobeNewswire,/news/stocks/updated-linvoseltamab-pivotal-data-demonstrated-strong-rates-and-depth-of-response-in-patients-with-heavily-pre-treated-multiple-myeloma-1032881517
1701.0,12/8/2023 10:41:01 AM,Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and Cooper Co (COO),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-and-cooper-co-coo-1032886919
1702.0,12/8/2023 12:50:25 PM,"Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Regeneron (REGN) and PAVmed (PAVM)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-rhythm-pharmaceuticals-rytm-regeneron-regn-and-pavmed-pavm-1032887057
1703.0,12/10/2023 6:30:00 PM,Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes,GlobeNewswire,/news/stocks/updated-odronextamab-data-from-relapsed-refractory-diffuse-large-b-cell-lymphoma-pivotal-trial-showed-deep-and-durable-responses-and-the-potential-of-ctdna-to-predict-long-term-outcomes-1032887779
1704.0,12/11/2023 1:30:00 AM,Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes,GlobeNewswire,/news/stocks/latest-odronextamab-data-in-relapsed-refractory-follicular-lymphoma-showed-compelling-responses-and-overall-maintenance-of-patient-reported-outcomes-1032887877
1705.0,12/11/2023 1:30:00 PM,Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year,GlobeNewswire,/news/stocks/regeneron-named-on-dow-jones-sustainability-world-index-for-fifth-consecutive-year-1032889265
1706.0,12/13/2023 10:20:00 AM,3 Gene-Editing Stocks With the Potential to Mint Millionaires,InvestorPlace,/news/stocks/3-gene-editing-stocks-with-the-potential-to-mint-millionaires-1032896336
1707.0,12/15/2023 10:26:05 AM,Regeneron Stock Assigned Sell Rating Amid Competitive Landscape and Commercial Execution Concerns,TipRanks,/news/stocks/regeneron-stock-assigned-sell-rating-amid-competitive-landscape-and-commercial-execution-concerns-1032906149
1708.0,12/15/2023 10:32:22 AM,"Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Bluebird Bio (BLUE) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-rxsight-rxst-bluebird-bio-blue-and-regeneron-regn-1032906173
1709.0,12/15/2023 1:51:19 PM,"Analysts Offer Insights on Healthcare Companies: Moderna (MRNA), Regeneron (REGN) and Teva Pharmaceutical (TEVA)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-moderna-mrna-regeneron-regn-and-teva-pharmaceutical-teva-1032906327
1710.0,12/16/2023 1:46:17 AM,RBC Capital Reaffirms Their Hold Rating on Regeneron (REGN),TipRanks,/news/stocks/rbc-capital-reaffirms-their-hold-rating-on-regeneron-regn-1032906522
1711.0,12/16/2023 6:00:00 PM,AI Meets Biotech: 3 Top Stocks Transforming Medical Science,InvestorPlace,/news/stocks/ai-meets-biotech-3-top-stocks-transforming-medical-science-1032906556
1712.0,12/18/2023 10:00:19 PM,14 Analysts Assess Regeneron Pharmaceuticals: What You Need To Know,Benzinga,/news/stocks/14-analysts-assess-regeneron-pharmaceuticals-what-you-need-to-know-1032910308
1713.0,12/18/2023 10:05:00 PM,Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference ,GlobeNewswire,/news/stocks/regeneron-announces-presentation-at-the-42nd-annual-j-p-morgan-healthcare-conference-1032910326
1714.0,12/22/2023 1:15:47 AM,7 Undervalued Nasdaq-100 Stocks for Bargain Hunters,InvestorPlace,/news/stocks/7-undervalued-nasdaq-100-stocks-for-bargain-hunters-1032920844
1715.0,12/22/2023 1:00:18 PM,Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Regeneron (REGN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-ionis-pharmaceuticals-ions-and-regeneron-regn-1032923499
1716.0,12/28/2023 8:18:25 AM,Biotech Stocks Facing FDA Decision In January 2024 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-january-2024-1032929267
1717.0,12/28/2023 10:31:27 AM,Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN) and Canopy Growth (CGC),TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-regeneron-regn-and-canopy-growth-cgc-1032931051
1718.0,12/28/2023 10:40:44 AM,Analysts Offer Insights on Healthcare Companies: Coherus Biosciences (CHRS) and Regeneron (REGN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-coherus-biosciences-chrs-and-regeneron-regn-1032931047
1719.0,1/5/2024 5:00:51 AM,"Analysts Offer Insights on Healthcare Companies: Cigna (CI), Agios Pharma (AGIO) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-cigna-ci-agios-pharma-agio-and-regeneron-regn-1032946766
1720.0,1/5/2024 10:55:41 AM,Eylea HD Launch Poised to Outperform and Drive Regeneron’s Stock Growth,TipRanks,/news/stocks/eylea-hd-launch-poised-to-outperform-and-drive-regeneron-s-stock-growth-1032947187
1721.0,1/5/2024 10:05:00 PM,"Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024",GlobeNewswire,/news/stocks/regeneron-to-report-fourth-quarter-and-full-year-2023-financial-and-operating-results-and-host-conference-call-and-webcast-on-february-2-2024-1032947034
1722.0,1/6/2024 1:50:27 AM,"Analysts Conflicted on These Healthcare Names: Innate Pharma SA (OtherIPHYF), Amgen (AMGN) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-innate-pharma-sa-otheriphyf-amgen-amgn-and-regeneron-regn-1032947412
1723.0,1/9/2024 10:18:37 AM,Regeneron Sell Rating Justified by Underperforming Sales and Competitive Pressures,TipRanks,/news/stocks/regeneron-sell-rating-justified-by-underperforming-sales-and-competitive-pressures-1032955184
1724.0,1/9/2024 10:30:16 AM,Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT) and Regeneron (REGN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-ptc-therapeutics-ptct-and-regeneron-regn-1032955211
1725.0,1/9/2024 1:30:34 PM,"Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Dexcom (DXCM)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-regeneron-regn-dexcom-dxcm-1032955405
1726.0,1/9/2024 2:30:20 PM,Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and Regeneron (REGN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biomarin-pharmaceutical-bmrn-and-regeneron-regn-1032955456
1727.0,1/9/2024 7:00:57 PM,Beyond The Numbers: 13 Analysts Discuss Regeneron Pharmaceuticals Stock,Benzinga,/news/stocks/beyond-the-numbers-13-analysts-discuss-regeneron-pharmaceuticals-stock-1032954730
1728.0,1/11/2024 6:34:48 AM,Positive Outlook for Regeneron: Buy Rating Affirmed Amidst Eylea’s Resilience and Promising Pipeline Developments,TipRanks,/news/stocks/positive-outlook-for-regeneron-buy-rating-affirmed-amidst-eylea-s-resilience-and-promising-pipeline-developments-1032959790
1729.0,1/12/2024 4:18:11 PM,Regeneron Pharma's Pipeline Makes This Analyst Turn Bullish,Benzinga,/news/stocks/regeneron-pharma-s-pipeline-makes-this-analyst-turn-bullish-1032964340
1730.0,1/15/2024 5:30:44 AM,"Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT), Regeneron (REGN) and Pediatrix Medical Group (MD)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-ptc-therapeutics-ptct-regeneron-regn-and-pediatrix-medical-group-md-1032966647
1731.0,1/16/2024 1:00:00 PM,Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement,GlobeNewswire,/news/stocks/dupixent-dupilumab-u-s-label-updated-with-data-further-supporting-use-in-atopic-dermatitis-with-moderate-to-severe-hand-and-foot-involvement-1032970179
1732.0,1/16/2024 6:51:12 PM,Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market,InvestorPlace,/news/stocks/healthcare-heroes-3-biotech-stocks-poised-to-cure-what-ails-the-market-1032971697
1733.0,1/18/2024 9:54:53 PM,EXCLUSIVE: The 'Buy Everything' Market Is Over: Synopsys-Ansys Merger Provides Fertile Ground For This Stock Picker,Benzinga,/news/etf/exclusive-the-buy-everything-market-is-over-synopsys-ansys-merger-provides-fertile-ground-for-this-stock-picker-1032978230
1734.0,1/22/2024 8:37:34 PM,"Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades",Benzinga,/news/stocks/aclaris-therapeutics-ati-1777-faces-uphill-battle-in-atopic-dermatitis-treatment-landscape-analyst-downgrades-1032984777
1735.0,1/22/2024 9:00:31 PM,"Analysts Offer Insights on Healthcare Companies: Agenus (AGEN), Regeneron (REGN) and Warby Parker (WRBY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-agenus-agen-regeneron-regn-and-warby-parker-wrby-1032987227
1736.0,1/23/2024 10:55:47 PM,3 Blue-Chip Healthcare Stocks to Buy and Hold Forever: January 2024,InvestorPlace,/news/stocks/3-blue-chip-healthcare-stocks-to-buy-and-hold-forever-january-2024-1032989675
1737.0,1/24/2024 6:00:00 PM,Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards,GlobeNewswire,/news/stocks/top-40-high-school-scientists-in-prestigious-regeneron-science-talent-search-to-compete-for-1-8-million-in-awards-1032993529
1738.0,1/24/2024 8:55:14 PM,"Slow Market Penetration For Biogen's Another Alzheimer's Drug: UBS Highlights Risks, Forecasts",Benzinga,/news/stocks/slow-market-penetration-for-biogen-s-another-alzheimer-s-drug-ubs-highlights-risks-forecasts-1032993934
1739.0,1/25/2024 7:56:31 PM,Regeneron/ Sanofi win label expansion for Dupixent in esophageal disorder,Seeking Alpha,https://seekingalpha.com/news/4058699-regeneron-sanofi-win-label-expansion-dupixent?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1740.0,1/25/2024 8:29:00 PM,Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE),GlobeNewswire,/news/stocks/dupixent-dupilumab-fda-approved-as-first-and-only-treatment-indicated-for-children-aged-1-year-and-older-with-eosinophilic-esophagitis-eoe-1032998309
1741.0,1/25/2024 11:04:47 PM,Regeneron Receives FDA Approval For Dupixent For Patients Aged 1 To 11 Years ,RTTNews,/news/stocks/regeneron-receives-fda-approval-for-dupixent-for-patients-aged-1-to-11-years-1032998682
1742.0,1/26/2024 8:00:55 PM,"Catalyst watch: Apple earnings, Boeing on the hot seat, FOMC meeting and Amer Sports IPO",Seeking Alpha,https://seekingalpha.com/news/4059230-catalyst-watch-apple-earnings-boeing-on-the-hot-seat-fomc-meeting-and-amer-sports-ipo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1743.0,1/28/2024 5:00:53 PM,Big Pharma earnings season in spotlight amid positive sentiment,Seeking Alpha,https://seekingalpha.com/news/4059361-big-pharma-earnings-spotlight-positive-sentiment?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1744.0,1/29/2024 12:20:49 PM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Regeneron (REGN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-regeneron-regn-1033006315
1745.0,1/29/2024 3:04:30 PM,"AI, Biotech, Energy Sectors Expect M&A Revival For 2024",Benzinga,/news/stocks/ai-biotech-energy-sectors-expect-m-a-revival-for-2024-1033005691
1746.0,1/29/2024 9:00:27 PM,Breaking Down Regeneron Pharmaceuticals: 14 Analysts Share Their Views,Benzinga,/news/stocks/breaking-down-regeneron-pharmaceuticals-14-analysts-share-their-views-1033006998
1747.0,1/30/2024 12:24:33 PM,2seventy stock rises as Regeneron acquires R&D assets,Seeking Alpha,https://seekingalpha.com/news/4059942-2seventy-stock-rises-as-regeneron-acquires-rd-assets?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1748.0,1/30/2024 12:25:34 PM,Piper Sandler Sticks to Its Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/piper-sandler-sticks-to-its-buy-rating-for-regeneron-regn-1033010906
1749.0,1/30/2024 1:00:41 PM,Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs,GlobeNewswire,/news/stocks/regeneron-announces-formation-of-regeneron-cell-medicines-with-the-acquisition-of-2seventy-bio-platforms-and-preclinical-and-clinical-programs-1033009547
1750.0,1/30/2024 1:20:20 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1033011102
1751.0,1/30/2024 1:32:55 PM,Regeneron Announces Formation Of Regeneron Cell Medicines With Acquisition Of 2seventy Bio ,RTTNews,/news/stocks/regeneron-announces-formation-of-regeneron-cell-medicines-with-acquisition-of-2seventy-bio-1033009635
1752.0,1/31/2024 8:47:11 PM,"Leerink ups 2seventy to outperform, cites attractiveness as takeover target",Seeking Alpha,https://seekingalpha.com/news/4060882-leerink-ups-2seventy-to-outperform-cites-attractiveness-as-takeover-target?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1753.0,2/1/2024 3:00:02 PM,Notable earnings before Friday's open,Seeking Alpha,https://seekingalpha.com/news/4061340-notable-earnings-before-fridays-open?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1754.0,2/1/2024 3:01:13 PM,What Wall Street expects from Regeneron Pharmaceuticals's earnings,Markets Insider Automation,/news/stocks/regeneron-stock-price-quarter-earnings-preview-q4-1033020713
1755.0,2/1/2024 4:33:16 PM,Regeneron Pharmaceuticals Q4 2023 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/4061447-regeneron-pharmaceuticals-q4-2023-earnings-preview?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1756.0,2/1/2024 10:00:00 PM,3 Top Pharma Stocks to Buy Now: February 2024,InvestorPlace,/news/stocks/3-top-pharma-stocks-to-buy-now-february-2024-1033022674
1757.0,2/2/2024 1:20:17 AM,"Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX), Sarepta Therapeutics (SRPT) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-quest-diagnostics-dgx-sarepta-therapeutics-srpt-and-regeneron-regn-1033022899
1758.0,2/2/2024 8:41:39 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1033024513
1759.0,2/2/2024 11:32:56 AM,Regeneron Pharmaceuticals beats top-line and bottom-line estimates; initiates FY24 outlook,Seeking Alpha,https://seekingalpha.com/news/4061930-regeneron-pharmaceuticals-beats-top-line-and-bottom-line-estimates-initiates-fy24-outlook?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1760.0,2/2/2024 12:00:04 PM,Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma,GlobeNewswire,/news/stocks/linvoseltamab-receives-ema-filing-acceptance-for-treatment-of-relapsed-refractory-multiple-myeloma-1033024336
1761.0,2/2/2024 12:13:00 PM,"Regeneron posts Q4 beat even as Eylea, COVID-19 sales dip",Seeking Alpha,https://seekingalpha.com/news/4061949-regeneron-posts-q4-beat-even-eylea-covid-19-sales-dip?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1762.0,2/2/2024 12:17:52 PM,Regeneron multiple myeloma therapy accepted for EU review,Seeking Alpha,https://seekingalpha.com/news/4061953-regeneron-multiple-myeloma-therapy-undergoes-eu-review?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1763.0,2/2/2024 12:20:11 PM,Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX) and Regeneron (REGN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-nurix-therapeutics-nrix-and-regeneron-regn-1033025736
1764.0,2/2/2024 12:30:00 PM,Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results,GlobeNewswire,/news/stocks/regeneron-reports-fourth-quarter-and-full-year-2023-financial-and-operating-results-1033024473
1765.0,2/2/2024 12:38:11 PM,Regeneron Pharmaceuticals: EMA To Review Marketing Authorization Application For Linvoseltamab ,RTTNews,/news/stocks/regeneron-pharmaceuticals-ema-to-review-marketing-authorization-application-for-linvoseltamab-1033024508
1766.0,2/2/2024 12:40:40 PM,"Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), MoonLake Immunotherapeutics (MLTX)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-regeneron-regn-moonlake-immunotherapeutics-mltx-1033025789
1767.0,2/2/2024 12:44:48 PM,"Regeneron Pharmaceuticals Q4 Profit Decreases, but beats estimates",RTTNews,/news/stocks/regeneron-pharmaceuticals-q4-profit-decreases-but-beats-estimates-1033024554
1768.0,2/2/2024 12:59:52 PM,Regeneron Pharma Q4 Results Top Estimates - Update ,RTTNews,/news/stocks/regeneron-pharma-q4-results-top-estimates-update-1033024580
1769.0,2/2/2024 8:15:19 PM,Strong Buy for Regeneron: Outperforming Earnings and Eylea HD’s Market Dominance,TipRanks,/news/stocks/strong-buy-for-regeneron-outperforming-earnings-and-eylea-hd-s-market-dominance-1033026653
1770.0,2/5/2024 1:10:32 PM,"Analysts Are Bullish on Top Healthcare Stocks: 4D Molecular Therapeutics (FDMT), Boston Scientific (BSX)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-4d-molecular-therapeutics-fdmt-boston-scientific-bsx-1033031034
1771.0,2/5/2024 1:20:36 PM,"Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Arcellx Inc (ACLX)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-regeneron-regn-arcellx-inc-aclx-1033031080
1772.0,2/6/2024 12:25:48 PM,Strong Buy: Regeneron’s Growth Potential and Strategic R&D Investments,TipRanks,/news/stocks/strong-buy-regeneron-s-growth-potential-and-strategic-r-d-investments-1033035958
1773.0,2/6/2024 12:50:37 PM,"Analysts’ Top Healthcare Picks: Intuitive Surgical (ISRG), Vertex Pharmaceuticals (VRTX)",TipRanks,/news/stocks/analysts-top-healthcare-picks-intuitive-surgical-isrg-vertex-pharmaceuticals-vrtx-1033036025
1774.0,2/6/2024 6:00:25 PM,Cantor Fitzgerald Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know,Benzinga,/news/stocks/cantor-fitzgerald-maintains-neutral-rating-for-regeneron-pharmaceuticals-here-s-what-you-need-to-know-1033036264
1775.0,2/6/2024 8:05:37 PM,"4D Molecular Therapeutics' 4D-150 Phase 2 Data Met Investor Expectations, Analyst Boosts Forecast",Benzinga,/news/stocks/4d-molecular-therapeutics-4d-150-phase-2-data-met-investor-expectations-analyst-boosts-forecast-1033036575
1776.0,2/6/2024 8:27:22 PM,Veru eyes better weight loss drugs as FDA clears Phase 2 trial,Seeking Alpha,https://seekingalpha.com/news/4063394-veru-eyes-better-weight-loss-drugs-fda-clears-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1777.0,2/6/2024 9:31:15 PM,The Top 25 Stocks to Buy Immediately According to AI: February 2024 Edition,InvestorPlace,/news/stocks/the-top-25-stocks-to-buy-immediately-according-to-ai-february-2024-edition-1033036939
1778.0,2/6/2024 10:05:00 PM,Regeneron Announces Investor Conference Presentations,GlobeNewswire,/news/stocks/regeneron-announces-investor-conference-presentations-1033036732
1779.0,2/7/2024 1:25:41 PM,Buy Rating Affirmed for Regeneron on Strong Drug Pipeline and Market Growth Potential,TipRanks,/news/stocks/buy-rating-affirmed-for-regeneron-on-strong-drug-pipeline-and-market-growth-potential-1033042014
1780.0,2/9/2024 3:02:33 PM,Ocular Therapeutix spikes as BofA starts at Buy on wet AMD prospects,Seeking Alpha,https://seekingalpha.com/news/4065169-ocular-therapeutix-stock-spikes-bofa-starts-at-buy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1781.0,2/11/2024 5:17:08 PM,"After Meta debuts a dividend, Goldman does the math if big names follow suit",Seeking Alpha,https://seekingalpha.com/news/4065357-after-meta-debuts-a-dividend-goldman-does-the-math-if-big-names-follow-suit?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1782.0,2/15/2024 8:20:40 AM,"Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT), Regeneron (REGN) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-health-catalyst-hcat-regeneron-regn-and-merck-company-mrk-1033071011
1783.0,2/16/2024 6:59:00 AM,Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU) ,GlobeNewswire,/news/stocks/japan-first-in-the-world-to-approve-dupixent-dupilumab-for-chronic-spontaneous-urticaria-csu-1033074497
1784.0,2/16/2024 7:35:52 AM,Sanofi's Dupixent Approved In Japan For Chronic Spontaneous Urticaria Treatment ,RTTNews,/news/stocks/sanofi-s-dupixent-approved-in-japan-for-chronic-spontaneous-urticaria-treatment-1033074564
1785.0,2/16/2024 11:17:43 AM,"Sanofi, Regeneron win Japan approval for Dupixent in CSU indication",Seeking Alpha,https://seekingalpha.com/news/4068079-sanofi-regeneron-win-japan-approval-for-dupixent-in-csu-indication?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1786.0,2/21/2024 12:13:01 PM,"Regeneron, Vertex Pharma join $100B club in biotech",Seeking Alpha,https://seekingalpha.com/news/4069456-regeneron-vertex-pharma-join-100b-club-biotech?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1787.0,2/21/2024 1:00:13 PM,Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review,GlobeNewswire,/news/stocks/linvoseltamab-bla-for-treatment-of-relapsed-refractory-multiple-myeloma-accepted-for-fda-priority-review-1033087202
1788.0,2/21/2024 1:14:13 PM,Regeneron multiple myeloma therapy granted FDA priority review,Seeking Alpha,https://seekingalpha.com/news/4069510-regeneron-wins-fda-priority-review-multiple-myeloma-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1789.0,2/21/2024 1:50:22 PM,Regeneron: Linvoseltamab BLA To Treat RR/MM Accepted For FDA Priority Review ,RTTNews,/news/stocks/regeneron-linvoseltamab-bla-to-treat-rr-mm-accepted-for-fda-priority-review-1033087414
1790.0,2/23/2024 7:00:00 AM,Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation,GlobeNewswire,/news/stocks/dupixent-dupilumab-sbla-accepted-for-fda-priority-review-for-treatment-of-copd-with-type-2-inflammation-1033095932
1791.0,2/23/2024 7:36:15 AM,Sanofi: Dupixent SBLA Accepted For FDA Priority Review For COPD With Type 2 Inflammation ,RTTNews,/news/stocks/sanofi-dupixent-sbla-accepted-for-fda-priority-review-for-copd-with-type-2-inflammation-1033096002
1792.0,2/23/2024 10:40:38 AM,"Sanofi, Regeneron win FDA priority review for Dupixent label expansion",Seeking Alpha,https://seekingalpha.com/news/4070961-sanofi-regeneron-win-fda-priority-review-for-dupixent-label-expansion?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1793.0,2/23/2024 12:25:57 PM,Buy Rating Affirmed: Regeneron’s Strategic Growth in Obesity Metabolic Space,TipRanks,/news/stocks/buy-rating-affirmed-regeneron-s-strategic-growth-in-obesity-metabolic-space-1033098082
1794.0,2/27/2024 5:30:17 AM,"Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Relay Therapeutics (RLAY) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-korro-bio-krro-relay-therapeutics-rlay-and-regeneron-regn-1033106016
1795.0,2/27/2024 12:47:34 PM,Truist Financial Gives a Buy Rating to Regeneron (REGN),TipRanks,/news/stocks/truist-financial-gives-a-buy-rating-to-regeneron-regn-1033108491
1796.0,2/27/2024 12:51:09 PM,"Analysts Are Bullish on Top Healthcare Stocks: ANI Pharmaceuticals (ANIP), Boston Scientific (BSX)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-ani-pharmaceuticals-anip-boston-scientific-bsx-1033108458
1797.0,2/27/2024 4:00:23 PM,The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 10 Experts,Benzinga,/news/stocks/the-analyst-verdict-regeneron-pharmaceuticals-in-the-eyes-of-10-experts-1033108205
1798.0,2/28/2024 9:52:49 AM,Biotech Stocks Facing FDA Decision In March 2024 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-march-2024-1033111344
1799.0,3/4/2024 9:09:21 PM,Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits,InvestorPlace,/news/stocks/biotechs-on-the-rise-3-stocks-to-buy-for-a-shot-of-profits-1033130269
1800.0,3/8/2024 12:30:38 PM,"Analysts Are Bullish on Top Healthcare Stocks: Amgen (AMGN), Regeneron (REGN)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-amgen-amgn-regeneron-regn-1033146997
1801.0,3/8/2024 1:00:26 PM,EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet,GlobeNewswire,/news/stocks/eylea-hd-aflibercept-injection-8-mg-pivotal-data-in-wet-age-related-macular-degeneration-wamd-and-diabetic-macular-edema-dme-published-in-the-lancet-1033145992
1802.0,3/11/2024 11:52:45 AM,Regeneron's Praluent injection gets FDA approval to treat kids with genetic form of high cholesterol,Seeking Alpha,https://seekingalpha.com/news/4077906-regenerons-praluent-injection-gets-fda-approval-to-treat-kids-with-genetic-form-of-high-cholesterol?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1803.0,3/11/2024 12:00:23 PM,Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol,GlobeNewswire,/news/stocks/praluent-alirocumab-injection-receives-fda-approval-to-treat-children-with-genetic-form-of-high-cholesterol-1033150190
1804.0,3/11/2024 12:33:30 PM,Regeneron Announces FDA Approval Extending Treatment Of Praluent To Children Aged 8 ,RTTNews,/news/stocks/regeneron-announces-fda-approval-extending-treatment-of-praluent-to-children-aged-8-1033150359
1805.0,3/13/2024 2:30:22 AM,"High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization",GlobeNewswire,/news/stocks/high-school-seniors-win-1-8-million-at-regeneron-science-talent-search-2024-for-innovative-scientific-research-on-artificial-intelligence-cancer-metabolism-and-mathematical-optimization-1033157063
1806.0,3/13/2024 9:01:16 AM,"Analysts’ Top Healthcare Picks: Cooper Co (COO), Regeneron (REGN)",TipRanks,/news/stocks/analysts-top-healthcare-picks-cooper-co-coo-regeneron-regn-1033159157
1807.0,3/13/2024 1:51:49 PM,NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday,Benzinga,/news/stocks/nvidia-to-rally-around-20-here-are-10-top-analyst-forecasts-for-wednesday-1033159347
1808.0,3/13/2024 2:55:32 PM,The 3 Most Undervalued Biotech Stocks to Buy in March 2024,InvestorPlace,/news/stocks/the-3-most-undervalued-biotech-stocks-to-buy-in-march-2024-1033160441
1809.0,3/15/2024 9:20:45 AM,"Analysts Are Bullish on These Healthcare Stocks: 89bio (ETNB), Intuitive Surgical (ISRG)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-89bio-etnb-intuitive-surgical-isrg-1033167884
1810.0,3/19/2024 5:36:55 AM,Buy Rating Affirmed for Regeneron on Eylea HD Success and Innovative Obesity Program,TipRanks,/news/stocks/buy-rating-affirmed-for-regeneron-on-eylea-hd-success-and-innovative-obesity-program-1033175060
1811.0,3/22/2024 4:40:30 PM,Intellia opts out of hemophilia pact with Regeneron,Seeking Alpha,https://seekingalpha.com/news/4082899-intellia-opts-out-of-hemophilia-pact-with-regeneron?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1812.0,3/22/2024 9:07:27 PM,Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs,InvestorPlace,/news/stocks/hot-stocks-the-3-best-opportunities-for-investing-in-weight-loss-drugs-1033190216
1813.0,3/25/2024 12:00:02 PM,Regeneron Provides Update on Biologics License Application for Odronextamab,GlobeNewswire,/news/stocks/regeneron-provides-update-on-biologics-license-application-for-odronextamab-1033192564
1814.0,3/25/2024 12:45:53 PM,Regeneron Says FDA Rejects BLA Approval For Odronextamab In Follicular Lyphoma ,RTTNews,/news/stocks/regeneron-says-fda-rejects-bla-approval-for-odronextamab-in-follicular-lyphoma-1033192791
1815.0,3/25/2024 2:29:37 PM,FDA declines to approve Regeneron lymphoma drug odronextamab,Seeking Alpha,https://seekingalpha.com/news/4083333-fda-declines-to-approve-regeneron-lymphoma-drug-odronextamab?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1816.0,3/25/2024 4:31:04 PM,Analysts Offer Insights on Healthcare Companies: Alphatec Holdings (ATEC) and Regeneron (REGN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-alphatec-holdings-atec-and-regeneron-regn-1033194555
1817.0,3/25/2024 4:40:14 PM,Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and Alphatec Holdings (ATEC),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-and-alphatec-holdings-atec-1033194548
1818.0,3/26/2024 8:51:41 AM,"Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Regeneron (REGN) and Intuitive Surgical (ISRG)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-united-therapeutics-uthr-regeneron-regn-and-intuitive-surgical-isrg-1033196448
1819.0,3/26/2024 10:44:00 AM,3 Biotech Stocks to Buy for the Next Bull Run: March 2024,InvestorPlace,/news/stocks/3-biotech-stocks-to-buy-for-the-next-bull-run-march-2024-1033196128
1820.0,3/26/2024 12:45:34 PM,Truist Financial Remains a Buy on Regeneron (REGN),TipRanks,/news/stocks/truist-financial-remains-a-buy-on-regeneron-regn-1033197883
1821.0,3/26/2024 3:01:15 PM,Decoding 12 Analyst Evaluations For Regeneron Pharmaceuticals,Benzinga,/news/stocks/decoding-12-analyst-evaluations-for-regeneron-pharmaceuticals-1033197081
1822.0,3/28/2024 5:11:15 PM,Xeris gains as Oppenheimer highlights drug technology,Seeking Alpha,https://seekingalpha.com/news/4085090-xeris-stock-gains-oppenheimer-bullish-view?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1823.0,4/1/2024 1:35:02 AM,Sanofi and Regeneron’s Dupixent set for large gains with likely COPD approval,Seeking Alpha,https://seekingalpha.com/news/4085383-sanofi-regeneron-dupixent-set-large-gains-likely-copd-approval?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1824.0,4/1/2024 10:05:00 PM,"Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024 ",GlobeNewswire,/news/stocks/regeneron-to-report-first-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-may-2-2024-1033212450
1825.0,4/2/2024 3:36:00 PM,Biotech Roundtable: Who will bring the next CRISPR drug to market?,Seeking Alpha,https://seekingalpha.com/news/4083199-biotech-roundtable-who-will-bring-the-next-crispr-drug-to-market?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1826.0,4/2/2024 8:30:04 PM,5 Healthcare Stocks to Buy for 2024,InvestorPlace,/news/stocks/5-healthcare-stocks-to-buy-for-2024-1033216722
1827.0,4/3/2024 11:03:07 PM,"LLY, REGN, BHVN: Which Biotech Stock Offers the Most Upside?",TipRanks,/news/stocks/lly-regn-bhvn-which-biotech-stock-offers-the-most-upside-1033220670
1828.0,4/7/2024 12:00:00 PM,"Phathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analyst",Seeking Alpha,https://seekingalpha.com/news/4087726-phathom-pharma-rhythm-vaxcyte-most-likely-takeover-targets-in-pharma-analyst?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1829.0,4/7/2024 10:00:12 PM,Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma,GlobeNewswire,/news/stocks/linvoseltamab-pivotal-data-presented-at-aacr-reinforce-high-response-rate-that-deepens-over-time-in-patients-with-heavily-pre-treated-multiple-myeloma-1033227781
1830.0,4/9/2024 9:50:10 AM,"Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Veeva Systems (VEEV) and Ultragenyx Pharmaceutical (RARE)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-veeva-systems-veev-and-ultragenyx-pharmaceutical-rare-1033233297
1831.0,4/9/2024 10:45:55 AM,Regeneron (REGN) Receives a Buy from RBC Capital,TipRanks,/news/stocks/regeneron-regn-receives-a-buy-from-rbc-capital-1033233582
1832.0,4/10/2024 9:09:55 PM,DOJ files complaint against Regeneron over Eylea Medicare pricing,Seeking Alpha,https://seekingalpha.com/news/4088761-doj-sues-regeneron-over-eylea-medicare-pricing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1833.0,4/11/2024 12:55:34 PM,DOJ files complaint against Regeneron over Eylea Medicare pricing,Seeking Alpha,https://seekingalpha.com/news/4088761-doj-files-complaint-regeneron-over-eylea-medicare-pricing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1834.0,4/11/2024 5:15:17 PM,Regeneron hits three-month low after DOJ complaint; RBC defends,Seeking Alpha,https://seekingalpha.com/news/4089001-regeneron-stock-defended-rbc-doj-suit?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1835.0,4/12/2024 9:20:20 AM,"Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Instil Bio (TIL) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-teladoc-tdoc-instil-bio-til-and-regeneron-regn-1033244090
1836.0,4/12/2024 12:33:13 PM,"Analysts Are Bullish on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Regeneron (REGN)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-biomarin-pharmaceutical-bmrn-regeneron-regn-1033245004
1837.0,4/12/2024 4:01:51 PM,Breaking Down Regeneron Pharmaceuticals: 13 Analysts Share Their Views,Benzinga,/news/stocks/breaking-down-regeneron-pharmaceuticals-13-analysts-share-their-views-1033244707
1838.0,4/16/2024 12:37:08 PM,Regeneron to 'vigorously defend' against DOJ on Eylea pricing complaint,Seeking Alpha,https://seekingalpha.com/news/4090005-regeneron-defend-in-eylea-pricing-lawsuit?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1839.0,4/17/2024 10:55:10 AM,Cantor Fitzgerald Reaffirms Their Hold Rating on Regeneron (REGN),TipRanks,/news/stocks/cantor-fitzgerald-reaffirms-their-hold-rating-on-regeneron-regn-1033258113
1840.0,4/17/2024 1:00:30 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1033258919
1841.0,4/17/2024 8:39:46 PM,Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick,Benzinga,/news/stocks/amgen-astrazeneca-s-asthma-drug-tezspire-vs-sanofi-regeneron-s-blockbuster-dupixent---analyst-gives-his-pick-1033259296
1842.0,4/22/2024 12:29:48 PM,Regeneron (REGN) Gets a Buy from Piper Sandler,TipRanks,/news/stocks/regeneron-regn-gets-a-buy-from-piper-sandler-1033271987
1843.0,4/22/2024 11:54:01 PM,Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT),GlobeNewswire,/news/stocks/regeneron-to-highlight-advances-in-genetic-medicine-research-at-american-society-of-gene-and-cell-therapy-asgct-1033272918
1844.0,4/24/2024 4:05:18 PM,Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO,GlobeNewswire,/news/stocks/regeneron-to-showcase-progress-in-advancing-novel-investigational-treatment-approaches-for-a-broad-range-of-solid-tumors-and-blood-cancers-at-asco-1033282725
1845.0,4/25/2024 9:44:05 AM,Wells Fargo Reaffirms Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/wells-fargo-reaffirms-their-buy-rating-on-regeneron-regn-1033287880
1846.0,4/25/2024 12:19:01 PM,"Regeneron, Mammoth in pact to develop CRISPR-based gene editing therapies",Seeking Alpha,https://seekingalpha.com/news/4094054-regeneron-mammoth-pact-develop-crispr-based-gene-editing-therapies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1847.0,4/25/2024 1:00:00 PM,Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases,GlobeNewswire,/news/stocks/regeneron-and-mammoth-biosciences-collaborate-to-pursue-next-generation-crispr-based-gene-editing-for-multiple-diseases-1033287218
1848.0,4/25/2024 3:24:05 PM,AbbVie reports positive results from Rinvoq versus Dupixent study,Seeking Alpha,https://seekingalpha.com/news/4094231-abbvie-reports-positive-results-from-rinoq-versus-dupixent-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1849.0,4/26/2024 8:48:18 AM,Barclays Sticks to Their Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/barclays-sticks-to-their-buy-rating-for-regeneron-regn-1033293611
1850.0,4/26/2024 12:21:27 PM,"Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-regeneron-regn-gilead-sciences-gild-1033295043
1851.0,4/29/2024 1:00:18 PM,EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases,GlobeNewswire,/news/stocks/eylea-hd-aflibercept-injection-8-mg-presentations-at-arvo-reinforce-sustained-and-clinically-meaningful-outcomes-in-serious-retinal-diseases-1033299551
1852.0,4/30/2024 11:20:27 AM,"Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), DocGo (DCGO) and Revvity (RVTY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-docgo-dcgo-and-revvity-rvty-1033307295
1853.0,5/1/2024 3:01:13 PM,Regeneron Pharmaceuticals earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/regeneron-q1-quarterly-earnings-preview-1033313159
1854.0,5/1/2024 3:30:13 PM,Regeneron Pharmaceuticals Q1 2024 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/4097429-regeneron-pharmaceuticals-q1-2024-earnings-preview?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1855.0,5/1/2024 5:18:37 PM,Adverum Biotechnologies a new buy at H.C. Wainwright on wet AMD gene therapy,Seeking Alpha,https://seekingalpha.com/news/4097663-adverum-biotechnologies-new-buy-hc-wainwright-wet-amd-gene-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1856.0,5/2/2024 10:32:10 AM,Regeneron Pharmaceuticals misses top-line and bottom-line estimates; updates FY24 outlook,Seeking Alpha,https://seekingalpha.com/news/4098262-regeneron-pharmaceuticals-misses-top-line-and-bottom-line-estimates-updates-fy24-outlook?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1857.0,5/2/2024 11:55:40 AM,Regeneron falls after Q1 miss; announces $3B share buybacks,Seeking Alpha,https://seekingalpha.com/news/4098419-regeneron-stock-falls-despite-3b-buybacks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1858.0,5/2/2024 12:30:00 PM,Regeneron Reports First Quarter 2024 Financial and Operating Results,GlobeNewswire,/news/stocks/regeneron-reports-first-quarter-2024-financial-and-operating-results-1033318764
1859.0,5/2/2024 1:11:00 PM,"4 stocks to watch on Thursday: NVO, AAPL and more",Seeking Alpha,https://seekingalpha.com/news/4098511-4-stocks-to-watch-on-thursday-nvo-aapl-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1860.0,5/2/2024 1:31:02 PM,"Regeneron Pharmaceuticals Q1 Profit Decreases, misses estimates",RTTNews,/news/stocks/regeneron-pharmaceuticals-q1-profit-decreases-misses-estimates-1033319178
1861.0,5/2/2024 2:53:50 PM,"REGN Stock Earnings: Regeneron Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024",InvestorPlace,/news/stocks/regn-stock-earnings-regeneron-pharmaceuticals-for-q1-of-2024-1033320985
1862.0,5/2/2024 7:42:06 PM,"Wall Street Inches Up After Powell's Inflation Remarks; Chipmakers Rebound; Gold, Crude Falter: What's Driving Markets Thursday?",Benzinga,/news/etf/wall-street-inches-up-after-powell-s-inflation-remarks-chipmakers-rebound-gold-crude-falter-what-s-driving-markets-thursday-1033321858
1863.0,5/3/2024 10:15:00 AM,Shhh! 3 Secret Pharma Stocks Flying Below Wall Street’s Radar,InvestorPlace,/news/stocks/shhh-3-secret-pharma-stocks-flying-below-wall-streets-radar-1033325813
1864.0,5/3/2024 10:36:35 AM,Buy Rating Affirmed: Regeneron’s Promising Pipeline and Potential for Surpassing Earnings Expectations,TipRanks,/news/stocks/buy-rating-affirmed-regeneron-s-promising-pipeline-and-potential-for-surpassing-earnings-expectations-1033326637
1865.0,5/3/2024 10:47:50 AM,Buy Rating Affirmed for Regeneron on Strong Product Performance and Promising Pipeline Developments,TipRanks,/news/stocks/buy-rating-affirmed-for-regeneron-on-strong-product-performance-and-promising-pipeline-developments-1033326775
1866.0,5/3/2024 11:30:30 AM,Truist Financial Keeps Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/truist-financial-keeps-their-buy-rating-on-regeneron-regn-1033327379
1867.0,5/3/2024 12:08:35 PM,Regeneron (REGN) Receives a Buy from Oppenheimer,TipRanks,/news/stocks/regeneron-regn-receives-a-buy-from-oppenheimer-1033327530
1868.0,5/3/2024 12:23:24 PM,"Analysts Are Bullish on These Healthcare Stocks: Elevation Oncology (ELEV), Moderna (MRNA)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-elevation-oncology-elev-moderna-mrna-1033327573
1869.0,5/3/2024 6:00:22 PM,Assessing Regeneron Pharmaceuticals: Insights From 16 Financial Analysts,Benzinga,/news/stocks/assessing-regeneron-pharmaceuticals-insights-from-16-financial-analysts-1033327843
1870.0,5/3/2024 7:00:00 PM,"Catalyst Watch: Disney earnings, Apple iPad event and Fed speakers back on the circuit",Seeking Alpha,https://seekingalpha.com/news/4098577-catalyst-watch-disney-earnings-apple-ipad-event-and-fed-speakers-back-on-the-circuit?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1871.0,5/4/2024 4:00:00 PM,3 Biotech Stocks With the Potential to Make You an Overnight Millionaire,InvestorPlace,/news/stocks/3-biotech-stocks-with-the-potential-to-make-you-an-overnight-millionaire-1033328809
1872.0,5/4/2024 7:30:00 PM,Pharma R&D productivity seen improving for the first time in years - Deloitte,Seeking Alpha,https://seekingalpha.com/news/4099974-pharma-research-development-productivity-improving-first-time-years?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1873.0,5/6/2024 5:15:24 AM,Buy Rating Affirmed for Regeneron on Strong Product Sales and Promising Pipeline,TipRanks,/news/stocks/buy-rating-affirmed-for-regeneron-on-strong-product-sales-and-promising-pipeline-1033331854
1874.0,5/6/2024 10:05:00 PM,Regeneron Announces Investor Conference Presentations,GlobeNewswire,/news/stocks/regeneron-announces-investor-conference-presentations-1033335104
1875.0,5/8/2024 6:31:56 AM,"Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (OtherSEMHF), Tilray (TLRY) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-siemens-healthineers-ag-othersemhf-tilray-tlry-and-regeneron-regn-1033346049
1876.0,5/8/2024 12:00:57 PM,Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks,GlobeNewswire,/news/stocks/latest-db-oto-results-show-dramatically-improved-hearing-to-normal-levels-in-a-child-with-profound-genetic-deafness-within-24-weeks-and-initial-hearing-improvements-in-a-second-child-at-6-weeks-1033346146
1877.0,5/8/2024 12:15:41 PM,Regeneron gene therapy improves hearing in child deafness,Seeking Alpha,https://seekingalpha.com/news/4102362-regeneron-therapy-improves-hearing-deaf-child?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1878.0,5/13/2024 7:00:00 AM,Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP),GlobeNewswire,/news/stocks/dupixent-dupilumab-sbla-accepted-for-fda-priority-review-for-treatment-of-adolescents-with-chronic-rhinosinusitis-with-nasal-polyposis-crswnp-1033366922
1879.0,5/13/2024 7:56:16 AM,Regeneron : Dupixent SBLA Accepted For FDA Priority Review For Adolescent Chronic Rhinosinusitis ,RTTNews,/news/stocks/regeneron-dupixent-sbla-accepted-for-fda-priority-review-for-adolescent-chronic-rhinosinusitis-1033367087
1880.0,5/14/2024 3:24:32 PM,Evercore says biotech ‘winter is finally thawing’,Seeking Alpha,https://seekingalpha.com/news/4105937-evercore-says-biotech-winter-is-finally-thawing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1881.0,5/15/2024 12:21:04 PM,"Analysts Are Bullish on These Healthcare Stocks: Taysha Gene Therapies (TSHA), Biogen (BIIB)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-taysha-gene-therapies-tsha-biogen-biib-1033385532
1882.0,5/17/2024 6:08:34 PM,Regeneron wins temporary restraining order preventing Eylea generic launch (update),Seeking Alpha,https://seekingalpha.com/news/4107951-regeneron-wins-temporary-restraining-order-preventing-eylea-generics?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1883.0,5/17/2024 7:45:49 PM,More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024,GlobeNewswire,/news/stocks/more-than-9-million-awarded-to-high-school-scientists-and-engineers-at-the-regeneron-international-science-and-engineering-fair-2024-1033400511
1884.0,5/18/2024 6:52:07 PM,"Novo Nordisk, J&J lead R&D rankings in big pharma: report",Seeking Alpha,https://seekingalpha.com/news/4108110-novo-nordisk-j-j-lead-rd-big-pharma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1885.0,5/20/2024 10:32:04 AM,"Analysts’ Top Healthcare Picks: Praxis Precision Medicines (PRAX), Corbus Pharmaceuticals (CRBP)",TipRanks,/news/stocks/analysts-top-healthcare-picks-praxis-precision-medicines-prax-corbus-pharmaceuticals-crbp-1033403502
1886.0,5/20/2024 4:16:50 PM,Regeneron Eylea generics approved by FDA,Seeking Alpha,https://seekingalpha.com/news/4108410-regeneron-eylea-generics-approved-by-fda?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1887.0,5/20/2024 5:34:36 PM,7 Biotech Stocks That Could Breathe New Life Into Your Portfolio,InvestorPlace,/news/stocks/7-biotech-stocks-that-could-breathe-new-life-into-your-portfolio-1033404432
1888.0,5/20/2024 8:15:00 PM,Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine,GlobeNewswire,/news/stocks/dupixent-dupilumab-late-breaking-data-from-notus-confirmatory-phase-3-copd-trial-presented-at-ats-and-published-in-the-new-england-journal-of-medicine-1033404505
1889.0,5/21/2024 12:11:09 PM,"Analysts Are Bullish on Top Healthcare Stocks: Progyny (PGNY), Regeneron (REGN)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-progyny-pgny-regeneron-regn-1033408140
1890.0,5/22/2024 9:16:57 AM,Wells Fargo Remains a Buy on Regeneron (REGN),TipRanks,/news/stocks/wells-fargo-remains-a-buy-on-regeneron-regn-1033411351
1891.0,5/23/2024 11:03:17 PM,Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO,GlobeNewswire,/news/stocks/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco-1033417552
1892.0,5/24/2024 5:42:55 PM,Sensei stock plunges 46% in wake of Phase 1 data,Seeking Alpha,https://seekingalpha.com/news/4110316-sensei-stock-plunges-in-wake-of-phase-1-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1893.0,5/29/2024 1:27:44 PM,Biohaven stock falls 30% premarket amid drug updates,Seeking Alpha,https://seekingalpha.com/news/4111145-biohaven-stock-falls-amid-drug-updates?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1894.0,5/29/2024 3:50:26 PM,AstraZeneca touts PCSK9 inhibitor in lowering LDL cholesterol when added to statin,Seeking Alpha,https://seekingalpha.com/news/4111181-astrazeneca-touts-pcsk9-inhibitor-lowering-ldl-cholesterol-added-statin?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1895.0,5/31/2024 7:00:00 AM,Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation,GlobeNewswire,/news/stocks/update-on-fda-priority-review-of-dupixent-dupilumab-for-the-treatment-of-copd-patients-with-type-2-inflammation-1033439668
1896.0,5/31/2024 7:05:00 AM,Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD,GlobeNewswire,/news/stocks/dupixent-dupilumab-recommended-for-eu-approval-by-the-chmp-to-treat-patients-with-copd-1033439672
1897.0,5/31/2024 7:18:51 AM,Regeneron : FDA Extends Review Period For Dupixent As COPD Treatment By Three Month ,RTTNews,/news/stocks/regeneron-fda-extends-review-period-for-dupixent-as-copd-treatment-by-three-month-1033439691
1898.0,5/31/2024 7:28:52 AM,"Sanofi, Regeneron: Dupixent Recommended For EU Approval By CHMP To Treat COPD  Patients ",RTTNews,/news/stocks/sanofi-regeneron-dupixent-recommended-for-eu-approval-by-chmp-to-treat-copd-patients-1033439706
1899.0,5/31/2024 10:49:06 AM,Regeneron/ Sanofi say FDA has delayed Dupixent COPD label,Seeking Alpha,https://seekingalpha.com/news/4111870-regeneron-stock-slips-dupixent-label-expansion-delayed?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1900.0,5/31/2024 1:40:09 PM,Analysts Conflicted on These Healthcare Names: Merit Medical Systems (MMSI) and Regeneron (REGN),TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-merit-medical-systems-mmsi-and-regeneron-regn-1033442296
1901.0,5/31/2024 6:47:47 PM,Buy Rating Affirmed for Regeneron Despite FDA Delay on Dupixent for COPD,TipRanks,/news/stocks/buy-rating-affirmed-for-regeneron-despite-fda-delay-on-dupixent-for-copd-1033442740
1902.0,6/2/2024 6:00:00 PM,Emerging and Chinese pharmas playing greater role in oncology drug development,Seeking Alpha,https://seekingalpha.com/news/4112099-emerging-chinese-pharmas-playing-greater-role-oncology-drug-development?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1903.0,6/3/2024 11:26:40 AM,Buy Rating Affirmed for REGN on Dupixent’s Strong Prospects Despite PDUFA Delay,TipRanks,/news/stocks/buy-rating-affirmed-for-regn-on-dupixent-s-strong-prospects-despite-pdufa-delay-1033446348
1904.0,6/3/2024 9:38:01 PM,"FibroGen stock rallies 30% after hours on FG-3165, FG-3175 updates",Seeking Alpha,https://seekingalpha.com/news/4112508-fibrogen-stock-rallies-after-hours-on-fg-3165-fg-3175-updates?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1905.0,6/4/2024 12:06:28 PM,RBC Capital Sticks to Its Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/rbc-capital-sticks-to-its-buy-rating-for-regeneron-regn-1033450355
1906.0,6/4/2024 4:01:20 PM,Navigating 14 Analyst Ratings For Regeneron Pharmaceuticals,Benzinga,/news/stocks/navigating-14-analyst-ratings-for-regeneron-pharmaceuticals-1033450002
1907.0,6/6/2024 2:47:18 PM,"Goldman cuts 2seventy bio to neutral, cites competition concerns",Seeking Alpha,https://seekingalpha.com/news/4113699-goldman-cuts-2seventy-bio-to-neutral-cites-competition-concerns?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1908.0,6/7/2024 8:30:54 PM,"Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside",Benzinga,/news/stocks/goldman-sachs-optimistic-about-regenxbio-s-gene-therapy-pipeline-sees-over-160-upside-1033462338
1909.0,6/11/2024 11:49:42 AM,"Regeneron, Sanofi win FDA label expansion for arthritis therapy Kevzara",Seeking Alpha,https://seekingalpha.com/news/4114761-regeneron-sanofi-win-new-fda-approval-kevzara?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1910.0,6/11/2024 1:00:03 PM,Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA),GlobeNewswire,/news/stocks/kevzara-sarilumab-approved-by-fda-for-the-treatment-of-active-polyarticular-juvenile-idiopathic-arthritis-pjia-1033468406
1911.0,6/11/2024 1:51:11 PM,"Regeneron, Sanofi Report FDA Approval Of Kevzara To Treat Active PJIA ",RTTNews,/news/stocks/regeneron-sanofi-report-fda-approval-of-kevzara-to-treat-active-pjia-1033468530
1912.0,6/11/2024 7:08:20 PM,Regeneron wins injunction blocking Mylan from launching generic version of its eye drug Eylea (update),Seeking Alpha,https://seekingalpha.com/news/4114936-regeneron-wins-permanent-injunction-blocking-generic-version-of-its-eye-drug-eylea?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1913.0,6/11/2024 11:11:16 PM,"Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), Becton Dickinson (BDX) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-intuitive-surgical-isrg-becton-dickinson-bdx-and-regeneron-regn-1033470821
1914.0,6/12/2024 11:36:51 AM,Regeneron’s Strategic Litigation and Market Exclusivity Uphold Buy Rating,TipRanks,/news/stocks/regeneron-s-strategic-litigation-and-market-exclusivity-uphold-buy-rating-1033473351
1915.0,6/12/2024 11:35:31 PM,"REGN, CI, BSX: Which “Strong Buy” Healthcare Stock Is the Best Bet?",TipRanks,/news/stocks/regn-ci-bsx-which-strong-buy-healthcare-stock-is-the-best-bet-1033474443
1916.0,6/13/2024 3:39:03 PM,"Regeneron's Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market",Benzinga,/news/stocks/regeneron-s-dupixent-copd-sales-to-reach-20b-by-2026-analyst-sees-larger-addressable-market-1033476295
1917.0,6/14/2024 11:50:28 AM,"Analysts Offer Insights on Healthcare Companies: R1 RCM (RCM), Regeneron (REGN) and Ocular Therapeutix (OCUL)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-r1-rcm-rcm-regeneron-regn-and-ocular-therapeutix-ocul-1033480394
1918.0,6/14/2024 4:44:17 PM,Regeneron wins injunction blocking Samsung Bioepis from launching generic Eylea,Seeking Alpha,https://seekingalpha.com/news/4116326-regeneron-wins-injunction-blocking-samsung-bioepis-from-launching-generic-eylea?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1919.0,6/14/2024 4:58:31 PM,Ocular Therapeutix jumps after investor day updates,Seeking Alpha,https://seekingalpha.com/news/4116345-ocular-therapeutix-stock-spikes-trial-update?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1920.0,6/16/2024 12:10:09 PM,Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma,GlobeNewswire,/news/stocks/updated-linvoseltamab-data-showcase-continued-deepening-of-responses-in-patients-with-heavily-pre-treated-multiple-myeloma-1033481447
1921.0,6/18/2024 12:20:24 PM,"Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), GeoVax Labs (GOVX) and Editas Medicine (EDIT)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-geovax-labs-govx-and-editas-medicine-edit-1033487871
1922.0,6/20/2024 6:04:17 PM,Regeneron (NASDAQ:REGN): Is This Stock-Split Contender a Strong Buy?,TipRanks,/news/stocks/regeneron-nasdaq-regn-is-this-stock-split-contender-a-strong-buy-1033494431
1923.0,6/21/2024 10:30:00 AM,Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for June 2024,InvestorPlace,/news/stocks/wall-street-favorites-3-cathie-wood-stocks-with-strong-buy-ratings-for-june-2024-1033495536
1924.0,6/24/2024 10:35:36 AM,RBC Capital Sticks to Their Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/rbc-capital-sticks-to-their-buy-rating-for-regeneron-regn-1033500064
1925.0,6/24/2024 6:01:12 PM,The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 13 Experts,Benzinga,/news/stocks/the-analyst-verdict-regeneron-pharmaceuticals-in-the-eyes-of-13-experts-1033500964
1926.0,6/24/2024 8:36:19 PM,Regeneron Pharmaceuticals' Approach To Improve Quality Of Weight Loss Has Merit: Goldman Sachs,Benzinga,/news/stocks/regeneron-pharmaceuticals-approach-to-improve-quality-of-weight-loss-has-merit-goldman-sachs-1033501399
1927.0,6/26/2024 7:37:00 AM,Buy Rating on Regeneron: Promising Obesity Treatment Prospects Amid Phase 2 Trials,TipRanks,/news/stocks/buy-rating-on-regeneron-promising-obesity-treatment-prospects-amid-phase-2-trials-1033506951
1928.0,6/26/2024 11:30:00 PM,Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine,GlobeNewswire,/news/stocks/dupixent-dupilumab-positive-phase-3-data-in-children-1-to-11-years-of-age-with-eosinophilic-esophagitis-published-in-the-new-england-journal-of-medicine-1033509296
1929.0,6/27/2024 7:55:39 AM,Evercore ISI Sticks to Its Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/evercore-isi-sticks-to-its-buy-rating-for-regeneron-regn-1033510820
1930.0,6/27/2024 10:40:00 AM,3 Biotech Stocks That Could Make Your Grandchildren Rich,InvestorPlace,/news/stocks/3-biotech-stocks-that-could-make-your-grandchildren-rich-1033510910
1931.0,6/27/2024 10:40:08 AM,Regeneron’s Linvoseltamab Outshines Competitor in Clinical Efficacy and Market Potential,TipRanks,/news/stocks/regeneron-s-linvoseltamab-outshines-competitor-in-clinical-efficacy-and-market-potential-1033511515
1932.0,6/27/2024 10:45:24 AM,"Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Nurix Therapeutics (NRIX) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-regeneron-regn-nurix-therapeutics-nrix-and-merck-company-mrk-1033511599
1933.0,6/27/2024 10:05:00 PM,"Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024",GlobeNewswire,/news/stocks/regeneron-to-report-second-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-august-1-2024-1033512982
1934.0,6/28/2024 12:39:53 PM,Regeneron lymphoma antibody drug endorsed for conditional approval in EU,Seeking Alpha,https://seekingalpha.com/news/4120552-chmp-recommends-regeneron-lymphoma-antibody-drug-for-conditional-approval?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1935.0,6/28/2024 1:00:00 PM,Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma,GlobeNewswire,/news/stocks/odronextamab-recommended-for-eu-approval-by-the-chmp-to-treat-relapsed-refractory-follicular-lymphoma-and-diffuse-large-b-cell-lymphoma-1033514556
1936.0,6/28/2024 1:20:06 PM,Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU ,RTTNews,/news/stocks/regeneron-says-chmp-recommends-conditional-marketing-authorization-for-odronextamab-in-eu-1033514600
1937.0,7/3/2024 7:00:00 AM,Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD,GlobeNewswire,/news/stocks/dupixent-dupilumab-approved-in-the-european-union-as-the-first-ever-targeted-therapy-for-patients-with-copd-1033525197
1938.0,7/3/2024 7:31:19 AM,"Regeneron, Sanofi: EU Approves Dupixent As First-ever Targeted Therapy For COPD Patients ",RTTNews,/news/stocks/regeneron-sanofi-eu-approves-dupixent-as-first-ever-targeted-therapy-for-copd-patients-1033525224
1939.0,7/3/2024 10:52:20 AM,"Sanofi, Regeneron win EU label expansion for Dupixent in COPD",Seeking Alpha,https://seekingalpha.com/news/4121994-sanofi-regeneron-win-eu-nod-dupixent-copd?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1940.0,7/3/2024 1:25:56 PM,Buy Rating for Regeneron Pharmaceuticals Amidst EU Approval of Dupixent and Positive Market Outlook,TipRanks,/news/stocks/buy-rating-for-regeneron-pharmaceuticals-amidst-eu-approval-of-dupixent-and-positive-market-outlook-1033527578
1941.0,7/4/2024 7:45:11 PM,7 High Priced Stocks That Would Benefit From a Stock Split,InvestorPlace,/news/stocks/7-high-priced-stocks-that-would-benefit-from-a-stock-split-1033530303
1942.0,7/5/2024 6:14:56 PM,The 3 Best Biotech Stocks to Buy in July 2024,InvestorPlace,/news/stocks/the-3-best-biotech-stocks-to-buy-in-july-2024-1033532887
1943.0,7/8/2024 10:00:00 AM,3 Pharma Stocks Already Ushering in the Next Biotech Boom,InvestorPlace,/news/stocks/3-pharma-stocks-already-ushering-in-the-next-biotech-boom-1033535178
1944.0,7/8/2024 2:05:14 PM,Regeneron Pharma Expects Q4 Results To Include $24 Mln In Acquired In-process R&D Charge ,RTTNews,/news/stocks/regeneron-pharma-expects-q4-results-to-include-24-mln-in-acquired-in-process-r-d-charge-1033535531
1945.0,7/8/2024 10:11:27 PM,Intellia sued for patent infringement by gene editing company BlueAllele,Seeking Alpha,https://seekingalpha.com/news/4122745-intellia-sued-for-patent-infringement-by-gene-editing-company-blueallele?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1946.0,7/9/2024 11:00:00 AM,The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024,InvestorPlace,/news/stocks/3-undervalued-gene-editing-stocks-for-patient-investors-1033538875
1947.0,7/10/2024 8:57:35 AM,Barclays Sticks to Its Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/barclays-sticks-to-its-buy-rating-for-regeneron-regn-1033542829
1948.0,7/11/2024 9:45:36 AM,Buy Rating for Regeneron: Anticipated Growth and Underappreciated Pipeline Offer Investment Opportunity,TipRanks,/news/stocks/buy-rating-for-regeneron-anticipated-growth-and-underappreciated-pipeline-offer-investment-opportunity-1033546987
1949.0,7/11/2024 10:01:18 PM,The Analyst Landscape: 14 Takes On Regeneron Pharmaceuticals,Benzinga,/news/stocks/the-analyst-landscape-14-takes-on-regeneron-pharmaceuticals-1033548491
1950.0,7/12/2024 8:12:28 AM,"This weight loss stock is the best alternative to Eli Lilly, Novo - SA Sentiment",Seeking Alpha,https://seekingalpha.com/news/4123754-weight-loss-amgen-stock-obesity-plays?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1951.0,7/13/2024 6:03:47 PM,"Morgan Stanley sees $180B patent cliff, $380B deal capacity fueling biopharma M&A",Seeking Alpha,https://seekingalpha.com/news/4124109-morgan-stanley-sees-180b-patent-cliff-380b-deal-capacity-fueling-biopharma-ma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1952.0,7/15/2024 10:55:52 AM,Buy Rating for Regeneron: Diverse Pipeline and Market Expectations Fuel Analyst Confidence,TipRanks,/news/stocks/buy-rating-for-regeneron-diverse-pipeline-and-market-expectations-fuel-analyst-confidence-1033555496
1953.0,7/17/2024 11:55:00 AM,Stocks to Buy: 7 Founder-Led Companies Set to Outperform,InvestorPlace,/news/stocks/stocks-to-buy-7-founder-led-companies-set-to-outperform-1033563731
1954.0,7/18/2024 11:55:00 AM,3 Standout Stocks to Buy for the Next Bull Market,InvestorPlace,/news/stocks/3-standout-stocks-to-buy-for-the-next-bull-market-1033568151
1955.0,7/18/2024 8:51:35 PM,"Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst",Benzinga,/news/stocks/johnson-johnson-prioritizes-sustainable-growth-in-m-a-amid-sector-diversification-says-analyst-1033569993
1956.0,7/19/2024 10:45:25 AM,Piper Sandler Remains a Buy on Regeneron (REGN),TipRanks,/news/stocks/piper-sandler-remains-a-buy-on-regeneron-regn-1033572493
1957.0,7/23/2024 10:40:23 AM,Piper Sandler Reaffirms Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/piper-sandler-reaffirms-their-buy-rating-on-regeneron-regn-1033582768
1958.0,7/23/2024 11:36:09 AM,TD Cowen Keeps Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/td-cowen-keeps-their-buy-rating-on-regeneron-regn-1033583302
1959.0,7/26/2024 6:54:05 AM,Barclays Keeps Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/barclays-keeps-their-buy-rating-on-regeneron-regn-1033599265
1960.0,7/26/2024 6:56:42 AM,Analysts’ Opinions Are Mixed on These Healthcare Stocks: Regeneron (REGN) and Roche Holding AG (OtherRHHVF),TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-regeneron-regn-and-roche-holding-ag-otherrhhvf-1033599249
1961.0,7/26/2024 8:47:42 AM,Buy Rating on Regeneron: Strong Dupixent Sales and Favorable Market Dynamics Support Positive Outlook,TipRanks,/news/stocks/buy-rating-on-regeneron-strong-dupixent-sales-and-favorable-market-dynamics-support-positive-outlook-1033599914
1962.0,7/28/2024 12:00:00 PM,"Earnings week ahead: MSFT, AMZN, AAPL, META, PFE, MCD, SBUX, XOM, CVX and more",Seeking Alpha,https://seekingalpha.com/news/4129069-earnings-week-ahead-msft-amzn-aapl-meta-qcom-pfe-mcd-sbux-ma-xom-cvx-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1963.0,7/29/2024 10:15:07 AM,Biotech Stocks Facing FDA Decision In August 2024 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-august-2024-1033605090
1964.0,7/30/2024 6:12:56 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Regeneron (REGN), AptarGroup (ATR) and AbbVie (ABBV)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-regeneron-regn-aptargroup-atr-and-abbvie-abbv-1033610735
1965.0,7/30/2024 12:35:45 PM,BioNTech posts mid-stage win for mRNA cancer drug with Regeneron’s Libtayo,Seeking Alpha,https://seekingalpha.com/news/4130080-biontech-stock-gains-win-mrna-cancer-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1966.0,7/30/2024 2:40:01 PM,Roche's Vabysmo gains indication in Europe for retinal vein occlusion,Seeking Alpha,https://seekingalpha.com/news/4130186-roche-vabysmo-gains-indication-europe-retinal-vein-occlusion?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1967.0,7/31/2024 1:30:00 PM,Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation,GlobeNewswire,/news/stocks/regeneron-announces-the-2024-winners-of-the-regeneron-prize-for-creative-innovation-1033617499
1968.0,7/31/2024 3:01:13 PM,Regeneron Pharmaceuticals earnings: here's what to expect,Markets Insider Automation,/news/stocks/regeneron-q2-earnings-preview-stock-1033618179
1969.0,7/31/2024 3:29:09 PM,Regeneron Pharmaceuticals Q2 2024 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/4131166-regeneron-pharmaceuticals-q2-2024-earnings-preview?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1970.0,8/1/2024 6:42:16 AM,Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and Regeneron (REGN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-qiagen-qgen-and-regeneron-regn-1033625195
1971.0,8/1/2024 10:32:04 AM,"Regeneron Pharmaceuticals Non-GAAP EPS of $11.56 beats by $0.94, revenue of $3.55B beats by $160M",Seeking Alpha,https://seekingalpha.com/news/4132020-regeneron-pharmaceuticals-non-gaap-eps-of-11_56-beats-0_94-revenue-of-3_55b-beats-160m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1972.0,8/1/2024 12:09:22 PM,Regeneron beats in Q2 as Eylea tops expectations,Seeking Alpha,https://seekingalpha.com/news/4132202-regeneron-stock-watch-q2-beat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1973.0,8/1/2024 12:30:00 PM,Regeneron Reports Second Quarter 2024 Financial and Operating Results,GlobeNewswire,/news/stocks/regeneron-reports-second-quarter-2024-financial-and-operating-results-1033625372
1974.0,8/1/2024 12:38:36 PM,Evercore ISI Reaffirms Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/evercore-isi-reaffirms-their-buy-rating-on-regeneron-regn-1033627919
1975.0,8/1/2024 12:59:30 PM,Regeneron Pharma Q2 Results Top Estimates - Update ,RTTNews,/news/stocks/regeneron-pharma-q2-results-top-estimates-update-1033625573
1976.0,8/1/2024 1:07:13 PM,Buy Rating Affirmed for Regeneron on Strong Financials and Positive Sales Outlook,TipRanks,/news/stocks/buy-rating-affirmed-for-regeneron-on-strong-financials-and-positive-sales-outlook-1033628206
1977.0,8/1/2024 1:12:04 PM,Buy Rating on Regeneron: Robust Financials and Growth Prospects,TipRanks,/news/stocks/buy-rating-on-regeneron-robust-financials-and-growth-prospects-1033628190
1978.0,8/1/2024 2:45:00 PM,Regeneron Pharmaceuticals hosts conference call for investors,Markets Insider Automation,/news/stocks/regeneron_conference-1030020015
1979.0,8/1/2024 6:26:08 PM,Regeneron’s Strong Market Performance and Financial Growth Bolster Buy Rating,TipRanks,/news/stocks/regeneron-s-strong-market-performance-and-financial-growth-bolster-buy-rating-1033629193
1980.0,8/2/2024 8:48:09 AM,Barclays Sticks to Its Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/barclays-sticks-to-its-buy-rating-for-regeneron-regn-1033631611
1981.0,8/2/2024 10:43:30 AM,Regeneron (REGN) Receives a Buy from RBC Capital,TipRanks,/news/stocks/regeneron-regn-receives-a-buy-from-rbc-capital-1033632290
1982.0,8/2/2024 11:11:29 AM,"Analysts Offer Insights on Healthcare Companies: Passage Bio (PASG), Regeneron (REGN) and Vir Biotechnology (VIR)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-passage-bio-pasg-regeneron-regn-and-vir-biotechnology-vir-1033632652
1983.0,8/2/2024 12:32:10 PM,Oppenheimer Sticks to Its Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/oppenheimer-sticks-to-its-buy-rating-for-regeneron-regn-1033633250
1984.0,8/5/2024 6:17:16 AM,Regeneron’s Promising Pipeline and Strong Financial Outlook Merit a Buy Rating with Increased Price Target,TipRanks,/news/stocks/regeneron-s-promising-pipeline-and-strong-financial-outlook-merit-a-buy-rating-with-increased-price-target-1033637869
1985.0,8/5/2024 6:30:08 AM,Balanced Outlook: Hold Rating on Regeneron Amid Robust Eylea Sales and Competitive Market Dynamics,TipRanks,/news/stocks/balanced-outlook-hold-rating-on-regeneron-amid-robust-eylea-sales-and-competitive-market-dynamics-1033637937
1986.0,8/5/2024 8:23:45 AM,"Analysts’ Top Healthcare Picks: Laboratory (LH), Humana (HUM)",TipRanks,/news/stocks/analysts-top-healthcare-picks-laboratory-lh-humana-hum-1033638405
1987.0,8/5/2024 10:22:21 AM,Strong Q2 Earnings and Robust Pipeline Reinforce Buy Rating for Regeneron,TipRanks,/news/stocks/strong-q2-earnings-and-robust-pipeline-reinforce-buy-rating-for-regeneron-1033639272
1988.0,8/7/2024 3:40:04 PM,3 Healthcare Stocks Positioned for Possible Market Outperformance,InvestorPlace,/news/stocks/3-healthcare-stocks-positioned-for-possible-market-outperformance-1033654380
1989.0,8/7/2024 10:05:00 PM,Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast,GlobeNewswire,/news/stocks/regeneron-announces-investor-conference-presentations-and-oncology-investor-webcast-1033655182
1990.0,8/8/2024 10:40:00 AM,3 Biotech Stocks With Promising Drug Pipelines: August 2024,InvestorPlace,/news/stocks/3-biotech-stocks-with-promising-drug-pipelines-august-2024-1033659855
1991.0,8/12/2024 9:13:25 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: United Therapeutics (UTHR), Waters (WAT) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-united-therapeutics-uthr-waters-wat-and-regeneron-regn-1033676813
1992.0,8/13/2024 11:30:00 AM,3 Biotech Stocks Poised for a Comeback After Last Week’s Market Meltdown,InvestorPlace,/news/stocks/3-biotech-stocks-poised-for-a-comeback-after-last-weeks-market-meltdown-1033681383
1993.0,8/13/2024 8:30:00 PM,7 Stocks That Usually Benefit From a Recession,InvestorPlace,/news/stocks/7-stocks-that-usually-benefit-from-a-recession-1033683968
1994.0,8/15/2024 6:02:28 PM,Alvotech’s biosimilar to Regeneron’s Eylea under EU review,Seeking Alpha,https://seekingalpha.com/news/4140717-alvotech-stock-gains-eu-review-for-eylea-rival?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1995.0,8/16/2024 7:00:27 PM,"Catalyst Watch: Eyes on Jackson Hole, Target earnings, and Canadian rails disruption",Seeking Alpha,https://seekingalpha.com/news/4141061-catalyst-watch-eyes-on-jackson-hole-target-earnings-and-canadian-rails-disruption?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1996.0,8/17/2024 6:00:44 PM,"J&J, Roche come out on top in S&P ratings of strongest pharma companies",Seeking Alpha,https://seekingalpha.com/news/4141255-johnson-johnson-roche-come-out-top-in-ratings-strongest-pharma-companies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1997.0,8/19/2024 11:30:16 AM,"Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), United Therapeutics (UTHR) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-transmedics-group-tmdx-united-therapeutics-uthr-and-regeneron-regn-1033704592
1998.0,8/19/2024 7:07:33 PM,Small-cap and mid-cap Health Care has room to rally - Roth MKM,Seeking Alpha,https://seekingalpha.com/news/4141609-small-cap-and-mid-cap-health-care-has-room-to-rally-roth-mkm?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
1999.0,8/20/2024 6:07:51 PM,"FTC says FDA biosimilar guidance would increase competition, lead to lower prices",Seeking Alpha,https://seekingalpha.com/news/4142026-ftc-says-fda-biosimilar-guidance-would-increase-competition-lead-lower-prices?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2000.0,8/21/2024 12:45:05 AM,Regeneron Provides Update on Biologics License Application for Linvoseltamab,GlobeNewswire,/news/stocks/regeneron-provides-update-on-biologics-license-application-for-linvoseltamab-1033708785
2001.0,8/21/2024 3:23:41 AM,FDA Issues Complete Response Letter For Regeneron's Linvoseltamab In R/R Multiple Myeloma ,RTTNews,/news/stocks/fda-issues-complete-response-letter-for-regeneron-s-linvoseltamab-in-r-r-multiple-myeloma-1033708812
2002.0,8/21/2024 9:53:49 AM,Regeneron receives anticipated FDA rejection for blood cancer therapy,Seeking Alpha,https://seekingalpha.com/news/4142191-regeneron-receives-anticipated-fda-rejection-for-blood-cancer-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2003.0,8/21/2024 10:02:12 AM,"Analysts Offer Insights on Healthcare Companies: Ansell (OtherANSLF), Alcon (ALC) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-ansell-otheranslf-alcon-alc-and-regeneron-regn-1033710994
2004.0,8/23/2024 11:07:44 AM,Piper Sandler Sticks to Their Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/piper-sandler-sticks-to-their-buy-rating-for-regeneron-regn-1033718550
2005.0,8/26/2024 7:00:00 AM,Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases,GlobeNewswire,/news/stocks/latest-dupixent-dupilumab-and-itepekimab-data-at-ers-highlight-scientific-innovation-and-leadership-in-respiratory-diseases-1033720628
2006.0,8/26/2024 11:26:02 AM,Regeneron’s cancer therapy gets EU approval,Seeking Alpha,https://seekingalpha.com/news/4143626-regenerons-cancer-therapy-gets-eu-approval?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2007.0,8/26/2024 1:00:00 PM,Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma,GlobeNewswire,/news/stocks/ordspono-odronextamab-approved-in-the-european-union-for-the-treatment-of-relapsed-refractory-follicular-lymphoma-and-diffuse-large-b-cell-lymphoma-1033721533
2008.0,8/26/2024 1:45:00 PM,Regeneron Pharma: European Commission Approves Ordspono - Quick Facts ,RTTNews,/news/stocks/regeneron-pharma-european-commission-approves-ordspono-quick-facts-1033721622
2009.0,8/29/2024 3:49:40 PM,J&J submits FDA application for myasthenia gravis drug nipocalimab,Seeking Alpha,https://seekingalpha.com/news/4145151-jj-submits-fda-application-for-myasthenia-gravis-drug-nipocalimab?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2010.0,9/2/2024 4:35:44 AM,Biotech Stocks Facing FDA Decision In September 2024 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-september-2024-1033738787
2011.0,9/5/2024 10:36:44 AM,RBC Capital Keeps Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/rbc-capital-keeps-their-buy-rating-on-regeneron-regn-1033750807
2012.0,9/6/2024 7:00:22 PM,"Catalyst Watch: Apple's iPhone event, Oracle earnings, Google antitrust trial, and the August CPI print",Seeking Alpha,https://seekingalpha.com/news/4147709-catalyst-watch-apples-iphone-event-oracle-earnings-google-antitrust-trial-and-the-august-cpi-print?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2013.0,9/9/2024 5:47:29 AM,Regeneron (REGN) Receives a Buy from Wells Fargo,TipRanks,/news/stocks/regeneron-regn-receives-a-buy-from-wells-fargo-1033756479
2014.0,9/9/2024 10:39:47 AM,RBC Capital Remains a Buy on Regeneron (REGN),TipRanks,/news/stocks/rbc-capital-remains-a-buy-on-regeneron-regn-1033757480
2015.0,9/9/2024 1:00:17 PM,Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO,GlobeNewswire,/news/stocks/regeneron-to-highlight-progress-across-its-differentiated-oncology-portfolio-and-pipeline-at-wclc-and-esmo-1033756819
2016.0,9/9/2024 11:00:00 PM,Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer,GlobeNewswire,/news/stocks/libtayo-cemiplimab-demonstrates-durable-survival-benefit-at-five-years-in-advanced-non-small-cell-lung-cancer-1033758649
2017.0,9/10/2024 5:25:55 AM,Regeneron's Five-Year Phase 3 Trial Shows Durable Survival Benefit Of Libtayo In PD-L1 High NSCLC ,RTTNews,/news/stocks/regeneron-s-five-year-phase-3-trial-shows-durable-survival-benefit-of-libtayo-in-pd-l1-high-nsclc-1033758778
2018.0,9/11/2024 6:59:00 AM,Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial,GlobeNewswire,/news/stocks/dupixent-dupilumab-is-the-first-and-only-biologic-to-achieve-significant-improvements-in-disease-remission-and-symptoms-in-bullous-pemphigoid-bp-positive-pivotal-trial-1033762412
2019.0,9/11/2024 7:04:00 AM,Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU),GlobeNewswire,/news/stocks/dupixent-dupilumab-phase-3-trial-confirms-significant-improvements-in-itch-and-hives-for-patients-with-chronic-spontaneous-urticaria-csu-1033762416
2020.0,9/11/2024 7:27:56 AM,"Sanofi, Regeneron: ADEPT Study Of Dupixent In Bullous Pemphigoid Meets Endpoints ",RTTNews,/news/stocks/sanofi-regeneron-adept-study-of-dupixent-in-bullous-pemphigoid-meets-endpoints-1033762443
2021.0,9/11/2024 11:35:11 AM,"Regeneron, Sanofi report mixed outcomes in late-stage trials for Dupixent",Seeking Alpha,https://seekingalpha.com/news/4148609-regeneron-sanofi-post-mixed-data-dupixent-trials?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2022.0,9/11/2024 12:25:33 PM,Buy Rating Affirmed: Regeneron’s Dupixent Poised for Market Expansion Following Positive Clinical Trials,TipRanks,/news/stocks/buy-rating-affirmed-regeneron-s-dupixent-poised-for-market-expansion-following-positive-clinical-trials-1033764645
2023.0,9/11/2024 1:00:46 PM,"EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile",GlobeNewswire,/news/stocks/eylea-hd-aflibercept-injection-8-mg-data-at-euretina-reinforce-long-term-durability-sustained-fluid-control-and-safety-profile-1033763482
2024.0,9/11/2024 9:05:14 PM,Sanofi reports positive Phase 3 results for Dupixent for CSU,Seeking Alpha,https://seekingalpha.com/news/4148829-sanofi-reports-positive-phase-3-results-for-dupixent-for-csu?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2025.0,9/12/2024 11:10:07 AM,Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN) and Sanofi (OtherSNYNF),TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-regeneron-regn-and-sanofi-othersnynf-1033767534
2026.0,9/13/2024 3:20:26 PM,Kiniksa draws buy at Jefferies on potential blockbuster status for lead drug,Seeking Alpha,https://seekingalpha.com/news/4149593-kiniksa-stock-draws-buy-jefferies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2027.0,9/13/2024 6:15:28 PM,Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP),GlobeNewswire,/news/stocks/dupixent-dupilumab-approved-in-the-u-s-as-first-and-only-treatment-for-adolescents-with-chronic-rhinosinusitis-with-nasal-polyps-crswnp-1033771127
2028.0,9/17/2024 9:30:44 AM,Analyst Issues Sell Rating for Regeneron Amid Competitive Challenges and Limited Market Potential,TipRanks,/news/stocks/analyst-issues-sell-rating-for-regeneron-amid-competitive-challenges-and-limited-market-potential-1033777087
2029.0,9/17/2024 10:39:14 AM,RBC Capital Reaffirms Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/rbc-capital-reaffirms-their-buy-rating-on-regeneron-regn-1033777349
2030.0,9/17/2024 11:16:08 AM,Buy Rating Affirmed: Regeneron’s Growth Potential Anchored by Strong Pipeline and Market Performance,TipRanks,/news/stocks/buy-rating-affirmed-regeneron-s-growth-potential-anchored-by-strong-pipeline-and-market-performance-1033777834
2031.0,9/20/2024 1:45:00 PM,Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old,GlobeNewswire,/news/stocks/dupixent-dupilumab-recommended-for-eu-approval-by-the-chmp-to-treat-eosinophilic-esophagitis-eoe-in-children-as-young-as-1-year-old-1033786209
2032.0,9/20/2024 9:10:51 PM,Regeneron/Sanofi Dupixent endorsed in EU for eosinophilic esophagitis for children,Seeking Alpha,https://seekingalpha.com/news/4151728-regeneron-sanofi-dupixent-endorsed-eu-eosinophilic-esophagitis-children?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2033.0,9/23/2024 5:41:45 PM,4D Molecular Therapeutics downgraded at Cantor following wet AMD asset data,Seeking Alpha,https://seekingalpha.com/news/4152160-4d-molecular-therapeutics-downgraded-cantor-following-wet-amd-asset-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2034.0,9/23/2024 7:13:36 PM,Regeneron falls after judge denies injunction blocking Amgen Eylea biosimilar,Seeking Alpha,https://seekingalpha.com/news/4152159-regeneron-falls-after-judge-denies-motion-for-injunction-in-a-patent-case-with-amgen?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2035.0,9/23/2024 8:15:22 PM,Buy Rating Affirmed for Regeneron Despite Eylea Legal Challenges: Growth and Diversification Fuels Optimism,TipRanks,/news/stocks/buy-rating-affirmed-for-regeneron-despite-eylea-legal-challenges-growth-and-diversification-fuels-optimism-1033791934
2036.0,9/24/2024 9:05:58 AM,Regeneron’s Strategic Resilience Justifies a Buy Rating Amidst Competitive Pressures,TipRanks,/news/stocks/regeneron-s-strategic-resilience-justifies-a-buy-rating-amidst-competitive-pressures-1033793378
2037.0,9/24/2024 10:05:24 AM,Regeneron’s Strategic Pipeline and Management Spark Buy Rating,TipRanks,/news/stocks/regeneron-s-strategic-pipeline-and-management-spark-buy-rating-1033793670
2038.0,9/24/2024 10:06:01 AM,Evaluating Regeneron’s Hold Rating Amid Biosimilar Litigation Uncertainty,TipRanks,/news/stocks/evaluating-regeneron-s-hold-rating-amid-biosimilar-litigation-uncertainty-1033793668
2039.0,9/24/2024 10:48:17 AM,Regeneron’s Strategic R&D and Financial Health Underpin Buy Rating,TipRanks,/news/stocks/regeneron-s-strategic-r-d-and-financial-health-underpin-buy-rating-1033793887
2040.0,9/24/2024 11:55:44 AM,Evercore ISI Keeps Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/evercore-isi-keeps-their-buy-rating-on-regeneron-regn-1033794402
2041.0,9/24/2024 1:03:50 PM,Regeneron downgraded at Leerink after Amgen’s court win; Truist defends,Seeking Alpha,https://seekingalpha.com/news/4152576-regeneron-stock-cut-leerink-amgen-court-win?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2042.0,9/25/2024 11:27:15 AM,Piper Sandler Sticks to Their Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/piper-sandler-sticks-to-their-buy-rating-for-regeneron-regn-1033797491
2043.0,9/25/2024 12:29:08 PM,Regeneron’s Patent Resilience and Market Positioning Justify a Buy Rating,TipRanks,/news/stocks/regeneron-s-patent-resilience-and-market-positioning-justify-a-buy-rating-1033797718
2044.0,9/25/2024 6:29:49 PM,Amgen stock slides 5% as analysts weigh in on drug study results,Seeking Alpha,https://seekingalpha.com/news/4153393-amgen-stock-slides-as-analysts-weigh-in-on-drug-study-results?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2045.0,9/26/2024 10:05:00 PM,"Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024",GlobeNewswire,/news/stocks/regeneron-to-report-third-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-october-31-2024-1033801999
2046.0,9/27/2024 1:00:04 PM,Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD),GlobeNewswire,/news/stocks/dupixent-dupilumab-approved-in-china-as-the-first-ever-biologic-medicine-for-patients-with-chronic-obstructive-pulmonary-disease-copd-1033803356
2047.0,9/27/2024 1:36:13 PM,"Regeneron, Sanofi Say Dupixent Approved In China To Treat Chronic Obstructive Pulmonary Disease ",RTTNews,/news/stocks/regeneron-sanofi-say-dupixent-approved-in-china-to-treat-chronic-obstructive-pulmonary-disease-1033803470
2048.0,9/27/2024 2:14:25 PM,"Sanofi, Regeneron get additional Chinese approval for Dupixent",Seeking Alpha,https://seekingalpha.com/news/4154122-sanofi-regeneron-get-additional-chinese-approval-for-dupixent?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2049.0,9/27/2024 3:35:08 PM,Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD,GlobeNewswire,/news/stocks/dupixent-dupilumab-approved-in-the-u-s-as-the-first-ever-biologic-medicine-for-patients-with-copd-1033803785
2050.0,9/27/2024 4:51:25 PM,"Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic Obstructive Pulmonary Disease Treatment ",RTTNews,/news/stocks/regeneron-sanofi-s-dupixent-get-fda-approval-for-chronic-obstructive-pulmonary-disease-treatment-1033804290
2051.0,9/27/2024 5:16:27 PM,Regeneron/ Sanofi granted FDA label expansion for Dupixent in COPD,Seeking Alpha,https://seekingalpha.com/news/4154190-regeneron-sanofi-win-fda-nod-dupixent-copd?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2052.0,9/28/2024 1:37:00 PM,"Notable analyst calls this week: Microsoft, Starbucks and GM among top picks",Seeking Alpha,https://seekingalpha.com/news/4154123-notable-analyst-calls-this-week-microsoft-starbucks-and-gm-among-top-picks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2053.0,9/29/2024 4:12:57 PM,"Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent set to advance in top drug sales",Seeking Alpha,https://seekingalpha.com/news/4154326-novo-nordisk-ozempic-regeneron-sanofi-dupixent-advance-top-drug-sales?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2054.0,9/30/2024 7:15:34 AM,Regeneron (REGN) Receives a Buy from Barclays,TipRanks,/news/stocks/regeneron-regn-receives-a-buy-from-barclays-1033806915
2055.0,9/30/2024 11:35:59 AM,Regeneron’s Growth Prospects Bolstered by Dupixent Approval and Promising Oncology Pipeline,TipRanks,/news/stocks/regeneron-s-growth-prospects-bolstered-by-dupixent-approval-and-promising-oncology-pipeline-1033808129
2056.0,10/7/2024 11:21:33 AM,Regeneron sees IPR&D impact of about $0.43/share on Q3 income,Seeking Alpha,https://seekingalpha.com/news/4156671-regeneron-sees-iprd-impact-of-about-043share-on-q3-income?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2057.0,10/7/2024 2:30:18 PM,Regeneron Pharmaceuticals: IPR&D Charge To Negatively Impact Q3 EPS By Approx. $0.43 ,RTTNews,/news/stocks/regeneron-pharmaceuticals-ipr-d-charge-to-negatively-impact-q3-eps-by-approx-0-43-1033824503
2058.0,10/9/2024 7:25:20 PM,Weight-loss drugs: How much should investors worry about side effects?,Seeking Alpha,https://seekingalpha.com/news/4157105-weight-loss-drugs-how-much-should-investors-worry-about-side-effects?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2059.0,10/11/2024 12:37:15 PM,Morgan Stanley Keeps Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/morgan-stanley-keeps-their-buy-rating-on-regeneron-regn-1033839265
2060.0,10/12/2024 5:58:03 PM,Weight loss drugs have one big issue; these companies want to fix it,Seeking Alpha,https://seekingalpha.com/news/4158061-these-companies-address-muscle-loss-glp-1s?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2061.0,10/14/2024 9:31:07 PM,Jasper gains 11% on data for briquilimab in urticaria,Seeking Alpha,https://seekingalpha.com/news/4158360-jasper-gains-on-data-for-briquilimab-in-urticaria?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2062.0,10/18/2024 11:05:00 PM,Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular...,GlobeNewswire,/news/stocks/three-year-results-for-eylea-hd-aflibercept-injection-8-mg-demonstrate-continued-durable-vision-gains-and-anatomic-improvements-with-extended-dosing-intervals-in-patients-with-diabetic-macular-1033860237
2063.0,10/19/2024 12:27:42 AM,Regeneron : EYLEA HD Three-Year Results Show Lasting Vision Gains In Diabetic Macular Edema Patients ,RTTNews,/news/stocks/regeneron-eylea-hd-three-year-results-show-lasting-vision-gains-in-diabetic-macular-edema-patients-1033860268
2064.0,10/21/2024 10:54:15 AM,Positive Outlook and Buy Rating for Regeneron Despite Expense Adjustment,TipRanks,/news/stocks/positive-outlook-and-buy-rating-for-regeneron-despite-expense-adjustment-1033864817
2065.0,10/22/2024 4:39:47 PM,Regeneron drops after court rejects request for temporary injunction for Eylea generic,Seeking Alpha,https://seekingalpha.com/news/4191238-regeneron-drops-after-court-rejects-request-for-temporary-injunction-for-eylea-generic?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2066.0,10/22/2024 5:25:18 PM,RBC would buy Regeneron on weakness with biosimilar Eylea priced in,TipRanks,/news/stocks/rbc-would-buy-regeneron-on-weakness-with-biosimilar-eylea-priced-in-1033873241
2067.0,10/22/2024 7:05:17 PM,"Regeneron price target lowered to $1,050 from $1,200 at Wells Fargo",TipRanks,/news/stocks/regeneron-price-target-lowered-to-1-050-from-1-200-at-wells-fargo-1033873548
2068.0,10/22/2024 7:30:16 PM,"Amgen to launch U.S. Eylea biosimilar, Reuters reports",TipRanks,/news/stocks/amgen-to-launch-u-s-eylea-biosimilar-reuters-reports-1033873540
2069.0,10/23/2024 7:18:06 AM,Barclays Keeps Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/barclays-keeps-their-buy-rating-on-regeneron-regn-1033877406
2070.0,10/23/2024 9:16:14 AM,Strategic Buy Rating for Regeneron Amid Competitive Challenges with Long-Term Growth Potential,TipRanks,/news/stocks/strategic-buy-rating-for-regeneron-amid-competitive-challenges-with-long-term-growth-potential-1033878018
2071.0,10/23/2024 9:40:16 AM,"Regeneron price target lowered to $1,080 from $1,220 at Barclays",TipRanks,/news/stocks/regeneron-price-target-lowered-to-1-080-from-1-220-at-barclays-1033878103
2072.0,10/23/2024 10:48:11 AM,Regeneron’s Legal Battles and Market Position Strengthen Buy Rating,TipRanks,/news/stocks/regeneron-s-legal-battles-and-market-position-strengthen-buy-rating-1033878720
2073.0,10/23/2024 11:39:35 AM,Piper Sandler Reaffirms Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/piper-sandler-reaffirms-their-buy-rating-on-regeneron-regn-1033879429
2074.0,10/23/2024 11:45:52 AM,Regeneron’s Growth Potential Solidified Amid Legal Challenges and Promising Pipeline,TipRanks,/news/stocks/regeneron-s-growth-potential-solidified-amid-legal-challenges-and-promising-pipeline-1033879605
2075.0,10/24/2024 10:16:01 AM,Regeneron: Buy Rating Reaffirmed Amid Eylea Biosimilar Challenge and Pipeline Strength,TipRanks,/news/stocks/regeneron-buy-rating-reaffirmed-amid-eylea-biosimilar-challenge-and-pipeline-strength-1033886245
2076.0,10/24/2024 10:21:01 AM,"JPMorgan cuts Regeneron target, says buy the recent selloff",TipRanks,/news/stocks/jpmorgan-cuts-regeneron-target-says-buy-the-recent-selloff-1033886211
2077.0,10/24/2024 12:26:23 PM,Evercore ISI Reaffirms Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/evercore-isi-reaffirms-their-buy-rating-on-regeneron-regn-1033887504
2078.0,10/24/2024 12:47:26 PM,"Regeneron, Sanofi announce presentation of Dupixent Phase 3 data in CSU",TipRanks,/news/stocks/regeneron-sanofi-announce-presentation-of-dupixent-phase-3-data-in-csu-1033887833
2079.0,10/24/2024 2:00:04 PM,Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI,GlobeNewswire,/news/stocks/dupixent-dupilumab-late-breaking-positive-phase-3-data-in-chronic-spontaneous-urticaria-to-be-presented-at-acaai-1033885634
2080.0,10/24/2024 2:45:32 PM,Cautious Hold Rating for Regeneron Amidst Competitive Threat from Amgen’s Eylea Biosimilar,TipRanks,/news/stocks/cautious-hold-rating-for-regeneron-amidst-competitive-threat-from-amgen-s-eylea-biosimilar-1033888437
2081.0,10/25/2024 11:45:05 AM,Sanofi posts Q3 revenue beat as Dupixent sales jump,Seeking Alpha,https://seekingalpha.com/news/4203950-sanofi-stock-gains-q-3-beat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2082.0,10/25/2024 11:50:26 AM,"Analysts’ Top Healthcare Picks: Inozyme Pharma (INZY), Tyra Bioscience (TYRA)",TipRanks,/news/stocks/analysts-top-healthcare-picks-inozyme-pharma-inzy-tyra-bioscience-tyra-1033893732
2083.0,10/25/2024 2:19:09 PM,Lilly's Ebglyss shown to be effective in former Dupixent users,Seeking Alpha,https://seekingalpha.com/news/4204992-lillys-ebglyss-shown-to-be-effective-in-former-dupixent-users?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2084.0,10/28/2024 9:01:15 AM,Regeneron (REGN) Gets a Buy from Barclays,TipRanks,/news/stocks/regeneron-regn-gets-a-buy-from-barclays-1033901235
2085.0,10/30/2024 3:14:14 PM,Regeneron Pharmaceuticals Q3 2024 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/4223936-regeneron-pharmaceuticals-q3-2024-earnings-preview?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2086.0,10/30/2024 6:00:59 PM,Notable companies reporting before tomorrow’s open,TipRanks,/news/stocks/notable-companies-reporting-before-tomorrow-s-open-1033921038
2087.0,10/31/2024 10:31:36 AM,"Regeneron Pharmaceuticals Non-GAAP EPS of $12.46 beats by $0.75, revenue of $3.72B beats by $50M",Seeking Alpha,https://seekingalpha.com/news/4227627-regeneron-pharmaceuticals-non-gaap-eps-of-12_46-beats-0_75-revenue-of-3_72b-beats-50m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2088.0,10/31/2024 10:36:20 AM,Regeneron lowers 2024 CapEx view to $700M-$740M from $750M-$820M,TipRanks,/news/stocks/regeneron-lowers-2024-capex-view-to-700m--740m-from-750m--820m-1033928418
2089.0,10/31/2024 10:37:36 AM,"Regeneron reports Q3 non-GAAP EPS $12.46, consensus $11.69",TipRanks,/news/stocks/regeneron-reports-q3-non-gaap-eps-12-46-consensus-11-69-1033928405
2090.0,10/31/2024 11:30:00 AM,Regeneron Reports Third Quarter 2024 Financial and Operating Results,GlobeNewswire,/news/stocks/regeneron-reports-third-quarter-2024-financial-and-operating-results-1033926680
2091.0,10/31/2024 11:50:35 AM,"Regeneron Pharmaceuticals Q3 Profit Increases, Beats Estimates ",RTTNews,/news/stocks/regeneron-pharmaceuticals-q3-profit-increases-beats-estimates-1033926762
2092.0,10/31/2024 1:01:20 PM,Morning Movers: Roblox surges and Estee Lauder sinks following earnings,TipRanks,/news/stocks/morning-movers-roblox-surges-and-estee-lauder-sinks-following-earnings-1033930078
2093.0,10/31/2024 2:40:37 PM,Regeneron down 10% despite top and bottom line beats,Seeking Alpha,https://seekingalpha.com/news/4228770-regeneron-down-10-despite-top-and-bottom-line-beats?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2094.0,10/31/2024 5:05:17 PM,Regeneron Buy Rating: Strong Earnings and Strategic Positioning Amid Market Challenges,TipRanks,/news/stocks/regeneron-buy-rating-strong-earnings-and-strategic-positioning-amid-market-challenges-1033931196
2095.0,10/31/2024 5:40:24 PM,"Regeneron price target lowered to $1,150 from $1,200 at Oppenheimer",TipRanks,/news/stocks/regeneron-price-target-lowered-to-1-150-from-1-200-at-oppenheimer-1033931388
2096.0,10/31/2024 5:51:09 PM,"Regeneron price target lowered to $1,215 from $1,260 at RBC Capital",TipRanks,/news/stocks/regeneron-price-target-lowered-to-1-215-from-1-260-at-rbc-capital-1033931458
2097.0,10/31/2024 7:10:48 PM,Eylea headwinds said to be behind Regeneron’s post-Q3 plunge,Seeking Alpha,https://seekingalpha.com/news/4231187-regeneron-stock-falls-eylea-headwinds?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2098.0,10/31/2024 8:42:14 PM,Regeneron files automatic mixed securities shelf,TipRanks,/news/stocks/regeneron-files-automatic-mixed-securities-shelf-1033931860
2099.0,10/31/2024 8:46:54 PM,Regeneron Pharmaceuticals files automatic mixed securities shelf,Seeking Alpha,https://seekingalpha.com/news/4231669-regeneron-pharmaceuticals-files-automatic-mixed-securities-shelf?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2100.0,11/1/2024 4:48:44 AM,Regeneron Pharmaceuticals Reports Strong Q3 2024 Results,TipRanks,/news/stocks/regeneron-pharmaceuticals-reports-strong-q3-2024-results-1033934659
2101.0,11/1/2024 7:25:40 AM,Barclays Reaffirms Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/barclays-reaffirms-their-buy-rating-on-regeneron-regn-1033935510
2102.0,11/1/2024 9:06:11 AM,Regeneron: Strategic Strengths and Future Prospects Justify Buy Rating Despite Challenges,TipRanks,/news/stocks/regeneron-strategic-strengths-and-future-prospects-justify-buy-rating-despite-challenges-1033936052
2103.0,11/1/2024 9:50:26 AM,"Regeneron price target lowered to $1,065 from $1,080 at Barclays",TipRanks,/news/stocks/regeneron-price-target-lowered-to-1-065-from-1-080-at-barclays-1033936358
2104.0,11/1/2024 10:25:27 AM,"Regeneron earnings selloff ‘serious overreaction,’ says Piper Sandler",TipRanks,/news/stocks/regeneron-earnings-selloff-serious-overreaction-says-piper-sandler-1033936589
2105.0,11/1/2024 10:36:59 AM,Regeneron Buy Rating: Strategic Growth Prospects Amid EYLEA Challenges and Opportunities,TipRanks,/news/stocks/regeneron-buy-rating-strategic-growth-prospects-amid-eylea-challenges-and-opportunities-1033936715
2106.0,11/1/2024 11:01:15 AM,Regeneron price target lowered to $800 from $820 at BofA,TipRanks,/news/stocks/regeneron-price-target-lowered-to-800-from-820-at-bofa-1033936938
2107.0,11/1/2024 11:39:43 AM,Truist Financial Reaffirms Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/truist-financial-reaffirms-their-buy-rating-on-regeneron-regn-1033937084
2108.0,11/1/2024 11:40:09 AM,Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME) and Regeneron (REGN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-zymeworks-zyme-and-regeneron-regn-1033937079
2109.0,11/1/2024 12:06:36 PM,Regeneron: A Buy Opportunity Amid Short-Term Setbacks and Promising Pipeline Potential,TipRanks,/news/stocks/regeneron-a-buy-opportunity-amid-short-term-setbacks-and-promising-pipeline-potential-1033937650
2110.0,11/1/2024 12:16:53 PM,Promising Outlook for Regeneron Amidst Challenges: Buy Rating Affirmed,TipRanks,/news/stocks/promising-outlook-for-regeneron-amidst-challenges-buy-rating-affirmed-1033937740
2111.0,11/1/2024 12:36:34 PM,Jefferies Sticks to Its Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/jefferies-sticks-to-its-buy-rating-for-regeneron-regn-1033937862
2112.0,11/1/2024 12:51:37 PM,"Regeneron selloff ‘overdone’ with pipeline catalysts coming, says Morgan Stanley",TipRanks,/news/stocks/regeneron-selloff-overdone-with-pipeline-catalysts-coming-says-morgan-stanley-1033937934
2113.0,11/1/2024 1:01:28 PM,"Regeneron price target lowered to $1,215 from $1,260 at RBC Capital",TipRanks,/news/stocks/regeneron-price-target-lowered-to-1-215-from-1-260-at-rbc-capital-1033938110
2114.0,11/1/2024 2:35:21 PM,"Regeneron price target lowered to $1,126 from $1,137 at Truist",TipRanks,/news/stocks/regeneron-price-target-lowered-to-1-126-from-1-137-at-truist-1033938445
2115.0,11/4/2024 12:25:45 PM,TD Cowen Reaffirms Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/td-cowen-reaffirms-their-buy-rating-on-regeneron-regn-1033945028
2116.0,11/5/2024 6:11:17 AM,"Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Travere Therapeutics (TVTX) and Regeneron (REGN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-madrigal-pharmaceuticals-mdgl-travere-therapeutics-tvtx-and-regeneron-regn-1033950256
2117.0,11/5/2024 12:11:44 PM,"Analysts Offer Insights on Healthcare Companies: Glaukos (GKOS), Regeneron (REGN) and IQVIA Holdings (IQV)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-glaukos-gkos-regeneron-regn-and-iqvia-holdings-iqv-1033952722
2118.0,11/6/2024 2:32:55 AM,"Analysts Are Bullish on These Healthcare Stocks: Argenx Se (ARGX), Regeneron (REGN)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-argenx-se-argx-regeneron-regn-1033957099
2119.0,11/6/2024 7:00:00 AM,Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis,GlobeNewswire,/news/stocks/dupixent-dupilumab-approved-in-the-european-union-as-the-first-and-only-medicine-for-young-children-with-eosinophilic-esophagitis-1033958445
2120.0,11/6/2024 7:53:22 AM,Regeneron: EC Approves Dupixent For Young Children With EoE ,RTTNews,/news/stocks/regeneron-ec-approves-dupixent-for-young-children-with-eoe-1033958624
2121.0,11/6/2024 10:35:14 AM,"Regeneron, Sanofi announce EC approval for Dupixent",TipRanks,/news/stocks/regeneron-sanofi-announce-ec-approval-for-dupixent-1033961176
2122.0,11/6/2024 11:35:34 AM,"Regeneron price target lowered to $1,000 from $1,150 at Oppenheimer",TipRanks,/news/stocks/regeneron-price-target-lowered-to-1-000-from-1-150-at-oppenheimer-1033961530
2123.0,11/8/2024 8:00:23 PM,"Catalyst Watch: Alibaba earnings, Disney drama, CPI print, 13F filings and more election scrambling",Seeking Alpha,https://seekingalpha.com/news/4266568-catalyst-watch-alibaba-earnings-disney-drama-cpi-print-13f-filings-and-more-election-scrambling?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2124.0,11/11/2024 10:05:00 PM,Regeneron Announces Investor Conference Presentations,GlobeNewswire,/news/stocks/regeneron-announces-investor-conference-presentations-1033994323
2125.0,11/13/2024 12:45:30 PM,"Regeneron announces new, updated data from hematology pipeline at ASH",TipRanks,/news/stocks/regeneron-announces-new-updated-data-from-hematology-pipeline-at-ash-1034009611
2126.0,11/13/2024 1:00:25 PM,Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH,GlobeNewswire,/news/stocks/regeneron-to-highlight-pioneering-pipeline-progress-across-multiple-modalities-spanning-10-types-of-blood-cancers-and-disorders-at-ash-1034007456
2127.0,11/13/2024 9:22:20 PM,Regeneron initiated with a Neutral at Citi,TipRanks,/news/stocks/regeneron-initiated-with-a-neutral-at-citi-1034011770
2128.0,11/14/2024 2:45:32 PM,"American upgraded, Regeneron initiated: Wall Street’s top analyst calls",TipRanks,/news/stocks/american-upgraded-regeneron-initiated-wall-street-s-top-analyst-calls-1034019984
2129.0,11/14/2024 7:26:46 PM,"Gilead, Vertex initiated as new big biotech buys at Citi",Seeking Alpha,https://seekingalpha.com/news/4291773-gilead-vertex-initiated-new-big-biotech-buys-citi?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2130.0,11/14/2024 9:21:44 PM,Regeneron initiated with an Outperform at Wolfe Research,TipRanks,/news/stocks/regeneron-initiated-with-an-outperform-at-wolfe-research-1034021156
2131.0,11/14/2024 11:40:12 PM,"Wolfe Research starts Regeneron at Outperform, sees ‘attractive entry point’",TipRanks,/news/stocks/wolfe-research-starts-regeneron-at-outperform-sees-attractive-entry-point-1034021568
2132.0,11/15/2024 6:59:51 AM,Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU),GlobeNewswire,/news/stocks/dupixent-dupilumab-sbla-accepted-for-fda-review-for-the-treatment-of-chronic-spontaneous-urticaria-csu-1034021994
2133.0,11/15/2024 7:36:25 AM,"Sanofi, Regeneron's Dupixent SBLA Accepted For FDA Review To Treat Chronic Spontaneous Urticaria ",RTTNews,/news/stocks/sanofi-regeneron-s-dupixent-sbla-accepted-for-fda-review-to-treat-chronic-spontaneous-urticaria-1034022058
2134.0,11/15/2024 10:25:30 AM,"Regeneron, Sanofi announce FDA accepts Dupixent sBLA for review",TipRanks,/news/stocks/regeneron-sanofi-announce-fda-accepts-dupixent-sbla-for-review-1034023973
2135.0,11/15/2024 12:50:21 PM,"Regeneron, Sanofi say resubmitted application to expand Dupixent label accepted in U.S.",Seeking Alpha,https://seekingalpha.com/news/4294221-regeneron-sanofi-bid-expand-dupixent-label-accepted?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2136.0,11/15/2024 2:40:28 PM,"Morgan Stanley, Comerica upgraded: Wall Street’s top analyst calls",TipRanks,/news/stocks/morgan-stanley-comerica-upgraded-wall-street-s-top-analyst-calls-1034025965
2137.0,11/22/2024 5:00:11 PM,FDA posts observations from previous Regeneron facility inspection,TipRanks,/news/stocks/fda-posts-observations-from-previous-regeneron-facility-inspection-1034056602
2138.0,11/22/2024 8:00:04 PM,"Catalyst Watch: Robotaxi IPO, OPEC+, holiday shopping data, and movie blockbusters",Seeking Alpha,https://seekingalpha.com/news/4322051-catalyst-watch-robotaxi-ipo-opec-holiday-shopping-data-and-movie-blockbusters?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2139.0,11/23/2024 1:26:02 PM,Pfizer meets amyloidosis rival as BridgeBio wins FDA nod for Attruby,Seeking Alpha,https://seekingalpha.com/news/4324609-pfizer-amyloidosis-rival-bridge-bio-wins-fda-nod?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
2140.0,11/25/2024 11:25:19 AM,Buy Rating on Regeneron Driven by Promising Factor XI Program and Market Potential,TipRanks,/news/stocks/buy-rating-on-regeneron-driven-by-promising-factor-xi-program-and-market-potential-1034060584
2141.0,11/25/2024 11:46:29 AM,Regeneron’s Pipeline Progress and Market Potential: Hold Rating Amidst Competitive Landscape,TipRanks,/news/stocks/regeneron-s-pipeline-progress-and-market-potential-hold-rating-amidst-competitive-landscape-1034060823
2142.0,11/25/2024 12:40:47 PM,Intellia announces FDA granted RMAT designation to nexiguran ziclumeran,TipRanks,/news/stocks/intellia-announces-fda-granted-rmat-designation-to-nexiguran-ziclumeran-1034061398
2143.0,11/28/2024 1:47:01 AM,RBC Capital Remains a Buy on Regeneron (REGN),TipRanks,/news/stocks/rbc-capital-remains-a-buy-on-regeneron-regn-1034074005
2144.0,12/3/2024 10:15:45 AM,Regeneron pays $1M milestone payment to Medigene,TipRanks,/news/stocks/regeneron-pays-1m-milestone-payment-to-medigene-1034091230
2145.0,12/3/2024 1:20:19 PM,"MAIA Biotechnology, Regeneron expand clinical supply agreement",TipRanks,/news/stocks/maia-biotechnology-regeneron-expand-clinical-supply-agreement-1034092896
,12/6/2024 9:21:18 PM,Lilly tops Morgan Stanley's biopharma pick list for 2025,Seeking Alpha,https://seekingalpha.com/news/4372587-lilly-tops-morgan-stanleys-biopharma-pick-list-for-2025?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/8/2024 1:00:31 AM,Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab,GlobeNewswire,/news/stocks/novel-combination-of-pozelimab-and-cemdisiran-poze-cemdi-achieved-greater-control-of-intravascular-hemolysis-in-patients-with-paroxysmal-nocturnal-hemoglobinuria-compared-to-ravulizumab-1034110553
,12/8/2024 2:27:19 AM,REGN : Poze-Cemdi Combo In Phase 3 Result Shows Superior Hemolysis Control In PNH Vs. Ravulizumab ,RTTNews,/news/stocks/regn-poze-cemdi-combo-in-phase-3-result-shows-superior-hemolysis-control-in-pnh-vs-ravulizumab-1034110559
,12/8/2024 12:10:16 PM,Regeneron announces Phase 3 data of exploratory cohort from ACCESS-1 trial,TipRanks,/news/stocks/regeneron-announces-phase-3-data-of-exploratory-cohort-from-access-1-trial-1034110945
,12/9/2024 4:22:43 PM,Kodiak stock rallies 32% after Jefferies upgrades to buy,Seeking Alpha,https://seekingalpha.com/news/4378725-kodiak-stock-rallies-after-jefferies-upgrades-to-buy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/9/2024 10:55:07 PM,Regeneron announces new data from odronextamab trial at ASH,TipRanks,/news/stocks/regeneron-announces-new-data-from-odronextamab-trial-at-ash-1034116513
,12/9/2024 11:45:23 PM,Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma,GlobeNewswire,/news/stocks/odronextamab-ash-presentations-underscore-impressive-potential-in-earlier-lines-of-treatment-and-additional-types-of-lymphoma-1034116183
,12/10/2024 12:05:45 PM,Regeneron reinstated with an Underperform at BofA,TipRanks,/news/stocks/regeneron-reinstated-with-an-underperform-at-bofa-1034119705
,12/10/2024 2:45:24 PM,"eBay downgraded, GM upgraded: Wall Street’s top analyst calls",TipRanks,/news/stocks/ebay-downgraded-gm-upgraded-wall-street-s-top-analyst-calls-1034120783
,12/10/2024 10:01:32 PM,BofA restarts coverage of 11 large-cap biopharmas,Seeking Alpha,https://seekingalpha.com/news/4384456-bofa-restarts-coverage-of-11-large-cap-biopharmas?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/16/2024 10:30:25 PM,Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year,GlobeNewswire,/news/stocks/regeneron-named-to-dow-jones-sustainability-world-index-for-sixth-consecutive-year-1034142872
,12/17/2024 12:10:56 PM,Regeneron announces primary endpoint met in Phase 3 QUASAR trial,TipRanks,/news/stocks/regeneron-announces-primary-endpoint-met-in-phase-3-quasar-trial-1034146452
,12/17/2024 12:49:43 PM,Regeneron posts Phase 3 win for Eylea HD in retinal vein occlusion,Seeking Alpha,https://seekingalpha.com/news/4387240-regeneron-posts-phase-3-win-eylea-hd?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/17/2024 1:00:00 PM,EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion,GlobeNewswire,/news/stocks/eylea-hd-aflibercept-injection-8-mg-phase-3-trial-meets-primary-endpoint-showing-improved-vision-with-extended-dosing-intervals-in-patients-with-macular-edema-following-retinal-vein-occlusion-1034145108
,12/17/2024 1:29:42 PM,Regeneron Pharma: Phase 3 Trial With EYLEA HD 8 Mg Meets Primary Endpoint - Quick Facts ,RTTNews,/news/stocks/regeneron-pharma-phase-3-trial-with-eylea-hd-8-mg-meets-primary-endpoint-quick-facts-1034145232
,12/17/2024 10:05:00 PM,Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference,GlobeNewswire,/news/stocks/regeneron-announces-presentation-at-the-43rd-annual-j-p-morgan-healthcare-conference-1034147948
,12/18/2024 5:37:08 AM,Leerink Partners Keeps Their Hold Rating on Regeneron (REGN),TipRanks,/news/stocks/leerink-partners-keeps-their-hold-rating-on-regeneron-regn-1034149445
,12/19/2024 12:12:10 PM,Regeneron to advance two Factor XI antibodies into broad Phase 3 program,TipRanks,/news/stocks/regeneron-to-advance-two-factor-xi-antibodies-into-broad-phase-3-program-1034156784
,12/19/2024 1:00:00 PM,Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results,GlobeNewswire,/news/stocks/regeneron-to-advance-two-factor-xi-antibodies-into-a-broad-phase-3-program-following-positive-phase-2-proof-of-concept-results-1034155335
,12/19/2024 6:16:03 PM,Regeneron reports positive results for two anti-coagulant drugs,Seeking Alpha,https://seekingalpha.com/news/4388091-regeneron-reports-positive-results-for-two-anti-coagulant-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/20/2024 6:27:22 PM,Regeneron’s Promising Drug Pipeline and Strong Safety Profile Justify Buy Rating,TipRanks,/news/stocks/regeneron-s-promising-drug-pipeline-and-strong-safety-profile-justify-buy-rating-1034163945
,12/20/2024 6:36:42 PM,Regeneron (REGN) Receives a Buy from Jefferies,TipRanks,/news/stocks/regeneron-regn-receives-a-buy-from-jefferies-1034164160
,12/22/2024 9:12:14 PM,SA Asks: Which Big Pharmas are likely to announce big M&A deals?,Seeking Alpha,https://seekingalpha.com/news/4389614-sa-asks-which-big-pharmas-are-likely-to-announce-big-m-deals?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,12/23/2024 5:35:08 PM,FDA revokes EUAs for some antibody treatments for COVID-19,TipRanks,/news/stocks/fda-revokes-euas-for-some-antibody-treatments-for-covid-19-1034169449
,12/28/2024 3:31:10 PM,Here are Morgan Stanley’s key oncology catalysts for 2025,Seeking Alpha,https://seekingalpha.com/news/4391298-morgan-stanley-lists-2025-oncology-catalysts?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/7/2025 8:27:42 AM,Bernstein Remains a Buy on Regeneron (REGN),TipRanks,/news/stocks/bernstein-remains-a-buy-on-regeneron-regn-1034199029
,1/7/2025 11:46:16 AM,"Regeneron price target lowered to $1,070 from $1,110 at Bernstein",TipRanks,/news/stocks/regeneron-price-target-lowered-to-1-070-from-1-110-at-bernstein-1034200272
,1/7/2025 1:41:00 PM,"Regeneron price target lowered to $1,184 from $1,215 at RBC Capital",TipRanks,/news/stocks/regeneron-price-target-lowered-to-1-184-from-1-215-at-rbc-capital-1034201268
,1/7/2025 10:05:00 PM,"Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025",GlobeNewswire,/news/stocks/regeneron-to-report-fourth-quarter-and-full-year-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-february-4-2025-1034202174
,1/8/2025 1:15:23 AM,"Regeneron price target lowered to $1,004 from $1,126 at Truist",TipRanks,/news/stocks/regeneron-price-target-lowered-to-1-004-from-1-126-at-truist-1034202853
,1/9/2025 1:56:22 PM,"Novo, Eli Lilly to dominate global pharma sales in 2025: report",Seeking Alpha,https://seekingalpha.com/news/4393716-novo-eli-lilly-lead-2025-global-pharma-sales?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/10/2025 11:37:48 AM,Oppenheimer Remains a Buy on Regeneron (REGN),TipRanks,/news/stocks/oppenheimer-remains-a-buy-on-regeneron-regn-1034214500
,1/10/2025 11:40:26 AM,Wells Fargo Releases a Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/wells-fargo-releases-a-buy-rating-on-regeneron-regn-1034214460
,1/10/2025 2:45:40 PM,"Regeneron price target lowered to $950 from $1,000 at Oppenheimer",TipRanks,/news/stocks/regeneron-price-target-lowered-to-950-from-1-000-at-oppenheimer-1034216027
,1/10/2025 4:18:38 PM,"4D Molecular, FDA agree on phase 3 design for DME candidate",Seeking Alpha,https://seekingalpha.com/news/4394159-4d-molecular-fda-agree-phase-3-design-dme-candidate?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/11/2025 8:06:44 PM,Can 2025 J.P. Morgan Healthcare Conference spark biotech M&A?,Seeking Alpha,https://seekingalpha.com/news/4394318-can-2025-jp-morgan-healthcare-conference-spark-biotech-ma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/13/2025 11:11:05 AM,Regeneron announces strategic collaboration with Truveta,TipRanks,/news/stocks/regeneron-announces-strategic-collaboration-with-truveta-1034220482
,1/13/2025 11:20:27 AM,Regeneron reports ‘positive’ results from Phase 3 C-POST trial,TipRanks,/news/stocks/regeneron-reports-positive-results-from-phase-3-c-post-trial-1034220620
,1/13/2025 12:05:00 PM,Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery,GlobeNewswire,/news/stocks/regeneron-collaborates-with-truveta-and-leading-american-health-systems-to-massively-extend-its-dna-sequence-linked-healthcare-database-to-further-advance-scientific-innovation-and-healthcare-delivery-1034219587
,1/13/2025 12:15:45 PM,Adjuvant Libtayo® (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial,GlobeNewswire,/news/stocks/adjuvant-libtayo-cemiplimab-significantly-improves-disease-free-survival-dfs-after-surgery-in-high-risk-cutaneous-squamous-cell-carcinoma-cscc-in-phase-3-trial-1034219684
,1/13/2025 12:28:12 PM,Regeneron Pharma Reports Positive Results From C-POST Trial With Libtayo - Quick Facts ,RTTNews,/news/stocks/regeneron-pharma-reports-positive-results-from-c-post-trial-with-libtayo-quick-facts-1034219670
,1/13/2025 12:30:00 PM,Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference,GlobeNewswire,/news/stocks/regeneron-provides-business-updates-and-highlights-from-broad-clinical-pipeline-at-the-43rd-annual-j-p-morgan-healthcare-conference-1034219683
,1/13/2025 1:15:39 PM,"Regeneron To Invest $119.5 Mln In Truveta's Financing Round, Launch Truveta Genome Project ",RTTNews,/news/stocks/regeneron-to-invest-119-5-mln-in-truveta-s-financing-round-launch-truveta-genome-project-1034219849
,1/13/2025 1:40:34 PM,Regeneron reports preliminary Q4 Eylea HD U.S. net product sales of $305M,TipRanks,/news/stocks/regeneron-reports-preliminary-q4-eylea-hd-u-s-net-product-sales-of-305m-1034221854
,1/13/2025 1:46:53 PM,"Regeneron down 5% after providing business updates, reporting Eylea sales",TipRanks,/news/stocks/regeneron-down-5-after-providing-business-updates-reporting-eylea-sales-1034222003
,1/13/2025 1:54:38 PM,Regeneron Pharmaceuticals met primary endpoint in cell carcinoma treatment trial,Seeking Alpha,https://seekingalpha.com/news/4394523-regeneron-pharmaceuticals-met-primary-endpoint-in-cell-carcinoma-treatment-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/13/2025 2:26:25 PM,4D Molecular downgraded at BMO on limited population for wet AMD candidate,Seeking Alpha,https://seekingalpha.com/news/4394529-4d-molecular-downgraded-bmo-limited-population-wet-amd-candidate?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/13/2025 2:31:01 PM,Regeneron announces IPR&D charges,Seeking Alpha,https://seekingalpha.com/news/4394553-regeneron-announces-iprd-charges?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,1/13/2025 8:38:14 PM,Regeneron Faces Sell Rating Amid Eylea’s Underperformance and Competitive Threats from Amgen’s Pavblu,TipRanks,/news/stocks/regeneron-faces-sell-rating-amid-eylea-s-underperformance-and-competitive-threats-from-amgen-s-pavblu-1034222992
,1/14/2025 1:02:22 AM,Regeneron price target lowered to $795 from $895 at Citi,TipRanks,/news/stocks/regeneron-price-target-lowered-to-795-from-895-at-citi-1034223287
,1/14/2025 1:05:16 AM,Regeneron’s Mixed Eylea Sales and Competitive Challenges Prompt Neutral Rating,TipRanks,/news/stocks/regeneron-s-mixed-eylea-sales-and-competitive-challenges-prompt-neutral-rating-1034223286
,1/14/2025 11:31:20 AM,Regeneron (REGN) Gets a Buy from Bernstein,TipRanks,/news/stocks/regeneron-regn-gets-a-buy-from-bernstein-1034225608
,1/14/2025 12:09:20 PM,Canaccord Genuity Reaffirms Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/canaccord-genuity-reaffirms-their-buy-rating-on-regeneron-regn-1034226107
,1/14/2025 12:46:42 PM,Regeneron’s Strategic R&D Focus and Robust Pipeline Drive Buy Rating,TipRanks,/news/stocks/regeneron-s-strategic-r-d-focus-and-robust-pipeline-drive-buy-rating-1034226387
,1/14/2025 11:45:13 PM,Regeneron CEO: We have 40 drugs in development,TipRanks,/news/stocks/regeneron-ceo-we-have-40-drugs-in-development-1034227811
,1/15/2025 7:14:27 AM,"Regeneron Faces Strategic Challenges and Sales Shortfall, Leading to Hold Rating",TipRanks,/news/stocks/regeneron-faces-strategic-challenges-and-sales-shortfall-leading-to-hold-rating-1034229620
,1/15/2025 11:17:22 AM,"Regeneron Buy Rating Supported by Eylea HD Launch, Dupixent Expansion, and Libtayo Success",TipRanks,/news/stocks/regeneron-buy-rating-supported-by-eylea-hd-launch-dupixent-expansion-and-libtayo-success-1034230575
,1/16/2025 11:20:31 AM,Regeneron downgraded to Neutral from Buy at UBS,TipRanks,/news/stocks/regeneron-downgraded-to-neutral-from-buy-at-ubs-1034235557
,1/16/2025 2:35:30 PM,"Netflix upgraded, AMD downgraded: Wall Street’s top analyst calls",TipRanks,/news/stocks/netflix-upgraded-amd-downgraded-wall-street-s-top-analyst-calls-1034237034
,1/17/2025 8:35:26 PM,Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations,TipRanks,/news/stocks/sector-spotlight-big-pharma-will-push-to-pause-medicare-drug-price-negotiations-1034241772
,1/21/2025 1:19:17 PM,Morgan Stanley Remains a Buy on Regeneron (REGN),TipRanks,/news/stocks/morgan-stanley-remains-a-buy-on-regeneron-regn-1034250543
,1/23/2025 1:58:02 AM,RBC Capital Sticks to Their Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/rbc-capital-sticks-to-their-buy-rating-for-regeneron-regn-1034257428
,1/23/2025 6:00:14 PM,America’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search,GlobeNewswire,/news/stocks/america-s-top-40-high-school-scientists-to-compete-for-1-8-million-in-awards-at-prestigious-regeneron-science-talent-search-1034261255
,1/27/2025 12:01:03 PM,Piper Sandler Remains a Buy on Regeneron (REGN),TipRanks,/news/stocks/piper-sandler-remains-a-buy-on-regeneron-regn-1034272491
,1/27/2025 1:50:31 PM,"Regeneron price target lowered to $1,013 from $1,195 at Piper Sandler",TipRanks,/news/stocks/regeneron-price-target-lowered-to-1-013-from-1-195-at-piper-sandler-1034273094
,1/28/2025 11:35:58 AM,Regeneron price target lowered to $750 from $795 at Citi,TipRanks,/news/stocks/regeneron-price-target-lowered-to-750-from-795-at-citi-1034277164
,1/29/2025 11:58:13 AM,Regeneron (REGN) Gets a Buy from TD Cowen,TipRanks,/news/stocks/regeneron-regn-gets-a-buy-from-td-cowen-1034282871
,1/30/2025 11:27:58 AM,Regeneron: Strong Buy Rating Driven by Dupixent’s Growth and Promising Pipeline Developments,TipRanks,/news/stocks/regeneron-strong-buy-rating-driven-by-dupixent-s-growth-and-promising-pipeline-developments-1034288305
,2/2/2025 1:00:00 PM,"Earnings week ahead: PLTR, AMZN, GOOG, AMD, LLY, PEP, F, PFE, MRK, PYPL and more",Seeking Alpha,https://seekingalpha.com/news/4401431-earnings-week-ahead-pltr-amzn-goog-amd-lly-pep-f-pfe-mrk-pypl-qcom-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/3/2025 7:10:20 PM,Notable companies reporting before tomorrow’s open,TipRanks,/news/stocks/notable-companies-reporting-before-tomorrow-s-open-1034305420
,2/3/2025 7:28:29 PM,Regeneron Pharmaceuticals Q4 2024 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/4402211-regeneron-pharmaceuticals-q4-2024-earnings-preview?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/3/2025 11:00:37 PM,Here's the major earnings before the open tomorrow,Seeking Alpha,https://seekingalpha.com/news/4402088-heres-the-major-earnings-before-the-open-tomorrow?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/4/2025 11:33:51 AM,Regeneron Pharmaceuticals beats top-line and bottom-line estimates; initiates FY25 outlook,Seeking Alpha,https://seekingalpha.com/news/4402560-regeneron-pharmaceuticals-beats-top-line-and-bottom-line-estimates-initiates-fy25-outlook?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/4/2025 11:36:02 AM,Regeneron sees 2025 CapEx $850M-$975M,TipRanks,/news/stocks/regeneron-sees-2025-capex-850m--975m-1034308376
,2/4/2025 11:36:40 AM,"Regeneron reports Q4 non-GAAP EPS $12.07, consensus $11.19",TipRanks,/news/stocks/regeneron-reports-q4-non-gaap-eps-12-07-consensus-11-19-1034308360
,2/4/2025 11:50:35 AM,"Regeneron Pharmaceuticals declares its first-ever dividend of $0.88, announces $3.0B buyback",Seeking Alpha,https://seekingalpha.com/news/4402577-regeneron-pharmaceuticals-declares-its-first-ever-dividend-of-088-announces-30b-buyback?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/4/2025 12:30:00 PM,Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to ~$4.5 Billion,GlobeNewswire,/news/stocks/regeneron-reports-fourth-quarter-and-full-year-2024-financial-and-operating-results-initiates-quarterly-dividend-and-increases-total-share-repurchase-capacity-to-4-5-billion-1034308299
,2/4/2025 12:39:38 PM,"Regeneron Pharmaceuticals Q4 Profit Decreases, But Beats Estimates ",RTTNews,/news/stocks/regeneron-pharmaceuticals-q4-profit-decreases-but-beats-estimates-1034308322
,2/4/2025 2:00:33 PM,Morning Movers: Spotify and Pfizer climb after fourth quarter results,TipRanks,/news/stocks/morning-movers-spotify-and-pfizer-climb-after-fourth-quarter-results-1034309577
,2/4/2025 2:01:16 PM,MAIA Biotechnology announces updated data from THIO-101 trial,TipRanks,/news/stocks/maia-biotechnology-announces-updated-data-from-thio-101-trial-1034309572
,2/4/2025 3:27:57 PM,"Regeneron's new dividend, Dupixent growth support strong Q4",Seeking Alpha,https://seekingalpha.com/news/4402668-regeneron-new-dividend-dupixent-growth-support-strong-q4?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/4/2025 5:05:31 PM,"China retaliates with tariffs on U.S., Merck falls after earnings: Morning Buzz",TipRanks,/news/stocks/china-retaliates-with-tariffs-on-u-s-merck-falls-after-earnings-morning-buzz-1034310568
,2/5/2025 10:35:41 AM,Oppenheimer Sticks to Their Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/oppenheimer-sticks-to-their-buy-rating-for-regeneron-regn-1034314353
,2/5/2025 11:16:10 AM,Regeneron upgraded to Outperform from Market Perform at Leerink,TipRanks,/news/stocks/regeneron-upgraded-to-outperform-from-market-perform-at-leerink-1034314595
,2/5/2025 11:40:02 AM,RBC Capital Reaffirms Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/rbc-capital-reaffirms-their-buy-rating-on-regeneron-regn-1034314684
,2/5/2025 12:17:11 PM,Truist Financial Reaffirms Their Buy Rating on Regeneron (REGN),TipRanks,/news/stocks/truist-financial-reaffirms-their-buy-rating-on-regeneron-regn-1034315105
,2/5/2025 12:31:05 PM,Regeneron price target lowered to $759 from $940 at Baird,TipRanks,/news/stocks/regeneron-price-target-lowered-to-759-from-940-at-baird-1034315231
,2/5/2025 1:25:29 PM,Regeneron price target raised to $575 from $565 at BofA,TipRanks,/news/stocks/regeneron-price-target-raised-to-575-from-565-at-bofa-1034315530
,2/5/2025 1:35:38 PM,Jefferies Sticks to Their Buy Rating for Regeneron (REGN),TipRanks,/news/stocks/jefferies-sticks-to-their-buy-rating-for-regeneron-regn-1034315682
,2/5/2025 1:41:28 PM,"Regeneron price target lowered to $1,045 from $1,059 at RBC Capital",TipRanks,/news/stocks/regeneron-price-target-lowered-to-1-045-from-1-059-at-rbc-capital-1034315662
,2/5/2025 2:35:44 PM,"AMD, Spotify downgraded: Wall Street’s top analyst calls",TipRanks,/news/stocks/amd-spotify-downgraded-wall-street-s-top-analyst-calls-1034316027
,2/5/2025 4:17:03 PM,EyePoint stock jumps 10% on Duravyu study results,Seeking Alpha,https://seekingalpha.com/news/4403524-eyepoint-stock-jumps-on-duravyu-study-results?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/5/2025 4:25:45 PM,Regeneron upgraded at Leerink following recent share weakness,Seeking Alpha,https://seekingalpha.com/news/4403603-regeneron-upgraded-leerink-following-recent-share-weakness?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/5/2025 5:11:12 PM,"Alphabet, Disney report quarterly beats: Morning Buzz",TipRanks,/news/stocks/alphabet-disney-report-quarterly-beats-morning-buzz-1034317040
,2/6/2025 12:10:50 PM,Immuneering announces clinical supply agreement with Regeneron,TipRanks,/news/stocks/immuneering-announces-clinical-supply-agreement-with-regeneron-1034321964
,2/7/2025 7:15:15 PM,Buy/Sell: Wall Street’s top 10 stock calls this week,TipRanks,/news/stocks/buy-sell-wall-street-s-top-10-stock-calls-this-week-1034329182
,2/8/2025 2:35:21 PM,"Notable analyst calls this week: AMD, Skyworks and Nike stocks among top picks",Seeking Alpha,https://seekingalpha.com/news/4405154-notable-analyst-calls-this-week-amd-skyworks-and-nike-stocks-among-top-picks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news
,2/8/2025 9:55:00 PM,Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with...,GlobeNewswire,/news/stocks/three-year-results-for-eylea-hd-aflibercept-injection-8-mg-in-patients-with-wet-age-related-macular-degeneration-demonstrate-continued-durable-vision-gains-and-anatomic-improvements-with-1034329786
,2/8/2025 11:40:16 PM,EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting,GlobeNewswire,/news/stocks/eylea-hd-aflibercept-injection-8-mg-positive-phase-3-results-in-patients-with-macular-edema-following-retinal-vein-occlusion-presented-at-angiogenesis-meeting-1034329795
,2/9/2025 5:17:46 AM,Regeneron : EYLEA HD Shows Sustained Vision Gains In Wet AMD Patients At 3 Years ,RTTNews,/news/stocks/regeneron-eylea-hd-shows-sustained-vision-gains-in-wet-amd-patients-at-3-years-1034329885
,2/9/2025 5:36:47 AM,Regeneron Announces Positive Phase 3 Results For EYLEA HD In Retinal Vein Occlusion Treatment ,RTTNews,/news/stocks/regeneron-announces-positive-phase-3-results-for-eylea-hd-in-retinal-vein-occlusion-treatment-1034329895
